

Volume 65

- Aakre, M, 2296
Aaltonen, LA, 10170, 4607
aan de Wiel-Ambagtsheer, G, 4300
Aarnoudse, CA, 5935
Aaronson, SA, 2602, 7554
Abaji, C, 11384, 4117
Abarzua, F, 9617
Abate-Shen, C, 6773
Abbruzzese, JL, 3716, 9164, 10371, 11510, 11658
Abbruzzese, J, 9064
Abdallah, BM, 3126, 9943
Abdel-Mageed, AB, 9891
Abdel-Malek, ZA, 4292
Abdollahi, A, 3643
Abdul-Hai, A, 9735
Abdullaev, Z, 7751, 7763
Abdulrahman, M, 4598
Abe, K, 1719
Abe, K, 11146
Abe, M, 828
Abe, M, 7824
Abei, M, 546
Abeler, VM, 5588
Aboagye, EO, 4202, 10104
Abol-Enein, H, 11580
Abounader, R, 9355
Abraham, LJ, 7628
Abraham, RT, 5325
Abrams, SL, 1045, 4376
Abroun, S, 2269
Abu-Ghazaleh, R, 4181
Abu-Isa, E, 5493
Aburatani, H, 372
Accart, N, 9536
Ackermann, J, 4005
Acres, B, 9536
Adam, L, 10524
Adam, RM, 8242
Adam, SJ, 9824
Adams, GE, 1471
Adams, J, 66
Adams, M, 7000
Adamson, DC, 919
Adamson, ED, 5133
Addis, A, 6388
Adelaide, J, 767
Adereth, Y, 7205
Adesina, A, 76
Adhami, VM, 1635, 11203
Adib, JN, 2636
Adjei, AA, 11071
Adler, LR, 1471
Adley, BP, 2234
Adnani, MT, 7763
Adrian, TE, 6011
Advani, SJ, 9479
Afaq, F, 1635
Agarwal, A, 4789
Agarwal, C, 1035
Agarwal, R, 7378
Agarwal, R, 1035, 4448
Agathangelou, A, 2690, 3497, 7653
Aggarwal, A, 186
Aggarwal, BB, 9555
Agostini, F, 1505
AgoulNIK, IU, 7959
Agrawal, KC, 9891
Aguero, MF, 3364
Aherne, W, 4918
Ahibom, A, 6459
Ahmadi, R, 11419
Ahmed, A, 2009
Ahmed, F, 6934
Ahmed-Belkacem, A, 4852
Ahmed-Choudhury, J, 2690
Ahn, J, 1105
Ahn, KY, 8993
Ahn, Y-H, 4896
Ahsan, H, 3454
Ai, Y, 4496
Aichberger, KJ, 9436
Airolti, L, 8042
Akatsuka, A, 203
Akel, NS, 11001
Akgül, B, 2216
Akira, S, 10977
Akkari, Y, 85
Aklilu, E, 5105
Al Rashid, ST, 10810
Al Saati, T, 11639
Alain, T, 9982
Alami, J, 2592
Alaminos, M, 2565
Alazzouzi, H, 10170
Albanese, C, 6557, 9934
Al-Batran, S-E, 3937
Albelda, SM, 8379, 11752
Alberg, AJ, 9566
Albero, MP, 3264
Albers, A, 11146
Albert, D, 2698
Albert, R, 7478
Albertella, MR, 9799
Alberti, L, 2
Alberti, P, 9369
Alberto, FL, 1693
Albertsen, H, 6063
Albini, A, 10637
Albrechtsen, R, 4754
Aldape, KD, 1678
Alekseev, S, 10298
Alessi, M, 1265
Alexander, J, 121
Alexandre, J, 948
Alhonen, L, 5390
Alhopuro, P, 4607
Ali, MA, 6178
Ali, S, 6934, 9064
Ali, S, 7194
Alicke, B, 2846, 8397
Ali-Seyed, M, 338
Alitalo, K, 4739, 6901
Al-Katib, W, 3396
Allart, S, 2787
Allavena, P, 2964
Allen, W, 8951
Allsup, DJ, 7328
Almeida, KH, 6394
Al-Nahhas, A, 10104
Alpini, G, 11437
Al-Saffar, NMS, 3356
Alsharabi, G, 8471
Alter, BP, 9574
Alt-Holland, A, 1783
Altieri, DC, 3531
Altman, J, 9029
Altmannberger, H-M, 3937
Altomare, DA, 5256, 8091
Altorki, NK, 5982, 664
Altschuler, D, 7516
Altucci, L, 8754
Altun, M, 7896
Alvarado, C, 8514
Alvarez, JV, 5054
Alvarez, K, 879
Alvarez, MJ, 5123
Alvarez, X, 465
Alvaro, D, 11437
Alves, A, 948
Alzabin, S, 3249
Amador, ML, 3003
Amalric, F, 11639
Aman, J, 226
Amano, T, 3307
Amariglio, N, 999
Amato, R, 5628
Ambartsumian, N, 3772, 6167
Ambesi, A, 148
Ambrosi, C, 8308
Ambrosone, CB, 1105
Amélie, R, 195
Amemiya, Y, 10401
Ames, SJ, 2125
Ameur, N, 8497
Amoh, Y, 2337, 4246, 5352
Amorphimoltham, P, 9953
Amos, CI, 11297, 427
Anand, G, 4228
Anazawa, Y, 4578
Andarawewa, KL, 10862
Andersen, MH, 2983
Andersen, RJ, 3040
Andersen, TL, 9943
Anderson, A-L, 5907
Anderson, KC, 5898, 7478, 7896, 8350, 11712
Anderson, RA, 7707
Anderson, RJ, 2373
Anderson, S, 5399
Andersson, T, 9142
Andreasson, K, 5953
Andreeff, M, 2890, 3307, 9962
Andreola, S, 2321
Andresen, L, 11136
Andreu, EJ, 3264
Andrew, A, 7081
Andrew, SE, 2626
Andrews, PW, 5588
Andriole, GL, 11779
Anema, J, 5628
Angel, I, 805
Angelino, NJ, 5917
Anguille, C, 10872
Anichini, A, 632, 3428
Ann, DK, 6622
Annabi, B, 8359
Annis, DS, 9338
Ansén, S, 10050
Antequera, F, 26
Anton, M, 8608
Anton-Culver, H, 9117
Antonescu, CR, 1748, 6631, 9226
Antony, L, 9269
Antony, S, 4844, 5337
Aoki, H, 3336
Aoki, T, 8836, 10613
Aoyagi, K, 2115
Aoyama, M, 4587
Apáti, A, 1770
Aperavich, BA, 9637
Aplan, PD, 7151
Aplenc, R, 2482
Apolito, K, 6660
Appelman, H, 493
Aprelikova, O, 5031
Aprikian, A, 8514
Aqeilan, RI, 4515, 6764, 11282
Aquilano, K, 11735
Aquino-Parsons, C, 7259
Aractingi, S, 1755
Aragona, F, 6668
Arakawa, H, 11704
Araki, K, 11704
Arango, D, 10170, 4607
Araten, DJ, 8111
Arbona, C, 3264
Arcese, W, 1505
Archambeau, J, 805
Arderiu, G, 7177
Aris, RM, 3374
Arizzi, M, 1897
Arlinghaus, RB, 2532
Arlt, A, 1316
Arlt, D, 7733
Arlt, MJE, 3523
Arlt, VM, 2644
Armeanu, S, 6321
Armengol, M, 10170
Armitage, ESM, 10536
Armstrong, DL, 76
Armstrong, E, 3328
Armstrong, SA, 10050
Arndt, K, 5358
Arnheim, N, 8662
Arnold, JT, 9269
Arnold, W, 394
Aronin, N, 9651
Aronow, BJ, 166
Arora, S, 3806
Arroyo, JD, 8183
Arteaga, CL, 2815
Artemov, D, 1425, 10801
Aruliah, S, 2662
Asada, S, 596
Asano, T, 9164
Asanuma, H, 8706, 11018
Asaoka, Y, 4562, 10822
Asaoku, H, 2269
Asatiani, E, 1164
Asea, A, 5238
Ashcroft, M, 4918
Ashfaq, R, 8209
Ashida, S, 4578, 4817
Ashman, LK, 9633
Ashok, BT, 6466
Asopa, S, 5163
Assaraf, YG, 8414, 10952
Asselain, B, 1376
Atchison, RE, 9294
Athar, M, 3236
Atherton, JA, 957
Atkins, D, 7926
Atkins, MB, 3044
Atkinson, SP, 7585
Atmaca, A, 3937
Attardi, LD, 6551
Attewell, JR, 2684
Auersperg, N, 2234, 8591
Augé, N, 526
Augenlicht, LH, 9363, 9861
Auricchio, F, 10585
Aurrand-Lions, M, 5703
Autar, B, 5730
Autrup, H, 8042
Avery, AC, 5654
Avery, PR, 5654
Aveyard, JS, 66
Avis, I, 4181
Avis, T, 7591
Avizienyte, E, 1335
Avogadri, F, 3920
Avraham, HK, 2840
Avraham, S, 2840
Awad, M, 5674
Awasthi, S, 951, 6022
Awasthi, YC, 991, 6022
Axten, CW, 2602
Ayala, G, 7959, 7976
Ayer, RE, 2125
Aymerich, MS, 5144
Aytac, U, 1973, 6950
Aznavorian-Cheshire, S, 6692
Azodi, M, 3762
Azuma, A, 6874
Azzarone, B, 2914
Ba, Y, 553

- Baader, E. 7888
 Baha, T. 4939
 Babbe, H. 6891
 Babcock, GF. 4568
 Babcock, G. 4292
 Bachelot, T. 2
 Bachinski, L.L. 427
 Backendorf, C. 10298
 Backora, MW. 9004
 Baddi, L. 3454
 Bae, J. 11712
 Bae, K-H. 1941
 Bae, M-K. 2520
 Bae, S-K. 2520
 Bae, S-C. 9347
 Bae, S-S. 7902
 Baeger, AC. 10854
 Baecuerle, PA. 2882
 Bafico, A. 7554
 Bagain, L. 7071
 Bagby, G. 1271
 Bagley, RG. 9741
 Bagli, E. 1877
 Bagnato, A. 11649
 Bai, J. 2344
 Bai, R. 3950
 Bai, S. 10891
 Bai, W. 9751
 Bai, Y. 4747
 Baik, I. 358
 Bailey, DK. 6071
 Bailey, K. 3911
 Bailey, S. 9712
 Bailey, SN. 7462
 Bailey, SM. 5544
 Baillat, D. 3011
 Bair, E. 9200
 Baird, K. 9226
 Baird, WM. 1251
 Bakal, C. 6685
 Baken, B. 5857
 Baker, CH. 7214, 10371
 Baker, DA. 957
 Baker, JR. 5317
 Baker, RA. 933
 Baker, SE. 9876
 Baksh, RI. 11129
 Balagurunathan, Y. 10164
 Balajee, AS. 10977
 Balaji, KC. 483
 Balakrishnan, L. 10977
 Balasenthil, S. 7724
 Balasis, M. 10536
 Balasubramanian, L. 9029
 Balderes, P. 1514
 Baldwin, C. 7561
 Bales, E. 692
 Balhara, K. 3226
 Bali, P. 10536
 Balkwill, FR. 10355
 Ballen, K. 358
 Ballestin, C. 9678
 Balloul, J-M. 9536
 Balmain, A. 6488
 Balme, B. 10901
 Balogh, LP. 5317
 Balsari, A. 6388
 Baluk, P. 2712
 Bambach, B. 3410
 Bancroft, L. 9363
 Band Horwitz, S. 2854
 Band, V. 4747
 Bandyopadhyay, D. 692
 Bandyopadhyay, K. 9834
 Banerjee, A. 6466
 Banerjee, R. 1554
 Banerjee, S. 3877, 9064
 Bang, Y-J. 1952
 Bangur, CS. 6425
 Banine, F. 3542
 Banks, C. 7462
 Banks, RF. 4598
 Bannasch, D. 7733
 Bannink, JE. 6425
 Banno, A. 5761
 Bañez-Coronel, M. 5647
 Bao, LW. 8366
 Bao, Y. 4134
 Bapat, SA. 3025
 Baptiste, T. 499
 Bar Haim, E. 6435
 Baranowska-Kortylewicz, J. 7824
 Barassi, F. 9687
 Baratelli, F. 5211
 Baraz, R. 3290
 Barbacid, M. 3846
 Barbaciou, C. 7446
 Barbara, M. 7151
 Barbas III, CF. 972
 Barber, TD. 4607
 Barbera, F. 2139
 Barbieri, CF. 2314
 Barbone, D. 5256
 Barbour, KW. 5390
 Barchetti, A. 925
 Bardelli, A. 1127
 Bardou, V-J. 767
 Bar-Eli, M. 692, 10524, 11185
 Bargou, R. 4078
 Baril, P. 10901
 Barker, HF. 2662
 Barker, PA. 4273
 Barkinge, J. 5301
 Barlogie, B. 10041
 Barnes, BJ. 7403
 Barnes, CJ. 10594
 Barnes, DJ. 8912
 Barnett, G. 5428
 Barnett, S. 4389
 Baron, AT. 3059
 Barraclough, R. 3796
 Barret, W. 2330
 Barrett, JC. 2778, 5031, 7751, 7763, 10602
 Barrett, JW. 9982
 Barriarte, A. 8042
 Barrios, R. 2054
 Barry, JB. 6120
 Barry, M. 9789
 Barry, ST. 4389
 Bar-Sinai, A. 7223
 Barsyte-Lovejoy, D. 5607
 Barth, W. 957
 Bartholomeusz, C. 8406
 Barthorpe, S. 7591
 Bartlett, C. 3542
 Bartlett, DL. 9991
 Bartlett, DW. 8984
 Bartucci, M. 11469
 Baruchel, S. 7267
 Basciani, S. 1897
 Bascom, JL. 8617
 Bashu, G. 7926
 Bassa, N. 7223
 Basset, WW. 2130
 Bassi, DE. 4162, 7310
 Bassi, R. 1514
 Bassilian, S. 5512
 Bast Jr., RC. 6701
 Bataille, F. 448
 Batchu, RB. 10041
 Bates, RC. 10938
 Bates, SE. 4852, 5785, 8414
 Bates, S. 7386
 Batinic-Haberle, L. 1401, 3745
 Batra, RK. 5211
 Batra, SK. 7840
 Batteux, F. 948
 Baudalet, C. 7911
 Bauer, C. 2422
 Bauer, TW. 7775
 Baughn, LB. 11345
 Bauman, Z. 1554
 Baumann, M. 5374
 Baumann, P. 10783
 Baumeister, P. 5785
 Bausero, MA. 5238
 Bauskin, AR. 2330
 Bavetsias, V. 11721
 Bavoux, C. 325
 Bay, S. 7880
 Bazett Jones, DP. 10810
 Bea, S. 2199
 Beach, D. 177, 2179
 Beamer, WG. 1259
 Beamish, H. 1670
 Beaudry, C. 8792
 Becerra, C. 8209
 Becerra, SP. 5144
 Bechtel, S. 7733
 Beck Jr., GR. 9236
 Beck, S. 4389
 Becker, CM. 11044
 Becker, C. 7007
 Becker, C. 6418
 Becker, JC. 553
 Becker, JC. 2983
 Becker, PS. 358
 Beckers, A. 2441
 Beckhove, P. 10079
 Becknell, B. 1277
 Bécue, P. 4282
 Bedard, LL. 1265
 Bedford, JS. 1670
 Beems, RB. 3610, 8166
 Beerman, TA. 5344
 Beermann, E. 4005
 Beghein, N. 7911
 Begum, S. 758
 Beheshti, J. 5561
 Behren, A. 11613
 Behringer, RR. 9206, 11297
 Beissert, T. 2537, 6080
 Beitel, LK. 8514
 Bekele, BN. 4716, 7568
 Belch, AR. 850
 Belcheva, A. 3664
 Belfiore, A. 1849
 Belharazem, D. 2583
 Belinsky, GS. 2636
 Béliveau, R. 8359
 Belkhi, A. 6583
 Bell, A. 3117
 Bell, DA. 99
 Bell, J. 9982
 Bell, RH. 6011
 Bellard, E. 11639
 Beldegrun, A. 5628
 Belli, F. 2321
 Bellis, SL. 4645
 Bellone, S. 4334
 Belloni, D. 7502
 Belliovin, DI. 10938
 Belluco, S. 6388
 Belmaaza, A. 4117, 11384
 Belouche-Babari, M. 3356
 Belting, M. 11109
 Beltinger, C. 7888
 Bemis, DI. 5263
 Benchimol, S. 6685
 Bendahl, P-O. 8009
 Bendall, LJ. 3290
 Ben-David, Y. 7045
 Bender, A. 3937
 Bendre, MS. 11001
 Benedetti, A. 11437
 Benedetti, F. 2662
 Benelli, R. 10637
 Benet, M. 3249
 Benezra, R. 8878
 Benini, S. 3868
 Benito, A. 8151
 Benito, M. 3811
 Benner, A. 6418, 8072
 Bennett, F. 6282
 Bennett, G. 10041
 Bennett, M. 4408
 Bensimon, A. 1174
 Benson III, AR. 805
 Benson, MC. 5263
 Bentel, JM. 8487
 Bentley, RC. 4490
 Bentz, M. 439
 Benveniste, EN. 5554
 Benvenuti, S. 11227
 Ben-Ze'ev, A. 11605
 Beppu, K. 4775
 Beraldi, F. 11083
 Berardi, MJ. 6891
 Berchet, A. 6521
 Berchtold, CM. 8558
 Berchuck, A. 5031
 Berciano, MT. 8151
 Berdel, WE. 1778, 9643
 Berean, K. 8017
 Berezky, B. 7186
 Berens, ME. 1748
 Berens, M. 8792
 Berezovskaya, O. 2378
 Berg, CH. 3772
 Bergan, RC. 3470
 Berger, AJ. 11185
 Berger, A. 1141
 Berger, FG. 5390
 Berger, MS. 4861
 Berger, U. 2662
 Bergers, M. 8801
 Berglund, G. 8042
 Berglund, P. 9727
 Bergman, AM. 9510, 10208
 Bergmann, S. 4078
 Bergoglio, V. 325
 Berkhout, B. 3347
 Berman, HK. 1792
 Bernacki, R. 9829
 Bernad, A. 3035
 Bernard, D. 2179
 Bernardo, MM. 3523
 Bernard-Pierrot, I. 1376
 Bernards, R. 4059
 Berney, D. 9137
 Bernhardt, EJ. 7902, 8433
 Bernheim, A. 6409
 Berns, A. 5730
 Bernt, KM. 4343
 Beroukheim, R. 5561
 Berquin, IM. 4442
 Berry, PA. 10946
 Bersani, I. 3428, 632
 Berta, P. 2193
 Bertagna, X. 7622
 Bertagnolli, MM. 1097
 Bentario, L. 11227
 Berthebaud, M. 2676
 Bertherat, J. 7622
 Bertotti, A. 10674
 Bertrand, C. 2770
 Bertucci, F. 2170, 767
 Berx, G. 6237
 Betta, PG. 3049
 Betten, MW. 5628
 Betz, BL. 10192
 Beverly, LJ. 7159
 Bevins, RL. 6957
 Beyer, M. 5516
 Bhalla, KN. 613
 Bhalla, K. 10536
 Bharara, S. 5535
 Bhattacharjee, G. 11109
 Bhattacharjee, M. 76
 Bhattacharjee, RN. 10977
 Bhattacharaya, S. 11001
 Bhuiyan, M. 9064
 Bhujwala, ZM. 1425, 11034
 Bhujwala, Z. 10801
 Bi, X. 4955
 Biaglow, JE. 3837
 Bianchi, G. 2964
 Bianco-Miotto, T. 8487
 Blankin, AV. 1619, 4031
 Bickau, E. 3815
 Bidart, J-M. 4353
 Bieler, CA. 2644
 Bierbaum, BE. 6130
 Bieri, B. 2296
 Biemann, C. 9643
 Bieth, A. 325

- Bigley, AL, 4389
Bignell, G, 7591
Bigner, DD, 919, 4051, 11276
Bilancio, A, 10585
Billadeau, DD, 2076
Billai, B, 9588
Billheimer, D, 2314
Bilsland, A, 8079, 8080
Binart, N, 8497
Binderup, L, 4762
Bindra, RS, 10734, 11597
Bingman, WE, 7959
Binhazim, A, 499
Binns, D, 9633
Biolatti, B, 907
Biota, C, 2
Bird, DK, 8766
Birembaut, P, 7691
Birger, Y, 6711
Birle, DC, 2825
Birnbaum, D, 767, 2170, 7231
Birnbaum, MJ, 7902
Birot, SL, 2846
Birot, S, 8397
Birrell, SN, 8487
Birrer, MJ, 3117, 10602
Birsner, AE, 3656
Bischof, M, 3643
Bishop, DK, 11704
Bissada, NK, 11581
Bissell, MJ, 8617
Bissonnette, R, 3462
Biswas, K, 5428
Biswas, S, 2815
Bitzer, M, 6321
Bizik, J, 9914
Björndahl Jr, MA, 9261
Blache, P, 2193
Blackband, SJ, 10149
Blackwell, K, 18
Blagosklonny, MV, 4401, 7386
Blair, A, 9588
Blair, JM, 1710
Blais, V, 2526
Blaney, SM, 76
Blankenstein, T, 2560
Blasco, MA, 10223
Blask, DE, 11174
Blau, I, 2662
Blaux, MD, 698
Blavier, L, 3200
Blay, JY, 2
Blaydon, D, 8597
Blazevic, V, 8101
Blencke, S, 379, 6919
Blick, T, 6139
Blickstein, D, 1984
Globel, CP, 9312
Bloodworth, L, 3053
Bloom, G, 1814
Bloom, G, 7169
Bloustain-Qimron, N, 9659, 11328
Blum, R, 999
Blumenthal, RD, 8809
Boardman, L, 383
Boccaccio, C, 8579
Bocchetta, M, 10120, 10273
Bockamp, EO, 840
Boczkowski, D, 11156
Boddy, SC, 7707
Bode, AM, 3596, 5818
Bodner, B, 6282
Boehrer, S, 2537, 6080
Boeing, H, 8042
Boerboom, D, 9206
Boerma, M, 3100
Boffetta, P, 5076
Boffey, SJ, 4389
Bogdanov Jr, AA, 9253
Bogenberger, J, 9294
Boghaert, E, 5358
Bohlen, H, 5516
Bohlen, P, 1294, 3185
Boiocchi, M, 587
Boise, LH, 11510
Boissy, P, 9943
Boivin, GP, 8655
Bol, DK, 572, 3781
Boland, CR, 3993
Bolesta, E, 3410
Bollen, AW, 3617, 5070
Bolt-de Vries, J, 4101
Bonafé, N, 3762
Bonardi, C, 2964
Bonavida, B, 264
Bond, GL, 5481
Bonham, L, 9415
Bonhoure, E, 11667
Bonish, BK, 6282
Bono, P, 2157
Bonome, T, 10602
Bononi, A, 587
Bonventre, JV, 2636
Bonyhadi, M, 2026
Boo, LM, 6622
Boon, K, 703
Boor, P, 6022
Borg, A, 2554, 7612
Borg, C, 6409
Borgen, E, 11051
Borgquist, S, 9727
Borgstrom, P, 11109
Borkan, SC, 2251
Bornstein, P, 8878, 9338
Bornstein, S, 9695
Boros, LG, 5512, 982
Borrello, I, 2026
Borst, P, 4425
Bos, R, 6443
Bosch, FX, 6543
Bosch, F, 2199
Boschelli, DH, 5358
Boschelli, F, 5358
Bosco, EE, 4568
Bose, M, 10623
Bosia, A, 516
Bosselhoff, A-K, 448
Bothos, J, 6568
Botnen, IV, 5105
Bouche, G, 11639
Boucher, Y, 5674
Boudreau, NJ, 7177
Bouffet, E, 5607
Bougeard, G, 4126
Boukerche, H, 10901
Bouraud, N, 3003
Bourdeau, A, 10088
Bourhis, J-H, 2914
Bousioutas, A, 4031
Boustany, L, 9426
Bouvet, M, 4246, 5352, 9829
Bouvier, R, 300
Bouzin, C, 7911
Bovey, R, 4261
Bowen, TJ, 8736
Bower, K, 2722
Bown, NP, 3053
Bowtell, DDL, 4031
Boxer, LM, 291
Boyapalle, S, 10536
Boyd, AW, 6745
Boyd, DAK, 309
Boyd, DD, 7775
Boyd, MT, 6498
Boylan, AM, 6228
Boylan, M, 4211
Boyle, JO, 664
Bozinov, D, 887
Brachmann, SM, 10992
Bracke, M, 8774
Brackenbury, L, 7591
Bradley, C, 3454
Bradley, SV, 4126
Bradshaw, TD, 3911
Bradsher, J, 2526
Bradstock, KF, 3290
Brady, HJM, 9245
Brady, J, 10602
Brady, M, 6498
Braem, CV, 4544
Braguer, D, 2433
Brahim, W, 6521
Brainard, GC, 11174
Brakenhielm, E, 9261
Brakenhoff, RH, 1271
Bram, E, 8414
Brama, M, 1897
Brambilla, D, 6080
Brand, R, 11193
Brandts, CH, 1778, 9643
Bräs, A, 7037
Brasseur, F, 7591
Brat, DJ, 1406
Brattain, MG, 5848
Braun, A, 1554
Brave, SR, 4389
Bravo, AI, 5123
Brayton, C, 2054
Breault, JE, 2130
Brechtel, M, 6745
Brecher, M, 3410
Bredel, C, 4088, 8679
Bredel, M, 4088, 8679
Breedveld, P, 2577
Breen, M, 5654
Breen, M, 6692
Brehmer, D, 379, 6919
Breit, SN, 2330
Breitkreutz, I, 11712
Bremer, E, 3380
Brennan, ML, 9670
Brennan, P, 5076
Brentani, H, 7127
Brentjens, R, 9080
Bresalier, RS, 10767
Bressan, P, 2572
Breyer, RM, 4496
Briand, C, 2433
Brickey, WJ, 3374
Briggs, K, 11501
Bright, RK, 2938
Brilliant, KE, 11010
Brinckerhoff, CE, 11101
Bringmann, P, 8397
Brinkmann, V, 7478
Brischwein, K, 2882
Bristow, RG, 10810, 11597
Bristow, R, 1994
Britigan, BE, 6346
Britton, JA, 1606
Brixel, LR, 840
Broadus, R, 11486
Brock, HW, 11367
Brodebeck, S, 11613
Broderick, DK, 919
Brodeur, GM, 9868
Brodie, AMH, 5380, 5439
Brodie, A, 3903
Brodie, C, 7301
Brodin, B, 2207
Broek, D, 4623
Broggini, M, 8339
Bronger, H, 11419
Bronson, RT, 6551, 9789, 10324
Bronson, R, 10280
Bronte, V, 3920
Brookes, AJ, 6459
Brooks, JD, 8118
Brooks, MN, 6159
Brooks, SC, 8747
Broomfield, S, 7580
Brosch, G, 2260
Brosh Jr, RM, 1223
Brouwer, E, 11335
Brown, AMC, 10113
Brown, DA, 2330
Brown, E, 9455
Brown, G, 10524
Brown, JM, 6151
Brown, JF, 11010
Brown, JC, 8233
Brown, KM, 1748, 10164
Brown, L, 6685
Brown, LG, 1710
Brown, M, 7580
Brown, M, 10280
Brown, PH, 3462
Brown, P, 3493
Brown, R, 8961
Brown, TJ, 7462
Brown, TJ, 6139
Brownlee, GR, 6139
Brubaker, LM, 8218
Brueck, J, 7007
Brueckner, B, 6305
Brugge, JS, 10992, 11572
Bruins, W, 3610
Brunborg, G, 5588
Brünker, P, 7934
Brunner, TB, 8433
Brunson, BA, 4645
Brunstein, F, 4300
Brunton, VG, 1335
Brusselmans, K, 2441, 6719
Bruyneel, E, 6237
Bucana, CD, 4716, 7775, 10371
Bucana, C, 6910
Buchanan, FG, 1822
Buchanan, G, 8487
Buchanan, IM, 9080
Büchler, MW, 10079
Buchler, MW, 6011
Buck, E, 9455
Buck, G, 7591
Buckanovich, RJ, 925
Buckley, PG, 2653
Bucur, M, 10079
Buday, L, 1770
Budhram-Mahadeo, VS, 3072
Budyanto, A, 6006
Bueno-De-Mesquita, HB, 8042
Buerger, H, 9643
Buerstedde, J-M, 11704
Buet, D, 2676
Buetow, KH, 2542
Buettnier, R, 9185
Bug, G, 2537
Buganim, Y, 4530
Bugelski, P, 3193
Buijs, JT, 7682
Bulk, E, 1778
Bullitt, E, 8218
Bullo, A, 3751
Burdette, JE, 7968
Burdick, MD, 11752
Burdick, M, 2738
Burdick, MJ, 2353
Burdick, MM, 5812
Burg, D, 4698
Burgan, WE, 6967
Burger, AM, 10401, 1489
Burger, H, 10801
Burger, RA, 3243
Burkhardt, A, 7533
Burnett, A, 4334
Burnett, RC, 5654
Burns, CP, 6346
Burns, JS, 9601
Burns, JS, 3126
Burns, MA, 3030
Burton, JB, 9261
Burzynski, GM, 1729
Buscarini, M, 4623
Büscher, K, 4172
Buselli, R, 3049
Busson, M, 4282
Bustin, M, 6711
Busuttil, RA, 11271
Butler, A, 7591
Butler, GS, 9377
Butler, LM, 8487
Butman, JA, 10847
Butnor, KJ, 9670
Buttitta, F, 9687
Buttayan, R, 5263
Buys, CHCM, 1729

- Buzard, GS, 8640
 Bygrave, M, 6337
 Byrd, JC, 10767
 Byrd, JC, 1277
 Byrski, T, 835
- Cabassa, C, 4888
 Cabello, G, 4282
 Cabezas-Herrera, J, 2059
 Cabioglu, N, 6493
 Cabon, F, 300
 Cabot, MC, 3861
 Cabrera, C, 11271
 Cacciotti, P, 5256
 Caccuri, AM, 3751
 Cagan, R, 3538
 Cai, B, 7926
 Cai, D, 3171
 Cai, F, 6425
 Cai, Q, 5015
 Cai, S, 3319
 Cai, X, 10912
 Caignard, A, 2914, 6409
 Caillat-Zucman, S, 6409
 Caillou, B, 8497
 Calcagnile, A, 432
 Caldwell, SA, 1045, 4376
 Calhoun, T, 6207
 Califano, JA, 758
 Califano, J, 1664
 Caligaris-Cappio, F, 7502
 Caligiuri, MA, 9099
 Calin, GA, 6576, 7065
 Callahan, J, 7775
 Callaway, ES, 887
 Callen, DF, 11304
 Callery, MP, 2344
 Calvani, M, 9047
 Calvet, C, 11667
 Camacho, C, 1693
 Camacho-Vanegas, O, 5761
 Camalier, CE, 6034
 Camargo, LP, 7127
 Cambus, J-P, 526
 Camenisch, TD, 6755
 Cameselle-Teijeiro, J, 10199
 Cammer, M, 5278
 Camp, ER, 7775
 Camp, RL, 5578
 Campa, MJ, 8853
 Campbell, F, 3218
 Campbell, JIA, 732
 Campbell, MR, 2626
 Campbell, MR, 99
 Campbell, RM, 7462
 Camphausen, K, 6967, 10389
 Campiani, G, 2397
 Campiglio, M, 7065
 Campo, E, 2199
 Campos, I, 11279
 Camuso, AE, 3781
 Canaff, L, 493
 Candido, KA, 5317
 Candolfi, M, 7194
 Cané, S, 4334
 Canevari, S, 9369
 Cannavo, E, 10759
 Cannon, MJ, 4334
 Canter, JA, 8028
 Cantley, LC, 10992
 Cantor, AB, 7169
 Cao, H, 6151
 Cao, H, 7283
 Cao, R, 9261
 Cao, X, 4947
 Cao, Y, 9261
 Cao, Y, 1124
 Cao, Y, 5498, 9126
 Cao, Z-H, 1909
 Cao, Z, 5317
 Capecci, MR, 7530
 Capella, G, 5512
 Capen, A, 7462
 Capen, D, 5740
- Capobianco, AJ, 7159
 Caprioli, RM, 7674, 10642
 Capurro, MI, 6245
 Capurro, M, 372
 Caput, D, 2787
 Carazo, A, 4282
 Carbley, R, 2026
 Carbone, A, 587
 Carbone, C, 5123
 Carbone, DP, 226, 3555
 Carbone, M, 10120, 10273
 Carboni, JM, 572, 3781
 Card, JW, 4707
 Cardellina, JH, 9047
 Cardiff, RD, 5792, 10113, 10243
 Cardoso, AA, 10050
 Carrette, JE, 9398
 Carew, JS, 613, 11510, 11658
 Carew, JF, 664
 Carey, LA, 9155
 Cariati, R, 587
 Carlson, D, 3063
 Carlson, GW, 1909
 Carlson, J, 2770, 10912
 Carlsson, H, 11326
 Carmeliet, P, 465
 Carnero, A, 177, 2179, 3846
 Carnevali, I, 2321
 Carney, JA, 4506
 Carosella, ED, 1755, 10139
 Carothers, AM, 1097, 10623
 Carr, AL, 1063
 Carrasco, D, 8324
 Carraway, KL, 473
 Carreira, S, 2280
 Carreiro, MP, 11010
 Carrie, D, 4211
 Carrière, V, 11639
 Carrio, M, 7177
 Carroll, PR, 2130
 Carroll, V, 4918
 Carson, DJ, 166
 Carson, WE III, 9099
 Carstensen, EV, 7470
 Carter, D, 2930
 Carter, KJ, 499
 Carter, NH, 622
 Carvajal, D, 1918
 Carvalho, AF, 7127
 Carvalho, AL, 4963
 Carvalho, AL, 1693
 Carver, B, 8350
 Casas, F, 4282
 Cascante, M, 5512
 Cascon, A, 9651
 Case, MC, 3053
 Casey, G, 3586
 Cason, J, 1112
 Cassidy, A, 1376
 Castanys, S, 4852
 Castelli, C, 2321, 3942
 Castellino, RC, 5683
 Castermans, K, 11520
 Castillero-Trejo, Y, 8698
 Castoria, G, 10585
 Castro, JG, 9601
 Castro, MG, 7194
 Catez, F, 6711
 Catley, L, 5898, 7478, 11712
 Catovsky, D, 4554
 Cattaneo, A, 2906
 Caux, C, 8479
 Cavalli, LR, 1164
 Cavallo, F, 1071
 Cavard, C, 7622
 Cavazos, D, 2730
 Cawley, JC, 7328
 Cazaux, C, 325
 Cebo, C, 2914
 Cecchini, MG, 7682
 Cecic, I, 1018
 Cejas, PJ, 10578
 Cejka, P, 10759
 Celik, I, 11044
- Cengel, KA, 8433
 Cenna, J, 7310
 Centeno, JA, 10854
 Cerella, C, 3751
 Cerhan, JR, 11214
 Cerignoli, F, 8308
 Cerna, D, 6967
 Cerniglia, GJ, 8256
 Cerutti, JM, 1693
 Cerveny, CG, 8331
 Cervera, N, 2170
 Cerwinka, WH, 2243, 7782
 Cha, T-L, 2287
 Chada, S, 3017
 Chagraoui, H, 3281
 Chahinian, P, 2602
 Chahilavi, A, 5428
 Chai, J, 10192
 Chaiswing, L, 1401, 3745
 Chakraborty, S, 493
 Chaloin, O, 9536
 Chambers, AF, 3396, 5231
 Chambers, SK, 3762
 Chambers, W, 11361
 Chan, AM, 5761
 Chan, DW, 1114
 Chan, EW, 9294
 Chan, FL, 5153
 Chan, JA, 6029
 Chan, JK, 3243
 Chan, KS, 5720
 Chan, K, 5272
 Chan, KW, 5153
 Chan, Q, 3040
 Chan, TK, 8646
 Chan, V, 8646
 Chan, W, 1606
 Chandramouli, GVR, 5031
 Chang, AE, 1063
 Chang, B-L, 1213
 Chang, C-C, 9771
 Chang, C-C, 4827
 Chang, HJ, 3162
 Chang, H-C, 9807
 Chang, I, 6111
 Chang, I-Y, 6811
 Chang, J, 5063
 Chang, K-S, 1277
 Chang, L, 8530
 Chang, M, 3523
 Chang, M-C, 9089
 Chang, P, 9807
 Chang, S-H, 2157, 4496, 10113
 Chang, Y, 8350
 Chang, Y-M, 76
 Chang, Z-J, 10838
 Chanock, S, 9574
 Chantrain, CF, 3200
 Chapkin, RS, 887
 Chaplin, T, 375, 8597, 9137
 Charafe-Jauffret, E, 767, 2170
 Charalambous, C, 10347
 Charalambous, C, 8826
 Charboneau, AL, 10192
 Charo, J, 2001
 Charron, MJ, 698
 Chase, A, 2662
 Chatterjee, D, 7790
 Chatterjee-Kishore, M, 939
 Chattopadhyay, C, 11501
 Chaturvedi, V, 6282
 Chatzioannou, AF, 622
 Chatzistamou, I, 1627
 Chau, N-M, 4918
 Chaudhary, I, 5358
 Chauhan, D, 7478, 8350, 11712
 Chauhan, SC, 7840
 Chavez-Reyes, A, 6910
 Chawannakul, D, 3837
 Che, C-M, 11553
 Cheadle, JR, 10179
 Chelbi-Alix, M, 2914
 Cheiouché, Lev, D, 5578
 Chemin, K, 8479
- Chen, AY, 9194
 Chen, BPC, 10810
 Chen, C-R, 6017
 Chen, C-S, 1561
 Chen, C-A, 4827, 9089
 Chen, C-H, 8455
 Chen, C-S, 1561
 Chen, C-L, 4707
 Chen, C-T, 2287
 Chen, D, 692
 Chen, DJ, 10810
 Chen, DY, 2755
 Chen, D, 11486
 Chen, D, 10413
 Chen, F, 9485
 Chen, F, 5561
 Chen, GA, 7763
 Chen, G, 4947
 Chen, H, 4987
 Chen, H, 6089
 Chen, J, 1606
 Chen, J, 4614
 Chen, J-X, 4707
 Chen, J, 3307
 Chen, K-S, 8558
 Chen, KG, 9388
 Chen, K-F, 1561
 Chen, L, 5599
 Chen, L, 1089
 Chen, L, 7045
 Chen, L, 1433
 Chen, L, 1547
 Chen, LL, 1115
 Chen, M, 6512
 Chen, M, 9807
 Chen, M, 1678
 Chen, M-W, 5263
 Chen, P-S, 4827
 Chen, P-C, 8662
 Chen, P-L, 1158
 Chen, Q, 2730
 Chen, S, 3470
 Chen, S, 6660
 Chen, S, 3179
 Chen, SS, 7485, 7926
 Chen, S, 18
 Chen, S-YJ, 2795
 Chen, TC, 10347
 Chen, T, 10381
 Chen, W, 1748, 8183
 Chen, X, 1647
 Chen, X, 6701
 Chen, X, 3011
 Chen, X, 9200
 Chen, X, 8200
 Chen, X-P, 10838
 Chen, X, 5835
 Chen, Y-C, 11771
 Chen, Y, 5009
 Chen, Y, 9226
 Chen, Y, 4614
 Chen, Y, 3454
 Chen, Y, 6466
 Chen, Y-C, 331
 Chen, Y, 10838
 Chen, Z, 4663
 Chen, Z, 9004
 Chen, ZY, 10394
 Chen, Z, 130
 Chen, Z, 7071
 Chen, Z, 1117
 Chenard, M-P, 10862
 Cheng, A, 10088
 Cheng, A-L, 6943
 Cheng, CK, 8646
 Cheng, C, 562
 Cheng, D, 8504
 Cheng, G, 264
 Cheng, JJ, 3155
 Cheng, JQ, 9185
 Cheng, K-h, 1664
 Cheng, KW, 2516
 Cheng, LL, 3030
 Cheng, LS-C, 805

- Cheng, P, 465, 5020
 Cheng, Q, 7194
 Cheng, W-F, 9089
 Cheng, X, 457
 Cheng, X, 8671
 Cheng, Y-C, 3894
 Cheng, Z, 4979
 Cheng, Z, 8233
 Chen-Kiang, S, 11345
 Chéreau, C, 948
 Chernukhin, I, 5112
 Cherry, JC, 4673, 6255
 Chester, R, 4389
 Cheung, HW, 1450
 Cheung, L, 11752
 Cheung, N-KV, 2565, 10562
 Cheung, VG, 7666
 Cheung, WC, 1306
 Chevrier, V, 7231
 Chew, E-H, 3911
 Chew, KL, 1792
 Chi, H, 1035
 Chiang, S, 349
 Chiao, PJ, 5045, 9064, 11510
 Chiba, S, 6071
 Chicoine, MR, 7121
 Chida, K, 7356
 Chien, J, 7091
 Chieppa, M, 2964
 Chigurupati, S, 8519
 Chin, K-V, 1631, 8049
 Chin, L, 10164, 8324
 Chin, WW, 6593
 Ching, J, 2147
 Ching, K, 7320
 Ching, L-M, 11752
 Ching, Y-P, 8861
 Chinnaiyan, AM, 1213, 3328, 4126, 11259
 Chinnaiyan, P, 3328
 Chinnappan, D, 9934
 Chintagumpala, M, 76, 8142
 Chiocci, EA, 2832, 6850, 9398, 11255
 Chiodoni, C, 3920, 553
 Chiou, S-H, 2921
 Chiquet-Ehrismann, R, 10783
 Chirgwin, JM, 11001
 Chirgwin, J, 7320
 Chiriboga, L, 6178
 Chiu, C, 2018
 Chiu, J-F, 11553
 Chmielik, E, 1587
 Cho, CH, 5272
 Cho, ES, 8993
 Cho, HJ, 11345
 Cho, H-J, 6811
 Cho, J-Y, 4728
 Cho, KR, 6543
 Cho, Y-Y, 3596, 5818
 Chodosh, LA, 681
 Choe, J, 1738
 Choi, BY, 3596, 5818
 Choi, CYH, 6151
 Choi, EW, 3823
 Choi, HS, 3596, 5818
 Choi, HH, 1952
 Choi, I, 4485
 Choi, J, 5554
 Choi, KB, 7926
 Choi, K-H, 6111
 Choi, K, 5554, 749
 Choi, S, 2035
 Cholujova, D, 9914
 Chong, H, 2009
 Chopin, DK, 5263
 Chopin, M, 10450
 Chou, C-H, 4827
 Chou, PM, 10183
 Chou, T-C, 9445
 Chouaib, S, 2914
 Choudary, A, 2861
 Choudhary, C, 9643
 Chow, K-C, 5917
 Chow, LWC, 8646
 Chow, S-N, 2921
 Christensen, C, 6167
 Christensen, JG, 1479
 Christensen, L-L, 34
 Christian, G, 195
 Christiani, D, 5561
 Christine, R, 195
 Christmann, M, 8920
 Chrysis, D, 9999
 Chu, B, 7717
 Chu, F, 10183, 5301
 Chu, F, 10478
 Chu, I, 18
 Chu, NR, 2018
 Chu, Y, 10569
 Chu, Y-C, 6943
 Chu, Z, 5841
 Chua, CW, 5153
 Chuang, EY, 579
 Chuang, EY-Y, 6734
 Chubb, S, 6874
 Chuluyan, HE, 5123
 Chumakov, K, 10273
 Chung, D, 7856
 Chung, F-L, 8538, 8548
 Chung, JJ, 8993
 Chung, J-H, 4108, 8096
 Chung, LWK, 2303, 6354
 Chung, M-H, 6811
 Chung, TD, 4782
 Chung, V, 6622
 Churchill, GA, 1259
 Chu, C-p, 2082
 Chytil, A, 2296
 Ciana, P, 5445
 Ciancia, E, 3049
 Cianfriglia, M, 3751
 Cicchilitti, L, 2397
 Cicek, M, 3586
 Cifola, I, 2321
 Cigudosa, JC, 3035
 Cigudosa, JC, 2179
 Cinar, B, 2547
 Ciociola, A, 10585
 Cipriani, G, 2577
 Ciriolo, MR, 11735
 Ciriolo, MR, 3751
 Cironi, L, 11459
 Clark, DE, 3108
 Clark, GJ, 2690, 3117
 Clark, J, 8085
 Clarke, AR, 10145, 410
 Clarke, L, 7041
 Clason, MK, 11597
 Claude, J-C, 4078
 Clauser, KR, 7533
 Clavel-Chapelon, F, 8042
 Clayman, GL, 11501
 Claypool, K, 6207
 Clayton, A, 7000
 Clement, V, 2990
 Clements, J, 7591
 Clements, VK, 11743
 Cleton-Jansen, A-M, 11304
 Cleutjens, KB, 5730
 Cleveland, JL, 1146
 Clézardin, P, 300, 4971
 Cliby, WA, 7091
 Cloven, NG, 3243
 Clyne, CD, 11762, 657
 Cnaan, A, 9868
 Coackley, C, 10810
 Coates, PJ, 5668
 Cobb, RR, 8397
 Cocco, P, 9588
 Cochran, BH, 6516
 Cochran, DM, 5711
 Cody, DD, 3226, 11478
 Coetzee, GA, 8003
 Coffey, P, 8151
 Coffey, R, 11712
 Cohen, BD, 957
 Cohen, EG, 664
 Cohen, GM, 11265
 Cohen, JG, 7071
 Cohen, M, 10316
 Cohen, SJ, 4993
 Cohen, Y, 4530
 Coignet, LJ, 4554
 Colburn, NH, 3745, 6034
 Colcher, D, 622, 7840
 Cole, DJ, 6228
 Cole, J, 7591
 Coleman, S, 7000
 Coles, B, 1105
 Coletta, RD, 2668
 Colin, C, 9651
 Colisson, R, 11411
 Colley, J, 10179
 Collier, J, 8331
 Collier, LS, 9607
 Collins, AT, 10946
 Collins, I, 4918
 Collins, MH, 1285
 Colman, H, 1678
 Cologne, JB, 5462
 Colombel, M, 300
 Colombo, C, 632
 Colombo, MP, 2321, 3437, 3920, 7942, 9113
 Colombo, T, 11411
 Colomer, D, 2199
 Colpaert, C, 2224
 Colt, JS, 11214
 Comajova, M, 9914
 Combs, KA, 5520
 Comegys, MM, 11010
 Comes, A, 1071
 Comoglio, PM, 8579, 10674
 Comoglio, P, 6167
 Comstock, ML, 6631
 Comuzzi, B, 5965
 Conacci-Sorrell, M, 11605
 Conaway, CC, 8538, 8548
 Conaway, M, 7320
 Condeelis, JS, 5278
 Condorelli, G, 6668
 Connelly, MC, 4993
 Conney, AH, 3577
 Connolly, M, 10324
 Connolly, PJ, 9038
 Conroy, J, 3548
 Conti, C, 1174
 Contractor, R, 2890, 9962
 Conus, N, 9633
 Cooch, NS, 3011
 Cook Jr., EH, 46
 Cooks, T, 7292
 Cookson, J, 3911
 Coomber, BL, 8134
 Coombes, RC, 10104
 Cooper, B, 957
 Cooper, CS, 7591
 Cooper, C, 8085
 Cooper, L, 4389
 Cooper, MS, 2373
 Cooper, RJ, 3319
 Cooper, WN, 3497
 Coopman, PJ, 10872
 Coppa, J, 3942
 Coppari, R, 4728
 Coppes, RP, 6509
 Coppes, RP, 3568
 Cops, EJ, 8487
 Coqueret, O, 8927
 Cora, EM, 3059
 Coradini, D, 2139, 5506
 Cordon-Cardo, C, 2186
 Corey, E, 1710
 Cornelisse, CJ, 822, 11304
 Cornelissen, IMHA, 8801
 Cornelius, J, 4292
 Cornillet-Lefebvre, P, 6521
 Coronel, J, 11071
 Corradetti, MN, 4126
 Corral, L, 868
 Corti, A, 2906
 Cosentino, F, 3049
 Costa, AM, 10199
 Costa, A, 5506
 Costa, F, 5785
 Costa, JL, 10208
 Costamagna, C, 516
 Costello, E, 3218
 Costello, JF, 3617, 5070
 Cotten, M, 379, 6919
 Couch, FJ, 383, 417
 Coukos, G, 925
 Counter, CM, 4490, 9824
 Courreges, MC, 925
 Courtin, A, 300
 Cousineau, I, 4117, 11384
 Coussens, LM, 3200
 Couturier, J, 1174, 1376
 Covelto, KL, 2277
 Cowan, CW, 5683
 Cowan, KH, 3986
 Cowan, K, 9004
 Cowan-Jacob, SW, 4500
 Cox, AD, 9883
 Cox, D, 5278
 Coxon, A, 7137
 Cozen, W, 11214
 Crabb, JW, 10891
 Crabbe, T, 9377
 Cramer, DW, 5974
 Cranston, DW, 8690
 Crawford, HC, 1783
 Crawford, J, 11304
 Cremers, N, 10783
 Creswell, K, 4614
 Crinò, Lucio, 11469
 Cristaudo, A, 3049
 Cristo, EB, 7127
 Crnogorac-Jurcevic, T, 3218
 Croce, CM, 1207, 4515, 6576, 6764, 7065, 7790, 11282
 Croci, S, 3868
 Crockart, N, 7911
 Cron, GO, 7911
 Cronwright, G, 2207
 Crooks, GM, 3200
 Cross, AJ, 8034, 11779
 Cross, NCP, 2662
 Crow, DM, 622
 Crow, D, 5907
 Crowley, D, 9789, 10280, 10324
 Croxton, R, 4799
 Crum, CP, 2162
 Crutchley, JM, 562
 Cryns, VL, 4799
 Crystal, RG, 254
 Csiszar, K, 11429
 Cuddihy, A, 10810
 Cuevas, IC, 5070
 Cuevas, J, 8151
 Cui, G, 2770
 Cui, R, 457
 Cui, X-S, 10646
 Cui, Y, 5015
 Cui, Y, 6864
 Cukierman, E, 7310
 Culig, Z, 5965
 Cullinane, C, 9633
 Cully, M, 10363
 Cumashi, A, 8339
 Cummins, JM, 919, 9485
 Cuneo, A, 587
 Cunha, GR, 10423
 Curcio, C, 5953
 Curiel, TJ, 465
 Curiel, T, 5020
 Curnis, F, 2906
 Curran, T, 4975
 Currie, A, 7580
 Curtin, JF, 7194
 Curtis, L, 5696
 Curto, J, 8961
 Curwen, JO, 4389
 Custer, M, 7751, 7763
 Cutrone, R, 10273
 Cutter, GC, 5654

- Cuvillier, O. 11667
 Cybulski, C. 835
 Cytron, S. 6435
 Czarniecka, A. 1587
- D'Amato, RJ. 5690
 D'Amore, PA. 5881
 D'Arcy, V. 5112
 D'Arrigo, C. 3072
 D'Ascenzo, S. 9369
 D'Atri, M. 9588
 D'Errico, M. 432
 D'Incalci, M. 2964, 11411
 D'Soutza, T. 7378
 da Rocha Dias, S. 10686
 Da Rocha, S. 2914
 da Silva, A. 2882
 da Silva, AM. 1693
 Dackor, J. 11478
 Dadachova, E. 698
 Dadfarmay, S. 743
 Dafni, H. 10316
 Dagher, M-C. 6054
 Dahia, PLM. 9651
 Dahiya, R. 2130
 Dai, D. 9517
 Dai, F. 1489
 Dai, H. 4059
 Dai, JL. 10289
 Dai, J. 7554, 8274, 10921
 Dai, S. 4947
 Dai, Y. 2422
 Dai, Z. 7446
 Daido, S. 4368
 Daidone, MG. 5506
 Daigo, Y. 5638, 7102, 9176, 11314
 Daikoku, T. 3735
 Dal Col, J. 587
 Dalerba, P. 2321
 Daley, GQ. 11572
 Dalianis, T. 5953
 Dallis, PB. 9236
 Dallol, A. 7653
 Dalrymple, S. 9269
 Daluski, A. 1748
 Dalvie, D. 957
 Dalwadi, H. 6275
 Daly, MB. 805
 Daly, RJ. 3273
 Dammann, R. 92
 Danaee, H. 7081
 Dandekar, S. 10700
 Daneshmand, S. 4623
 Dang, CV. 5620
 Dang, DT. 9485
 Dang, LH. 9485
 Dang, NH. 1973, 6950
 Dang, TP. 3555
 Dang, TD. 8887
 Daniel, B. 5020
 Daniel, D. 2018
 Daniels, D. 6858
 Daniels, G. 2009
 Danielsen, M. 54
 Danishefsky, SJ. 9445
 Danjoh, I. 2115
 Danks, MK. 6850
 Dannenberg, AJ. 664, 3462, 5982, 10113
 Dantzig, AH. 6593
 Darcy, P. 2207
 Darga, TE. 3146, 9479
 DaRocha Dias, S. 11493
 Darzynkiewicz, Z. 4401
 Das, B. 7267
 Das, I. 6692
 Das, S. 10692
 Dasgupta, B. 236, 2755, 9843
 Datta, J. 10891
 Daub, H. 379, 6919
 Dauchy, RT. 11174
 Daud, AI. 3815
 Dauser, R. 76
 Davalos, V. 10170
 Davalos, V. 2565
- Davey, S. 1265
 David, MD. 7485
 Davidson, B. 331
 Davidson, DJ. 4663
 Davidson, LA. 887
 Davidson, LK. 11174
 Davidson, MM. 3236
 Davies, H. 7591
 Davies, S. 9517
 Daviet, L. 7231
 Davino, N. 8142
 Davis, C. 5390
 Davis, DW. 11185
 Davis, DA. 3299
 Davis, DP. 9751
 Davis, E. 4554
 Davis, JN. 3624, 3633
 Davis, JJ. 6380
 Davis, ME. 8984
 Davis, S. 11214
 Davis, S. 9226
 Davis, SL. 2125
 Davison, A. 4979
 Davis-Searles, PR. 4448
 Davrinche, C. 2787
 Davydova, JG. 10154
 Dawson, MI. 4909
 Day, ML. 3624, 3633
 Day, NE. 8042
 de Andrade, M. 383
 De Benedetti, A. 2547
 de Boeck, G. 4300
 de Braud, F. 2964
 de Bruijn, EA. 4300
 de Craene, B. 6237
 de Crombrughe, B. 1124
 de Falco, A. 10585
 De Felice, L. 1505
 De Franco, R. 4728
 de Graaf, EJ. 10188
 de Groot, JF. 1934
 de Gruilj, FR. 10298
 De Guise, S. 2636
 de Haas, M. 4425
 de Herreros, AG. 11649
 de Juan, A. 8151
 de Juan, C. 3811
 de Krijger, R. 5730
 de la Fuente, R. 3035
 de Leij, LFMH. 3380
 de Leval, L. 9463
 De Lorenzo, MS. 664
 de los Ríos, Laura. 26
 De Luca, G. 1897
 De Luca, N. 432
 De Marco, MA. 10120
 De Maria, F. 3751
 De Maria, R. 907
 De Maria, R. 11649
 De Marzo, AM. 9269
 De Morrow, S. 11437
 de Noronha, RG. 605
 de Pillis, LG. 7950
 De Rienzo, A. 8090
 De Roos, AJ. 11214
 de Rycke, Y. 1376
 de Sauvage, FJ. 9751
 De Schrijver, E. 2441, 6719
 De Silva, I. 9245
 De Simone, M. 8754
 de Stanchina, E. 11411
 de Thé, H. 8754
 De Toni, EN. 6780
 de Vere White, RW. 54
 De Vivo, I. 5974
 de Vries, A. 3610, 8166
 de Waal, RMW. 8317
 Dean, NM. 4870
 DeAngelo, D. 7338
 Deavers, MT. 6910
 Deb, DK. 3470
 Deb, S. 1839
 Deb, SP. 1839
 Debatin, K-M. 7888, 10502
- Debernardi, S. 375, 9152
 Debes, JD. 708, 5965
 Debilli, N. 3281
 Debniski, W. 6459
 Debniski, B. 835
 Deboel, L. 2441
 Debus, J. 3643
 DeClerck, YA. 1129, 3200
 Declercq, J. 4544
 Decollogne, S. 11729
 Dedhar, S. 11649
 Deen, DF. 10389
 Deffenbaugh, AM. 417, 10096
 Degan, P. 177
 Degen, H. 6919
 Degeorges, A. 300
 Degli Esposti, M. 8286
 Degos, L. 1117
 DeGraff, W. 579
 Deguchi, A. 8442
 Deguchi, M. 2130
 Dehm, SM. 5965
 Deininger, MWN. 4500, 9436
 Dejmek, A. 9142
 Dejmek, J. 9142
 dela Cerda, J. 1808
 Delabesse, E. 6521
 Delabie, J. 2199
 Delaissé, J-M. 9943
 Delaney, AB. 7436
 Delattre, O. 1376, 11520
 Delaval, B. 7231
 DeLeo, A. 11146
 Dellaire, G. 10810
 Delpapa, E. 358
 DeLuca, NA. 5310
 Demarco, R. 9991
 Dembinski, J. 3307
 Demers, M. 5205
 Demicco, EG. 11375
 Demidenko, ZN. 4401, 7386
 Demirjian, A. 2344
 Demou, ZN. 5674
 Demple, B. 6097
 den Boer, AT. 6984
 den Boer, ML. 10050
 DeNardo, D. 3462
 Deng, C-X. 8747
 Deng, H. 8671
 Deng, JM. 11297
 Deng, J. 3257
 Deng, Q. 8298
 Deng, XW. 5835
 Demicourt, C. 10646
 Denko, NC. 3171
 Denner, J. 4172
 Dennis, JH. 3072
 Dennis, N. 8085
 Dennis, PA. 2070, 7137, 8423
 Dent, P. 2422, 6022
 Deppert, W. 1187
 Dercamp, C. 8479
 Derdak, S. 9436
 Derua, R. 2441
 Deryugina, EI. 10959
 Desai, AA. 46
 Desai, SA. 4309
 Descheny, L. 5750
 Desiderio, DM. 10214
 Désille, Y. 1376
 Desmond, JC. 2488
 Desmots, F. 11447
 Dessain, S. 6130
 Dettin, LE. 3950
 Detwiller, KY. 5881
 Deuel, B. 11061
 Deutsch, P. 4059
 Deutschmann, N. 394
 Devarajan, E. 10289
 Devarajan, K. 8090
 Deveney, R. 7151
 Devilee, P. 822
 DeVito, WJ. 358
 DeWald, DB. 713
- Dewals, B. 9463
 DeWeese, TL. 6773
 Dewhurst, MW. 1369, 5163, 5498
 Dewa, M. 5454
 Dey, SK. 1822, 3735
 Dezube, BJ. 5084
 Dhaliwal, H. 4202
 Dhara, S. 1619
 Dhillon, AS. 1244
 Dhillon, NK. 10700
 Dhir, R. 4097
 Di Carlo, E. 1071
 Di Castro, V. 11649
 Di Cristofano, A. 5172
 Di Domenico, M. 10585
 Di Falco, MR. 8359
 Di Giovine, S. 9415
 Di Giulio, I. 2321
 Di Liberto, M. 11345
 Di Pietro, A. 4852
 Di Renzo, MF. 907
 di Sant'Agnes, A. 9807
 di Tomaso, E. 5740
 Di, C. 919
 Diamond, P. 1700
 Dias, MM. 7059
 Dias-Neto, E. 1693
 Diaz, RM. 2009
 Díaz-López, A. 3811
 Dicks, E. 7591
 Dickson, KM. 4273
 Diebold, J. 4218
 Diederichs, S. 1778
 Diegelman, P. 5390
 Diehl, AJ. 10524
 Diehl, JA. 6476
 Diehl, V. 5516
 Dierssen, JWF. 10188
 Dietel, M. 4078
 Dietrich, N. 4754
 Dietz, C. 11044
 DiFeo, A. 1213, 5761
 Difilippantonio, MJ. 8266
 DiGiovanni, J. 5720
 Dignam, J. 10692
 Dikmen, ZG. 7866
 Dilda, PJ. 11729
 Dillard, A. 9923
 Dillon, R. 10113
 Dimitroff, CJ. 5750
 Ding, F. 9582
 Ding, L. 11259
 Ding, W. 6526
 Ding, W-Q. 3389
 Ding, X-Z. 6011
 Ding, Y. 805
 Dinney, CPN. 4902, 10524
 Dinter, H. 2846, 8397
 Dippold, W. 8072
 Dirven, CMF. 9398
 DiSaia, PJ. 3243
 Disbrow, GL. 6534, 10854
 Discifani, C. 5358
 Disis, ML. 650
 Distel, L. 4881
 Ditlev, JA. 5628
 DiTullio Jr., RA. 7533
 Dixon, DA. 9132
 Dizon, D. 8662
 Djajadibroto, M. 7393
 Dmitrovsky, E. 6476
 Dobra, A. 4051
 Dobrowsky, RT. 2636
 Docherty, AJP. 9377
 Docherty, SE. 4929
 Dockray, GJ. 7363
 Dockquier, F. 5112
 Dodson, A. 3218
 Dogan, P. 7866
 Doglioni, C. 587
 Dogliotti, E. 432
 Dohadwala, M. 6275
 Doherty, KM. 1223
 Dohi, T. 6220

- Doi, S. 1541
Dolan, ME. 46
Dolcetti, R. 587
Dolci, S. 1897
Dolios, G. 9216
Doll, D. 6521
Dolnick, BJ. 5917
Dolnick, R. 5917
Dolnikov, A. 797
Dolo, V. 9369
Domany, E. 4530
Dombrowski, F. 7013
Domingo, E. 10170
Dominguez, I. 5792
Dominici, C. 8308
Donahue, JM. 3823
Donald, EJ. 1063
Donati, V. 6764
Donato, IJ. 8193
Dondog, B. 8072
Done, SJ. 10363
Dong, D. 5785
Dong, F. 6380
Dong, H. 1089
Dong, H. 9445
Dong, J. 2602
Dong, JJ. 1961
Dong, Q. 4520
Dong, Y. 3487, 9073
Dong, Z. 898
Dong, Z. 3596, 5818
Doré, JJ. 10431
Dörfler, A. 5374
Dorn-Beineke, A. 1925
Dornhöfer, N. 2997
Dorow, DS. 9633
Dorr, RT. 3828
Dorricott, H. 5112
Dorronsoro, M. 8042
Dorward, AM. 1259
Dosaka-Akita, H. 10776
Dosemeci, M. 9574
Doss, H. 6459
Doss, M. 1471
Dostmann, N. 8072
Dote, H. 6967
Double, JA. 1489
Dougan, G. 3920
Douglas, JA. 5488
Douglas, L. 7436
Douglas-Jones, A. 410
Doumerc, N. 11667
Dowd, P. 9751
Dowdy, SC. 2684
Dowdy, SF. 10646
Downey, DB. 6337
Downie, DL. 4490
Doyle, GV. 4993
Dracopoli, NC. 8587
Dragovic, AF. 5493
Dragulev, B. 4134
Drake, K. 6022
Dralle, H. 1343
Drapkin, R. 2162
Dreher, MR. 5498
Dresser, K. 6425
Dressman, HK. 4051, 8869
Drew, R. 805
Dries, V. 1394
Druker, BJ. 4500, 9436
Drummond, DC. 11631
du Manoir, J. 5365
Du, B. 5982, 664
Du, J. 457
Du, Y. 1647
Duale, N. 5588
Duan, W. 4520
Duan, X. 1124
Dubé, N. 10088
Dubinett, SM. 5211, 6275
Dubinett, S. 11287
Dubocovich, ML. 11174
DuBois, RN. 1822, 3735, 8583
duBois, W. 7644
Dubreuil, P. 7231
Dubus, P. 3846
Duc, A. 2
Ducos, B. 2588
Dudley, S. 8662
Dufes, C. 8079, 8080
Dufresne, M. 2770
Dugan, AS. 10970
Duigou, GJ. 8936
Dukes, M. 4389
Dumanski, JP. 2653
Dumont, RA. 562
Duncan, T. 10472
Dunn, GP. 3447
Dunn, G. 10273
Dunner Jr., K. 11510, 11658
Dunning, A. 8042
Dupont, J. 5417, 9415
Dupont, J. 6864
Durán, GE. 9388
Duray, PH. 9226
Durdin, DL. 1406
Durham, S. 8017
Durrant, D. 10016
Durrant, MC. 2059
Duval, C. 7363
Dvinge, HK. 7470
Dwivedi, S. 6022
Dyer, MJS. 11265
Earp, HS. 3404, 10514
Easton, DF. 7591
Ebara, S. 9617
Eberhardt, NL. 2684
Eberhart, CG. 2353, 703
Eberhart, C. 9355
Ebetino, FH. 4971
Ebisawa, S. 10159
Eckel-Passow, JE. 2985
Eckfeld, K. 3117
Eckloff, BW. 11071
Eddy, M. 5890
Eddy, SF. 11395
Edell, ES. 8905
Edens, M. 10431
Edgerton, SM. 246
Edgerton, S. 879
Edgington, TS. 11109
Edkins, S. 7591
Edl, J. 2815
Edmiston, JS. 4782
Edwards, E. 4987
Edwards, IJ. 4442
Edwards, K. 7591
Edwards, LE. 562
Efanov, A. 11282, 4515
Efferson, CL. 2930
Egan, DA. 4663
Egan, SE. 8530
Egawa, S. 2899
Eggen, BJL. 1729
Eggermont, AMM. 4300
Eggleston, S. 2330
Egozcue, J. 10223
Eguchi, H. 105, 3092
Eguchi-Kasai, K. 10159
Ehman, M. 2207
Ehrhardt, H. 7888
Eibl, G. 11536, 2738, 982
Eicheler, W. 5374
Eichenberger, S. 3555
Eichhorst, ST. 6780
Eickhoff, J. 6919
Eickhoff, JC. 1180
Eijk, PP. 9510
Eilers, PHC. 10188
Eisenbach, L. 6435
Eisenberg, D. 3531
Eissa, NT. 7984
Eksborg, S. 9999
El-Abaseri, TB. 3958
Elam, C. 3117
El-Deiry, WS. 4475
Elder, DE. 9328
Elenbaas, B. 10423
Elenius, K. 1384
Elgavish, A. 6692
Elghazi, L. 11447
El-Hashemite, N. 2474
Elhason, K. 10096
Eliazar, S. 8698
Eliceiri, D. 7699
Eliceiri, KW. 1180, 8766
Elkahloun, AG. 1619
Elkind, NB. 1770
Elliott, WM. 7926
Ellis, CA. 3117
Ellis, IR. 10742
Ellis, LM. 3664, 7775
Ellwood-Yen, K. 11565
El-Naaman, C. 3772
El-Naggar, A. 3883
El-Rifai, Wael. 6583
El-Sheikh, A. 11109
El-Shemerly, M. 3604
Elston, RC. 805
Elvin, P. 1376
Ely, KA. 2314
Ely, S. 11345
Emanuel, S. 9038
Emberley, ED. 5696, 10265
Emdad, L. 10901
Emens, LA. 8059
Emilie, D. 465
Emmenegger, U. 7045
Emmert-Buck, MR. 2542
Emuss, V. 9719
Enders, GH. 780
Endo, H. 9121
Endo, K. 4998
Endo, M. 10613
Enerbäck, C. 11326
Enewold, L. 9566
Eng, C. 4108, 8096
Eng, JP. 787
Engbring, JA. 7370, 10494
Engel, JB. 5857
Engelman, JA. 6401, 10992
Engels, B. 2560
Englert, C. 1187
English, C. 5133
English, MA. 8174
Enholm, S. 4607
Enk, AH. 7007
Enke, CA. 7824
Enklaar, T. 840
Enokida, H. 2130
Enoksson, J. 2554
Enomoto, T. 8640
Ensinger, C. 1141
Epanchintsev, A. 4218
Epstein, CJ. 1401
Epstein, JB. 8017
Eramo, A. 11469
Erba, E. 2964
Erbele, T. 9194
Erdem, H. 7976
Erdeme, H. 7959
Erdman, SE. 3998
Erdmann, B. 2560
Erdos, G. 10059
Erdreich-Epstein, A. 1129
Erez, N. 4530
Erik, B. 195
Erin, N. 713
Errington, TM. 3108
Errington, TM. 1027
Erwin, CR. 8655
Eschrich, S. 7169
Escuin, D. 9021, 9406
Espanis-Ogando, A. 6801
Espín, E. 10170
Espina, V. 6526
Esteller, M. 2565
Esterbauer, H. 9436
Esteve, FJ. 8406, 11118
Esteves, GH. 7127
Estilo, C. 3063
Estrov, Z. 2890
Esumi, H. 4769
Etienne, C. 5358
Eto, M. 10032
Ettinger, S. 11083
Euvrard, S. 1755
Evans, AE. 9868
Evans, C-O. 10214
Evans, D. 11164
Evans, DB. 3664, 7775
Evelhoch, J. 7041
Everhart, L. 1719
Evert, M. 7013
Ewend, MG. 9155
Ewing, SJ. 861
Fabbri, A. 1207
Fabbri, M. 7065
Faber, H. 6509
Facchinetti, F. 4012
Facchinetti, MM. 3364
Fackenthal, J. 10692
Fadda, D. 9588
Fagin, JA. 2465, 4238
Fähling, H. 5872
Faix, JD. 6151
Falasca, M. 8339
Fallen, S. 6199
Falo Jr., LD. 10059
Falus, A. 4458
Fan, D. 10371, 3707
Fan, F. 7775
Fan, H. 3243
Fan, J. 6927
Fan, RS. 2738
Fan, S. 6557
Fan, ST. 219, 3691
Fan, X. 9355
Fanburg, BL. 10881
Fandrey, J. 4690
Fang, B. 6380
Fang, D. 1858
Fang, D. 9328
Fang, G. 8730
Fang, Y. 6504
Fanger, GR. 6425
Fanger, NA. 6425
Fantin, VR. 6891
Farago, M. 5792
Farber, MJ. 3011
Farhana, L. 4909
Farkas, T. 8975
Farnir, F. 9463
Farooqui-Kabir, S. 3072
Farrar, D. 5112
Farrar, WL. 4673, 6255
Farrugia, AN. 1700
Farrugia, D. 417
Farsetti, A. 9687
Farzaneh, F. 1687
Fasching, CL. 2722
Fassnacht, M. 11156
Fata, JE. 8617
Fattorusso, C. 2397
Faulkes, DJ. 3072
Faulkner, EC. 99
Fava, G. 11437
Favre, M. 1174
Fawell, SE. 10423
Fawell, S. 8944
Fayad, R. 6990
Fazli, L. 11083
Fearn, C. 7699, 8784
Fearon, ER. 5488
Fears, CY. 9338
Febbo, PG. 5054
Fedarko, NS. 11545
Federici, G. 3751
Fees, SA. 840
Fehrenbacher, N. 2993, 8975
Feigal, EG. 8587
Feinberg, AP. 11236
Feinmark, SJ. 8442
Feith, DJ. 572

- Feldman, D. 7917
 Felicioni, L. 9687
 Felix, R. 5872
 Felsner, DW. 4471, 7159
 Feng, B. 10164
 Feng, L. 613
 Feng, L. 7984
 Feng, Q. 8591
 Feng, Q. 6476
 Feng, Z. 11193
 Fenster, A. 5231, 6337
 Fenton, SL. 2690
 Ferbeyre, G. 2872
 Ferguson, BE. 8723
 Ferguson, DA. 8209
 Ferketich, AK. 9099
 Ferkowicz, MJ. 3319
 Ferlini, C. 2397
 Fernandes, A. 7902
 Fernandes, E. 2097
 Fernández, Y. 6294
 Fernandez-Luna, JL. 8151
 Fernandez-Zapico, ME. 2076
 Fernando, NT. 5881
 Feron, O. 7911
 Ferracin, M. 7065
 Ferrand, A. 2770
 Ferrara, C. 7934
 Ferrara, N. 671
 Ferrari, S. 3604
 Ferrarini, M. 7502
 Ferrario, A. 9473
 Ferrer, F. 3788
 Ferrero, E. 7502
 Ferrini, S. 1071
 Ferris, RL. 11146, 2147
 Ferrone, S. 3410, 6001, 6418, 6976, 10139, 11146
 Fesik, SW. 7249
 Feuerstein, BG. 1678
 Fey, GH. 3380
 Feyerhagen, M. 6459
 Fichtner, I. 2882
 Fidler, IJ. 3707, 3716, 4716, 10371, 10794, 11529
 Fiegl, H. 1141
 Fields, AP. 8905
 Fietze, L. 4544
 Fietze, E. 4078
 Figlin, R. 5628
 Figueiredo, JL. 9253
 Figueras, A. 5512
 Filiberti, R. 3049
 Filippetti, F. 2397
 Filleur, S. 5144
 Filleur, S. 300
 Filmus, J. 372, 6245
 Filomeni, G. 3751, 11735
 Fincham, VJ. 1335
 Findeisen, P. 8072
 Fine, BM. 291, 4059
 Fine, HA. 2353
 Finegold, M. 85
 Finetti, P. 2170
 Fingrut, O. 1984
 Finke, JH. 5428
 Finkel, E. 6435
 Finkelstein, DM. 6850
 Finkelstein, SE. 2001
 Finko, R. 9328
 Finlay, GA. 10881
 Finnell, RH. 887
 Fiorini, R. 1505
 Fischer, F. 10739
 Fischer, SM. 1808, 9304, 11486
 Fischette, MR. 7223, 7763
 Fishbein, MC. 11287
 Fishbein, T. 4228
 Fisher, AM. 9473
 Fisher, C. 8085
 Fisher, LW. 11545
 Fisher, NL. 54
 Fisher, PB. 9056, 10128, 10901
 Fisher, RL. 4554
 Fisher, RJ. 9047
 Fiskus, W. 10536
 Fitzgerald, M. 11061
 Fitzgibbon, J. 9152
 Flament, C. 6409
 Flanagan, AM. 7591
 Flanagan, DL. 11010
 Flanagan, PT. 7751, 7763
 Flaws, JA. 681
 Fleischmann-Mundt, B. 7393
 Flescher, E. 1984
 Flesken-Nikitin, A. 787
 Flies, DB. 1089
 Flombaum, CD. 4888
 Florence, B. 2125
 Florence, MM. 10742
 Floryk, D. 11588
 Flowers, L. 11164
 Flynn, C. 2636
 Flynn, DC. 5535
 Flynn, JC. 8471
 Foddiss, R. 3049
 Foekens, JA. 4101
 Fogelgren, B. 11429
 Fogt, F. 4228
 Foidart, J-M. 7691
 Fojo, T. 11694, 7386, 9388
 Folk, NL. 3762
 Folkard, M. 10810
 Folkman, J. 11044, 3656
 Follettie, MT. 5181
 Fölsch, UR. 1316
 Fomenkov, A. 758
 Fong, S. 7007
 Fong, KM. 1642
 Fong, K. 4031
 Fong, LYY. 7790
 Fong, SFT. 11429
 Fontana, JA. 4909
 Foot, NJ. 375, 8597
 Forbes, S. 7591
 Force, J. 11044
 Ford, HL. 2668
 Ford, J. 10457
 Ford, JL. 1277
 Fordyce, CA. 1792
 Foreman, TL. 7111
 Forissier, S. 6521
 Forni, G. 5953
 Fornsaglio, JL. 6394
 Forrest, MS. 9574
 Forrester, E. 2296
 Forster, MD. 11721
 Forsyth, PA. 9982
 Fortis, C. 7502
 Fossá, SD. 5588
 Fotsis, T. 1877
 Foudi, A. 2676
 Foufelle, F. 2441
 Foulk, BW. 4993
 Fourny, D. 2770
 Fournier, P. 300
 Fournier, PGJ. 4971
 Fourquet, A. 1376
 Foustier, M. 10298
 Fox, BA. 10569
 Fox, EA. 1479
 Fox, JG. 3998, 10709, 10912
 Fox, JW. 4134
 Fox, MH. 5544
 Fox, SR. 4568
 Fox, SD. 4673
 Foy, TM. 6425
 Fracchioli, S. 925
 Fraga, MF. 2565
 Fraig, MM. 6228
 Fraker, DL. 8433
 Frame, MC. 1335
 Frame, S. 5399
 Franci, C. 9294
 Francia, G. 5365, 7045
 Francis, H. 11437
 Francis, J. 1523
 Francis, MK. 2085
 Francisco, B. 9388
 Franco, OE. 10423
 François, M. 8359
 Frangou-Plemmenou, M. 1627
 Frank, BC. 1814
 Frank, DA. 5054
 Frank, MH. 4320
 Frank, NY. 4320
 Franke, C. 11094
 Franklin, RA. 5408
 Franovic, A. 5221
 Franssen, MF. 6984
 Frantz, G. 9751
 Frappier, L. 1577
 Frasca, F. 1849
 Fraser, MM. 6228
 Frati, L. 8308
 Frattini, M. 2321, 11227
 Frazier, ML. 11297
 Frazier, ML. 1115
 Frech, MS. 681
 Frede, S. 4690
 Frederick, M. 11501
 Freedman, ML. 7516
 Freeman, BA. 9670
 Freeman, JW. 2861
 Freeman, MR. 2547, 8242
 Freemantle, SJ. 6476
 Frei, E. 2644
 Freire, T. 7880
 Freitag, P. 4690
 French, PJ. 11335
 Frenkel, B. 5769
 Friborg, J. 8567
 Fridman, R. 3523, 898
 Friedländer, E. 473
 Friedlos, F. 5003, 10686
 Friedman, SL. 1213, 5761, 9216
 Friedrichsen, DM. 1213
 Friend, S. 4059
 Friera, AM. 9294
 Frierson Jr., HF. 3108, 7320
 Friess, H. 6011
 Fritz, B. 439
 Fritz, G. 840
 Fröhlich, C. 4754
 Frolov, A. 7959
 Frost, AR. 4645
 Früh, K. 5084
 Frum, R. 1839
 Fruman, DA. 2047
 Fruttschi, M. 4005
 Frydman, V. 10316
 Fu, H. 7052
 Fu, M. 6557
 Fu, T. 1577
 Fu, X-N. 4707
 Fu, X-Y. 10838
 Fuchs, PG. 2216
 Fuchs, P. 1394
 Fuchs, SY. 1904
 Fuchs, U. 7888
 Fuentes-Pesquera, A. 9038
 Fuhrman, J. 3958
 Fuhrmann, G. 8298
 Fujarewicz, K. 1587
 Fujii, N. 10450, 1700
 Fujii, T. 4253
 Fujii, Y. 7874
 Fujime, M. 4817
 Fujimori, A. 10159
 Fujimoto, N. 11478
 Fujimura, S. 5925
 Fujioka, T. 4578, 4817
 Fujisawa, T. 1642
 Fujita, M. 8640
 Fujiwara, H. 5284
 Fujiwara, K. 3336, 4368
 Fukasawa, K. 4568
 Fukaya, M. 2115
 Fukuchi, J. 2082
 Fukuda, I. 1868
 Fukuda, K. 546
 Fukuda, M. 6
 Fukuda, ME. 5190
 Fukuda, S. 8224
 Fukuhara, H. 10663
 Fukumori, T. 3535, 7546
 Fukunaga, R. 6220
 Fukushima, M. 1055
 Fukushima, N. 1619
 Fukushima, T. 11704
 Fukushima, Y. 5864
 Fukuyama, R. 3586
 Fukuyama, S. 7276
 Fulda, S. 10502
 Fuller, GN. 3562
 Fuller, G. 1934
 Fults, DW. 919
 Fumey, G. 7622
 Fuqua, SAW. 10594
 Furberg, H. 1105
 Furge, KA. 5628
 Furihara, M. 4578
 Furneaux, H. 2157
 Furte, IE. 11051
 Fürstenberger, G. 1808
 Furth, PA. 681
 Furukawa, C. 7102
 Furukawa, F. 157
 Furukawa, T. 2899
 Furumai, R. 8853
 Furusawa, T. 6711
 Furusawa, Y. 113
 Furuya, M. 2617
 Fusco, A. 10199
 Fusenig, NE. 1294, 1783
 Futami, K. 2979
 Futami, K. 5628
 Futin, N. 9536
 Futreal, PA. 7591
 Gabanti, E. 1115
 Gabet, A-S. 1234
 Gable, CM. 9883
 Gabra, H. 8961
 Gabrilovich, DL. 9525
 Gaddy, D. 11001
 Gade, TPF. 9080
 Gagang, V. 805
 Gaikwad, A. 2054
 Gaillard, S. 11762
 Gailly, P. 7348
 Gaiser, T. 5857
 Gala, J-L. 7348
 Galappathi, K. 2387
 Galardy, PJ. 7896
 Galup, A. 4353
 Galfione, M. 7984
 Galiege-Zouitina, S. 4554
 Galindo, L. 10079
 Galinsky, I. 7338
 Galipeau, J. 8359
 Gallagher, PG. 4134
 Gallant, P. 6485
 Galle, PR. 10830, 10255
 Gallego-Ortega, D. 5647
 Gallez, B. 7911
 Galli, L. 4012
 Gallick, GE. 3664, 6493, 7214
 Galligan, L. 8951
 Gallino, G. 2321
 Gallo, D. 2397
 Galter, D. 9261
 Gammaro, F. 4852
 Gambhir, SS. 622, 5907, 7413
 Gamcsik, MP. 10149
 Gamelin, E. 8927
 Gammon, MD. 1606
 Gan, B. 6676
 Ganesaguru, K. 2373
 Gangula, RD. 4309
 Gansbacher, B. 8608
 Gansmuller, A. 10862
 Ganter, H. 5872
 Gantzer, M. 9536
 Gao, AC. 3487
 Gao, P. 1433

- Gao, Q. 4747
Gao, Y. 3518
Gao, Y. 10401
Gao, Y-T. 5015
Garban, HJ. 11287
Garbay, S. 5096
Garbi, A. 2964
Garcia Boy, R. 6305
Garcia, AM. 11271
Garcia, GE. 7984
Garcia, V. 11667, 526
Garcia-Aranda, C. 3811
García-Cánovas, F. 2059
Garcia-Castro, J. 3035
García-Echeverría, C. 3868, 11459
García-Escudero, R. 2216
García-España, A. 1150
García-Rostán, G. 10199
Gardner, B. 5211
Gardner, GJ. 10602
Gardner, J. 7533
Gardner, TA. 1941
Gargiulo, L. 8111
Garlick, DS. 3531
Garlick, JA. 1783
Garner, HR. 8209
Garner, D. 6130
Garnett, M. 9719
Garnis, C. 7561
Garofalo, M. 6668
Garraway, L. 5561
Garte, S. 8042
Gartel, AL. 3980
Gartenhaus, RB. 10651
Garwood, M. 7041
Gasche, C. 3993
Gasparri, A. 2906
Gasser, M. 4320
Gastpar, R. 5238
Gattini, V. 3049
Gaudino, G. 5256
Gauger, MA. 6828
Gauthier, ML. 1792
Gauvin, GP. 6130
Gavert, N. 11605
Gavrikova, T. 10154
Gawron, LS. 5344
Gaynor, RB. 8209
Gazdar, AF. 1642, 7568
Gazdar, A. 226
Gaziano, JM. 2498
Ge, Z. 3998
Geay, J-F. 2676
Gebert, JF. 10170
Gebert, J. 6418, 8072
Gee, MFW. 7267
Geehanage, S. 7462
Gehrmann, M. 5238
Geiger, TR. 7033
Geijtenbeek, TBH. 5935
Geller, L. 805
Gellermann, J. 5872
Gellert, GC. 7866
Gelman, R. 9659, 11326
Germann, ER. 1164
Gelmetti, V. 1505
Gendron-Fitzpatrick, A. 1180
Geneix, J. 767
Generali, D. 8690
Genescà, A. 10223
Geneviève, P. 195
Geng, L. 4987
Genther Williams, SM. 6534
Gentiletti, F. 9687
Gentile, D. 4598
Geoghegan, JC. 11101
George, JA. 10381
George, M. 10700
Gerald, WL. 2565
Gérard, R. 195
Gerber, H-P. 671
Gerbes, AL. 6780
Gerdes, C. 7934
Gerdes, M. 562
Gerg, M. 3523
Gerritsen, WR. 9398
Gershenson, DM. 10602
Gershenwald, JE. 11185
Gery, S. 4762
Getzenberg, RH. 4097, 7145
Geyer, P. 5374
Ghali, L. 2216
Ghia, P. 10050
Ghibelli, L. 3751
Ghigo, D. 516
Ghilardi, JR. 9426
Ghobrial, I. 2985
Ghoneim, MA. 11581
Ghosh, A. 727
Ghosh, AK. 718
Ghosh, D. 11259
Ghosh, SK. 6466
Ghosh, S. 8936
Ghoshal, K. 10891
Ghoshal, P. 4554
Ghossein, R. 3063
Giacca, AJ. 3171, 6151
Giacomini, CP. 9200
Giagkousiklidis, S. 10502
Gianella-Borradori, A. 5399
Giannakakou, P. 605, 3883, 9021, 9406
Gianni, D. 9398
Giannini, G. 8308
Gibbs, AR. 2602
Gibbs, DD. 11721
Giblett, S. 11493
Gibson, N. 9455
Gibson, SL. 10734, 11597
Gibson, SB. 5696
Gicquel, C. 7622
Giel-Moloney, M. 1887
Giffen, C. 2542
Giglio, S. 9687
Giguère, V. 6120
Gil, J. 177, 2179
Gilbert, B. 6237
Gilboa, E. 11156
Gilestro, G. 6167
Gill, PS. 4623
Gilles, C. 7691
Gillespie, GY. 5535
Gillespie, MT. 4929
Gillet, L. 9463
Gillian, TL. 10149
Gillies, SD. 6976
Gillis, AJM. 8085
Gillot, L. 6521
Gills, JJ. 8423
Gilly, R. 7186
Gilmire-Hebert, M. 3762
Gimm, O. 1729
Ginestier, C. 767
Ginn-Pease, ME. 4108
Ginsberg, D. 4530
Ginsburg, E. 7509
Ginzinger, DG. 9695
Giordano, TJ. 5488
Giovannucci, E. 2498, 11771
Girardo, AA. 8471
Giranda, VL. 2698
Girard, J-P. 11639
Girard, L. 226, 5561
Giraudier, S. 3281
Giraudou, E. 2018
Girlanda, S. 7502
Giuliano, AE. 3861
Giulotto, E. 11411
Gjerset, RA. 9834
Glackin, C. 5153, 10801
Gladson, CL. 5535, 9338
Glas, AM. 9155
Glaser, S. 11437
Gläsker, Sven. 10847
Glasow, A. 7856
Glasspool, RM. 7585
Glatfelter, AA. 9226
Glazer, PM. 10734, 11597
Glazer, RI. 3950
Gleave, M. 11083
Glennie, MJ. 7493
Glick, D. 10700
Glick, A. 562
Glinskii, AB. 2378
Glinsky, GV. 2378
Gliwa, E. 11193
Gloghini, A. 587
Glogowska, A. 1343
Gluckman, E. 1271
Gluckman, PD. 317
Glunde, K. 11034
Gmeiner, WH. 4844
Gnarra, JR. 6576
Gnessi, L. 1897
Godage, HY. 8339
Godfrey, TE. 2147
Goding, CR. 2260
Godl, K. 379, 6919
Godwin, AK. 3011
Goebel, G. 1141
Goel, A. 3993
Goel, HL. 6692
Goggins, M. 1619
Gökmen-Polar, Y. 9406
Golas, JM. 5358
Golas, J. 5358
Goldberger, O. 6435
Golde, DW. 8111
Goldenberg, DD. 3617
Goldenberg, DM. 8809
Goldfinger, N. 4530
Goldgar, D. 417
Goldman, JM. 8912
Goldsmith, CM. 7370
Goldstein, AM. 2542
Goldstraw, P. 7591
Goldwasser, F. 948
Gollob, JA. 8869
Golubeva, OG. 5380, 5439
Golzio, M. 11667
Gomer, CJ. 9473
Gomes, LI. 7127
Gomez, J. 2996
Gomez-Roman, J. 8151
Gona, P. 8286
Gong, L-M. 10838
Gong, MC. 9080
Gong, W. 2746, 4809
Gonzalez, A. 3555
Gonzalez, CA. 8042
Gonzalez, M. 6901
Gonzalez, S. 2186
González Trotter, DE. 1471
Goode, R. 7462
Goodell, V. 650
Goodglick, L. 11287
Gooding, WE. 2147
Gooding, W. 11146
Goodison, S. 6042
Goodlett, DR. 3081
Goodman, MM. 967
Goodman, SL. 9377
Gopalan, B. 3017
Gorden, L. 499
Gordon, AH. 3209
Gordon, KA. 8331
Gorgoulis, VG. 7533
Gorlick, R. 1748
Gormally, E. 8042
Gorska, AE. 2296
Górski, B. 835
Górski, DH. 1414
Górski, JJ. 10265
Gorton, M. 7591
Goss, KH. 166
Goswami, S. 5278
Götherström, C. 2207
Goto, N. 8448
Gottardis, M. 3781
Gottesman, MM. 7223
Göttgens, B. 7596
Gottlieb, B. 8514
Gouazé, V. 3861
Gould, MN. 8558, 9637
Goulvestre, C. 948
Gowans, ID. 3527
Graf, TN. 4448
Graff, JR. 7462
Graff, JM. 8209
Graham, A. 1376
Graham, KC. 5231
Gramatzki, M. 3380
Grammer, JR. 5535, 9338
Graña, X. 10174
Grandemange, S. 4282
Grandis, JR. 1459
Grant, S. 2422
Granville, L. 85
Grati, FR. 2139
Graulund, M. 7470
Gray, D. 9751
Gray, DR. 6640
Gray, JW. 8125, 9695
Gray, JW. 2516
Gray, K. 7591
Gray, MJ. 3664, 7214
Greco, A. 2572
Greedy, B. 10536
Green, A. 7591
Green, CM. 9799
Green, M. 11721
Green, SR. 5399
Green, S. 11493
Greenberg, CS. 1369
Greenberg, NM. 1761, 6337, 6640, 6692
Greenhalf, W. 3218
Greenman, C. 7591
Greenston, JK. 5488
Greer, AF. 3781
Greer, PA. 3518
Greff, Z. 379
Gregg, JP. 10700
Grégoire, V. 7911
Gregorj, C. 1505
Gregory, CW. 3404
Gregory, RI. 3509
Gregory, SG. 2653
Greshock, JD. 7612
Greten, TF. 2457
Greulich, H. 7533, 8968
Grewal, IS. 8331, 11712
Grewal, N. 2001
Gribble, GW. 4789
Grier, DG. 9245
Griffin, BE. 1523
Griffin, C. 1678
Griffin, G. 9455
Griffin, JD. 8968
Griffioen, AW. 11520
Griffith, KA. 8366
Grigorian, M. 3772
Grimm, J. 6330
Grimwade, D. 8754
Grippio, P. 6011
Griscelli, F. 4353
Grodén, J. 166, 5520
Grogan, T. 4554
Groh, V. 7502
Grompe, M. 85
Gröne, H-J. 3643
Gronemeyer, H. 8754
Gronthos, S. 1700
Gronwald, J. 835
Groom, AC. 5231
Großmann, M. 1316
Gross, C. 5238
Grossman, A. 2854
Groussin, L. 7622
Gruber, SB. 5488
Grum-Schwensen, B. 3772
Gruninger, RH. 9038
Grushko, TA. 10692
Gruss, OJ. 6919
Gruver, AM. 2089
Gryaznov, S. 7866
Grygalewicz, B. 8085
Grygiel, JJ. 2330

- Gu, J. 6843
Gu, S. 1647
Gu, Y. 6631
Gu, Z. 9495
Guan, B. 11486
Guan, H. 1124
Guan, J.-L. 6676
Guan, R. 2698
Guan, X.-Y. 6504
Guan, X.-Y. 8125
Guarente, L. 2730
Gubala, E. 1587
Gubbins, EF. 4663
Gubish, CT. 1459
Gudi, R. 5301
Guenther, BD. 9406
Guenther, L. 5683
Guerini, V. 5445
Guglielmi, G. 3049
Guglielmi, J. 30C
Guha, S. 2738
Gui, C.-Y. 7832
Guidez, F. 7856, 8754
Guidoboni, M. 587
Guiducci, C. 2321, 3437
Guilhot, F. 6409
Guilleaume, B. 7733
Guimarães, GS. 1693
Guise, TA. 11001
Guise, T. 7320
Gül, H. 2537
Guldberg, P. 3126, 6167
Guleng, B. 4562, 5864, 10822
Gulino, A. 8308
Gumin, J. 3307
Gumaratnam, I. 5221
Gunawardane, RN. 11572
Gunawardane, R. 3542
Günes, C. 1187
Gunnarsdottir, S. 4425
Gunset, G. 9080
Gunther, EJ. 681
Gunther, T. 11361
Günzburg, WH. 6651
Guo, F. 10536
Guo, S. 3011
Guo, S. 11375
Guo, W. 6380
Guo, W. 10006
Guo, Y. 9762
Guo, Y. 6874
Guo, Y. 1761, 5263
Guo, Y. 1146
Guo, Y. 722, 9582
Guo, ZS. 9991
Guo, Z. 11631
Guo, Z. 1577
Guo, Z. 758
Gupta, AK. 8256
Gupta, K. 4598
Gustafson, D. 10006
Gutierrez, AM. 9555
Gutkind, JS. 9953
Gutmann, DH. 236, 2755, 7121, 9843
Guy, C. 10179
Gysin, S. 4870
- Haab, BB. 11193
Haack, H. 9789
Haag, JD. 9637
Haberey, M. 5374
Haché, R J.G. 10750
Hacia, JG. 3837, 11676
Hackanson, B. 7086
Hackett, N. 11061
Haddad, BR. 1164
Haddada, H. 2787
Hadjipanyis, CG. 5310
Haddell, DL. 3781
Haegens, A. 9670
Hagemann, T. 10355
Hagen, W. 8662
Hagiwara, K. 7276
Hagiwara, T. 2979
- Haglund, C. 2157
Hagneré, A.-M. 7622
Hagos, F. 10692
Hahn, SM. 8433
Hahn, T. 11094
Hahn, WC. 8183
Hahne, F. 7733
Hahtola, S. 8101
Haiman, CA. 7516
Hainaut, P. 5076, 8042
Haines, DS. 9236
Haines, DC. 6711
Haining, WN. 10050
Hait, WN. 3806, 6660
Hakim, SG. 10486
Hakimi, M.-A. 3011
Hakoda, M. 5462
Hakuma, N. 10776
Halama, ED. 681
Halazonetis, TD. 6568, 7533
Halbrook, J. 4987
Hale, G. 2373
Haley, JD. 9455
Halford, S. 11361
Halicka, D. 4401
Halicka, HD. 8538
Halks-Miller, M. 8397
Hall, AG. 3053
Hall, AG. 9712
Hall, CL. 7554
Hall, EJ. 933, 9876
Hall, J. 8961
Hall, SJ. 9080
Hallahan, DE. 4987
Hallak, LK. 5292
Hallden, G. 1523
Hallenbeck, P. 5003
Halliday, K. 7591
Halmos, B. 7096
Halmos, G. 5857
Halpern, EF. 3030
Halushka, PV. 11486
Halvorsen, KG. 9426
Hamada, H. 546
Hamanaka, Y. 9121
Hamasaki, M. 7478
Hamburger, N. 7301
Hamel, E. 3883
Hamelinck, D. 11193
Hamilton, MG. 9982
Hamilton, SR. 3716, 11486
Hampton, G. 7320
Han, G.-Z. 387
Han, HC. 7743
Han, I. 9899
Han, P. 2482
Han, SS. 1306
Han, X.-Y. 2542
Han, X. 8671
Hanagiri, T. 5945
Hanahan, D. 2018
Hanai, T. 401
Hanaoka, F. 5720
Hanash, S. 5488
Handa, M. 6450
Hande, MP. 10977
Handley, M. 7363
Handratta, V. 5439
Haneveld, F. 3136
Hangaishi, A. 6071
Hanifin, JP. 11174
Hanley, WD. 5812
Hanna, AE. 11478
Hanna, KR. 7462
Hanna, WM. 10401
Hanover, JA. 7223
Hans, C. 4051
Hansen, HJ. 8809
Hansen, LA. 3958
Hansen, M. 1479
Hao, B. 722
Hao, K. 10602, 9651
Haque, M. 3299
Haque, RM. 2353
- Haque, SJ. 2956
Hara, T. 7356
Harada, N. 4653
Harano, M. 10032
Harari, PM. 3328
Harbeck, N. 4101
Harbott, J. 1442
Harding, TC. 6901
Harding, T. 4739
Hardwick, JM. 309
Hariono, S. 9695
Harkin, DP. 10265
Harkins, R. 8397
Härkönen, P. 1384
Harms, JF. 7370
Harper, UL. 9226
Harris, AL. 4147, 8690
Harris, CC. 1223, 2526, 4530, 9132, 9566, 10255
Harris, DM. 11129
Harris, D. 2890
Harris, E. 3911
Harris, JM. 8487
Harris, RA. 5112
Harris-Brandts, M. 6685
Harrison, R. 7591
Harsh, GR. 4088, 8679
Hart, JL. 11276
Hart, J. 5740
Hart, J. 3146
Hartge, P. 11214
Hartley, C. 284
Hartman, PS. 203
Hartmann, D. 10854
Hartwell, JR. 3319
Haruki, N. 3555
Haruta, S. 10464
Harvell, DME. 9779
Harwood, CA. 8597
Hasan, S. 11536
Hashimoto, K. 540
Hashimoto, N. 11704
Haskell, A. 5740
Haskell, C. 4663
Hassen, W. 9080
Hassoun, J. 767
Hata, F. 8706
Hata, T. 2899
Hatada, EN. 11345
Hatake, K. 4998
Hatakeyama, S. 7874
Hatano, H. 7573
Hauben, E. 11520
Hauer-Jensen, M. 3100
Haugen, DAL. 708
Hauptschein, RS. 1887
Hauser, CA. 5325
Hauser, J. 4292
Häusler, T. 10634
Haverkamp, H. 5516
Haviv, I. 4031
Hawkins, CE. 5607
Hawkins, LK. 5003
Hawkins, S. 5301
Hawks, CL. 6512
Hawthorne, VS. 4716
Hay, C. 5003
Hay, J. 8017
Hay, N. 3257
Hay, T. 10145, 410
Hayama, S. 5638, 9176, 11314
Hayami, R. 6
Hayashi, M. 7699, 8784
Hayashi, S.-I. 4653, 6450
Hayashi, T. 5462, 9771
Hayashida, CY. 9651
Hayashida, Y. 8836, 10613
Hayashita, Y. 9628
Hayes, RB. 8034, 9574, 11779
Hayette, S. 6521
Hayward, SW. 3633, 10423
Hazen, SL. 9670
He, B. 743
He, D. 8350
- He, F. 722
He, G. 9304
He, J. 6601
He, J. 10289
He, J. 3707, 3716
He, K.-L. 5009
He, L. 309
He, Q. 4202
He, Q. 10725
He, Q.-Y. 11553
He, W. 3030
He, X. 9155
He, Y. 10016
He, YD. 4059
He, Y. 4739, 6901
He, Z. 3596
Heads, RJ. 3072
Healey, JH. 1748
Heathcott, R. 2592
Hebbring, S. 1213
Hecht, JL. 2162
Hecht, SM. 1027
Hecht, SS. 8548
Hedenfalk, I. 9727
Hedley, DW. 1497
Hedley, D. 5003
Heemers, HV. 708
Heerdt, BG. 9861
Hegarty, C. 3454
Hegedus, B. 9843
Hegyesi, H. 4458
Helmman, R. 2662
Hei, TK. 3236, 9876
Heidel, JD. 8984
Heidmann, T. 2588
Heiland, S. 3643
Heilmaier, C. 4690
Heimbrook, DC. 1918
Heimerdinger, CK. 840
Heinmann, K. 4525
Heinonen, KM. 10088
Heinonen, M. 2157
Heinrich, MC. 4500
Heintz, N. 9670
Heldin, P. 6139
Helfrich, W. 3380
Helgason, CD. 2947
Helleday, T. 325
Hellingner, N. 7847
Helman, LJ. 2406
Helman, L. 8142
Hemenway, D. 9670
Hemers, E. 7363
Hemstreet, GP. 483
Henderson, CJ. 2644, 4211
Henderson, E. 11721
Henderson, M. 499
Henderson, Y. 11501
Hendrickson, BC. 10096
Hendrix, MJC. 6282, 9851, 10164, 11429, 11520
Hendy, GN. 493
Heng, H. 8747
Hengstler, JG. 840
Henkin, J. 4663
Hennequin, LF. 4389
Hennig, R. 6011
Hennighausen, L. 6864
Henriksen, K. 2387
Henriksson, M. 1361
Henriksson, R. 6459
Henry, MM. 1748
Henshall, SM. 2330, 4031, 4623
Hentschel, S. 3307
Herbst, R. 11478
Hergenhahn, M. 2583
Herlevsen, MC. 7111
Herlyn, M. 9328
Hermeking, H. 4218
Hermsem, MJA. 10199
Hermesen, MAJA. 1271
Hernandez, C. 3044
Hernandez, G. 6089, 9906
Hernández, L. 2199

- Hernandez, R, 10199
Hernando, E, 2186
Herold-Mende, C, 11419
Herranz, M, 2565
Herrero, A, 10199
Herrick, J, 6063
Herrick, J, 1174
Herrlich, P, 6105
Herrmann, M, 4881
Hershberger, PA, 1598
Herzer, K, 10830
Hess, AR, 11429, 9851
Hess, D, 3604
Hess, JL, 11367
Hessel, F, 5374
Hesson, L, 3117
Heston, WD, 9080
Heston, WDW, 727
Hewison, M, 2488
Heyfets, A, 1984
Heymach, JV, 11044
Heywood, M, 8944
Hibino, S, 10494
Hibshoosh, H, 2554
Hicklin, DJ, 1514, 3185, 5365
Hicks, J, 8142
Hicks, RJ, 9633
Hickson, JA, 10984
Hida, K, 2507
Hida, Y, 5690
Hidalgo, M, 130, 3003
Hideshima, T, 5898, 7478, 7896, 8350, 11712
Hienonen, T, 4607
Higashihara, M, 7628
Highshaw, RA, 11658
Higuchi, S, 8448
Hipakka, RA, 2082
Hikiba, Y, 4562
Hildebrandt, B, 4078
Hildebrandt, B, 5872
Hill, DL, 8200
Hill, J, 3493
Hill, R, 10243
Hillemann, T, 2457
Hillen, F, 11520
Hill-Kapturczak, N, 4789
Hillman, DW, 3059
Hills, K, 7591
Hilmer, SC, 1748
Hilsenbeck, SG, 3462
Himmeler, G, 7934
Hines, OF, 982, 2738, 11536
Hino, O, 203
Hinson, SR, 417
Hinton, J, 7591
Hiong, KC, 7743
Hippo, Y, 372
Hirai, K, 6220
Hirai, T, 7356
Hirai, Y, 8617
Hirano, F, 1089
Hirano, S, 11704
Hirata, A, 4253
Hirata, K, 8706, 11018
Hirata Jr., R, 7127
Hirato, J, 4587
Hirohashi, S, 8836, 10613
Hirohashi, Y, 8706, 11018
Hiroi, J, 6
Hirose, Y, 4861
Hirota-Tsuchihara, M, 6685
Hirsch, O, 8754
Hirshfeld, J, 1213
Hirukawa, S, 1352
Hiscott, J, 7485
Hishikawa, Y, 113
Hishiki, T, 9868
Hisplop, G, 8017
Hitchens, MR, 4097
Hitoshi, Y, 9294
Hittelman, WN, 3226
Hittelman, W, 6874
Hiwasa, T, 5190
Hixson, DC, 11010
Hiyama, E, 9623
Hiyama, K, 1055, 9623
Hjelmeland, AB, 11276
Hjelmeland, MD, 11276
Hla, T, 2157, 3788, 4496, 10113
Ho, A, 6685
Ho, CP, 3781
Ho, C-L, 1994
Ho, CSW, 5607
Ho, DW, 219
Ho, H-N, 2921
Ho, M, 291
Ho, R, 9868
Ho, S-M, 3726
Ho, VV, 3837
Ho, WC, 4273
Hoang, BH, 9762
Hoang-Vu, C, 1343
Hoare, SF, 7585
Hobbs, RM, 8575
Hochegger, H, 11704
Hochhaus, A, 2662
Hochman, J, 7223
Hock, T, 4789
Höckel, M, 2997
Hockfield, S, 6726
Hod, E, 1213, 5761
Hodge, DR, 4673, 6255
Hodgson, JG, 3617, 9695
Hodivala-Dilke, KM, 5703
Hoebeke, J, 9536
Hoek, G, 8042
Hoek, JB, 10545
Hoelzer, D, 2537, 6080
Hoering, A, 2985
Hoffman, MP, 10494
Hoffman, RM, 2337, 2378, 4246, 5352, 9829
Hoffmann, F, 11459
Hoffmann, J-S, 325
Hoffmann, J, 4881
Höfler, H, 4101, 5038
Hofman, FM, 10347
Hofmann, F, 3868
Hofmann, M, 4172
Hofmann, TG, 10830
Hofseth, AB, 9132
Hofseth, LJ, 10255, 9132
Hofstra, RMW, 1729
Hogan, M, 465
Hogan, V, 3535, 7546
Hogarth, LA, 3053
Hogendoorn, PCW, 11520
Hogervorst, FBL, 822
Hogg, PJ, 11729
Hogue, D, 9751
Hokey, DA, 10059
Holck, P, 4754
Holcombe, RF, 9762
Holdcraft, RW, 166
Holicky, EL, 8233
Holland, EC, 2065, 7429
Holland, JF, 1112
Holland, SJ, 9294
Hollema, H, 1729
Hollister, B, 9038
Holloway, AJ, 4031
Hollstein, MC, 2583
Holm, K, 2554
Holmen, SL, 8250
Holmen, S, 2009
Holmes, AM, 9517
Holopainen, T, 4739
Holzer, RG, 8896
Homicks, K, 6882
Homma, Y, 2610
Homolya, L, 1770
Homoyouni, A, 1325
Honda, K, 8836, 10613
Honda, T, 4789
Honda, Y, 4789
Honeychurch, J, 7493
Hong, C, 3617
Hong, JA, 7751, 7763
Hong, J, 8049, 10623
Hong, K, 11631
Hong, SH, 4896
Hong, S, 4614
Hong, S-H, 3162
Hong, WK, 7568
Hong, Y-S, 5554
Hong, Y, 9582
Honore, S, 2433
Hood, L, 3081
Hoogervorst, EM, 3610
Hooi, SC, 10330
Hooijberg, JH, 4425
Hoon, DSB, 1800, 11536
Hooper, AT, 3185
Hoopes, PJ, 6371
Hope, C, 9762
Hopkins, KM, 933
Horie, R, 7628
Horie-Inoue, K, 3700
Horii, A, 2899
Horinaka, M, 5662, 6364
Horio, Y, 10680
Horner, JS, 6551
Hornsby, PJ, 6512
Horsfall, DJ, 8487
Horsthemke, B, 10634
Horton, LG, 1259
Horton, SJ, 9245
Horvath, Z, 6919
Horwack, I, 3410
Horwitz, KB, 9779
Höschele, I, 11044
Hosoda, F, 10233
Hosoi, F, 4253
Hosoi, H, 10233
Hosokawa, M, 3092
Hosoya, N, 6071
Hossain, R, 10494
Hosseini, G, 9377
Hotary, KB, 6543
Hotfilder, M, 1442
Hotz, S, 9328
Hou, M, 9999
Hou, Z, 10623, 8049
Houde, C, 4554
Houghtaling, S, 85
Houghton, JA, 7436, 11447
Houghton, JM, 10912
Houlgate, R, 2170
Hour, T-C, 8455
Houston, AM, 9817
Houston, B, 4211
Houston, MA, 9861
Houvenaeghel, G, 767
Hovan, A, 8017
Hoving, S, 4300
Howard, BA, 8853
Howard, DL, 4963
Howard, EF, 7660
Howe, LR, 10113
Howes, A, 5325
Hoyer-Hansen, M, 8975
Hozumi, N, 4417
Hruban, RH, 1619
Hsieh, C-Y, 4827, 9089
Hsieh, C-C, 358
Hsieh, J-T, 6089, 9906
Hsieh, M, 9206
Hsieh-Li, H-M, 4041
Hsu, S-H, 4041
Hsu, S-M, 2921
Hsu, T, 7205
Hu, B, 8613
Hu, C-a, A, 1647
Hu, C-L, 4827
Hu, G, 7403
Hu, G-f, 1352
Hu, H-M, 10569
Hu, L, 6504
Hu, M, 8715
Hu, M, 11326
Hu, N, 2542
Hu, W, 5481
Hu, X, 11026
Hu, Y, 2542
Hu, Y, 9991
Hu, Z, 9155
Huang, A, 5607
Huang, B, 5009
Huang, C, 7743
Huang, C-L, 9906
Huang, C-J, 6943
Huang, C, 6601, 9287
Huang, C, 8613
Huang, DP, 8125
Huang, FY, 5272
Huang, H, 5144
Huang, H, 3454
Huang, H-Y, 4041
Huang, J, 925, 7612
Huang, J, 8461
Huang, J-W, 1561
Huang, LE, 3299
Huang, L-Q, 1079
Huang, L, 10413
Huang, M, 5211
Huang, P-H, 4041
Huang, P, 613, 6874, 11510, 11658
Huang, R-Y, 5890
Huang, S, 1800
Huang, S, 3328
Huang, S-C, 2921
Huang, S-F, 338
Huang, S, 246
Huang, S, 2746, 4809
Huang, T-T, 11271
Huang, W, 5750
Huang, W-C, 2303
Huang, W-X, 1164
Huang, X, 4408
Huang, X, 3470
Huang, X, 1079
Huang, Y, 5778
Huang, Y, 4320, 7446, 10725
Huang, Y, 226
Huang, Y, 6990
Huang, Z, 8869
Hubeek, I, 9510
Huber, E, 11613
Huber, PE, 3643
Huber, V, 3942
Huber, W, 7733
Huberman, E, 11588
Hublin, C, 9595
Huddart, R, 8085
Hudis, C, 10113
Hudson, D, 8397
Hudson, LG, 2234, 9280
Huebner, K, 6576, 7790, 8613
Huerta-Yepez, S, 264
Huff, JW, 8209
Huff, LM, 9388
Hughes, SV, 2488
Huh, N-h, 9617
Hui, AB-Y, 8125
Hui, MKC, 5272
Hu-Lieskova, S, 4633, 8984
Hu-Lowe, D, 9253
Hummer, A, 9415
Humphreys, V, 10179
Hung, C-F, 309
Hung, KW-K, 8125
Hung, M-C, 338, 1961, 2287, 2511, 3257, 8406
Hung, RJ, 5076
Hungerford, W, 957
Hunt, JD, 5076
Hunt, JL, 2147
Hunt, J, 11146
Hunter, C, 7591
Hunter, DJ, 11771
Hunter, M, 2330
Huntsman, D, 8591
Hunziker, W, 7691
Huribert, W, 3781
Hurt, EM, 4673

- Husain, AN, 1479
Huselson, C, 5358
Huso, DL, 5620
Huso, D, 1514
Huss, KL, 7462
Huss, WJ, 6640
Hussain, SP, 9132, 10255
Huvos, AG, 1748
Huynh, L, 1277
Huzarski, T, 835
Hwang, CY, 4485
Hyatt, JL, 6850
Hyde, C, 10946
Hyer, ML, 4799
Hyer, M, 210
Hynes, RO, 9789, 10324
- Iaccarino, I, 4525
Iacobelli, S, 8339
Iacovelli, S, 9687
Ibrahim, NO, 11094
Ichihashi, M, 6006
Ichikawa, M, 1089
Ichiki, Y, 5945
Ichimiya, H, 2979
Ida, H, 7743
Idema, S, 9398
Idogawa, M, 8836
Idziaszczyk, S, 10179
Iezzi, M, 1071, 8339
Ifegun, I, 8414, 10952
Ifner, T, 11613
Igawa, M, 2130
Iggo, RD, 6882
Iglesias, A, 11694
Ihrle, RA, 6551
Ijichi, H, 5864, 10822
Ikabuchi, Y, 540
Ikeda, H, 2617
Ikeda, Y, 4417
Ikegami, Y, 1541
Ikewiri, B, 10847
Ikejiri, K, 2979
Ikenoue, T, 4562, 10822
Ikezo, T, 4762
Ikde, DN, 622
Ilag, LL, 1887
Ilaria Jr., RL, 8698
Ilakias, G, 4020, 10223, 11292
Illidge, TM, 7493
Ilslay, JNM, 2636
Ilyas, M, 11361
Imai, K, 10170
Imai, M, 10562
Imai, Y, 596
Imaizumi, N, 2979
Imamura, J, 4562, 10822
Imamura, K, 4769
Imhof, BA, 5703
Imoto, I, 10233
Imreh, S, 1361
Inagaki, K, 10464
Inai, K, 9176
Inazawa, J, 10233
Indik, S, 6651
Ingelman-Sundberg, M, 5105
Ingle, JN, 3059
Ingles, SA, 5470
Iniesta, P, 3811
Innocenti, F, 46
Innocenti, P, 8339
Ino, Y, 10663
Ino, Y, 8836
Inoue, H, 401
Inoue, J, 10233
Inoue, M, 7743
Inoue, M, 2018, 9121
Inoue, S, 3700
Inoue, T, 9611
Inusah, S, 5654
Inuzuka, H, 4587
Invernizzi, AM, 1071
Ioannides, CG, 2930, 6001
Iorio, E, 9369
- Iorio, MV, 7065
Ip, C, 3487, 9073
Iragavarapu-Charyulu, V, 10578
Irby, RB, 1814
Irie, HY, 10992
Irving, JAE, 3053, 9712
Isaacs, JT, 9269
Isaacs, SD, 1213
Isaacs, WB, 1213
Isakoff, SJ, 10992
Iscove, NN, 7151
Ishiai, M, 11704
Ishibashi, H, 6450
Ishibashi, M, 4683
Ishida, T, 657
Ishihara, H, 10159
Ishii, D, 7573
Ishii, G, 4769
Ishii, N, 203
Ishii, T, 203
Ishikawa, E, 596
Ishikawa, H, 2269
Ishikawa, N, 5638, 7102, 9176, 11314
Ishikawa, O, 105, 3092
Ishikawa, T, 4998
Ishikawa, T, 8622
Ishikura, H, 2617
Ishioka, C, 2108
Ishitsuka, K, 7478
Ishiwata, I, 2617
Ishizaka, Y, 4998
Iskander, K, 2054
Isola, J, 1384, 473
Isoyama, T, 7782
Israely, T, 10316
Itami, S, 5720
Itamochi, H, 8406
Itie-YouTen, A, 6685
Ito, E, 7596
Ito, K, 4417
Ito, K, 7743
Ito, R, 2617
Ito, T, 7743
Ito, T, 5638, 7102, 11314
Ito, Y, 7743, 9347
Itoh, A, 1541
Itoh, K, 7628
Itoi, T, 10613
Ittmann, MM, 7959
Ittmann, M, 7976
Iussich, S, 907
Ivanov, V, 3236
Ivanova, M, 10578
Iversen, ES, 4051
Iversen, PW, 6593, 7462
Ivorra, C, 3264
Iwade, Y, 5190
Iwai, T, 10032
Iwamoto, Y, 9623
Iwanaga, K, 11478
Iwata, KK, 9455
Iyer, NG, 9012
Izawa, JL, 6337
Izeradjene, K, 7436
Izraeli, S, 7596
Izzo, JG, 3226
- Jäättelä, M, 2993, 8975
Jabbour, HN, 7707
Jablons, DM, 743
Jaboin, J, 2070
Jackman, AL, 11721
Jacks, T, 3610, 8166, 10280
Jackson, DG, 1425
Jackson, E, 3356
Jackson, EL, 10280
Jackson, JA, 4389
Jackson, LE, 3356
Jackson, S, 7866
Jaco, I, 10223
Jacob, JB, 8471
Jacob, ST, 10891
Jacob-Hirsch, J, 999
Jacobsen, SJ, 1213
- Jacquemier, J, 767, 2170
Jaffee, EM, 1079, 8059
Jagadeesh, S, 1479
Jagadeenwaran, R, 1479
Jäger, Elke, 3937
Jaggi, M, 483
Jahnen-Dechent, W, 499
Jahnukainen, K, 9999
Jain, M, 7840
Jain, RK, 5674, 5711, 5740
Jain, S, 8736
Jaiswal, AK, 2054
Jalali, F, 10810
Jalil, A, 2914
James, CR, 10265
James, J, 887
James, NH, 4389
Jamieson, L, 8905
Jamin, SP, 9206
Jan, B, 3347
Jan, K-Y, 8455
Jang, ER, 11400
Jang, J, 815
Jänne, J, 5390
Jänne, PA, 5561, 7525, 8968
Jans, DA, 7059
Janscak, P, 3604
Jansen, AP, 6034
Jansen, G, 4425, 8414
Janz, S, 1306, 7644
Janzon, L, 8042
Jarbo, C, 2653
Jarman, WE, 6022
Jarrett, J, 10651
Jarrier, P, 2676
Jarvholm, B, 8042
Järvinen, H, 4607
Jarzab, B, 1587
Jarzab, M, 1587
Jasani, B, 7000
Jasin, M, 11597
Jassar, AS, 8379, 11752
Jasser, SA, 4716, 11174
Javaherian, K, 3656
Javonovic, B, 1761
Jay, DG, 1887, 10930
Jay, P, 2193
Jayakumar, A, 11510
Jayapal, M, 10977
Jazag, A, 4562, 5864, 10822
Jazirehi, AR, 264
Jeang, K-T, 4467
Jeeninga, RE, 3347
Jefferies, WA, 7485, 7926
Jeffries, AP, 7926
Jelovac, D, 3903, 5380, 5439
Jeltsch, M, 4739
Jen, K-Y, 7666
Jendreyko, N, 972
Jeng, M-H, 1941
Jenkins, H, 10145
Jenne, Jürgen, 3643
Jensen, LH, 7470
Jensen, PB, 7470
Jeon, E, 3162
Jeon, J-H, 4485
Jeong, G, 11400
Jeong, H-W, 507, 4153
Jeong, J-W, 2520
Jeong, P, 9347
Jeremias, I, 7888
Jeruss, JS, 7968
Jhanwar, SC, 8091
Jhanwar-Uniyal, M, 8538
Ji, H, 7096
Jia, L, 8003
Jia, S-F, 1124
Jia, T, 4500
Jia, Z, 3518
Jian, W, 1961
Jiang, J-D, 7635
Jiang, J-G, 4707
Jiang, J, 8968
Jiang, M, 10457
- Jiang, P, 2337, 4246
Jiang, Q, 4554
Jiang, S-W, 2684
Jiang, W, 7023
Jiang, W-W, 4963
Jiang, Y, 6874
Jiang, Y, 7790
Jiang, Z, 3726
Jiao, W, 4067
Jiguet-Jiglaire, C, 11639
Jiménez, JA, 1941
Jiménez, M, 3249
Jimeno, A, 3003
Jimeno, J, 2964
Jin, DK, 3185
Jin, D-Y, 1450, 8861
Jin, F, 2684
Jin, F, 6354
Jin, L, 1136
Jin, S, 6593, 7533
Jin, T, 5063
Jing, T, 1858
Jing, Y, 7847, 7856
Jiricny, J, 3604, 4525, 10759
Jirstrom, K, 8009, 9727
Jobst, J, 6321
Jodele, S, 3200
Joenje, H, 1271
Joensuu, H, 1384, 2157
Joesting, MS, 10423
Johansson, FK, 2065
John, B, 6022
John, EM, 5470
Johnen, H, 2330
Johnson, BE, 7525
Johnson, D, 805
Johnson, FB, 2730
Johnson, JC, 6425
Johnson, KR, 483
Johnson, KN, 2314
Johnson, MD, 7674
Johnson, MM, 11185
Johnson, M, 8142
Johnson, MR, 383
Johnston, D, 713
Johnston, PG, 8951, 10265
Jolliffe, L, 9038
Jones, AG, 4979
Jones, B, 4051
Jones, D, 7591
Jones, PA, 11241
Jones, RT, 9566
Jones, R, 5740
Jones, SJ, 10742
Jong, H-S, 1952
Jonkers, J, 8166
Jönsson, G, 7612
Jooss, K, 2449, 4739, 6901
Jorcyk, CL, 8896
Jordan, BF, 7911
Jordan, MA, 2433
Jordan, VC, 8504, 10651
Joseph, J, 3100
Joshi, N, 7137
Jost, CM, 7013
Jovanovic, B, 246
Jove, R, 7169, 9185
Jovin, TM, 473
Ju, J, 10623
Juarez, J, 3290
Jubb, AM, 9751
Judd, J-G, 325
Jenkins, T, 10096
Jullian, E, 7622
Jun, DY, 1079
Jun, HJ, 9501
Jun, P, 3617, 5070
Junankar, S, 2330
Jung, C, 1941
Jung, JM, 4896
Jung, K-K, 898
Jung, M-S, 3162
Jungmann, I, 2882
Junttila, TT, 1384

- Jurado, GA, 4645
 Jürchott, K, 4078
 Jürgens, H, 1442
 Jürgensmeier, JM, 4389
 Juric, D, 4088, 8679, 9388
 Juroske, DM, 3226
 Juroske, D, 226
 Jurukovski, V, 7421, 10024
- Kanijk, P, 6443
 Kaaks, R, 8042
 Kabat, GC, 1606
 Kadekaro, AL, 4292
 Kadin, ME, 7628
 Kadowaki, T, 4769
 Kadoya, K, 5325
 Kaetzel, DM, 5523
 Kagawa, K, 113
 Kähkönen, M, 8101
 Kahn, HJ, 10401
 Kahnoski, R, 5628
 Kauna, B, 8920
 Kaiser, LR, 11752, 8379
 Kaiser, S, 6321
 Kakeji, Y, 2979
 Kaklamani, VG, 3454
 Kakudo, Y, 2108
 Kaladidi, A, 8042
 Kalas, W, 8878
 Kalis, M, 4530
 Kallab, V, 11631
 Kallianpur, AR, 8028
 Kallioniemi, O, 5588
 Kalluri, R, 3967
 Kalofoutis, A, 1627
 Kaloulis, K, 11459
 Kaloulis, K, 4005
 Kalthoff, H, 1316
 Kalyankrishna, S, 226, 11478
 Kamath, RV, 246
 Kambara, H, 2832, 11255
 Kamiguchi, K, 8706, 11018
 Kamiguti, AS, 7328
 Kaminishi, M, 4769
 Kamiryo, Y, 10032
 Kamiyama, Y, 157
 Kamizono, J, 5284
 Kammertoens, T, 2560
 Kamoto, T, 9611
 Kampffmann, M, 2537
 Kampinga, HH, 3568, 6509, 10632
 Kanai, F, 4562, 5864, 10822
 Kanai, M, 2746
 Kanamori, T, 1655
 Kanao, H, 8640
 Kanayama, H-o, 5628, 7546
 Kanayama, N, 10464
 Kanazawa, M, 7276
 Kanda, S, 6820
 Kane, AB, 8090
 Kaneda, A, 11236, 11828
 Kanehira, T, 7660
 Kaneko, K, 1089
 Kaneko, T, 5063
 Kanetake, H, 6820
 Kaneuchi, M, 2130
 Kang, BS, 3596, 5818
 Kang, HJ, 2520
 Kang, HW, 9253
 Kang, Y, 7763
 Kanitakis, J, 1755
 Kankuri, E, 9914
 Kannall, HD, 8961
 Kannan-Thulasiraman, P, 9029
 Kanoh, K, 9623
 Kansara, M, 9633
 Kanterewicz, B, 1598
 Kanteti, PVS, 5301
 Kanto, H, 4292
 Kantoff, PW, 2498
 Kanzawa, T, 3336
 Kao, C, 1941
 Kaou, M, 6576, 6764
 Kapunen, AI, 473
- Kaper, F, 3171
 Kaplan, A, 11605
 Kaplan, DM, 10646
 Kaplan, MH, 10024
 Kaplan-Singer, BR, 7370
 Kapoor, V, 8379, 11752
 Kappel, BJ, 4888
 Kappen, C, 887
 Kaprio, J, 9595
 Karadag, A, 11545
 Karagas, MR, 7081
 Karajannis, MA, 3185
 Karaman, MW, 3837, 11676
 Karbach, J, 3937
 Karenko, L, 8101
 Karhu, A, 4607
 Karhu, R, 8101
 Karim, B, 5620
 Karjala, G, 3040
 Karl, E, 5063
 Karmakar, P, 1223
 Karpf, AR, 8635
 Karrison, T, 3146
 Kashishian, A, 4987
 Kasibhatla, MS, 10149
 Kasid, U, 579
 Kasimir-Bauer, S, 2882
 Kasir, J, 9735
 Kasman, IM, 2712
 Kasper, HU, 1394
 Kasperczyk, H, 10502
 Kaspers, GJL, 291
 Kaspers, G, 4425
 Kasprzyska, M, 7800
 Kassem, M, 3126, 9601, 9943
 Kassouf, W, 10524
 Kast, WM, 1570
 Kastemar, M, 2065
 Kasuya, H, 3823
 Katagiri, T, 105, 3092, 4578, 4817
 Kataoka, K, 5720
 Kataoka, N, 5015
 Katayama, M, 4861
 Kath, JC, 957
 Kathmann, I, 4425, 8414
 Kato, H, 2617
 Kato, M, 7276
 Kato, S, 2108
 Kato, T, 5638, 7102, 9176, 11314
 Kato, Y, 10801
 Katsaros, D, 925
 Katschinski, DM, 11094
 Katsoulidis, E, 9029
 Katsuki, M, 7356
 Katsuoka, K, 2337, 5352
 Katuri, V, 4228
 Katz, A, 1213
 Katz, EB, 698
 Katz, MH, 9829
 Katzenberger, T, 2199
 Katzenellenbogen, BS, 5445, 6557
 Kavanagh, R, 4292
 Kawabe, T, 4562, 5864, 10822
 Kawachi, Y, 4817
 Kawagishi, R, 540
 Kawaguchi, A, 113
 Kawaguchi, KS, 3555
 Kawaguchi, R, 10464
 Kawahara, K, 9628
 Kawakami, K, 8388
 Kawakami, M, 8388
 Kawamoto, T, 11712
 Kawamura, YI, 6220
 Kawano, K, 2930, 6001
 Kawano, MM, 2269
 Kawasaki, H, 9415
 Kawasaki, H, 3823
 Kawashima, R, 6220
 Kay, RA, 10742
 Kayastha, G, 7386
 Kaye, FJ, 7137
 Kaygusuz, G, 8118
 Kazanjian, K, 11536
 Kazeronian, S, 11129
- Kazimirsky, G, 7301
 Keating, MJ, 613
 Keats, JJ, 850
 Kedzia, Cécile, 8497
 Keely, PJ, 8766
 Keith, B, 2277
 Keith, WN, 7585, 8080, 8079
 Keller, C, 7530
 Keller, ET, 7554, 8274, 8818, 10921
 Keller, G, 5857
 Keller, JM, 10921
 Keller, J, 8274
 Keller, PJ, 9883
 Keller, S, 2854
 Keller-Peck, CR, 8896
 Kelley, JA, 4673
 Kelley, JR, 6228
 Kelley, KMM, 4431
 Kelley, MR, 3319
 Kelly, L, 2147
 Kelly, PA, 8497
 Kelly, T, 5778
 Kelm, O, 5076
 Kelsell, DP, 8597
 Kelsey, KT, 7081
 Kemp, Z, 11361
 Kenanova, VE, 5907
 Kenanova, V, 622
 Kench, JG, 2330
 Kendall, SDS, 9824
 Kendrew, J, 4389
 Kennedy, GC, 6071
 Kennedy, RD, 10265
 Kennedy, RH, 3100
 Kennedy, RC, 2938
 Kennedy, W, 10441
 Kenny, LM, 10104
 Kenny, MK, 1223
 Keppler, D, 11419
 Kerai, P, 2179
 Kerbel, RS, 5365, 7045
 Kéri, G, 379, 1770, 6919
 Kerkhofs, P, 1234
 Kesavan, P, 3193
 Keshava, C, 1251
 Kesicki, EA, 4987
 Kessler, BM, 7896
 Kessler, P, 2592
 Ketkar, S, 11771
 Key, TJ, 8042
 Keyomarsi, K, 692
 Khalili, J, 2026
 Khan, A, 3307
 Khan, MK, 5317
 Khan, M, 8379
 Khan, MA, 9132
 Khan, N, 11203
 Khanna, C, 2406
 Kharas, MG, 2047
 Kharbanda, S, 10413
 Khaw, AK, 10977
 Kherzai, A, 4663
 Kho, DH, 8993
 Khodarev, NN, 3146
 Khoor, A, 8905
 Khosravi-Far, R, 8286
 Khosrotehrani, K, 1755
 Khrebtukova, I, 3081
 Khuri, FR, 3883, 6354, 7052, 9169
 Khuri, F, 5841
 Khwaja, F, 605
 Kiaris, H, 1627
 Kickhoefer, VA, 8846
 Kiechle, M, 4101
 Kiefer, JA, 1710
 Kierpiec, KA, 10854
 Kiessling, R, 5953
 Kiguchi, K, 5720
 Kikuchi, A, 3535
 Kikuchi, K, 11704
 Kikuchi, S, 10613
 Kilburn, LL, 4389
 Kim, A, 879
 Kim, D-G, 2804, 6312
- Kim, D, 749
 Kim, D, 9185
 Kim, D-M, 2520
 Kim, E-J, 9347
 Kim, GE, 9501
 Kim, H, 8118
 Kim, H-T, 3462
 Kim, H-B, 6811
 Kim, H-S, 1941
 Kim, HS, 6111
 Kim, H-RC, 898
 Kim, HS, 9501
 Kim, HL, 5628
 Kim, I-A, 7902
 Kim, I-H, 2804
 Kim, I-S, 507, 4153
 Kim, JY, 6111
 Kim, J, 8242
 Kim, J, 6189, 7984
 Kim, J, 5554
 Kim, J, 9347
 Kim, JYH, 5683
 Kim, J-H, 2804, 6312
 Kim, JS, 1306, 7644
 Kim, J, 1800, 11536
 Kim, JS, 3682
 Kim, J, 1952
 Kim, K, 749
 Kim, KK, 8993
 Kim, K-W, 2520
 Kim, M-H, 6811
 Kim, M, 3986
 Kim, M, 8324
 Kim, M-S, 686
 Kim, M-Y, 8993
 Kim, MS, 4963
 Kim, NS, 8993
 Kim, N-C, 4448
 Kim, R, 5750
 Kim, R, 6042
 Kim, S, 9574
 Kim, SG, 1952
 Kim, SY, 815
 Kim, S-H, 2520
 Kim, S-J, 1761
 Kim, S-J, 686
 Kim, S-J, 3707, 3716, 4716
 Kim, S-W, 8784
 Kim, S-Y, 2520
 Kim, TW, 309
 Kim, T-Y, 1952
 Kim, TY, 1952
 Kim, WD, 4809
 Kim, WH, 11271
 Kim, W-J, 9347
 Kim, YH, 3682
 Kim, YH, 226, 9200
 Kim, YR, 9253
 Kim, Y-T, 6312
 Kim, Y-J, 137
 Kimchi, ET, 3146
 Kimmig, R, 2882
 Kimura, MT, 3548
 Kimura, T, 8640
 Kindem, K, 2387
 King, GD, 7194
 King, JC, 11565
 Kinniry, PA, 8379
 Kinoshita, H, 9611
 Kinoshita, I, 10776
 Kinsella, TJ, 4362
 Kioi, M, 8388
 Kioussis, D, 9245
 Kipp, HH, 708
 Kira, M, 5720
 Kiriakova, G, 5578
 Kirkpatrick, J, 9126
 Kirkwood, JM, 805
 Kirma, N, 11164
 Kirpotin, DB, 11631
 Kirsch, IR, 7137
 Kirschenbaum, A, 5761
 Kirschmann, DA, 10164, 11429, 11520
 Kirschner, LS, 4506, 10307

- Kirsh, VA, 11779
 Kisfalvi, K, 2738
 Kishida, T, 4598
 Kishimoto, K, 1352
 Kisiel, N, 5390
 Kisker, O, 11044
 Kisselev, P, 2972
 Kitada, Y, 10371
 Kitagawa, Y, 10921
 Kitajewski, J, 5263
 Kitamura, T, 3700
 Kitahara, T, 10464
 Kitano, Y, 828
 Kitayama, J, 9159
 Kitazaki, T, 1541
 Kitchen, C, 8846
 Kitching, R, 10401
 Kitlinska, J, 1719
 Kittrell, FS, 3493
 Kiyoshima, K, 10032
 Kizaki, M, 4417
 Kladny, J, 835
 Klagsbrun, M, 2507
 Klebig, C, 394
 Klebl, B, 379
 Kleer, CG, 8366, 11259, 11326
 Klein, E, 727
 Klein, L, 6443
 Klein, RM, 148
 Klein, RD, 1808
 Kleindienst, P, 2882
 Kleinerman, ES, 1124
 Kleinman, HK, 7370, 10494
 Klein-Szanto, AJ, 3011, 4162, 7310
 Klenova, E, 5112
 Klibanov, AL, 533
 Klien, HC, 6305
 Klijn, JGM, 4101
 Kline, ER, 9021
 Klingelhofer, J, 3772
 Klisovic, MI, 1277
 Klijavin, N, 9751
 Klocker, H, 1141, 8397
 Klonisch, T, 1343
 Kloog, Y, 999, 7292
 Kloor, M, 6418, 8072
 Klöppel, G, 1316
 Klos, KS, 1858
 Kluger, HM, 5578
 Kluger, Y, 5578
 Klusman, K, 8331
 Kluth, A, 4101
 Kmet, M, 868
 Knauf, JA, 2465, 4238
 Kneel, DA, 1615
 Knight, D, 8286
 Knopp, M, 7041
 Knowles, DM, 11345
 Knowles, M, 7591
 Knowles, MA, 66, 10441
 Knox, SJ, 284
 Knudsen, ES, 3542, 4568
 Knudsen, KE, 54
 Knuth, A, 3937
 Knutsen, H, 121
 Knuutila, S, 6583
 Ko, B, 5785
 Ko, EC, 6976
 Ko, S-G, 1952
 Kobayashi, H, 10464
 Kobayashi, K, 7276
 Kobayashi, N, 4292
 Kobayashi, R, 10478, 11118
 Kobayashi, S, 7096
 Kobayashi, Y, 4653
 Koblinski, JE, 7370
 Koch, A, 8567
 Koch, I, 5038
 Koch, WM, 758
 Kocherginsky, M, 3146, 10984
 Kodama, E-I, 6927
 Koed, K, 34
 Koefler, HP, 2488, 4762
 Koenig, T, 4101
 Koeppen, H, 9751
 Koga, T, 7241
 Koga, T, 9121
 Kogan, I, 4530
 Koh, E, 11572
 Koh, Y, 6927
 Kohlhaas, SL, 11265
 Kohlhaagen, G, 4844, 5337
 Kohli, M, 9485
 Kohn, EC, 3853
 Kohno, N, 9176, 9623
 Kohno, S, 1541
 Koistinen, R, 4607
 Kok, TW, 3691
 Koki, A, 767
 Kokko, A, 10170
 Kokontis, JM, 2082
 Kolb, H-J, 2662
 Kolch, W, 1244, 5485
 Kolinski, A, 3410
 Kominsky, S, 10801
 Komiya, A, 1213
 Komiya, S, 5284
 Komura, E, 3281
 Kon, OL, 186
 Kon, T, 9126
 Konaka, H, 2303
 Kondo, R, 9436
 Kondo, S, 5638
 Kondo, S, 3336, 4368
 Kondo, S, 10822
 Kondo, T, 6450
 Kondo, T, 10464
 Kondo, Y, 3336, 4368
 Kondo, Y, 2610
 Kondoh, H, 177
 Kong, D, 9047
 Kong, G, 3462
 Kong, Y-M, 8471
 Konicek, BW, 7462
 König, J, 11419
 Konnikova, L, 6516
 Kono, E, 9495
 Kono, S, 2979
 Konopleva, M, 2890, 9962
 Konrad, L, 10170
 Konstantopoulos, K, 5812
 Kontos, CD, 11276
 Koo, J, 5470
 Kook, H, 8993
 Kool, H, 10298
 Koomen, JM, 10478
 Koon, H, 5084
 Koong, AC, 6151
 Kopelovich, L, 664, 5982
 Kopitz, C, 3523, 8608
 Koplevich, L, 3950
 Koppen, A, 3136
 Koppikar, CB, 3025
 Kopplov, K, 11419
 Koprivnikar, K, 6901
 Korangy, F, 2457
 Korbelik, M, 1018
 Kore, M, 3243
 Kort, EJ, 5628
 Kortessidis, A, 1700
 Kortum, RJ, 3986
 Kortylewicz, ZP, 7824
 Kosai, K-I, 5284
 Koshikawa, N, 11622
 Kosik, KS, 6029
 Koskenvuo, M, 9595
 Kosmehl, H, 10486
 Kosmidou, V, 7591
 Koster, R, 1729
 Kosuge, T, 10613
 Kotecki, M, 6516
 Kottke, T, 2009
 Koty, Z, 8359
 Keul, D, 1678
 Koutcher, JA, 9080
 Kouwenhoven, MCM, 11335
 Kovacic, A, 657, 11762
 Kovacs, K, 1136
 Kovarik, P, 246
 Kowalczyk, A, 4031
 Kowalczyk, A, 3410
 Kowalski, D, 5890
 Kowalski, LP, 1693
 Koyanagi, K, 1800
 Kozbor, D, 3410
 Kozikowski, AP, 3950
 Kraft, AS, 1615
 Kraft, P, 11771
 Krahe, R, 427
 Krajewska, M, 4799
 Krajewski, S, 4799
 Kramata, P, 3577
 Kramer, DL, 5390
 Krammer, PH, 10830
 Krasna, MJ, 9566
 Krasnoperov, V, 4623
 Krause, JA, 11174
 Krauth, M-T, 9436
 Krebs, I, 8101
 Kreitman, RJ, 8388
 Kress, CL, 4799
 Kretschmer, PJ, 8397
 Krex, D, 3117
 Krichevsky, AM, 6029
 Krimpenfort, P, 5730
 Krishna, C, 3171
 Krishna, MC, 579
 Krishnamachary, B, 6178
 Krishnan, AV, 7917
 Krishnan, V, 6593
 Kristensen, GB, 331
 Kroese, F, 10783
 Kroesen, B-J, 3380
 Krogh, V, 8042
 Kroll, DJ, 4448
 Kronblad, Åsa, 8009
 Kronen-Herzig, A, 5133
 Kronqvist, P, 4754
 Krontiris, TG, 805
 Krop, I, 11326, 9659
 Kropshofer, H, 10068
 Kros, JM, 11335
 Krüger, A, 3523, 8608
 Krüger, JA, 5027
 Krüger, MM, 6516
 Krüger, WW, 9038
 Krusch, M, 6321
 Kryczek, I, 465, 5020
 Krysan, K, 6275
 Krzyzanowski, M, 8042
 Kuang, S-Q, 7993
 Kubacka, S, 7393
 Kubota, K, 9426
 Kubota, N, 4769
 Kuchner, EB, 9355
 Kucuk, O, 6934
 Küçükali, T, 6199
 Kudahetti, SC, 9137
 Kudoh, S, 10494
 Kufe, D, 10413
 Kufer, P, 2882
 Kuffner, T, 2330
 Kühle, O, 1187
 Kühnel, F, 7393
 Kuick, R, 5488
 Kukowska-Latallo, JF, 5317
 Kukreja, P, 9891
 Kulbe, H, 10355
 Kulesza, P, 3003
 Kulkarni, T, 8519
 Kulldorff, M, 8034
 Kulp, AN, 9328
 Kulp, SK, 1561
 Kumagai, J, 3700
 Kumagai, T, 2488
 Kumakura, S-I, 2778
 Kumar, R, 2511, 3179, 5571, 7724, 10594
 Kumar, R, 11304
 Kumar, SR, 4623
 Kumar, S, 7478
 Kumaraswamy, S, 10536
 Kurnle, M, 8042
 Kumon, H, 9617
 Kundrand, MN, 499
 Kung, AL, 8324, 11392
 Kunicki, J, 4401
 Kunisada, M, 6006
 Kuntzen, C, 6780
 Kuo, L, 1719
 Kuo, M-L, 4827
 Kuo, W-L, 8125
 Kuperwasser, C, 6130
 Kupiec-Weglinski, J, 7194
 Kupriyanova, TA, 10959
 Kurie, JM, 11478, 226, 3226
 Kurimoto, N, 9623
 Kurita, N, 10464
 Kurizaki, T, 7824
 Kurley, SJ, 7088
 Kurrr, JM, RJ, 1994
 Kuroda, T, 10663
 Kurokawa, M, 6071
 Kurose, K, 9617
 Kurosumi, M, 4653
 Kurotaki, T, 8706
 Kurrey, NK, 3025
 Kurtenbach, A, 379
 Kurth, R, 4172
 Kuruppu, DK, 3823
 Kurzawski, G, 835
 Kusama, T, 9121
 Kusewitt, DF, 4506
 Kushner, PJ, 6557
 Kussick, SJ, 2795
 Kusters, B, 8317
 Kusunoki, Y, 5462
 Kutay, H, 10891
 Kutok, JL, 5750
 Kuwahara, K, 5925
 Kuwai, T, 10371
 Kuwano, H, 3535, 4939
 Kuwano, M, 4253
 Kuzel, T, 1761
 Kveiborg, M, 4754
 Kwan, A, 8792
 Kweon, M-H, 11203
 Kwiatkowski, DJ, 2474, 10881
 Kwok, WK, 5153
 Kwon, HJ, 9899
 Kwon, K-S, 4485
 Kwon, SM, 3577
 Kwon, S, 9355
 Kwong, JQ, 1655
 Kyewski, B, 6443
 Kyoizumi, S, 5462
 Kyprianou, N, 11230
 Kytölä, Soili, 8101
 L'Hôte, CG, 10441
 La, M, 2482
 Laban, M, 10330
 Lacal, JC, 5647
 Laceyfield, JC, 5231, 6337
 Lackmann, M, 6745
 Lackner, A, 465
 Lacout, C, 3281
 Lacroix, L, 8497
 Ladant, D, 641
 Lader, A, 1479
 Lafarga, M, 8151
 Lafky, JM, 3059
 LaFleur, B, 1748
 LaFramboise, T, 5561
 Lagiou, P, 358
 Lagonigro, MS, 1115
 Lahad, JP, 2516
 LaHair, MM, 5408
 Lai, K-P, 4827
 Lai, T-S, 1369
 Laiho, P, 10170
 Laird, DW, 2705
 Lake, RA, 7580
 Lakhani, SR, 7591
 Lal, A, 5070
 Lal, B, 9355
 Lalani, AS, 6901

- Lam, CT, 219
 Lam, CN-Y, 8125
 Lam, EKY, 5272
 Lam, WL, 7561, 8017
 Lamagna, C, 5703
 Laman, R, 7591
 Lamb, J, 4059
 Lambert, PF, 6534, 8266
 Lamfers, MLM, 9398
 Lampen, N, 11061
 Lamph, WW, 3462
 Lan, K-H, 1858
 Lan, Q, 9574
 Land, S, 1598
 Landberg, G, 732, 8009, 9727
 Landen Jr., CN, 6910
 Landen, C, 10562
 Landesman-Bollag, E, 5792, 11375
 Landowski, TH, 3828
 Landsittel, D, 4097
 Lane, DP, 5399
 Lane, J, 11345
 Lane, MA, 9923
 Lane, TF, 4496
 Lang, FF, 3307
 Langdon, SP, 6789
 Lange, A, 465, 5020
 Lange, B, 2482
 Lange, D, 1587
 Lange, PH, 3081
 Langer, R, 5038
 Langford, CF, 2653
 Langley, RR, 3707, 10794
 Languino, LR, 6692
 Lannigan, DA, 1027, 3108
 Lantz, O, 1755
 Lantzi, C, 2364
 Lapidot, T, 1700
 Lapin, V, 6685
 Lapointe, J, 8118
 Lappin, TRJ, 9245
 Lara, MF, 9678
 Largaespada, DA, 9607
 Larocca, LM, 11469
 Laronde, D, 8017
 Larregina, AT, 10059
 Larsen, B, 8397
 Larson, GP, 805
 Larson, SM, 9080
 Lasaga, J, 9294
 Lashinger, LM, 4902
 Lassmann, H, 7194
 Laszlo, A, 10632
 Latchman, DS, 3072
 Laterra, J, 5248, 9355
 Latif, F, 2690, 3117, 3497, 4598, 7653
 Latigo, JR, 4202
 Latouche, J-B, 5417
 Latre, L, 10223
 Lau, C, 3691
 Lau, CC, 76, 8142
 Lau, JS, 1089
 Lau, K-M, 3726
 Lau, TCM, 5153
 Lauer, I, 10486
 Lauer, UM, 6321
 Laughton, CA, 3911
 Launonen, V, 4607
 Laurent, A, 948
 Laurie, NA, 11010
 Lausch, EU, 840
 LaVallee, TM, 9406
 Lavin, ME, 1670
 Law, C-L, 8331
 Lawrence, N, 10536
 Lawrence, TS, 5493, 6835
 Lawrie, S, 6789
 Lazarus, R, 11771
 Lazennec, G, 5480, 8784
 Lazzari, C, 432
 Le Blanc, K, 2207
 Le Calvez, F, 5076
 Le Danff, C, 1755
 Le Marchand, L, 7516
 Le, LP, 10154
 Le, ND, 8017
 Le, Q-T, 6151
 Le, X, 4809
 Leach, MO, 3356
 Leach, SD, 1619
 Leal, AD, 1414
 Leary, DJ, 246
 LeBeau, MM, 11565
 LeBlanc, R, 7896
 Lehman, DA, 4782
 LeBon, T, 10338
 Lecane, PS, 11676
 Lecane, P, 3837
 Leclair, B, 10096
 Leclerc, C, 641
 LeCoudic, JR, 3281
 Leder, P, 6891
 Lednický, J, 10273
 Lee, AV, 3781
 Lee, AY, 743
 Lee, AS, 5785
 Lee, B-C, 2840
 Lee, B-H, 4153
 Lee, C, 9834
 Lee, C-H, 686
 Lee, C, 186
 Lee, C-N, 9089
 Lee, CR, 7045
 Lee, C, 1761
 Lee, CL, 7984
 Lee, D, 6534
 Lee, EW, 1719
 Lee, EJ, 7968
 Lee, FL, 7984
 Lee, F-T, 6745
 Lee, FY, 3781, 4500, 9185
 Lee, H, 1642
 Lee, J, 11304
 Lee, J, 11156
 Lee, J, 2353
 Lee, JC, 5561
 Lee, J-D, 7699, 8784
 Lee, JH, 8993
 Lee, J-H, 137, 749, 5554
 Lee, J-H, 9185
 Lee, J-H, 309
 Lee, J-Y, 10602
 Lee, J-S, 11400
 Lee, J-S, 11694
 Lee, JW, 815
 Lee, JW, 1952
 Lee, JY, 815
 Lee, K, 3986
 Lee, K-N, 4485
 Lee, K-O, 317
 Lee, M-J, 8049
 Lee, MP, 2542
 Lee, M-S, 6111
 Lee, NH, 1814
 Lee, N-Y, 11061
 Lee, RM, 10016
 Lee, S, 1035
 Lee, S, 5221
 Lee, S-H, 4870
 Lee, S-H, 137, 686, 749
 Lee, S-J, 1941
 Lee, S-O, 6312
 Lee, S-h, 7984
 Lee, SA, 3072
 Lee, SO, 3487
 Lee, SH, 815
 Lee, TL, 7071
 Lee, T-H, 2840
 Lee, T-W, 5153
 Lee, W-NP, 5512
 Lee, WJ, 5802
 Lee, WP, 8331
 Lee, YJ, 898
 Lee, YM, 11400
 Lee, Y-S, 6811
 Leek, RD, 4147
 Leemans, CR, 1271
 Leenders, F, 4078
 Leenders, WPJ, 8317
 Lee Loy, A, 10088
 Lees-Miller, SP, 1670
 Lehmann, AR, 9799
 Lehmann, M, 2433
 Lehtonen, H, 4607
 Lehtonen, R, 4607
 Leishear, K, 9328
 Leite-Browning, ML, 499
 Leitzmann, MF, 2498
 Lejeune, L, 8359
 Lelièvre, H, 7231
 Lemoine, N, 3218
 Lemoine, NR, 1523
 Lemonnier, F, 6435
 Lemp, N, 4762
 Lengauer, C, 919
 Lentsch, AB, 4568
 Leof, EB, 10431
 Leong, H-S, 9012
 Leong, SH, 186
 Leopoldino, AM, 325
 Lepley, D, 3788
 Lepp, C, 3837
 LeRoy, S, 6850
 Leslie, KK, 9517
 Lesma, E, 2139
 Lesniewski, R, 4663
 Lesoon, A, 6593
 Lesperance, J, 5325
 Lesslie, DR, 7214
 Létard, S, 7231
 Letwin, N, 1814
 Leung, PCK, 8591
 Leung, SY, 7591
 Leung, SY, 9200
 Leung, TH-Y, 8861
 Leung, Y-K, 3726
 Levenson, AS, 10651
 Levenson, JD, 2698
 Levin, B, 11486
 Levin, TR, 6063
 Levine, A, 5761
 Levine, A, 5481
 Levine, CG, 787
 Lewis, M, 1514
 Levitsky, H, 2026
 Levy, DE, 939, 5828
 Lévy, E, 948
 Levy, R, 5958
 Lewis, JE, 7462
 Lewis, JS, 8397
 Lewis, JD, 2938
 Lewis, KA, 7091
 Lewis, MM, 1909
 Lewis, RE, 3986
 Ley-Ebert, C, 166
 Leyton, J, 4202
 Li, A, 3781
 Li, B, 2449
 Li, C, 7169
 Li, C, 5561, 6042, 9651
 Li, CJ, 6017, 7809
 Li, C-Y, 5498, 7541, 9126
 Li, C, 8118
 Li, C, 7205
 Li, D, 9216
 Li, D, 7603
 Li, F, 9126
 Li, F, 5358
 Li, F-J, 2269
 Li, G, 8350, 9574
 Li, H, 10912
 Li, H, 2498
 Li, H, 1514
 Li, H, 5009
 Li, H, 4979
 Li, H, 4041
 Li, JT, 1547
 Li, JJ, 10338
 Li, J, 92
 Li, J, 6601, 9287
 Li, J, 6843
 Li, J, 4747
 Li, J-L, 8690
 Li, L, 7249
 Li, L, 2560
 Li, L, 1719
 Li, L, 5907, 11193
 Li, L, 4126
 Li, L, 2337, 5352
 Li, L-C, 2130
 Li, M, 8200
 Li, M, 5045
 Li, N, 4947
 Li, P, 8591
 Li, P, 11129
 Li, P, 1858
 Li, Q, 4809
 Li, Q, 1063
 Li, Q, 8622
 Li, Q, 3691
 Li, Q-L, 9347
 Li, R, 1259
 Li, R, 10569
 Li, R, 7205
 Li, S, 5835
 Li, W, 236
 Li, W, 2592
 Li, W, 8671
 Li, X-F, 11712
 Li, X, 5898
 Li, X, 8671
 Li, X, 6017
 Li, X, 1941
 Li, YM, 3257
 Li, Y, 1577
 Li, Y, 6874
 Li, Y, 722
 Li, Y, 8298
 Li, Y, 1904
 Li, Y, 6934
 Li, Y, 1514
 Li, Y, 2560
 Li, Y, 9029
 Li, Y, 1277
 Li, Y, 822
 Li, Y, 9355
 Li, Y-H, 10838
 Li, Z, 2070
 Li, Z, 6557
 Li, Z, 5195
 Li, X, 11326
 Lia, M, 2854
 Lian, Y, 8209
 Liang, A, 7984
 Liang, G, 722
 Liang, H, 1007, 5133
 Liang, J, 9363
 Liang, S, 925
 Liang, Z, 967
 Liao, C-W, 9089
 Liao, J, 10623
 Liao, L, 7993
 Liao, R, 8298
 Liao, S, 919
 Liao, S, 2082
 Liao, WS-L, 6701
 Liao, X-H, 4238
 Liao, Z-Y, 4844
 Liao, Z-y, 5337
 Libener, R, 3049
 Liber, HL, 5544
 Libermann, TA, 4728
 Libertini, SJ, 10700
 Liby, K, 4789
 Licht, JD, 8174
 Lichter, P, 439
 Lidar, Z, 6858
 Liebel, U, 7733
 Lieber, A, 4343
 Lieberman, HB, 933
 Light, Y, 10686
 Lilge, L, 10810
 Lillard-Wetherell, K, 5520
 Lillberg, K, 9595
 Lillington, DM, 375
 Lillington, D, 9152

- Lim, CUK, 5544
 Lim, J-H, 6711
 Lim, M, 10569
 Lim, S, 8504
 Lim, S, 5512
 Lim, S-J, 3162
 Lim, WG, 4520
 Limite, G, 6668
 Lin, A, 10984, 8372
 Lin, B, 3081
 Lin, D, 722, 9582
 Lin, HH, 6622
 Lin, H-H, 2921
 Lin, H-M, 4067
 Lin, JM, 2449
 Lin, JM, 6901
 Lin, J, 957
 Lin, K, 7328
 Lin, M, 5561
 Lin, PC, 2815
 Lin, R, 8397
 Lin, R, 9038
 Lin, S-H, 7976, 7984
 Lin, W, 8218
 Lin, X, 7249
 Lin, Y, 2162
 Lin, Y-W, 7151
 Lin, Y, 10623
 Lin, Z, 8331
 Linardic, CM, 4490, 9824
 Lind, GE, 5588
 Lind, SE, 3389
 Linda Bl, W, 6726
 Lindahl, T, 10472
 Lindblad-Toh, K, 5654
 Lindencrona, JA, 5953
 Lindsay, TH, 9426
 Lindtner, B, 9643
 Linehan, WM, 4775, 6498
 Linet, M, 9574
 Ling, M-t, 1450
 Ling, M-T, 5153
 Ling, X, 2532
 Link, CJ, 10555
 Linke, SP, 2526
 Linkels, M, 8317
 Linkov, I, 9415
 Linseisen, J, 8042
 Lioe, TF, 10265
 Liotta, LA, 3853, 6526
 Liou, JS, 2125
 Lipkin, SM, 5488, 8662, 10759
 Lippman, SM, 6189, 8442, 11486
 Lips, EH, 10188
 Lipscomb, EA, 10970
 Lipson, KE, 3643
 Lisanti, MP, 6557
 Liskay, RM, 8662
 Lissoni, A, 2964
 List, T, 7707
 Lister, TA, 375, 9152
 Little, JB, 6734
 Litvak, A, 3017
 Litvin, J, 10174
 Litwin, S, 7310
 Litzl, T, 5031
 Liu, B, 3389, 879
 Liu, C-G, 7065, 7790
 Liu, C, 3419
 Liu, C, 1277
 Liu, C, 7194
 Liu, D, 10413
 Liu, D, 3796
 Liu, ET, 9012
 Liu, G, 8747
 Liu, G, 4191
 Liu, G, 7041
 Liu, H, 7635
 Liu, H, 8504
 Liu, J, 10016
 Liu, J, 8372
 Liu, J, 7635
 Liu, J, 9206
 Liu, J, 982
 Liu, J, 3454
 Liu, K, 9891
 Liu, KJ, 1647
 Liu, K, 1045, 4376
 Liu, L, 2804, 6312
 Liu, L, 1830, 4191
 Liu, L, 10838
 Liu, L, 92
 Liu, L, 7338
 Liu, LH, 8655
 Liu, M, 5325, 7081
 Liu, N, 879
 Liu, Q, 7743
 Liu, Q, 358
 Liu, R, 1532
 Liu, S, 2269
 Liu, S, 7541, 9126
 Liu, S, 1277
 Liu, S, 1352
 Liu, S, 4947
 Liu, S-X, 3236
 Liu, TJ, 1934
 Liu, T, 2330
 Liu, V, 1761
 Liu, W, 46
 Liu, W, 7635
 Liu, W, 7775
 Liu, W-j, 2602
 Liu, X, 6354, 9169
 Liu, X, 7800
 Liu, X, 6874
 Liu, X, 99
 Liu, X-W, 898
 Liu, Y-G, 11164
 Liu, Y, 1687
 Liu, YY, 10623
 Liu, Y, 4955
 Liu, Y-Y, 3861
 Liu, Y, 3404
 Liu, Y, 3470
 Liu, Y, 9280
 Liu, Y, 3691
 Liu, Z-g, 9287
 Liu, Z, 1647
 Liu, Z, 9582
 Liu, Z-J, 387, 5802
 Liu, Z, 2583
 Livasy, C, 9155
 Livingstone, M, 7533
 Llansa, ND, 6189
 Lledó, Elisa, 3264
 Leonart, ME, 177
 Leonart, M, 2179
 Lloyd, AC, 3035
 Lloyd, D, 11493
 Lloyd, RV, 1136
 Lo, H-W, 338
 Lo, J-F, 8784
 Lo, K-W, 8125
 Lobanenko, VV, 7751, 7763
 Lobanenko, V, 5112
 Lobe, C, 6245
 Loberg, Else Marit, 121
 Lobie, PE, 317
 Locke, M, 8944
 Lockwood, G, 8530
 Loda, M, 5054
 Lodygin, D, 4218
 Loeffler, M, 5027
 Loetzsch, E, 11613
 Loewen, R, 7091
 Loffredo, CA, 9566
 Loftus, JC, 5292
 Logie, JJ, 5740
 Logothetis, CJ, 6189
 Lohi, J, 7691
 Lohmann, DR, 10634
 Lohse, CM, 708, 8905
 Lohner, H, 7934
 Lokeshwar, BL, 2243, 7782
 Lokeshwar, VB, 2243, 7782
 Lollini, P-L, 3868
 Lombaerts, M, 11304
 Lombardi, M, 10585
 Lombardo, C, 2321
 Long, BJ, 5380
 Long, B, 3903
 Long II, DJ, 2054
 Longhi, R, 3920
 Longley, DB, 8951
 Lönn, S, 6459
 Lonser, RB, 10847
 Loo, WTY, 8646
 Looijenga, LHJ, 7591, 8085
 Look, MP, 4101
 Loonen, AH, 291
 Lopez De Cicco, R, 7310
 López de Cicco, R, 4162
 Lopez, DM, 10578
 Lopez, JL, 6755
 Lopez-Albaiteiro, A, 11146
 Lopez-Barcons, L, 2854
 Lopez-Berestein, G, 6910
 López-Guillermo, A, 2199
 Lopez-Vega, JM, 8151
 Lorenczewski, G, 2882
 Lorens, JB, 9294
 Lorimore, SA, 3527, 5668
 Lorimore, S, 4211
 Lotan, R, 1117, 6354, 9555
 Lothe, RA, 5588
 Lothstein, L, 10016
 Lotti, F, 11469
 Lotze, MT, 9991
 Lou, W, 3487
 Lou, Y-R, 3577
 Lou, Y, 7926
 Lou, Z, 1007
 Louache, F, 2676
 Louie, SG, 6622
 Louis, DN, 5523
 Louis, M, 7348
 Loukinov, DI, 7751, 7763
 Loukinov, D, 5112
 Love, DC, 7223
 Low, GKM, 10977
 Lowdell, MW, 2373
 Lowe, SW, 6294
 Lowell, AM, 6401
 Lowenstein, PR, 7194
 Löwik, C W.G.M., 7682
 Lozano, G, 427
 Lu, E, 533
 Lu, H, 5015
 Lu, H-R, 8613
 Lu, H, 1647
 Lu, J, 4769
 Lu, J, 1858
 Lu, KH, 10602
 Lu, L, 6450
 Lu, M, 4799
 Lu, M, 6159
 Lu, P, 698
 Lu, S, 8747
 Lu, W, 3081, 7301
 Lu, W, 913
 Lu, X, 6843
 Lu, Y-P, 3577
 Lu, Y, 8274
 Lu, Y-J, 9137
 Lu, Z, 6701
 Lualdi, E, 4012
 Luan, B, 6901
 Luan, C, 5628
 Lübbert, M, 1117, 7086
 Lubin, JH, 11214
 Lubinski, J, 835
 Luca, FC, 6568
 Lucas, J, 5358
 Lucock, MD, 8573
 Ludwig, DL, 1514
 Lugassy, G, 6435
 Lugg, R, 7591
 Luider, TM, 11335
 Luk, JM, 219
 Lukanidin, E, 3772, 6167
 Lukas, S, 3868
 Lukashev, A, 6882
 Luketich, JD, 2147
 Luksiene, Z, 11051
 Lulé, J, 2787
 Lum, CT, 219
 Lun, X, 9982
 Lundberg, C, 805
 Lundin, J, 1384, 2157
 Lundin, M, 1384
 Lunter, PC, 8801
 Luo, A, 9582
 Luo, AZ, 4309
 Luo, C, 7635
 Luo, J, 10992
 Luo, RZ, 6701
 Luo, S, 349
 Luo, SW, 5272
 Luo, W, 7976
 Luo, X, 10725
 Luo, X, 10716
 Luo, Y, 2698
 Luo, Y, 553, 3419
 Lupetti, R, 632
 Lupton, JR, 887
 Luqman, M, 5898
 Lusic, EA, 7121
 Luthra, R, 11164
 Luthra, SK, 10104
 Luts, L, 7612
 Lutterbuese, R, 2882
 Lüttges, J, 3218
 Lutzko, C, 3200
 Lutzky, VP, 5123
 Luzzatto, L, 8111
 Lyddane, C, 9080
 Lyker, JS, 1459
 Lyko, F, 6305, 7086
 Lyle, SR, 10970
 Lyman, M, 7121
 Lynch, DK, 3273
 Lynch, DT, 11174
 Lynch, MJ, 572
 Lynch, P, 11486
 Lynch, RL, 7462
 Lynch, RM, 3828
 Lyons, GE, 1570
 Lyssikatos, JP, 957
 M'Rini, C, 11639
 Ma, C, 5417, 9415
 Ma, CX, 11071
 Ma, D, 1433
 Ma, DWL, 887
 Ma, D, 5523
 Ma, J, 10623
 Ma, J, 2498
 Ma, L, 5365
 Ma, PC, 1479
 Ma, Q, 6601, 9287
 Ma, W-Y, 3596
 Ma, X, 10578
 Ma, X, 4238
 Ma, X, 5730
 Ma, Y, 6476
 Ma, Y, 6557
 Ma, Z, 2269
 MacCalli, C, 3942
 MacCallum, DE, 5399
 MacDonald, D, 805
 MacDonald, IC, 5231
 MacDonald, JM, 10149
 MacDonald, TJ, 1748
 Macedo, L, 5380, 5439
 MacFarlane, M, 11265
 Machado, AA, 1693
 Machado, CR, 325
 Machelon, V, 465
 Machida, T, 5190
 Machlenkin, A, 6435
 Machol, K, 7596
 Mackay, A, 5112
 Mackenzie, IC, 8944
 MacKenzie, LT, 5231
 Macleod, K, 6789
 MacLeod, V, 5778

- MacNaughton, WK, 8604
Madsen, MA, 10959
Madura, K, 5599
Madzalan, P, 1554
Maeda, T, 8575
Maehara, Y, 2979, 7241
Maekawa, T, 2979
Maestro, R, 587
Maffucci, T, 8339
Mafune, K-i, 4769
Magaud, J-P, 6521
Magda, D, 3837, 11676
Magdelénat, H, 1376
Maggi, A, 5445
Maghami, E, 3063
Magnaldo, T, 5205
Magni, F, 2906
Magnon, C, 4353
Magnussen, A, 2712
Magoffin, D, 9651
Magri, E, 7065
Mahadevan, B, 1251
Mahajan, NP, 10514
Maher, ER, 2690, 4598, 7653
Maher, VM, 1007
Mahmood, A, 4979
Mahmood, U, 9253
Mahnke, K, 7007
Maia, S, 10050
Maier, S, 4101
Maier, SE, 6858
Maihle, NJ, 3059
Maina, EN, 4598
Maitland, NJ, 10946
Maitra, A, 1619, 3003
Majest, S, 4663
Majety, M, 7733
Majmudar, K, 1642
Majoros, JJ, 5317
Majumdar, APN, 3877
Majumder, S, 3404
Majumder, S, 10891
Mak, TW, 6685, 10363
Makary, E, 650
Maki, K, 6612
Malavaud, B, 11667
Malaveille, C, 8042
Malek, RL, 1814
Malek, T, 9695
Maleszka, R, 835
Mali, AM, 3025
Malkin, D, 7267
Malkowicz, B, 7591
Mallucci, L, 1631
Malmer, B, 6459
Malmström, P-O, 2554
Malumbres, M, 3249, 3846
Mamot, C, 11631
Man, S, 7045
Man, T-K, 8142
Manara, MC, 3868
Manavathi, B, 5571, 7724
Manavis, J, 1700
Mancini, F, 9687
Mancini, R, 6576
Mancini, UM, 1693
Mancl, ME, 7403
Mandal, M, 4716
Mandal, SK, 5696
Mandelker, DL, 4963
Manekeller, S, 7013
Manfredi, G, 1655
Manfredi, JJ, 2602
Mang, W, 6017
Mangeat, PH, 10872
Mangeney, M, 2588
Mangues, R, 5512
Mani, J, 698
Manka, D, 11689
Manley, PW, 4500
Manni, A, 11026
Manning, CM, 6891
Manns, MP, 2457
Manns, M, 7393
Manola, KN, 11292
Mansukhani, M, 2554
Mant, C, 1112
Mantovani, A, 9113
Mantovani, R, 758
Mantyh, PW, 9426
Manzke, O, 5516
Manzo, E, 3040
Mao, C, 8671
Mao, J-H, 6488
Mao, L, 5841
Mao, M, 4059
Mao, X, 6701
Marais, R, 5003, 9719, 10686, 11493
Maranchie, JK, 9190
Maraninchi, D, 767
Marasco, W, 2344
Marc, B, 195
Marcelli, M, 1849
Marchesi, F, 2964
Marchetti, A, 9687
Marchion, DC, 3815
Marciniak, DJ, 3877
Marciniak, RA, 2730
Marcucci, G, 1277
Marcus, AI, 3883
Marcuzzi, GP, 1394
Mardor, Y, 6858
Margaryan, A, 4320
Margaryan, NV, 9851
Margulies, AG, 11001
Margulis, A, 1783
Mariadason, JM, 10170
Mariani, L, 1207, 3942
Mariani, S, 1897
Mariano Schiavone, E, 8754
Maric, D, 2353
Maringer, M, 840
Marini, F, 3307, 9962
Marino, J, 9132
Maris, J, 9868
Marker, PC, 10423
Markland, F, 5785
Marks, AJ, 2373
Marks, DL, 8233
Marks, JD, 1471
Marks, PA, 7832
Marques, MR, 6551
Marques, SM, 7127
Marquez-Garban, DC, 11287
Marra, G, 10759, 4525
Marrero, JA, 11193
Marsac, C, 4282
Marsh, S, 8961
Marsit, CJ, 7081
Martínez, A, 4181
Martínez-Climent, JA, 3264
Martella, C, 9687
Martelli, M, 11230
Martens, JWM, 4101
Marth, C, 1141
Martenssen, R, 11241
Martignetti, JA, 1213, 5761, 9216
Martin, H, 2787
Martin, J, 5003
Martin, JM, 11304
Martin, ME, 11367
Martin, NMB, 10145
Martin, SK, 1700
Martin, SA, 10657
Martin, S, 11447
Martin, MC, 3035
Martin, M, 10223
Martin-Caballero, J, 3846
Martín-Cantalejo, Y, 5647
Martinek, V, 2644
Martínez, A, 11001
Martínez, C, 8042
Martínez, D, 177
Martini, L, 5445
Martini, PGV, 5445
Martinoli, C, 3920
Martins, WK, 7127
Martuza, RL, 10663
Marucci, L, 11437
Marumoto, T, 2899
Maruyama, O, 4817
März, A, 11326
Marzec, M, 7800
Marzoni, M, 11437
Mascolo, MG, 1505
Mason, C, 9719
Mason, MD, 7000
Mason, T, 879
Masood, R, 4623
Massa, C, 7942
Massarelli, E, 11478
Massey, TE, 1265
Massimi, I, 8308
Massion, PP, 226, 3555
Masucci, MG, 1361
Masurier, C, 6409
Matallanas, D, 5485
Mateo-Lozano, S, 9320
Matheu, A, 26
Mathew, P, 3707
Mathiesen, B, 2387
Mathiesen, T, 2653
Matrai, Z, 7328
Matrisian, LM, 499
Matsuda, A, 6874
Matsuhashi, N, 2251
Matsui, S-I, 5344, 8635
Matsui, W, 2026
Matsuishi, T, 5284
Matsumura, M, 4562
Matsunaga, A, 9147
Matsuoka, M, 4467, 6927
Matsushita, K, 4683
Matsuura, H, 9623
Matsuura, N, 113
Matsuyama, S, 4998
Matsuyama, T, 6820
Matsuzaki, K, 157
Matsuzaki, Y, 546
Mattei, M, 3751
Matthews, CS, 3911
Matthews, RT, 6726, 10930
Matullo, G, 8042
Matyakhina, L, 4506
Matzke, A, 6105
Mauch, C, 4134
Maude, SL, 780
Mauger, DT, 6526
Maul, RS, 6159
Maunakea, A, 3617
Maupas-Schwalm, F, 526
Maurer, M, 2554, 9639
Mautino, MR, 10555
Mautner, J, 1079
Maximov, V, 4515, 11282
Maxwell, CA, 850
Maxwell, GL, 5031
Maxwell, PH, 10847, 11520
Maybaum, J, 6835
Mayburd, A, 4181
Mayer, I, 5009
Mayerhofer, M, 9436
Mayhew, CN, 4568
Maynard, J, 10179
Mazae, AP, 7775
Mazerolles, C, 11667
Mazieres, J, 743
Mazooz, G, 1369
Mazumdar, A, 11501
Mazumdar, T, 7984
Mazurchuk, RV, 9829
Mazurek, N, 10767
Mazza, BA, 1748
Mazzafarro, V, 3942
Mazzocca, A, 4728
McAlhany, SJ, 8887
McAllister, S, 5084
McArthur, GA, 9633
McBride, WH, 4836
McCabe, F, 3193
McCabe, MT, 3624, 3633
McCaig, C, 7363
McCall, W, 3404
McCarthy, MM, 5578
McCarthy, S, 7169
McCarty, MF, 3664
McClatchey, AL, 8091
McConkey, DJ, 4902, 10524, 11510, 11658
McCormick, F, 10669, 743
McCormick, JJ, 1007
McCready, DR, 8530
McCubrey, JA, 2890, 4401, 5408, 9962
McCubrey, J, 9164
McCutcheon, IE, 1547
McDaid, HM, 2854
McDaniel, B, 3454
McDermott, D, 3044
McDermott, MW, 5070
McDermott, U, 8951
McDevitt, MR, 4888
McDevitt, M, 5620
McDonald, DM, 2712, 5740
McDonald, E, 4918
McDonald, J, 6755
McDonnell, DP, 11762
McDonnell, SK, 1213
McDonough, WS, 1748
McDougal, WS, 3030
McEarchern, JA, 8331
McFadden, G, 9982
McGahren-Murray, M, 692
McGavern, DB, 972
McGinley, JN, 7023
McGonigle, GJ, 9245
McGowan, CH, 2526
McGroarty, M, 1325
McHugh, MM, 5344
McIlrath, JM, 3527, 5668
McIntee, EJ, 8548
McIntyre, A, 8085
McIntyre, A, 9137
McKean-Cowdin, R, 7516
McKee, KS, 1973, 6950
McKee, T, 4005
McKee, T, 5674
McKeehan, WL, 1830, 4191
McKenna, WG, 7902, 8256, 8433
McKeown-Longo, PJ, 148
McKimney, C, 879
McKirdy, R, 11304
McLachlan, E, 2705
McLaughlin, J, 9294
McLaughlin, LM, 6097
McLendon, RE, 919, 4051
McLeod, HL, 8961
McMahill, M, 11061
McMahon, M, 4870, 9643
McNeil, N, 1306
McNulty, AM, 7462
McQueen, T, 9962
McWilliams, R, 383
Meade, BR, 10646
Meazza, R, 1071
Mecklin, J-P, 4607
Medda, M, 5390
Medema, RH, 7037
Medina, A, 925
Medina, D, 3493, 7993
Medrano, EE, 692
Meeke, K, 8504
Meertens, H, 6509
Megli, CJ, 3828
Mehlman, T, 1369
Mehra, R, 11259
Mehrie, A, 7733
Mehta, AI, 3853
Mehta, AB, 2373
Meijer, GA, 5935, 10208
Meijer-Van Gelder, ME, 4101
Meininger, C, 11437
Mekhal, K, 5221
Melamed, J, 6178
Melani, C, 7942
Melbye, M, 8567
Melcher, A, 2009

- Melief, CJM, 6443, 6984
 Melillo, G, 9047
 Melis, M, 9588
 Melkounian, ZK, 6676
 Mellone, M, 8308
 Melo, JV, 8912
 Meltzer, PS, 9226
 Melville, J, 5399
 Memeo, L, 2554
 Mena, P, 9971
 Ménard, S, 1071, 6388, 7065
 Mendoza, A, 2406
 Mendoza, G, 6189
 Meng, A, 11597
 Meng, L-h, 5337
 Méné, V, 410
 Menigatti, M, 10759
 Menkens, A, 7041
 Menssen, A, 4218
 Menter, DG, 6189
 Menzel, U, 2653
 Menzies, A, 7591
 Merajver, SD, 8366
 Merbs, SL, 10634
 Mercer, K, 11493
 Merchan, JR, 5292
 Mercola, D, 5133
 Mercurio, AM, 2761, 4754, 10938, 10970
 Mérezegue, Fabrice, 10872
 Meric-Bernstam, F, 1961
 Merle, C, 300
 Mernaugh, R, 2815
 Meropol, NJ, 4993
 Mertani, HC, 317
 Merx, S, 8072
 Mesa Jr., C, 2465
 Mesfin, M, 3837
 Mesivala, AK, 6835
 Messing, EM, 9807
 Mestian, J, 4500
 Metcalf III, CA, 1335
 Mettus, RV, 10174
 Metzger, R, 1778
 Meyer, E, 4261
 Meyer, W, 8142
 Meyers, PA, 1748
 Meyerson, M, 5561, 7096, 8968
 Mezhr, JJ, 3146, 9479
 Mezzananza, D, 9369
 Mhashikar, AM, 3017
 Miao, H-Q, 5778
 Miao, X, 722, 9582
 Mibu, R, 2979
 Michel, LS, 3454
 Michelman, MV, 6891
 Mick, R, 8256
 Mickley Huff, L, 11694
 Middleton, SA, 9038
 Miele, L, 4554, 6282
 Mier, J, 3044
 Migliaccio, A, 10585
 Mihich, E, 11251
 Mikami, I, 743
 Mikhail, FM, 7603
 Miki, T, 5662, 6364
 Miki, Y, 657, 6450
 Mikolaenko, I, 2353
 Milam, N, 692
 Milan, J, 10347
 Miled, C, 5096
 Miles, D, 3837
 Miletto-González, KE, 6660
 Millar, H, 3193
 Miller, BS, 10123
 Miller, CJ, 1792
 Miller, C, 6493
 Miller, E, 6789
 Miller, MC, 4993
 Miller, ML, 8655
 Miller, N, 8530
 Miller, RA, 11676, 3837
 Miller, TP, 6294
 Millhorn, DE, 11689
 Millikan, RC, 8028
 Millimaggi, D, 9369
 Millinger, S, 1141
 Mills, GB, 1961, 2516, 3336, 6701
 Mills, L, 692
 Milne, TA, 11267
 Milner, J, 10457
 Milsom, C, 8878
 Milyavsky, M, 4530
 Mima, S, 1868
 Mimori, K, 4963
 Mimura, H, 4998
 Min, CK, 11400
 Mine, S, 401
 Mineo, R, 1849
 Minkin, C, 1129
 Minna, JD, 226, 1642, 7568, 11478
 Minna, J, 5561
 Minor, P, 10273
 Minto, L, 9712
 Minturn, JE, 9868
 Mintz, MR, 1748
 Miozzo, M, 2139
 Miracca, E, 1693
 Miraglia, E, 516
 Mirancea, N, 1294
 Mirkin, BL, 10183
 Mirochnik, Y, 5144
 Mironchik, Y, 10801
 Mirosevich, J, 9185
 Mirzoeva, OK, 4861
 Misawa, A, 10233
 Misk, DE, 5488
 Mishra, B, 4228
 Mishra, L, 4228
 Misra, A, 1678
 Misra, D, 9415
 Misteli, T, 4067
 Mitani, K, 6612
 Mitchell, E, 11721
 Mitchell, H, 10431
 Mitchell, JB, 579
 Mitchell, SA, 933
 Mitsiades, CS, 7478
 Mitsiades, N, 8350
 Mitsutake, N, 2465, 4238
 Mitsutake, S, 2465
 Mittal, S, 5133
 Mittelman, A, 6466
 Miwa, S, 8818
 Mixan, BJ, 8331
 Miyagawa, M, 4253
 Miyagishi, M, 5864, 10822
 Miyamoto, K, 11
 Miyamoto, M, 5638
 Miyamoto, S, 8558
 Miyata, Y, 6820
 Miyatake, T, 8640
 Miyazaki, M, 9617
 Miyazawa, H, 7276
 Miyazawa, T, 9623
 Miyazu, YM, 9623
 Mizokami, A, 8818
 Mizoue, T, 2979
 Mizukami, I, 4126
 Mizukami, M, 5945
 Mizuno, H, 5818
 Mizuno, M, 7573
 Mizushima, T, 1868
 Mizutani, M, 553, 3419
 Mizutani, N, 553, 3419
 Mizutani, Y, 5662, 6364
 Mizzen, LA, 2018
 Mo, W, 1079
 Moedel, RM, 698
 Mobashery, S, 3523
 Mobley, J, 3726
 Mochan, TA, 7533
 Mochizuki, M, 10494
 Mochizuki, Y, 6820
 Model, F, 4101
 Modena, P, 4012
 Modiano, JF, 5654
 Modzelewski, RA, 533
 Moeller, BJ, 5498
 Moeziffard, R, 1887
 Mohammad, KS, 11001
 Mohapatra, S, 7717
 Mohla, S, 8583
 Mohler, JL, 3404, 6640, 10514
 Mok, SC, 2162, 10602
 Molineux, G, 284
 Molinolo, AA, 9953
 Moll, UM, 9971
 Molla, A, 632
 Moller, K, 34
 Moller, MTN, 11051
 Momota, H, 7429
 Mondal, D, 9891
 Mondello, C, 11411
 Mondesire, WH, 1961
 Monks, A, 3911, 7847, 9047
 Monni, O, 5588
 Montagna, C, 8736
 Montagnini, A, 7127
 Montaldi, E, 3428
 Montcourrier, P, 10872
 Montellano, R, 2730
 Montero, JC, 6801
 Montet, X, 6330
 Montgomery, RB, 650
 Montiel-Duarte, C, 3264
 Montserrat, E, 2199
 Moon, C, 758
 Moon, E-J, 686
 Moons, L, 465
 Moore, GW, 1207
 Moore, JH, 7674
 Moore, MJ, 1489
 Moore, NL, 8487
 Moore, RE, 6593
 Moore, S, 10265
 Moosmayer, P, 7733
 Moossa, AR, 4246
 Moossa, AR, 2337, 5352, 9829
 Mora, J, 2565
 Moraitis, D, 664
 Moran, AE, 1097
 Moran, A, 3811
 Moran, E, 9236
 Moraski, G, 957
 Moravcevic, K, 7533
 Moreau, P, 10139
 Moreno, AM, 10041
 Moreno, CS, 10214
 Moreno, J, 7917
 Moreno, JG, 4993
 Moretti, F, 9687
 Morgan, J, 11051
 Morgan, MA, 6835
 Mörgelein, M, 732
 Mori, E, 10632
 Mori, K, 9159
 Mori, M, 401, 4963
 Mori, N, 11034
 Mori, S, 157
 Mori, T, 3548
 Mori, T, 1800
 Mori, T, 5720
 Mori, Y, 4998
 Morikane, K, 5864
 Morimoto, C, 1973, 6950
 Morin, PJ, 331, 7378, 9603
 Morishige, K-i, 540
 Moriya, T, 657, 6450
 Moriyasu, F, 10613
 Morley, M, 5221
 Morreau, H, 10188
 Morris, JS, 11486
 Morris, MR, 4598
 Morrison, DJ, 8174
 Morrison, PJ, 10265
 Morrow, JD, 3735
 Morrow, M, 9245
 Morse III, HC, 1306
 Morse, H, 7751
 Mortarini, R, 3428
 Mortensen, N, 11361
 Morteux, F, 1234
 Moser, J, 10298
 Moser, M, 448
 Moses, AV, 5084
 Moses, HL, 2296
 Mosher, DF, 9338
 Moskaluk, C, 6583
 Mosley, RL, 7824
 Moss, B, 9991
 Mossman, B, 10120
 Mossman, BT, 9670
 Motoi, F, 2899
 Motrescu, ER, 10862
 Motta, M, 5445
 Mottram, P, 465, 5020
 Moulding, DA, 9245
 Moulés, V, 1234
 Moussa, M, 6337
 Moussa, O, 11581
 Mozzetti, S, 2397
 Mucha, SR, 6780
 Muchardt, C, 3542
 Mudde, GC, 7934
 Mudryj, M, 10700
 Muehlbauer, K-R, 2583
 Mueller, MM, 1294
 Mueller-Holzner, E, 1141
 Muenster, MR, 8209
 Mürköster, S, 1316
 Mukai, M, 9121
 Mukeria, A, 5076
 Mukerji, P, 277
 Mukhopadhyay, UK, 2872
 Mukhtar, H, 1635, 11203
 Mulder, KM, 6526
 Mullan, B, 4353
 Mullan, PB, 10265
 Mullany, S, 7091
 Mullen, P, 6789
 Mullenders, LHF, 10298
 Muller, AJ, 8065
 Müller, K, 4458
 Müller, S, 379, 6919
 Muller, WJ, 2296, 3518, 9695, 10113, 10363
 Müller-Decker, K, 1808
 Müller-Tidow, C, 1778, 9643
 Müller-Tiemann, B, 2846
 Mulligan, K, 10265
 Mulshine, JL, 4181
 Multhoff, G, 5238
 Munaco, AJ, 4126
 Mund, C, 7086
 Munn, LL, 5674, 5740
 Munnia, A, 8042
 Muñoz, DR, 9601
 Muñoz, N, 6543
 Muñoz-Martínez, F, 4852
 Munroe, DJ, 4673, 6255
 Munsell, M, 9962
 Munshi, NC, 5898, 11712
 Munster, PN, 3815
 Murakami, A, 4417
 Murakami, H, 9176
 Muramatsu, M, 3700
 Murata, T, 546
 Murata, T, 907
 Murata, Y, 11762
 Murata, Y, 540, 8640
 Muro-Cacho, C, 9525
 Murofushi, Y, 5284
 Murphy, C, 1877
 Murphy, G, 9377
 Murphy, JT, 5390
 Murphy, LC, 5696
 Murphy, ME, 8069
 Murray, J, 2602
 Murray, JL, 2930
 Murray, J, 8142
 Murray, R, 2712
 Murtaugh, MA, 6063
 Musafia-Jeknic, T, 1251
 Musch, T, 6305
 Muschel, RJ, 7902, 8256
 Mushinski, JF, 1306

- Musiani, P. 1071, 7065
Musib, L. 7462
Muthukumaran, N. 6660
Mutoh, M. 562
Mutoh, T. 562
Mutti, L. 3049, 5256
Muzik, H. 9982
Muzikansky, A. 10938
Myers, C. 7177
Myers, D. 4929
Myers, JN. 4716, 5696
Myers-Irvin, JM. 7145
- Naase, M. 9137
Naber, SR. 6130
Nabeta, C. 8706
Nabors, LB. 5535
Nacheva, E. 4554
Nadella, KS. 10307
Nadiminty, N. 3487
Nadkar, A. 6022
Nadler, LM. 10050
Nadobny, J. 5872
Nadrowitz, R. 10486
Nagai, MA. 1693
Nagai, Y. 7276
Nagai, Y. 5190
Nagaich, AK. 4067
Nagano, J. 2979
Nagano, S. 5284
Nagaraj, S. 9525
Nagase, H. 3548
Nagata, Y. 1858
Nagawa, H. 9159
Nagel, JHA. 11335
Nagl Jr., NG. 9236
Nagpal, S. 3837
Nagy, A. 5857
Nagy, P. 473
Nahta, R. 11118
Naik, A. 9991
Nair, HB. 11164
Nair, S. 11156
Nair, SS. 5571, 7724
Naito, S. 4253, 10032
Nakabeppu, Y. 6006
Nakachi, K. 5462, 9771
Nakada, MT. 3193
Nakada, M. 8792
Nakagawa, H. 105, 3092, 4578
Nakagawa, K. 7241
Nakagawara, A. 828, 4587
Nakahara, S. 7546
Nakaichi, M. 907
Nakajima, A. 2251, 4769
Nakamizo, A. 3307
Nakamura, A. 4929
Nakamura, E. 9611
Nakamura, F. 6612
Nakamura, H. 8017
Nakamura, K. 4775
Nakamura, K. 7356
Nakamura, N. 1136
Nakamura, T. 105, 3092
Nakamura, Y. 1541
Nakamura, Y. 6612
Nakamura, Y. 105, 1197, 3092, 4578, 4817, 5638, 7102, 9176, 11486
Nakanishi, K. 8706
Nakanishi, M. 2636
Nakanishi, T. 1868
Nakanishi, Y. 4448
Nakano, K. 1655
Nakano, T. 7241
Nakano, Y. 7660
Nakao, K. 7356
Nakao, M. 6927
Nakar, C. 11061
Nakashima, K. 1124
Nakashima, R. 8640
Nakata, S. 5662, 6364
Nakatomi, K. 1541
Nakayama, K. 254
Nakayama, KI. 7874
- Nakazaki, K. 6071
Nakazato, T. 4417
Nalbantoglu, J. 8359
Nallasura, V. 1479
Nam, D-H. 3716
Nam, J-O. 4153, 507
Nam, S. 9185
Nam, SW. 815
Namba, M. 9617
Nambiar, PR. 3998
Namiki, M. 8818
Nan, B. 6543
Nanayakkara, M. 10585
Nanda, R. 10692
Nangia-Makker, P. 10767
Nannya, Y. 6071
Naoki, K. 1479, 5561
Naor, Z. 7707
Napier, C. 9038
Narayanan, D. 1471
Nardo, T. 432
Narko, K. 2157
Narla, G. 1213, 5761, 9216
Narod, SA. 10401
Nasu, Y. 9617
Natali, PG. 22649
Natarajan, L. 3993
Näthke, IS. 5195
Nation, PN. 2626
Natsume, A. 7573
Naumovski, L. 11676
Navarro, C. 8042
Navarro-Perán, E. 2059
Navenot, J-M. 10450
Navsaria, H. 2216
Nawrocki, ST. 11510, 11658
Nawrocki-Raby, B. 7691
Nayar, R. 246
Naylor, TL. 7612
Ndebele, K. 8286
Ndisang, D. 3072
Nearman, J. 7824
Nebbio, A. 8754
Nederlof, PM. 822
Nedosztyko, B. 8101
Needham, LL. 11214
Neeman, M. 1369, 1425, 10316
Nefedova, Y. 9525
Nègre-Salvayre, A. 526
Negri, T. 1115
Negrini, M. 7065
Neidle, S. 1489
Neilsen, PM. 11304
Neliu, T. 5144
Nelson, C. 11083
Nelson, DW. 6151
Nelson, HH. 7081
Nelson, L. 1631
Nelson, PS. 6228
Nelson, WG. 6773
Nemani, P. 1664
Német, K. 1770
Nenci, I. 7065
Neoptolemos, J. 3218
Neri, M. 3049
Neri, P. 8350
Nerio, E. 7429
Nervi, C. 1505, 6080
Nesland, JM. 5588, 11051
Nessling, M. 439
Nesterov, A. 1615
Neubauer, BL. 7462
Neuberg, D. 805
Neugut, AI. 1606
Neumaier, M. 1925
Neumann, A. 3937
Nevala, H. 8101
Neves, EJ. 7127
Nevins, JR. 4051
Newgreen, DE. 5991, 5996
Newman, RA. 6189, 8442, 10113, 11486
Newton, A. 8397
Nezu, M. 4683
Ng, IO-L. 8861
- Ng, S-W. 4067
Ngai, I. 3063
Ngo, L. 7832
Nguyen, C. 2170
Nguyen, DM. 7763
Nguyen, D. 3179
Nguyen, H. 939
Nguyen, T. 9517
Nguyen, TK. 9328
Nguyen, V. 5750
Nguyen, XD. 10068
Ni, J. 9807
Ni, S. 4343
Nicchitta, CV. 9126
Nico, C. 948
Nichols, M. 1598
Nicholson, AC. 605
Nicholson, AG. 7591
Nickoloff, BJ. 6282, 9851, 10164
Nicol, T. 5628
Nicolau, KC. 605
Nicolau, A. 5872
Nicoletti, G. 3868
Nicolini, G. 632
Nicotra, MR. 11649
Nielsen, CK. 732
Nies, AT. 11419
Niesvizky, R. 3185, 11345
Nigavekar, SS. 5317
Nigro, JM. 1678
Niikawa, H. 6450
Nikiforov, YE. 4238
Nikitakis, NG. 9953
Nikitin, AY. 787
Nikitina, EY. 787, 4309
Nilsson, MB. 7214, 10794
Nilsson, SK. 6139
Nimer, SD. 7151
Nimmrich, I. 4101
Nimura, Y. 5190
Ning, S. 284
Ning, Y. 9280
Ning, Y-G. 4707
Niño, MR. 10120
Nisato, RE. 9377
Nischt, R. 4134
Nishida, K. 401
Nishigaki, M. 2115
Nishigori, C. 6006
Nishikawa, T. 6
Nishimoto, A. 6701
Nishimura, H. 9176
Nishimura, M. 10776
Nishimura, MI. 1570
Nishimura, N. 2617
Nishino, M. 7984
Nishino, Y. 4998
Nishio, K. 4998
Nishiyama, M. 1055, 9623
Nittka, S. 1925
Niu, J. 5045
Niu, Y. 5696
Nivens, M. 3883
Noble, CO. 11631
Noël, A. 2441
Noel, E. 9137
Noel, MW. 2353
Noguchi, T. 1055
Noh, EJ. 11400
Noisternig, T. 4881
Nojima, K. 113, 10159
Nojima, K. 11704
Nolan, RP. 2602
Nolta, JA. 1129
Nomizu, M. 10494
Nomoto, T. 2610
Nomura, F. 4683
Nomura, M. 1642
Nomura, S. 4769
Nonaka, D. 1207, 3428
Nonn, L. 7917
Noonan, DM. 10637
Noonan, K. 2026
Nor, J. 10921
- Nör, JE. 5063, 9294
Norberg, S. 2712
Norris, A. 6159
North, JM. 2373
Norton, MJ. 10096
Nos, C. 1376
Notario, V. 9320
Notaro, R. 8111
Novakova-Jiresova, A. 3568, 6509
Nowak, NJ. 3548
Noy, N. 8193
Ntziachristos, V. 6330
Nucifora, G. 7603
Nullmeyer, KD. 3823
Nummer, D. 10079
Nunez, G. 5063
Nupponen, NN. 4607
Nupponen, N. 8101
Nurmio, M. 9999
Nürnberg, H. 6080
Nutt, CL. 5523
Nyberg, P. 3967
- O'Brate, A. 3883
O'Brian, CA. 10478
O'Brien, KA. 6593
O'Brien, TG. 1146
O'Brien-Jenkins, A. 925
O'Connell, J. 9817
O'Connor, MJ. 9799
O'Connor, W. 3374
O'Driscoll, A. 2662
O'Dwyer, PJ. 805
O'Hara, A. 10569
O'Hara, SM. 4993
O'Hare, MJ. 5112
O'Hare, T. 4500
O'Keefe, RJ. 3209
O'Kelly, J. 2488, 4762
O'Malley, BW. 7993
O'Malley, ME. 9991
O'Meara, S. 7591
O'Neill, A. 3044
O'Neill, EE. 5485
O'Reilly, MA. 6622
O'Reilly, S. 1007
Obata, M. 2269
Obata, T. 4562
Oberley, TD. 1401, 3745
Oberlies, NH. 4448
O-charoenrat, P. 3063
Ocherashvili, A. 6858
Ochiai, A. 4769
Ochiai, T. 4683
Ochieng, J. 499
Ochoa, AC. 3044
Oczko-Wojciechowska, M. 1587
Oda, H. 1655
Oda, K. 10669
Oddoux, C. 3454
Odoric, S. 8530
Odum, N. 11136
Oehlen, B. 8442
Offit, K. 3454
Offner, G. 10394
Offringa, R. 6443, 6984
Ogata, T. 113
Ogawa, O. 9611
Ogawa, S. 6071
Ogawa, T. 9771
Ogi, T. 325
Ogilvie, DJ. 4389
Ogilvie, LM. 5003
Ogushi, T. 3700
Oh, DH. 8723
Oh, E-S. 9899
Oh, SC. 4809
Oh, S-H. 137, 749
Ohashi, A. 417
Ohd, JE. 732
Ohdo, S. 8448
Ohigashi, H. 4417
Ohigashi, H. 105, 3092
Ohira, M. 828, 4587

- Ohki, M, 10233
 Ohm, JE, 226
 Ohmura, N, 2899
 Ohmura, T, 8706, 11018
 Ohnishi, S, 2251
 Ohnishi, T, 10632
 Ohno, R, 1117
 Ohnuma, K, 1973, 6950
 Ohshima, K, 5925
 Ohta, M, 4562, 5864, 10822
 Ohta, R, 10562
 Ohta, S, 1655
 Ohta, T, 6
 Ohtani-Kaneko, R, 6
 Ohzeki, M, 11704
 Ojopi, EPB, 1693
 Oka, M, 1541
 Oka, N, 7546
 Okada, H, 6685
 Okada, K, 210
 Okada, K, 3535
 Okada, Y, 982, 11536
 Okamoto, M, 401
 Okamoto, Y, 4587
 Okamura, T, 2979
 Okano, H, 2832
 Okano, S, 7241
 Okaya, T, 4568
 Okayasu, R, 10159
 Okazaki, K, 157
 Okhrimenko, H, 7301
 Okino, ST, 2130
 Okor, M, 10214
 Okulicz, W, 358
 Okusaka, T, 10613
 Okuyama, H, 6178
 Okuyama, R, 1063
 Olafsen, T, 622, 5907
 Old, LJ, 3447
 Oldenburg, RA, 822
 Oldfield, EH, 10847
 Olek, A, 4101
 Olimpio, CO, 2964
 Olive, KP, 8166, 10280
 Olive, P, 7259
 Oliver, RTD, 9137
 Olivero, M, 907
 Olopade, OI, 10692
 Olsen, OR, 8567
 Olson, JJ, 605
 Olson, KA, 1352
 Olson, MF, 11247
 Olson, S, 3555
 Olson, S, 85
 Olsson, H, 7612
 Olstorn, HB, 121
 Olteanu, H, 1554
 Olufemi, S-E, 427
 Omata, M, 4562, 5864, 10822
 Onate, SA, 3487
 Ondrey, F, 4181
 Ong, C-N, 7815
 Ong, DE, 8118
 Onimaru, M, 7241
 Ono, HA, 10154
 Ono, M, 8836
 Ono, M, 4253
 Oosterhuis, JW, 8085
 Oosting, J, 10188
 Opeiz, C, 6780
 Opiari Jr., AW, 6294
 Opolon, P, 4353
 Oppenheim, JJ, 1433
 Oppenheimer, D, 3003
 Or, YY-Y, 8125
 Oravec-Wilson, KI, 4126
 Orchard, KH, 2373
 Orzechowski, R, 11193
 Ordóñez-Ercan, D, 879
 Orelli, BJ, 11704
 Örend, G, 10783
 Örenstein, A, 6858
 Orfi, L, 6919
 Organe, S, 2441
 Orian-Rousseau, V, 6105
 Ormandy, LA, 2457
 Ørntoft, Torben F., 34
 Oro, C, 7059
 Orsulic, S, 3735
 Orth, G, 1174
 Osada, H, 9628, 10680
 Osada, H, 7455
 Osada, M, 758, 4963
 Osborn, JC, 2089
 Osborne, JR, 9080
 Osborne, MR, 2644
 Oshima, H, 9147
 Oshima, M, 8622, 9147
 Oshima, RG, 5325
 Osinaga, E, 7880
 Osinga, J, 1729
 Osipo, C, 8504, 10651
 Osman, S, 10104
 Ostenfeld, MS, 8975
 Osthus, RC, 5620
 Östman, Arne, 7824
 Ostrander, EA, 1213, 5654
 Ostrand-Rosenberg, S, 11743
 Östrer, H, 3454
 Otsuka, K, 2108
 Otsuki, T, 5898
 Otsuyama, K-i, 2269
 Ott, G, 2199
 Ottenga, F, 3049
 Otter, C, 5105
 Ottey, M, 6568
 Ottmann, OG, 2537, 6080
 Otto, T, 4690
 Ouchi, T, 10657
 Ouchi, Y, 3700
 oude Egbrink, MGA, 11520
 Öudejans, CBM, 10208
 Ougolkov, AV, 2076
 Ouyang, W, 6601, 9287
 Ouyang, X, 6773
 Overall, CM, 9377
 Overvad, K, 8042
 Øvrebo, S, 5105
 O-Wang, J, 325
 Owen, JL, 10578
 Owens, CR, 7111
 Owens, JD, 1306
 Oxford, G, 7111
 Oyesiku, NM, 10214
 Ozaki, T, 4587
 Ozawa, T, 10389
 Ozburn, N, 1678
 Özvegy-Laczka, C, 1770
 Pack, SD, 7751, 7763
 Pack, S, 5112
 Pacyna-Gengelbach, M, 394
 Padilla-Nash, H, 9388
 Padula, F, 1505
 Pafiti-Kondi, A, 1627
 Pagano, RE, 8233, 10431
 Paglin, S, 11061
 Paik, J-H, 3788
 Paik, J, 10472
 Päävinen, S, 8101
 Pajonk, F, 4836
 Pajusola, K, 4739
 Paku, S, 7186
 Palaiologou, D, 8912
 Palamarchuk, A, 4515, 6764, 11282
 Palazzo, JP, 7065
 Pali, ES, 9294
 Palli, D, 8042
 Pallini, R, 11469
 Palmieri, M, 4334
 Palomeque, C, 1606
 Pals, G, 1271
 Pan, D, 6843
 Pan, E, 1678
 Pan, H, 1664
 Pan, J, 3671, 9109
 Pan, Q, 8366
 Pan, Y, 3257
 Pan, Z, 10623
 Pandiella, A, 6801
 Pandini, G, 1849
 Pandolfi, PP, 5172, 8575
 Panico, S, 8042
 Panis, Y, 948
 Pankhurst, GJ, 2330
 Panopoulou, E, 1877
 Panousopoulou, E, 8912
 Pantelias, GE, 11292
 Pantoja, C, 26
 Papadopoulos, T, 4881
 Papagiannakopoulos, T, 10959
 Papandreou, I, 3171
 Papapoulos, SE, 7682
 Papkoff, J, 868
 Paquet, M, 2054, 9206
 Paquola, ACM, 1693
 Paraghamian, A, 7045
 Paramio, JM, 9678
 Pardee, AB, 7809
 Pardoll, DM, 1079
 Paredes, J, 8774
 Parenza, M, 2321
 Parihar, R, 9099
 Parijs, LV, 1761
 Parikh, NU, 6493
 Park, A, 5454
 Park, BJ, 3063
 Park, D-C, 10602
 Park, EJ, 9047
 Park, ES, 9056
 Park, EY, 9923
 Park, H, 9899
 Park, HL, 4963
 Park, J-G, 3162
 Park, JO, 3146
 Park, J-H, 2804
 Park, JS, 9501
 Park, J, 749
 Park, JK, 2353
 Park, JM, 3633
 Park, JW, 11631
 Park, J, 1738
 Park, K, 5554, 749
 Park, K, 137
 Park, M-S, 137
 Park, M-J, 686
 Park, R-W, 4153
 Park, S-Y, 3894
 Park, SS, 1306, 7644
 Park, WS, 815
 Park, W-R, 1197
 Park, YG, 815
 Park, Y-M, 9073
 Park, Y-S, 7137
 Park, YW, 4716
 Parker, A, 7591
 Parker, HG, 5654
 Parker, MT, 9659
 Parkes, D, 8397
 Parl, FF, 8028
 Parmar, S, 9029
 Parmiani, G, 632, 2321, 3942
 Parrella, P, 10634
 Parrett, TJ, 919
 Parry, G, 2846, 8397
 Parry, GC, 7775
 Parry, R, 2846, 8397
 Parsels, JD, 6835
 Parsels, LA, 6835
 Parsons, K, 6498
 Parsons, R, 2554, 9659
 Parthoens, E, 2224
 Partinen, M, 9595
 Partridge, JJ, 10959
 Parvinen, M, 9999
 Pascale, S, 1505
 Pasche, B, 3454
 Paschen, A, 10068
 Pasquier, E, 2433
 Pass, GJ, 4211
 Pass, HI, 10120
 Passioura, T, 797
 Pastorino, JG, 10545
 Pastorino, S, 2353
 Patel, C, 3072
 Patel, NS, 8690
 Patel, S, 1414
 Patel, T, 11437
 Patel, V, 9953
 Pathak, AP, 1425, 10801
 Pathil, A, 6321
 Patlolla, JM, 8022
 Patrawala, L, 6207
 Patsialou, A, 9236
 Pattacini, L, 8912
 Patterson Jr., DG, 11214
 Patterson, JB, 5785
 Patti, M, 11469
 Patuzzo, R, 3428
 Patz, EF Jr., 8853
 Paul, B, 4097
 Paul, S, 9536
 Paulmurugan, R, 7413
 Paulsen, JE, 121
 Paulsen, KD, 6371
 Paulsson, J, 7824
 Pauwels, P, 11520
 Pavan, A, 587
 Pavan, A, 9369
 Pawlaczek, A, 1587
 Pawlita, M, 8072
 Paxton, L, 8662
 Payan, DG, 9294
 Payne, SG, 2422
 Payne, SL, 11429
 Paz, A, 6435
 Paz, MF, 2565
 Pchejetski, D, 11667
 Pearce, BE, 1285
 Pearlman, RV, 10992
 Pecaj, A, 1251
 Peckham, DW, 6425
 Pecorelli, S, 4334
 Pedersen, MT, 11136
 Pedriali, M, 7065
 Peduto, L, 9312
 Peehl, DM, 7917
 Peek Jr., RM, 8583
 Peek, VL, 6593
 Peeper, DS, 7033
 Peeters, PH, 8042
 Peguillet, I, 1755
 Peh, BK, 7743
 Pei, H, 7205
 Peiper, SC, 10450
 Peipp, M, 3380
 Pekarsky, Y, 4515, 6576, 6764, 11282
 Pelicano, H, 613
 Pellemounter, L, 11071
 Pellicer, A, 1150, 3249
 Pelosof, A, 7127
 Peltz, C, 5163
 Pelus, LM, 8224
 Peluso, M, 8042
 Pen, LB, 10347
 Pena, SDJ, 325
 Penard-Lacronique, V, 3281
 Pende, D, 3942
 Pendurthi, UR, 9705
 Peng, A, 1158
 Peng, B, 4673, 6255
 Peng, G, 1577
 Peng, J, 1961
 Peng, L, 1306
 Peng, L, 6976
 Peng, Q, 11051
 Peng, X-H, 1909
 Peng, X, 6676
 Peng, X, 5523
 Peng, Y, 1670
 Penheiter, SG, 10431
 Penn, LZ, 5607
 Pennacchioli, E, 3428
 Penney, KL, 7516
 Peoples, GE, 2930
 Pepper, MR, 9923

- Pepper, MS, 9377
Pepperkok, R, 7733
Perdichizzi, S, 3868
Pereira, GG, 1693
Pereira, MM, 605
Pereira-Castro, I, 10199
Perentes, JY, 5674
Perez, CA, 2314
Perez, EA, 3059
Perez, G, 7832
Pérez de Castro, I, 3249
Pérez-Calvo, Javier, 3264
Perez-Losada, J, 6488
Perez-Perez, MM, 2186
Pérez-Roger, Ignacio, 3264
Pérez-Soler, Román, 2854
Pérez-Victoria, JM, 4852
Pergolizzi, RG, 254
Perlaky, L, 76, 8142
Perlemonne, K, 7622
Perlmutter, D, 9566
Perou, CM, 9155
Perrault, R, 4020
Perret, C, 7622
Perri, SR, 8359
Perricaudet, M, 4353
Perrier, S, 10742
Perrin, S, 10423
Perrotti, D, 1277
Perry, A, 236, 7121, 11392
Perry, G, 10578
Perry, J, 7591
Perry III, WL, 6593
Persaud, R, 9876
Pertsemidis, A, 8209
Perumal, M, 4202
Pervaz, S, 6264
Pescarmona, G, 516
Peschke, R, 3643
Peschle, C, 11469
Pesonen, M, 8101
Pessemesse, L, 4282
Pestell, RG, 6557, 698
Pestell, R, 9934
Peters, AA, 8487
Peters, G, 4425
Peters, G, 177, 2179
Peters, GJ, 8414, 9510, 10208
Peters, U, 8034, 11779
Petersen, G, 383
Petersen, I, 394
Peterson, P, 8101
Petrangolini, G, 5506, 6388
Petrrella, G, 6668
Petroenko, O, 9971
Petricoin III, EF, 3853
Petrico, K, 1117, 7856
Petrovskaya, L, 3920
Petrovsky, A, 9253
Petrucchi, MT, 1505
Petti, F, 9455
Petty, R, 7591
Peyton, M, 11478, 226
Pezzone, G, 9415
Pfeifer, GP, 7653, 92
Pfeifer, H, 2537
Pfister, HJ, 2216
Pfister, H, 1394
Pham, DK, 3063
Pham, H, 3243
Philip, PA, 6934, 9064
Phillips, DC, 11447
Phillips, DH, 2644
Phillips, JL, 2602
Philpott, MP, 8597
Phukan, S, 3454
Picard, D, 5607
Picci, R, 3868
Pico, E, 8339
Pickering, CR, 1792
Pickl, WF, 9436
Pidkova, N, 6583
Piedrahita, JA, 887
Piekorz, RP, 10363
Pienta, KJ, 4993, 5750
Piepenbrock, C, 4101
Pieper, RO, 1406, 4861
Piepmeyer, J, 6726
Pierce, AJ, 11597
Pierotti, MA, 1115, 2572, 5506, 7591, 11227
Pietenpol, JA, 2314
Pieters, R, 10050, 1442
Pietras, K, 7824
Pietras, RJ, 11287
Pilarski, LM, 850
Pilla, L, 3942
Piloto, O, 1514
Pilotti, S, 1115, 4012, 5506, 11227
Pimanda, JE, 7596
Pinilla, C, 2378
Pino, MS, 11658
Pins, M, 1761, 5628
Pinski, JK, 4623
Pinsky, PF, 8034
Pinyol, M, 2199
Pinzani, M, 4728
Piontek, G, 5038
Piper, JT, 7370
Pisano, C, 1897
Pise-Masison, C, 10602
Pitari, GM, 11129
Pitossi, FJ, 5123
Pitt, E, 10441
Pittman, B, 8548
Pittman, DL, 2089
Pittman, GS, 99
Pitts, TEM, 1710
Pixley, FJ, 5278
Pizzoferrato, E, 8461
Place, AE, 4789
Plass, C, 1277
Platanias, LC, 3470, 9029
Platt-Higgins, A, 3796
Plautz, GE, 9547
Plaza Menacho, I, 1729
Pledger, WJ, 7717
Plescia, J, 3531
Plesner, T, 9943
Plewka, S, 1778
Ploegh, HL, 7896
Plotkin, J, 11061
Pluim, D, 2577
Plumb, C, 8134
Plumb, M, 11493
Plunkett, W, 6874
Png, CE, 5628
Poch, E, 3264
Podar, K, 5898, 7478, 8350, 11712
Podhajcer, OL, 5123
Podo, F, 9369
Podratz, KC, 2684
Pogo, BGT, 1112
Pogue, BW, 6371
Poh, CF, 8017
Poh, TW, 6264
Pohl, G, 1994, 331
Pohle, T, 1778
Polakiewicz, RD, 1306
Polette, M, 7691
Poletti, A, 5445
Poliani, PL, 2321
Politi, V, 4134
Pollack, JR, 226, 4031, 8118, 9200
Pollack, V, 957
Pollock, CB, 1244
Pollock, PM, 6282
Pollok, KE, 3319
Polverini, PJ, 5063
Polyak, K, 11326, 9659
Pomeroy, SL, 5683
Pomier, C, 1234
Pommier, Y, 4844, 5337
Pomponi, F, 587
Ponnazhagan, S, 10041
Ponniah, S, 10330
Pons, J, 1719
Ponta, H, 6105
Ponte, JF, 1664
Pontecorvi, A, 9687
Ponti, D, 5506
Pontoglio, M, 5096
Ponzielli, R, 5607
Poon, APW, 9479
Poon, IKH, 7059
Poon, RT, 219, 3691
Poonepalli, A, 10977
Popescu, NC, 6042
Popkov, M, 972
Popovic, P, 9991
Porta, C, 5256
Porta, G, 2139
Portengen, H, 4101
Porter, CW, 5390
Porter, D, 9659
Portolan, G, 2770
Pós, Zoltán, 4458
Poser, I, 448
Posner, MC, 3146, 9479
Possemato, R, 8183
Post, DE, 1406
Post, M, 9705
Postenka, CO, 3396, 5231
Postnikov, YV, 6711
Postovit, L-M, 9851
Poteet-Smith, CE, 1027
Pothlichet, J, 2588
Potter, BVL, 8339
Potter, M, 7644
Potter, PM, 6850
Poullart, P, 1376
Poulsom, R, 8690
Poupon, M-F, 325
Pourroy, B, 2433
Poustka, A, 7733, 8101
Powell, JA, 11304
Powell, MJ, 9294
Powell, SN, 8613
Powers, KL, 861
Pozza, A, 4852
Prada, F, 5123
Pradayrol, L, 2770
Pranpat, M, 10536
Prasad, NB, 1619
Prasad, V, 8655
Pratesi, G, 5506, 6388
Prawitt, D, 840
Prel, RA, 2449
Prendergast, GC, 5991, 8065
Prescott, JE, 5620
Press, MF, 5907
Prévile, X, 641
Price, JE, 5578, 6493, 10767
Price, JT, 4929
Price, RE, 11478, 3226
Prickett, CS, 3861
Priel, S, 1115
Priddy, R, 8017
Prieto, J, 7194
Prieto, VG, 11185
Prime, W, 3218
Primus, FJ, 4939
Prise, KM, 10810
Pritchard, C, 11493
Proby, CM, 8597
Prochownik, EV, 2097
Prodromo, A, 9687
Prorock, A, 4134
Prosper, Felipe, 3264
Protopopov, A, 10164
Proutski, I, 8080
Provero, P, 11459
Pruss, D, 10096
Prymakowska-Bosak, M, 6711
Pu, L, 2097
Pu, Y-S, 8455
Puccetti, E, 6080
Puduvalli, VK, 1547
Pugacheva, E, 7751
Pühringer, F, 5038
Pujana, MAG, 9651
Pumiglia, KM, 148
Pumiglia, K, 6493
Puntel, M, 7194
Puntoni, R, 3049
Pupa, SM, 1071
Puri, RK, 8388
Purkis, T, 9137
Purov, BW, 2353
Purov, B, 10389
Puzas, JE, 3209
Pyka, J, 1343
Pyo, H, 9501
Pyrzynska, B, 605
Pytowski, B, 3185
Qian, J, 5045
Qian, J, 5493
Qian, X, 1136
Qian, Y, 7007
Qiao, L, 6990
Qiao, RF, 5761
Qiao, R, 2602
Qin, J-Z, 6282
Qin, W, 6843
Qiu, L, 2287
Qiu, X, 3100
Qualman, S, 4490
Quan, C, 9347
Quax, PHA, 9398
Quax, WJ, 1729
Quayle, L, 8134
Que, I, 7682
Queen, MM, 8896
Querzoli, P, 7065
Quesenberry, PJ, 358
Quiceno, D, 3044
Quigley, JP, 10959
Quinn, DI, 4623
Quinn, JE, 1710
Quinn, JE, 10265
Quinn, JMW, 4929
Quiros, J R, 8042
Quon, KC, 1615
Raaschou-Nielsen, O, 8042
Raats, J, 8317
Rabbani, ZN, 8853, 10149
Rabe, K, 383
Rabiasz, G, 6789
Rabkin, SD, 1532
Rademaker, A, 3454
Rader, C, 972
Rademacher, K, 7911
Radhakrishnan, SK, 3980
Radice, P, 2139
Radlwimmer, B, 439
Radonovich, M, 10602
Radunskaya, AE, 7950
Radvanyi, F, 1376
Rafferty, P, 3193
Rafii, S, 3185
Rafiyani, M-R, 3937
Rago, C, 5084
Raghavan, M, 375, 8597, 9137, 9152
Rago, C, 9485
Ragot, T, 8497
Rahal, P, 1693
Rahaman, SO, 2956
Rahav, O, 6858
Rahman, KMW, 364
Rahman, N, 7612
Rahmani, M, 2422
Rai, D, 4747
Raine, K, 7591
Rainis, L, 7596
Raja, S, 2147
Rajantie, I, 4739
Raje, N, 7478
Rajnakova, A, 7743
Rak, JW, 8134
Rak, J, 5365, 8878
Ralston, S, 957
Ram, Z, 6858
Raman, V, 10801, 11034
Ramanathan, B, 8455

- Ramani, V. 11001
Ramanujam, N. 1180, 8766
Ramanujam, VMS. 3656
Ramaswamy, S. 5054, 11326
Rambhatla, L. 3155
Ramdas, L. 10767
Rameau, P. 3281
Ramesh, R. 3017
Ramirez, AG. 2996
Ramirez de Molina, A. 5647
Ram-Mohan, S. 3155
Ramnarine, N. 9455
Ramon, C. 9369
Ramoscelli, L. 2139
Ramqvist, T. 5953
Ramsay, K. 8487
Ramsey, KE. 1748
Randolph, A. 9056, 10901
Rane, SG. 4067, 10174
Rank, F. 4754
Ranki, A. 8101
Rao, CV. 8022
Rao, GN. 7283
Rao, JV. 6159
Rao, LVM. 9705
Rao, M. 6557
Rao, PS. 483
Rao, SM. 6011
Rao, VP. 3998
Rapisarda, A. 4775
Rappaport, SM. 9574
Rashbaum, WK. 3185
Rasheed, BKA. 4051
Rashid, A. 11297
Rasiah, KK. 2330
Raskay, B. 805
Rasmussen, H. 1877
Rásó, E. 7186
Raspaglio, G. 2397
Ratain, MJ. 46
Ratnam, M. 4431
Ratovitski, E. 758
Rau, B. 5872
Raubitschek, AA. 622, 5907
Rauscher, FJ. I. 11229
Raut, CG. 8628
Raval-Fernandes, S. 8846
Ravatt, R. 1631
Raveh, S. 11605
Ray, RB. 718
Ray, S. 499
Rayala, S. 3179
Rayman, P. 5428
Raynaud, F. 11721
Raz, A. 1136, 3535, 7292, 7546, 10767
Rdzanek, MA. 10120
Real, PJ. 8151
Rebbaa, A. 10183
Rebeck, T. 2482
Rebel, H. 10298
Reber, HA. 982, 11536
Reber, H. 2738
Rebhun, RR. 3716
Rechavi, G. 999
Recht, LD. 4088, 8679
Reckamp, KL. 6275
Reckamp, K. 5211
Reddel, RR. 2722
Reddi, AH. 5769
Reddy, BS. 8022
Reddy, EP. 4228, 10174
Reddy, JC. 2044
Reddy, HKDL. 10174
Reddy, PV. 7809
Reddy, R. 4623
Reddy, SP. 10289
Reddy, SAG. 9164
Redling, D. 11779
Redman, R. 4228
Redston, M. 1097
Reed, JC. 210, 2378, 4799
Reed, JA. 692
Reedijk, M. 8530
Reese, E. 2422
Reeve, AE. 2592
Reeves, HL. 1213, 5761
Refetoff, S. 4238
Regala, RP. 8905
Reguart, N. 743
Reich, S. 9735
Reichardt, W. 9253
Reichenbach, R. 11437
Reichenberger, KJ. 2668
Reichert, M. 1234
Reichling, T. 166
Reichow, D. 8662
Reid, G. 10265
Reid, G. 4425
Reifenberger, G. 7121
Reigan, P. 10006
Reiman, T. 850
Reis, EM. 1693
Reis, LFL. 7127
Reisfeld, RA. 553, 3419, 5027,
Reiter, A. 2662
Reiter, RE. 9495
Reitz, A. 10068
Religa, P. 9261
Remy, C. 9536
Ren, H. 5841
Ren, Z. 6701
Renard, M. 2588
René-Corail, F. 7622
Rennebeck, G. 11230
Renner, O. 3846
Rennert, G. 5488
Rescigno, M. 3920
Resnick-Silverman, L. 2602
Ressler, SJ. 8887
Restifo, NP. 2001, 10569
Reszka, AP. 1489
Reszka, KJ. 6346
Retter, MW. 6425
Reuter, VE. 9312
Reutzel, D. 840
Reyal, F. 1376
Reyno, LM. 2044
Reynolds, AB. 2224
Reynoso, J. 5352
Rezaishiraz, H. 1105
Reznik, TE. 9355
Rho, SB. 749
Rho, S-B. 137
Ribas, A. 7194
Riboli, E. 8042
Ricci, G. 3751
Ricciardelli, C. 8487
Ricci-Vitiani, L. 6668, 11469
Rich, JN. 11276, 4051
Richards, JAS. 9206
Richards, WG. 5561
Richards, W. 1479
Richardson, A. 5054
Richardson, CD. 6685
Richardson, JA. 8698
Richardson, PG. 7478
Richardson, P. 5898, 8350, 11712
Richmond, AL. 5428
Richmond, GHP. 4389
Richter, K. 439
Ricketts, C. 2690
Ried, T. 1306, 8736, 9388
Riesbeck, K. 732
Riethdorf, S. 1187
Rietz, C. 1089
Rifón, J. 3264
Riganti, C. 516
Riggi, N. 11459
Riggins, GJ. 5070, 703
Riley, AM. 8339
Riley, S. 7516
Rimm, DL. 5578, 10938, 11185
Rimokh, R. 6521
Rinaldi, C. 8308
Ring, JE. 10970
Ringner, M. 7612
Rinker-Schaeffer, CW. 10984
Rio, M-C. 10862
Risberg, B. 331
Rischin, D. 4031
Rischmann, P. 11667
Risinger, JL. 5031, 7751, 7763
Risingsong, R. 4789
Ristimäki, A. 2157
Ritz, JM. 1187
Rivas, G. 805
Rivera-Bermudez, MA. 11174
Rivière, I. 9080
Rivoltini, L. 2321, 3942
Rizzo, P. 6282, 10273
Rizzo, S. 587
Roach, PD. 8573
Robbins, PF. 1079, 2001
Roberge, M. 3040
Roberson, RS. 2795
Roberts Jr., CT. 1849
Roberts, WG. 957
Robertson, ES. 7800
Robertson, GP. 2412
Robey, RW. 8414
Robinet, C. 526
Robinson, AF. 5112
Robinson, BS. 10700
Robinson, BWS. 7580
Robinson, MK. 1471
Robles, AJ. 10255
Roccaro, AM. 7478
Roccatto, E. 2572
Rocchi, P. 11083
Rocha, K. 10536
Rock, KL. 6425
Roda, JM. 9099
Rode, M. 9643
Rödel, C. 4881
Rödel, F. 4881
Rodriguez, A. 11271
Rodriguez, PC. 3044
Rodriguez, OE. 1164
Rodriguez-López, JN. 2059
Rodriguez-Mora, OG. 5408
Rodriguez-Rodriguez, L. 6660
Roecker, AJ. 605
Roerig, P. 439, 7121
Rofstad, EK. 1877, 2387
Roger, P. 4282
Rogers, AB. 10709
Rogers, CG. 5628
Rogers, P. 4918
Rogoff, HA. 6017
Rogulski, K. 2097
Rogus, J. 9651
Röhlin, TA. 10068
Roizman, B. 9479
Rokita, H. 3410
Rofle, M. 6593
Rollag, MD. 11174
Roman, JJ. 4334
Romanova, LY. 7386
Rome, LH. 8846
Romer, J. 4975
Romieu-Mourez, R. 11375
Ronen, SM. 3356
Rong, Y. 1406
Roninson, IB. 8927
Roodink, I. 8317
Rooimans, MA. 1271
Root, HA. 3136
Roots, I. 2972
Ropero, S. 2565
Rosano, L. 11649
Rose, GS. 3243
Rosemann, A. 1442
Rosen, EM. 5248, 6557
Rosenbauer, A. 9525
Rosenberg, A. 7065
Rosenberg, DW. 2636
Rosenberg, LM. 7052
Rosenberg, M. 9280
Rosenberg, SA. 2001
Rosenblatt, M. 6130
Rosenfeld, J. 8878
Rosenfelder, H. 7733
Rosenquist, M. 8286
Rosenthal, E. 7596
Rosenwald, A. 2199
Roshly, S. 898
Rosidi, B. 4020
Rosier, RN. 3209
Rosin, MP. 7561, 8017
Rosman, D. 3454
Rosner, A. 5792
Rosol, TJ. 9426
Ross, D. 10006
Ross, K. 9651
Ross, TS. 4126
Rossella, F. 2139
Rossi, C. 8339
Rossi, GR. 10555
Rossini, A. 8754
Rossini, A. 6388
Rossiter-Thornton, M. 11729
Roszkiewicz, J. 8101
Roszkowski, JJ. 1570
Rotem, R. 1984
Roth, G. 8397
Roth, JA. 349, 7568
Roth, Y. 6858
Rothermund, K. 2097
Rothhammer, T. 448
Rothman, N. 11214, 8034, 9574
Rotilio, G. 11735
Rotkiewicz, P. 3410
Rottapel, R. 6685
Rotter, V. 4530
Röttgers, S. 1442
Rouas-Freiss, N. 10139
Rouault, F. 6651
Rouffiac, V. 4353
Rougmont, J. 2170, 767
Rouleau, C. 9741
Roussel, M. 5991
Rowan, A. 11361
Rowe, N. 6022
Rowinsky, E. 5991
Rowley, BR. 3781
Rowley, DR. 8887
Roy-Burman, P. 4623, 5769
Royce, DB. 4789
Royer, H-D. 4078
Royer-Pokora, B. 4078
Roz, L. 1207
Rozakis-Adcock, M. 2520
Rozek, LS. 5488
Rozenblum, E. 7137
Rozenfurt, E. 2738, 6275
Rozmiarek, A. 835
Ruan, H. 7533
Ruan, Z-X. 5015
Rubin, BP. 6631
Rubin, JS. 10423
Rubin, MA. 1213, 5561, 5750
Rubin, JB. 11392
Rubio, D. 3035
Rubio-Viqueira, B. 3003
Ruckdeschel, JC. 805
Rucker, N. 9473
Rudland, PS. 3796
Rudolph, C. 2662
Rudolph, KL. 7393
Rudzinski, JJ. 10120
Ruebel, KH. 1136
Rugg, CA. 9038
Ruggeri, A. 2139
Ruhl, R. 5084
Ruiz i Altaba, A. 2990
Ruiz van Haperen, VWT. 9510
Ruiz, S. 9678
Ruiz-Cabello, J. 3846
Rumio, C. 2572, 6388
Rupnow, BA. 3781
Rusch, VW. 3063
Ruschhaupt, M. 7733
Rush, JL. 6294
Rush, LJ. 1277
Rusmini, P. 5445
Russell, PJ. 2330

- Russell, RG, 3950
 Russell, SJ, 5292
 Russo, AL, 1664
 Russo, A, 579
 Rustgi, AK, 9287
 Rustum, YM, 9829
 Ruthardt, M, 2537, 6080
 Rutka, JT, 8792
 Rutten, F, 8792
 Ryan, AE, 9817
 Ryan, A, 3538
 Ryan, RE, 8896
 Rydén, Lisa, 8009
 Ryeom, SW, 5881
 Rygaard, J, 3126
- Saai, LH, 2554
 Sabatella, G, 2572
 Sabates-Bellver, J, 10759
 Sabbioni, S, 7065
 Sabel, MS, 8366, 11259, 11329
 Saberi, A, 11704
 Sabichi, AL, 1808, 6189
 Sabnis, GJ, 3903
 Sabnis, G, 5380
 Sacchi, A, 9687
 Sacchi, A, 2906
 Sachs, A, 4059
 Sackstein, R, 5812
 Sadée, W, 4320, 7446
 Sadelain, M, 5417, 9080
 Saeck, Y, 11255, 2832, 6850
 Saenz, CC, 10646
 Safe, SH, 2890
 Saffrich, R, 3643
 Säfholm, A, 9142
 Saifi, R, 11762
 Sáfrány, Géza, 4458
 Saglimbeni, GN, 6660
 Sahai, E, 5278
 Sahin, AA, 6493, 7724
 Sahuquet, A, 10872
 Saiardi, A, 8339
 Said, A, 4228
 Saif, Z, 11304
 Saito, A, 4998
 Saito, R, 657
 Saito, Y, 7356
 Sakaguchi, H, 8448
 Sakaguchi, M, 9617
 Sakaguchi, N, 5925
 Sakai, H, 6337
 Sakai, T, 5662, 6364
 Sakaida, N, 157
 Sakamoto, C, 2846
 Sakamoto, H, 2115
 Sakamoto, Y, 10464
 Sakamoto, Y, 4817
 Sakata, M, 540
 Saksele, K, 8101
 Sakuma, T, 4998
 Sakumi, K, 6006
 Sakurai, T, 11605
 Salamanca, C, 8591
 Salavaggione, OE, 11071
 Salazar, E, 1150
 Salbaum, JM, 887
 Saldanha, U, 9355
 Saleem, M, 11203
 Sales, KJ, 7707
 Salgia, R, 1479, 5301
 Salhia, B, 8792
 Salih, HR, 6321
 Sallan, SE, 10050
 Sallum, RA, 7127
 Salmon, JS, 226
 Salmons, B, 6651
 Salovaara, R, 4607
 Salto-Tellez, M, 7743
 Salvatierra, E, 5123
 Salvatore, G, 10199
 Salvayre, R, 526
 Salz, W, 3531
 Samady, L, 3072
- Samant, RS, 713
 Samir, A, 195
 Sammallakorpi, H, 4607
 Samowitz, WS, 6063
 Sampath, J, 6593, 8224
 Sampson, DF, 3380
 Sampson, JR, 10179
 Sams, L, 7462
 Samudio, IJ, 2890
 Samuel, T, 210
 Samuelson, DJ, 9637
 Samuni, AM, 579
 Sanada, M, 6071
 Sancar, A, 6828
 Sanchez, P, 2990
 Sanchez-Perez, L, 2009
 Sanda, MG, 4126
 Sanders, KL, 9406
 Sanderson, RD, 5778
 Sandra, F, 8286
 Sands, BJ, 6755
 Sang, S, 8049
 Sangaletti, S, 3437
 Sangrar, W, 3518
 Sano, K, 1868
 Sano, S, 5720
 Sano, Y, 4998
 Sansom, OJ, 10145, 410
 Santella, RM, 1606
 Santin, AD, 4334
 Santinami, M, 3428
 Santoro, M, 10199
 Santos, D, 5898
 Santos, E, 9080
 Santos, M, 9678
 Saracci, R, 8042
 Sarbia, M, 5038
 Sarfaraz, S, 1635
 Sargin, B, 9643
 Saric, M, 2602
 Sarkadi, B, 1770
 Sarkar, D, 10901, 9056
 Sarkar, FH, 364, 3877, 6934, 9064
 Sarkaria, IS, 3063
 Sarmentero, J, 5647
 Sartippour, MR, 6159
 Sartor, CI, 3404
 Sartorius, CA, 9779
 Sasaki, H, 9659
 Sasaki, H, 2115
 Sasaki, M, 7628
 Sasaki, T, 10371
 Sasano, H, 6450, 657
 Sasazuki, T, 1244
 Sassano, A, 9029
 Sass-Kuhn, S, 572
 Sastre-Garau, X, 1174, 1376
 Sata, M, 10822, 5864
 Sata, S, 7241
 Satcher Jr., RL, 10651
 Satchi-Fainaro, R, 3656
 Sato, K, 1973
 Sato, K, 6
 Sato, M, 11018
 Sato, M, 11478
 Sato, N, 11018, 8706
 Sato, T, 8706
 Sato, T, 1973, 6950
 Sato, Y, 6612
 Satoh, H, 372
 Satomi, S, 3548
 Sau, D, 5445
 Saubermann, LJ, 2251
 Saudemont, A, 9080
 Sauer, LA, 11174
 Sauer, R, 4881
 Sauermann, M, 7733
 Sauk, JJ, 9953
 Saulnier, M, 3781
 Sausville, EA, 7847, 9953
 Sausville, E, 5337
 Savage, D, 957
 Savaugot, J, 9269
 Savellano, MD, 6371
- Savoy, DN, 2076
 Sawada, K, 540
 Sawai, E, 10700
 Sawai, H, 11536
 Sawaya, R, 4368
 Sawyer, TK, 1335
 Sawyers, CL, 11565
 Saya, H, 2899
 Sayegh, MH, 4320
 Sayyah, J, 8423
 Scaccianoce, E, 5445
 Scambia, G, 2397
 Scanlon, I, 5003
 Scarito, A, 3428
 Schaap, MM, 8166
 Schadendorf, D, 10068
 Schaefer, C, 11146
 Schaefer, E, 1479
 Schaefer, KL, 2251
 Schäfer, H, 1316
 Schageman, JJ, 8209
 Schagen, FHE, 9398
 Schaid, DJ, 1213
 Schaid, D, 11071
 Schally, AV, 5857
 Schamus, S, 6394
 Schaner, ME, 9388
 Schaper, ID, 1394
 Schattton, T, 4320
 Schätzlein, AG, 8079
 Schauer, DB, 3998
 Scheffer, GL, 10952
 Scheinberg, DA, 4888
 Scheithauer, BW, 1136
 Schellens, JHM, 2577
 Schepelmann, S, 5003
 Scher, HI, 9312
 Scherneck, S, 394
 Schiffer, IB, 840
 Schiffman, K, 650
 Schild-Poulter, C, 10750
 Schimmer, AD, 2378
 Schindler, J, 8350
 Schinkel, AH, 2577
 Schippers, JM, 6509
 Schirmacher, V, 10079
 Schlegel, R, 6199, 6534, 10854
 Schlegelberger, B, 2662
 Schlereth, B, 2882
 Schlesinger, K, 5828, 939
 Schlossman, R, 11712, 5898
 Schlunk, C, 2746
 Schmandt, R, 6910
 Schmeiser, HH, 2583, 2644
 Schmid, I, 7888
 Schmidt, C, 7733
 Schmidt, H, 9479
 Schmidt, LJ, 5965
 Schmidtke, P, 840
 Schmitt, M, 4101
 Schmitt, S, 840
 Schmitz-Winnenthal, FH, 10079
 Schned, AR, 7081
 Schneider, A, 4663
 Schneider, D, 2846, 8397
 Schneider, GB, 9851
 Schneider, PM, 1778
 Schneider-Broussard, R, 6207
 Schnitt, S, 11326
 Schober, W, 10767
 Schoch, C, 2662
 Schofield, DE, 4633
 Scholes, J, 6089
 Scholl, T, 10096
 Schoonjans, L, 4544
 Schor, AM, 10742
 Schor, SL, 10742
 Schorge, J, 8209
 Schramek, D, 3273
 Schrappe, M, 1442
 Schrauder, A, 1442
 Schreiber, RD, 3447
 Schroder, HD, 3126
 Schroeder, JA, 5238
- Schroeder, JA, 6755
 Schroeder, T, 5163
 Schroit, AJ, 11529
 Schroit, AJ, 913
 Schrumpp, DS, 7751, 7763
 Schulte, AP, 2668
 Schultes, CM, 1489
 Schulteis, B, 8912
 Schultze, JL, 5516
 Schulze, M, 2846
 Schunck, W-H, 2972
 Schupp, I, 7733
 Schuster, M, 7934
 Schwab, RM, 11613
 Schwäble, J, 1778, 9643
 Schwaenen, C, 439
 Schwager, C, 7934
 Schwartz, GG, 5470
 Schwartz, JE, 8548
 Schwartz, J, 8538
 Schwartz, SA, 7674
 Schwartz Jr., S, 10170
 Schwartzbaum, J, 6459
 Schwarz, D, 2972
 Schwarz, EM, 3209
 Schwarz, K, 2537
 Schwegler, C, 1925
 Schweigert, FJ, 1114
 Schweighoffer, T, 2321
 Schwemberger, SJ, 4568
 Schwemberger, S, 4292
 Sciambi, CJ, 8869
 Sciorati, C, 7502
 Sciot, R, 11520
 Scotlandi, K, 3868
 Scott, AM, 6745
 Scott, C, 2653
 Scott, G, 4292
 Scott, RJ, 835
 Scott, T, 10389
 Scott-Browne, JP, 6631
 Screpanti, I, 8308
 Scudiero, DA, 7470
 Scuto, A, 7169
 Seales, EC, 4645
 Sebastiani, V, 3003
 Sebo, TJ, 708
 Sebt, SM, 9525
 Sedgwick, B, 10472
 Sedivy, J, 2097
 Seftor, EA, 9851, 10164, 11429
 Seftor, REB, 10164, 9851
 Segal, NH, 5881
 Segall, JE, 5278
 Segawa, T, 9611
 Segers, J, 2441
 Segrelles, C, 9678
 Sehested, M, 7470
 Sehouli, J, 1114
 Seidah, NG, 4162
 Seiler, M, 7733
 Seitz, S, 394
 Seki, N, 5190
 Seki, T, 157
 Sekido, Y, 9628
 Sekimoto, G, 157
 Sekula, D, 6476
 Seldin, DC, 5792, 11375
 Seliger, B, 7926
 Seligson, D, 5628
 Sell, C, 2085
 Selli, S, 6388
 Sellers, WR, 5561, 8968, 11251
 Selzer, E, 9436
 Semenza, GL, 6178
 Semizarov, D, 7249
 Senderowicz, AM, 2872, 3364
 Senger, DI, 9982
 Sengupta, S, 2526
 Sensi, M, 632
 Senyuk, V, 7603
 Seo, E, 546
 Seo, T, 1738
 Seo, Y-W, 8993

- Serafini, P. 2026
 Seregina, TM. 10555
 Serody, JS. 3374
 Serra, M. 3868
 Serrano, M. 26, 2186
 Serre, CM. 300
 Serrels, B. 1335
 Serve, H. 1778, 9643
 Seshire, A. 6080
 Seth, AK. 10401
 Seth, NP. 10050
 Setiadi, AF. 7485
 Setién, F. 2565
 Sette, G. 11469
 Seva, C. 2770
 Sevcik, MA. 9426
 Severson, RK. 11214
 Sevginani, C. 6576
 Sewell, J. 6789
 Seyer, P. 4282
 Sgagias, MK. 3986
 Sgouros, G. 4888
 Sgroi, DC. 11572
 Shachaf, CM. 4471
 Shacter, E. 6054
 Shaffer, AL. 7644
 Shaffer, DR. 9312
 Shafran, A. 8414
 Shah, G. 8519
 Shah, M. 3911
 Shah, N. 7743
 Shahrzad, S. 8134
 Shahzidi, S. 11051
 Shaked, Y. 7045
 Shaklai, M. 1984
 Shaller, C. 1471
 Shalom-Feuerstein, R. 7292
 Sham, JST. 6504
 Sham, JS-T. 8125
 Sham, MH. 1687
 Shan, J. 7421
 Shan, S. 5498
 Shanahan, F. 9817
 Shanshaz, P. 5523
 Shannon, P. 3081
 Shantz, LM. 572
 Shao, Q. 2705
 Shapiro, GI. 6401
 Sharif-Afshar, A-R. 2296
 Sharma, A. 2412
 Sharma, DK. 8233, 10431
 Sharma, S. 5211, 6275
 Sharma, S. 3017
 Sharma, S. 1223
 Sharp, PA. 10750
 Shatnawi, A. 4431
 Shats, I. 4530
 Shay, JW. 3513, 7866, 11478
 She, M. 3671
 Shearer, MH. 2938
 Sheehan, KCF. 3447
 Sheikh, MS. 10725
 Sheleg, Z. 3364
 Shellenberger, TD. 11501
 Shelton, DL. 9426
 Shelton, JG. 9962
 Shen, H-M. 7815
 Shen, J. 8142
 Shen, KC. 8747
 Shen, L. 2125
 Shen, MR. 9294
 Shen, M. 9574
 Shen, R. 11259
 Shen, S. 797
 Shen, T. 9779
 Shen, T. 1277
 Shen, W. 3290
 Shen, Y. 7249
 Shendrik, I. 3958
 Shepard, A. 3493
 Shepard, RL. 6593
 Shepherd, R. 7591
 Sherley, JL. 3155
 Sherman, LS. 3542
 Sherrington, PD. 7328
 Shertzer, HG. 4292
 Shete, S. 427
 Sheu, B-C. 2921
 Shi, F. 246
 Shi, H. 1647
 Shi, J. 1687
 Shi, Q. 11276
 Shi, Q. 919
 Shi, R-X. 7815
 Shi, Y. 9962
 Shi, Y. 10716
 Shi, Z-Q. 9982
 Shiao, C-W. 1561
 Shibata, H. 2108
 Shibuya, M. 4939, 7267
 Shibuya, M. 10494
 Shida, D. 9159
 Shidara, Y. 1655
 Shido, K. 3185
 Shiekhattar, R. 3011, 3509
 Shields, PG. 9566
 Shifftan, L. 10316
 Shigematsu, H. 226, 1642, 7568
 Shigeno, K. 2130
 Shih, I-M. 331, 1994
 Shih, L-Y. 2488
 Shih, M-C. 5974
 Shih, S-J. 9194
 Shih, WJ. 6660, 10623
 Shiina, H. 2130
 Shikada, Y. 7241
 Shim, H. 967
 Shim, KD. 8471
 Shim, M. 861
 Shimada, H. 4683
 Shimada, H. 1129, 3200, 4633
 Shimamura, T. 6401
 Shimizu, K. 11
 Shimizu, N. 1642
 Shimizu, T. 6220
 Shimizu, Y. 10776
 Shimizu, Y. 9611
 Shimo, K. 387
 Shimokuni, T. 1055
 Shimura, M. 4998
 Shimura, T. 3535
 Shin, I. 2815
 Shin, S-H. 686
 Shin, S. 2761
 Shin, S. 9164
 Shin, VY. 5272
 Shin, YK. 9501
 Shin, Y-K. 3162
 Shinohara, ET. 4987
 Shiozawa, K. 1541
 Shipley, J. 8085, 9137
 Shir, Y. 4987
 Shirai, T. 2610
 Shirashi, N. 7478
 Shirashi, T. 5662, 6364
 Shirasawa, S. 1244, 8134
 Shishodia, S. 9555
 Shiu, J. 10363
 Shivasani, RA. 8715
 Shively, JE. 622, 5907, 10338
 Shmidt, EN. 787
 Shoemaker, A. 7249
 Shoemaker, RH. 7470, 9047
 Shokrani, M. 499
 Shoop, PL. 572
 Shope, JC. 713
 Shousha, S. 10104
 Shrader, M. 4902
 Shridhar, V. 7091
 Shringarpure, R. 7896
 Shroff, EH. 5144
 Shu, H. 6843
 Shu, S. 9547
 Shu, X-O. 5015
 Shuin, T. 4578, 4817
 Shulga, N. 10545
 Shull, GE. 8655
 Shultz, KL. 1259
 Shumway, SD. 11354
 Shureigi, I. 8442, 11486
 Shyjan, A. 6593
 Shyr, Y. 7674
 Sibon, D. 1234
 Sibson, DR. 3796
 Siddiqui, N. 8961
 Sidransky, D. 758, 1664, 4963
 Sieber, O. 11361
 Siedlecki, P. 6305
 Sieg, P. 10486
 Siegel, D. 10006
 Siegel, ER. 4334
 Siegfried, JM. 1459, 1598
 Sieuwerts, AM. 4101
 Siewert, J. R. 5038
 Sigal-Zafrani, B. 1376
 Signore, M. 11469
 Signorelli, M. 2964
 Signoretti, S. 3044
 Signoroni, S. 11227
 Sihto, H. 8101
 Sijmons, B. 7682
 Sikic, BI. 4088, 8679, 9388
 Sillaber, C. 9436
 Sillevs Smitt, PA. 11335
 Silverberg, MB. 11752
 Simek, K. 1587
 Simeone, MC. 6516
 Simi, B. 8022
 Simila, HA. 8487
 Simizu, S. 7455
 Simon, C. 11613
 Simon, MC. 2277
 Simoneau, AR. 3479, 9762
 Simoni, G. 2139
 Simons, B. 9807
 Simons, LA. 10651
 Simonson, SJS. 8266
 Simpson, ER. 657, 11762
 Simpson, JC. 7733
 Simpson, KJ. 10970
 Simpson, NE. 10149
 Sims, NA. 4929
 Singer, DS. 9117
 Singer, J. 9415
 Singh Jaggi, J. 4888
 Singh, AP. 7840
 Singh, B. 681
 Singh, B. 3063
 Singh, KK. 1105
 Singh, RR. 10594
 Singh, RK. 9004
 Singh, RP. 1035
 Singh, RN. 3577
 Singh, SV. 2035
 Singhal, J. 991, 6022
 Singhal, SS. 991, 6022
 Sinha, D. 11581
 Sinha, P. 11743
 Sinha, R. 8034, 11779
 Sinn, H-P. 439
 Sipos, B. 1187, 1316
 Sircar, K. 8514
 Sirchia, SM. 2139
 Srisawad, M. 11676
 Sirois, J. 9206
 Sirotni, M. 10255
 Sirrenberg, C. 9377
 Sizemore, N. 3586
 Sjölander, A. 732, 9142, 9727
 Skala, MC. 1180
 Skeen, J. 2592
 Skele, KL. 8091
 Skinner, RA. 11001
 Skitzki, JJ. 1063
 Skotheim, RI. 5588
 Skoulakis, S. 375, 8597, 9137, 9152
 Skov, S. 11136
 Slany, RK. 11367
 Slape, C. 7151
 Slater, J. 805
 Slattery, ML. 6063
 Slavin, S. 9735
 Slawin, KM. 4309
 Sledge Jr, GW. 9406
 Sleeman, JP. 10783
 Sleight, SD. 1007
 Slingerland, J. 18
 Sloan, D. 6042
 Sloan, KE. 10930, 1887
 Sloane, BF. 898
 Slocum, AL. 5070
 Slupianek, A. 7800
 Slupsky, JR. 7328
 Slusarczyk, A. 246
 Small, A. 7591
 Small, D. 1514
 Smart, RC. 861
 Smid, K. 9510, 10208
 Smilenov, LB. 933
 Smiraldi, PG. 2089
 Smirnov, DA. 4993
 Smirnov, I. 1678
 Smirnov, I. 6321
 Smith, BD. 5620
 Smith, BA. 9834
 Smith, CL. 7959
 Smith, CD. 2412
 Smith, D. 2330
 Smith, DJ. 483
 Smith, DS. 10891
 Smith, EP. 4238
 Smith, GJ. 6640
 Smith, GCM. 10145
 Smith, HJ. 277
 Smith, JA. 3108
 Smith, JA. 1027
 Smith, K. 5221
 Smith, KD. 3146, 9479
 Smith, K. 805
 Smith, L-L. 9152
 Smith, MT. 9574
 Smith, ML. 9152
 Smith, NR. 4389
 Smith, R. 7591
 Smith, SC. 7111
 Smock, A. 6990
 Smyth, C. 8961
 Smyth, JF. 6789
 Smyth, N. 1394
 Snijders, PJF. 1271
 Snyder, EL. 10646
 So, T. 5945
 Soares, FA. 7127
 Sobhanifar, S. 7259
 Sobol, RW. 6394
 Socc, ND. 3063
 Soda, H. 1541
 Soddu, S. 432, 9687
 Sodek, J. 2303
 Söder, O. 9999
 Soderstrom, C. 957
 Soderstrom, E. 957
 Sodha, P. 562
 Sodhi, A. 9953
 Soengas, MS. 6294
 Sogn, JA. 9117
 Sohara, Y. 1129
 Sohn, JJ. 3998
 Sokilde, B. 7470
 Sokoll, LJ. 9269
 Solheim, JC. 9004
 Solomon, H. 7591
 Solomon, J. 10716
 Solomon, L. 4663
 Somasundaram, K. 8628
 Somcio, RJ. 7775
 Sommers, JA. 1223
 Son, MJ. 137
 Soncin, F. 448
 Sone, S. 7102
 Sonenshein, GE. 11375
 Song, E-S. 686
 Song, L. 4554
 Song, SH. 1952
 Song, SW. 3562
 Song, W. 11712

- Song, W, 4309
Song, W, 5958
Song, Y, 10243
Soni, T, 5133
Sonoda, E, 11704
Sonuc, Nilüfer, 6780
Sood, AK, 6910, 10602
Sopko, B, 2644
Sordet, O, 4844
Soslow, R, 9415
Sotillo, JE, 9426
Sotillo, R, 3846
Soubrane, O, 948
Soubry, A, 2224
Soule, SE, 9406
Soulter, J, 1271
Soung, YH, 815
Sovena, G, 3942
Sowers, R, 1748
Sozzi, G, 1207, 4012
Spadaro, F, 9369
Spagnoli, GC, 10041
Spanevello, M, 6745
Spangenberg, C, 840
Spanjaard, RA, 2125
Sparaco, G, 9687
Speksnijder, EN, 8166
Spencer, DM, 787, 4309
Spencer, JA, 8209
Spencer, ML, 3226
Spera, G, 1897
Sperandio, K, 6130
Spernyak, J, 9829
Spicas, E, 11061
Spicer, Z, 11689
Spiegel, S, 2422
Spiegelman, VS, 1904
Spiegelstein, O, 887
Spies, T, 7502
Spina, M, 587
Spinella, F, 11649
Spirkoska, V, 6745
Spitz, DR, 6346
Spitz, MR, 349
Spizzo, R, 7065
Sporn, MB, 4789, 4799
Spraggon, C, 1376
Spriggs, D, 9415
Springer, CJ, 5003
Springer, C, 10686
Springett, GM, 9415
Sproull, M, 10389
Squarcina, P, 3942
Squirrell, JM, 1180
Sreekumar, A, 4126
Sridharan, L, 5358
Srinivasan, R, 4228
St. Clair, DK, 3745
St. Clair, D, 1401
St. Clair, W, 1401
Staal, J, 7612
Stabile, LP, 1459
Stack, MS, 2234, 9280
Stadler, WM, 10984
Stadler, W, 5628
Stahl, M, 698
Staih, F, 10255
Stål, Olle, 8009
Stallcup, WB, 5325
Stamenkovic, I, 4261, 11459
Stampfer, MJ, 2498
Stanbridge, EJ, 7259
Stanford, JL, 1213
Stanley, ER, 5278
Stantz, KM, 1941
Stark, GR, 939
Starling-Emerald, B, 317
Stassi, G, 6668, 11469
Staubach, A, 54
Staudt, LM, 7644
Staugaitis, SM, 939
Staver, M, 7249
Stavropoulou, V, 1361
Stearns, M, 2085
Steele, AJ, 2373
Steele, R, 718
Steelman, LS, 9962
Stefanich, ED, 10709
Stefanini, M, 432
Stefanski, J, 9080
Steffen, B, 1778
Steffensen, B, 130
Steffensen, I-L, 121
Stegmaier, K, 7856
Stein, HJ, 5038
Stein, JP, 4623
Steiner, H-H, 11419
Steiner, P, 6294
Steinle, A, 6321
Stendahl, M, 8009
Stennett, L, 6282
Stephan, DA, 1748
Stephan, M, 9080
Stephanie, LV, 5917
Stephen, AG, 9047
Stephens, LC, 11297
Stephens, P, 7591
Stephens, Y, 7591
Stermann, DH, 8379
Stern, R, 10316
Sternberg, D, 7338
Sternlicht, MD, 130, 8617
Serry, W, 4172
Stettner, MR, 5535
Stevens, C, 7591
Stevens, MFG, 3911
Stevens, MV, 6755
Stevens, RG, 9595
Stevenson, D, 8826
Stewart, GE, 10265
Stewart, JA, 805
Stewart, JK, 10930
Stewart, JE, 9338
Stewart Jr., S, 8730
Stiborova, M, 2644
Stiehl, DP, 11094
Stighall, M, 9727
Stiles, C, 5785
Stiles, CD, 9651
Stocking, C, 1925
Stoeger, SM, 3986
Stoffregen, EP, 4500
Stoicov, C, 10912
Stokoe, D, 10669
Stoll, I, 10862
Stone, C, 8134
Stone, R, 7338
Stoolman, LM, 1063
Stoop, J, 8085
Stoppa-Lyonnet, D, 1376
Storey, A, 2216
Storgard, CM, 5292
Storkus, WJ, 8461
Storm, H, 8567
Stoughton, R, 4059
Stove, C, 6237, 8774
Stove, V, 8774
Stower, MJ, 10946
St-Pierre, Y, 5205
Strack, P, 7533
Stram, DO, 7516
Stransky, N, 1376
Stratakis, CA, 4506
Stratford, I, 4147
Strathdee, G, 8961
Stratton, MR, 7591
Stratton, M, 7612
Strehl, S, 7596
Stresemann, C, 7086
Stricker, PD, 2330
Strieter, RM, 5063, 11752
Strieter, R, 2738
Strong, LC, 427
Struski, S, 6521
Stuart Salmon, J, 226
Stubenrauch, F, 11613
Stuckler, D, 991
Studený, M, 3307
Sturgeon, S, 358
Sturla, L-M, 5683
Stylianou, C, 6745
Su, J, 76
Su, J-L, 4827
Su, Q, 2353
Su, T, 2554
Su, Y-N, 9089
Su, YS, 10347
Su, Z-z, 10901, 9056
Subbaramaiah, K, 664, 5982, 10113
Subbarayan, M, 622
Subbarayan, V, 6189
Sudol, M, 6764
Sueishi, K, 7241
Suemasu, K, 4653
Sufrin, JR, 5917
Sugarbaker, D, 1479, 5561
Sugasawa, K, 5720
Sugaya, M, 5945
Sugimoto, T, 10233
Sugimoto, Y, 596
Sugimura, T, 11, 2610
Sugino, Y, 10233
Sugio, K, 5945
Suh, CO, 9501
Suh, KS, 562
Suh, N, 4789, 4799
Suh, Y, 11271
Suhai, S, 6305
Sui, J, 2344
Sullivan, DM, 3815
Sullivan, D, 7041
Sültmann, H, 7733
Suman, VJ, 3059
Summers, R, 11437
Summersgill, B, 8085
Summy, JM, 7214
Summy, J, 6493
Sun, B, 6512
Sun, H, 4442
Sun, H, 10716
Sun, H, 6864
Sun, J, 8379, 11752
Sun, J, 1018
Sun, L, 3671
Sun, P, 8298
Sun, P, 10401
Sun, RW-Y, 11553
Sun, R, 1433
Sun, S-Y, 6354, 7052, 9169
Sun, T-T, 1150, 3531
Sun, Y, 1352
Sun, YJ, 10767
Sunamura, M, 2899
Sunar-Reeder, B, 6151
Sundaresan, G, 622, 5907
Sundaresan, T, 2353
Sundvall, M, 1384
Sung, J, 7169
Sung, YM, 9304
Supino, R, 2364
Suraokar, M, 6189
Suriano, R, 6466
Sürücü, O, 11044
Sutcliffe, MJ, 11265
Sutherland, RL, 2330, 4031, 4623
Sutphen, R, 805
Sutter, C, 8072
Sutton, KL, 1497
Suva, LJ, 11001, 5778
Suvà, M-L, 11459
Suy, S, 579
Suzuki, C, 11314
Suzuki, E, 8379, 11752
Suzuki, K, 10431
Suzuki, K, 1868
Suzuki, M, 1642
Suzuki, S, 6450
Suzuki, S, 2610
Suzuki, T, 6450, 657
Suzumoto, Y, 113
Sveen, L, 10692
Swagemakers, SMA, 11335
Swain, F, 11001
Swami, S, 7917
Swart, GWM, 8801
Sweatman, T, 10016
Sweeney, C, 1105, 6063
Swenson, S, 5785
Świerniak, A, 1587
Swift, SE, 9294
Swinnen, JW, 2441, 6719
Syed, DN, 11203
Sylvie, R, 195
Symonds, G, 797
Symowicz, J, 2234
Syrjä, S, 8101
Syu, M-H, 9089
Szabó, K, 1770
Szadkowski, M, 4525
Szekely-Szucs, K, 11447
Szentpétery, Z, 1770
Szewc, R, 957
Szlosarek, PW, 10355
Szmania, SM, 10041
Szpak, S, 1587
Taaij, D, 9670
Tabach, Y, 4530
Tabi, Z, 7000
Tabuchi, M, 8448
Taccioli, GE, 10223
Tada, K, 7743
Tada, M, 10822
Tae Chung, S, 1306
Taffetani, S, 11437
Tagawa, M, 325
Taguchi, H, 4762
Tahara, H, 4939
Tahara, M, 540
Tahashi, Y, 157
Tai, S-K, 5841
Tai, Y-T, 5898, 7478, 11712
Taichman, R, 8818
Taira, K, 5864, 10822
Tajara, EH, 1693
Tajeddine, N, 7348
Takagi, S, 5720, 7455
Takagi, T, 7660
Takahashi, A, 10632
Takahashi, H, 2251
Takahashi, JA, 11704
Takahashi, M, 5628
Takahashi, S, 3700, 8388
Takahashi, S, 10159
Takahashi, T, 1642
Takahashi, T, 4739, 9628, 10680
Takahashi, Y, 113
Takaishi, M, 9617
Takano, A, 9176
Takano, H, 8125
Takata, M, 11704
Takata, Y, 982
Takato, T, 828
Takeda, J, 5720
Takeda, M, 1868
Takeda, S, 11704
Takei, H, 4653
Takenaga, K, 11622
Takenaka, K, 2979
Takenaka, Y, 3535, 7546
Takenoyama, M, 5945
Takeshima, Y, 9176
Taketani, Y, 10669
Taketo, MM, 8622, 9206
Taketo, MM, 9147
Takeuchi, A, 8448
Takeuchi, H, 3336
Takeuchi, H, 1800
Takeuchi, T, 3700
Takeya, M, 5925
Takiguchi, M, 5190
Takimoto, S, 9829
Talamonti, MS, 6011
Talbot, SG, 3063
Tallman, MS, 1117, 9029
Talmadge, JE, 9004

- Talos, F. 9971
 Talukder, AH. 10594
 Tam, P. 1687
 Tamada, K. 1089
 Tamae, D. 10338
 Tamagnone, L. 6167
 Tamai, K. 3548
 Tamamura, H. 1700
 Tamasaku, K. 4998
 Tamborini, E. 1115
 Tamura, H. 1089
 Tamura, K. 4578
 Tamura, M. 7660
 Tamura, Y. 7455
 Tan, BJ. 4520
 Tan, C. 605
 Tan, EH. 10330
 Tan, G. 2026
 Tan, J. 4987
 Tan, J. 9012
 Tan, M. 1858
 Tan, M-H. 5628
 Tan, N. 6843
 Tan, P. 186
 Tan, PH. 5628
 Tan, W. 722, 9582
 Tanabe, KK. 3823
 Tanaka, M. 2979
 Tanaka, N. 546
 Tanaka, T. 7276
 Tanaka, Y. 4562, 5864, 10822
 Tanaka, Y. 4963
 Tanas, MR. 6631
 Tang, DG. 6207
 Tang, D-J. 6504
 Tang, L. 7338
 Tang, Q. 6526
 Tang, T. 868
 Tang, W. 1904
 Tang, X. 4530
 Tang, X. 11478, 7568
 Tang, X. 3236
 Tang, Y. 3193, 4228, 8324
 Tang, Z-Z. 2542
 Tani, T. 7660
 Tanière, P. 5076
 Tanigami, A. 8640
 Tanimoto, K. 1055
 Taniuchi, K. 105, 3092
 Taniwaki, M. 9176
 Tannenbaum, C. 5428
 Tanner, M. 1384, 473
 Tannock, IF. 2825
 Tantin, D. 10750
 Tanzawa, H. 5190
 Tapang, P. 2698
 Tarapore, P. 4568
 Tarin, D. 5991, 5996
 Tarpin, C. 2170
 Tarutani, M. 5720
 Tasaka, K. 540
 Tatarelli, C. 1505
 Tateishi, K. 4562, 5864, 10822
 Tatematsu, Y. 10680, 9628
 Tatsugami, K. 10032
 Tatsumi, T. 8461
 Tatsuta, M. 9121
 Taube, ME. 898
 Taubert, R. 6443
 Tauler, J. 4181
 Tavecchio, L. 1207
 Taverna, D. 10324
 Tavtigian, SV. 417
 Taylor, CC. 10381
 Taylor, JL. 3030
 Taylor, JMG. 5488
 Taylor, NS. 10709
 Taylor, PC. 2662
 Taylor, PR. 2542
 Taylor, ST. 4389
 Teague, J. 7591
 Tedesco, D. 8298
 Teesch, LM. 6346
 Tegerstedt, K. 5953
 Teh, BS. 5628
 Teh, BT. 5628, 7591
 Teh, B. 4598
 Teh, M. 7743
 Teh, M-T. 8597
 Teicher, BA. 9741
 Teissie, J. 11667
 Teissier, S. 1174
 Teitelbaum, SL. 1606
 Teixeira, MR. 4012
 Tekmal, RR. 11164
 Teknos, TN. 8366
 Telford, N. 2662
 Tellez, C. 11185
 ten Hagen, TLM. 4300
 Tenen, DG. 7096
 Teng, Q. 605
 Teng, Y. 8671
 Tennant, RW. 3958
 Teodoridis, JM. 8961
 Terada, K. 6850
 Teraishi, F. 6380
 Terakawa, N. 8406
 Terao, T. 10464
 Terashima, M. 2130
 Terauchi, Y. 4769
 Terme, M. 6409
 Terrassa, M. 465
 Terrasson, J. 2787
 Terry, KL. 5974
 Terry, MR. 1606, 9659
 Terry, S. 5263
 Terstappen, LWM. 4993
 Terui, Y. 4998
 Terzieva, S. 4292
 Terzoudi, GI. 11292
 Teshima, T. 113
 Teson, M. 432
 Tessarollo, L. 1306
 Testa, JR. 5256, 8091
 Thaker, PH. 3716
 Thaler, HT. 8111, 10113
 Thalmann, GN. 7682
 Thames, HD. 5374
 Thannickal, VJ. 10881
 Theele, DP. 9517
 Thelwall, PE. 10149
 Theodorescu, D. 7111, 7320
 Therneau, TM. 2985
 Theti, DS. 11721
 Theuring, F. 4078
 Thiagalingam, A. 1664
 Thiagalingam, S. 1664
 Thibodeau, SN. 1213
 Thibodeaux, CA. 10854
 Thiele, CJ. 2070, 4775
 Thierry, F. 1174
 Thiers, J-C. 526
 Thierry, JP. 1376
 Thomas, AM. 1079
 Thomas, B. 7091
 Thomas, DM. 9633
 Thomas, L. 10901
 Thomas, M. 4334
 Thomas, M. 1778
 Thomas, R. 5654
 Thomas, S. 8519
 Thomas, TP. 5317
 Thomas-Tikhonenko, A. 1904, 5454
 Thompson, A. 9245
 Thompson, C. 3218
 Thompson, EW. 4929, 5991, 5996, 6139
 Thompson, GMA. 1693
 Thompson, HJ. 7023
 Thompson, J. 2482
 Thompson, J. 2009
 Thompson, RC. 7674
 Thomsen, B. 6167
 Thomsen, C. 8975
 Thomson, S. 9455
 Thor Straten, P. 2983, 11136
 Thor, AD. 246
 Thor, A. 879
 Thordarson, G. 3493
 Thorneley, RNF. 2059
 Thorne, PS. 7267
 Thornton, D. 7462
 Thorpe, PE. 4408
 Thougard, AV. 7470
 Threadgill, DW. 6534, 11478
 Thurn, KE. 10651
 Tian, D. 8548
 Tian, K. 7421, 10024
 Tian, X-x. 4747
 Ticozzi, P. 7502
 Tien, AH. 2947
 Tieu, A-T. 4343
 Tigaud, I. 6521
 Tighe, M. 6593
 Tilan, J. 1719
 Tilley, WD. 8487
 Tilli, MT. 681
 Tillman, DM. 7436
 Tilly, W. 5872
 Timár, J. 7186
 Timchenko, N. 692
 Timmerman, B. 641
 Timmermans, L. 2441
 Timmons, JC. 8183
 Timmons, J. 4067
 Timpson, P. 3273
 Tindall, DJ. 708, 5965
 Ting, JPY. 3374
 Tirado, OM. 9320
 Tirosch, B. 6435
 Tischler, V. 4754
 Tisdale, MJ. 277
 Tissier, F. 7622
 Titsch, C. 5358
 Titus, BJ. 7111
 Titus, B. 7320
 Titus-Ernstoff, L. 5974
 Tiwari, RK. 6466
 Tjin Tham Sjin, RM. 3656
 Tkacz-Stachowska, K. 11051
 Tkalecic, G. 957
 Tlsty, TD. 1792
 Tiziana, N. 1115
 To, C. 6745
 To, H. 8448
 To, K-F. 8125
 To, LB. 1700
 Tobias, JW. 5454
 Tobler, A. 868
 Todaro, M. 6668
 Todo, T. 10663
 Todoroki, T. 546
 Toes, REM. 6984
 Tofflon, PJ. 6967, 10389
 Tofts, C. 7591
 Togashi, A. 4817
 Toge, T. 1055
 Tognon, M. 3049
 Toker, A. 4728
 Toki, T. 7596
 Tokita, H. 4587
 Tokuhara, M. 6220
 Tokumaru, Y. 4963
 Tokumou, M. 9771
 Toledo, SPA. 9651
 Tolle, KC. 10113
 Tollenaar, RAEM. 10188
 Toloczko, A. 7888
 Tomasello, C. 10862
 Tombal, B. 7348
 Tomicic, MT. 8920
 Tomida, S. 9628
 Tominaga, Y. 6006
 Tomisato, W. 1868
 Tomita, K. 4246
 Tomkinson, B. 1361
 Tomlins, SA. 3328
 Tomlinson, DC. 10441
 Tomlinson, I. 11361
 Tomlinson, S. 10562
 Tommasi, S. 92, 7653
 Tomonaga, T. 4683
 Tomotsune, D. 4587
 Toms, SA. 7674
 Tonetti, C. 3281
 Toney-Earley, K. 1285
 Tong, Q. 6601
 Tong, R. 5711
 Tong, WP. 9445
 Tong, X. 5898
 Torabinejad, J. 713
 Torchinsky, C. 2125
 Torrella, C. 1887
 Toretsky, JA. 1719, 6199
 Torigoe, T. 8706, 11018
 Torimaru, Y. 85
 Torkin, R. 7267
 Torres, D. 9253
 Torres-Roca, JF. 7169
 Torrey, TA. 1306
 Torroella-Kouri, M. 10578
 Tortoreto, M. 6388
 Toretto, F. 10637
 Tóth, Sára. 4458
 Tothill, RW. 4031
 Tournilhac, O. 5898
 Tovar, C. 1918
 Tóvári, J. 7186
 Towns, WH. 4506
 Toy, P. 8397
 Toy, P. 2846
 Toyama-Sorimachi, N. 6220
 Toyomura, K. 2979
 Toyooka, S. 1642
 Traganos, F. 8538
 Tran, J. 2085
 Tran, MGB. 10847, 11520
 Tran, T. 4431
 Tran, TT. 9705
 Tranguch, S. 3735
 Transidico, P. 3920
 Trapasso, F. 6764
 Trapman, J. 5730
 Trefzer, U. 4172
 Treloar, AE. 10930
 Tremblay, ML. 10088
 Tremblay, P. 3928
 Trempeux, C. 3958
 Trent, JM. 6282, 8587, 10164
 Trentin, GA. 2520
 Treon, SP. 11712
 Tresoldi, M. 7502
 Tressler, R. 7866
 Tretiakova, MS. 1479
 Tretiakova, M. 5628, 10692
 Trevino, JG. 3664, 7214
 Triche, TJ. 4633, 8984
 Triche, T. 8142
 Trichopoulos, D. 358, 8042
 Trichopoulos, A. 8042
 Tricot, G. 10041
 Tridandapani, S. 9099
 Trifiro, M. 8514
 Trimis, G. 1627
 Trinchieri, G. 3437, 8479
 Trink, B. 758
 Trivedi, NR. 2412
 Trivedi, RN. 6394
 Trivers, GE. 9132
 Trosko, JE. 9771
 Trost, D. 4078
 Trost, TM. 840
 Trostel, S. 7386
 Trotta, R. 9099
 Troup, S. 5696
 Trovato, A. 1105
 Trujillo, N. 5750
 Trumpp, A. 4005, 11459
 Trusolino, L. 10674
 Tsai, J. 1814
 Tsai, KKC. 6734
 Tsai, M-J. 7976
 Tsai, SY. 7976
 Tsan, R. 11529
 Tsang, RK-Y. 8125
 Tsang, YTM. 76
 Tsao, C-Y. 3410

- Tsao, M-S, 5045
Tsao, SW, 1450
Tsark, WM, 92
Tseng, C-C, 10394
Tseng, C-P, 6089, 9906
Tsuchida, A, 8836, 10613
Tsuchida, R, 7267
Tsuchihara, K, 6685
Tsuchiya, E, 7102, 9176, 11314
Tsuchiya, H, 4246
Tsuchiya, T, 1868
Tsuda, N, 2930
Tsui, K, 4246
Tsui, T, 1352
Tsujimoto, H, 1055
Tsujino, Y, 2610
Tsukumo, F, 1693
Tsuneyoshi, M, 10032
Tsuno, T, 7573
Tsunoda, T, 4939
Tsuruma, T, 8706
Tsuruo, T, 5864
Tsurutani, J, 1541, 7137, 8423
Tsutsui, T, 2778
Tsutsui, TW, 2778
Tsutsumi, S, 1868
Tsutsumi, S, 3535
Tsuyma, N, 2269
Tu, GH, 6901
Tu, S-w, 6089
Tu, S-W, 9906
Tuck, AB, 3396
Tucker, JM, 5390
Tullus, C, 5953
Tumino, R, 8042
Tung, C-H, 9398
Turella, P, 3751
Turhan, AG, 2676, 2914, 6409
Turner, JR, 2251
Tusell, L, 10223
Tuttle, RL, 6568
Tuveson, DA, 2412, 8166, 10280
Tuxhorn, JA, 8887
Tuzlali, S, 6493
Tyminski, E, 6850
Tzehoal, E, 6435
- Uchegbu, IF, 8079
Uckert, W, 2560
Udabage, L, 6139
Udagawa, H, 401
Udagawa, K, 7276
Udagawa, T, 5690
Ueda, M, 6006
Ueda, S-i, 4253
Ueda, Y, 8640
Uede, T, 10783
Uehara, H, 3707
Uemura, Y, 157
Ueno, K, 4998
Ueno, NT, 8406
Ueno, Y, 8640
Ugai, H, 546
Uhrbom, L, 2065
Ujhelly, O, 1770
Ulkon, K, 1055
Ulrich, AM, 6990
Ulrich, A, 6919
Umaki, T, 10613
Umana, P, 7934
Umar, A, 5031
Umetani, N, 1800
Umezawa, K, 7628
Underhill, CB, 4614
Unfer, RC, 10555
Ung, E, 957
Unger, C, 1887
Unkeless, JC, 5009
Upadhyay, S, 758
Urakami, S, 2130
Urano, T, 3700
Urba, WJ, 10569
Urcis, R, 5133
Üren, A, 6199
- Urquidí, V, 6042
Urrutia, RA, 2076
Usheva, A, 2840
Ushijima, H, 1868
Ushijima, T, 11, 828, 2610
Usuhitán, Alp, 6199
Utleg, AG, 3081
Utsunomiya, T, 401
Uzgare, AR, 9269
- Vacek, P, 9670
Vachani, A, 8379
Vacher-Lavenu, M-C, 7622
Vacherot, F, 5263
Vadai, E, 6435
Vadlamudi, RK, 3179, 5571, 7724
Vágó, A, 7186
Vahanian, N, 10555
Vaheiri, A, 9914
Vaid, A, 7959
Vaid, M, 10810
Vainchenker, W, 2676, 3281
Valdez, P, 8331
Valent, P, 9436
Valenti, M, 11721
Valentijn, LJ, 3136
Valentine, PJ, 4389
Valentini, SR, 1693
Valerie, K, 9056, 10901
Vales, A, 9436
Vallabhaneni, G, 3328
Vallieres, E, 2795
Vallières, L, 3928
Vallon-Christerson, J, 7612
Valtieri, M, 6576
van Asperen, R, 3136
van Beek, H, 8801
van Beers, EH, 822
Van Belle, PA, 9328
Van Besien, K, 1570
Van Beusechem, VW, 9398
van Bokhoven, H, 8317
van Bruggen, I, 7580
van Buren, L, 4698
Van Damme, B, 4544
van de Rijn, M, 8118
Van de Sande, T, 2441
Van de Ven, WJM, 4544
van de Vijver, M, 4059
van de Water, B, 4698
van de Wiel, MA, 10208
van den Aardweg, GJ, 3610
van den Bent, MJ, 11335
Van Den Berg, D, 5470
van den Berg, H, 3347
van den Berg, J, 3610, 8166
Van Den Bossche, K, 8774
van den IJssel, P, 9510
van den Oord, JJ, 692
van der Born, K, 4425
van der Heijden, I, 4425
van der Korput, HA, 5730
van der Kwast, TH, 5730
van der Linden, B, 3347
van der Most, RG, 7580
van der Pluijm, G, 7682
van der Schaft, DWJ, 11520
van der Sloot, AM, 1729
van der Sluis, T, 1729
van der Spek, P, 11335
van der Vliet, A, 9670
van der Zwaag, B, 8317
van Deventer, HW, 3374
Van Diest, P, 10801
van Duijn, P, 5730
van Duiker, S, 6443
Van Dyck, F, 4544
Van Dyke, T, 5172, 8218, 10243
van Eijk, R, 10188
van Genne, L, 3380
van Gisbergen, KPJM, 5935
van Goor, H, 3568
van Gurp, RJHLM, 8085
van Hall, T, 6443
- van Hasselt, CA, 8125
van Hengel, J, 2224
van Kilsdonk, JWW, 8801
van Kooyk, Y, 5935
van Laar, RK, 4031
Van Le, T-S, 7145
van Luijk, P, 3568, 6509
Van Marck, E, 2224
Van Marck, V, 8774
Van Meir, EG, 605, 1406
van Mierlo, GJD, 6984
van Muijen, GNP, 8801
van Nimwegen, MJ, 4698
Van Nostrand, K, 3243
van Oostrom, CTM, 3610
van Ophoven, A, 4836
Van Pelt, CS, 1808
van Rhee, F, 10041
van Rooijen, N, 7194
van Roy, F, 2224, 6237
Van Schoor, M, 7348
van Steeg, H, 3610, 8166
van Tellingen, O, 2577
van Tiel, ST, 4300
Van Valckenborgh, IC, 4544
van Vugt, MATM, 7037
Van Waes, C, 7071
van Welsem, T, 822
van Wezel, T, 10188
van Zeeburg, HJT, 1271
van't Slot, R, 10188
van't Veer, L, 4059
van't Veer, LJ, 822, 9155
VanBroeklin, M, 11193
Vance, KW, 2260
Vande Woude, GF, 11193
Vander Griend, DJ, 10984
Vander Haeghen, Y, 8774
Vanderhoydonc, F, 2441
Vanderplassen, A, 9463
Vandertop, WP, 9398
VanOsdol, SJ, 7370
VanRoey, MJ, 6901
VanRoey, M, 2449
Vanstraelen, D, 2662
Vantghem, SA, 3396
Váradi, A, 1770
Várady, G, 1770
Varambally, S, 3328, 11259
Varani, J, 493
Varela-Garcia, M, 2668
Varga, J, 9029
Varga, N, 7186
Varghese, S, 1532
Varian, J, 7591
Varney, ML, 9004
Varrichio, L, 10585
Varro, A, 7363
Vartanian, S, 868
Varticoski, L, 10255
Vasicek, TJ, 3081
Vaslet, CA, 8091
Vasquez, AC, 1598
Vassilev, LT, 1918, 7386
Vatolin, S, 5112, 7751, 7763
Vaughan, EM, 8766
Vaught, JL, 3389
Vearing, C, 6745
Vecchione, A, 1207, 6576
Vecil, G, 3307
Veerman, G, 9510
Veglia, F, 8042
Veitch, GH, 2705
Velaparthi, U, 3781
Velculescu, VE, 919
Velez, JM, 3745
Veliceasa, D, 5144, 10651
Venere, M, 7533
Venkatasubbarao, K, 2861
Venkatraman, G, 7840
Venter, J, 11437
Venturelli, S, 6321
Verderame, MF, 11026
Verhaegen, M, 6294
- Verhoef, S, 822
Verhoeven, G, 2441, 6719
Verjovski-Almeida, S, 1693
Verkasalo, PK, 9595
Verkoeijen, S, 4698
Verma, A, 9029
Vermeij, M, 5730
Vermeulen, R, 9574
Veronese, A, 7065
Verratti, K, 1814
Verrijp, K, 8317
Verschraegen, C, 9517
Versteeg, R, 3136
Vesci, L, 1897
Vessella, RL, 1710, 11083
Vesuna, F, 10801
Vettori, D, 1631
Vezzani, C, 925
Viale, A, 3063
Viapiano, MS, 6726
Viarsio, D, 516
Vicari, AR, 3437, 8479
Vicari, A, 7502
Vidal, B, 10872
Vidal, M, 3538
Viens, P, 767, 2170
Vieusseux, J, 4929
Viglianti, BL, 5163
Vigneri, R, 1849
Vigneron, A, 8927
Vigneron, D, 7041
Vigushin, DM, 10104
Vijg, J, 11271
Vile, RG, 2009
Villanueva, FS, 533
Villeneuve, J, 3928
Viloria-Petit, A, 5365
Vimalachandran, D, 3218
Vincent, Loic, 3185
Vincent-Salomon, A, 1376
Vineis, P, 8042
Visakorpi, T, 8101
Visvanathan, J, 8142
Vitalis, TZ, 7926
Vitetta, ES, 6371
Vittoux, D, 8754
Vivaldi, A, 3049
Vizan, P, 5512
Vizzotto, L, 2572
Vlatković, N, 6498
Vo, A, 1830, 4191
Vogel, CL, 2044
Vogel, H, 4088, 8679
Vogelbaum, MA, 2956
Vogelbaum, M, 5428
Vogelstein, B, 4607
Vogelzang, NG, 5628
Vogler, M, 10502
Vogt, AB, 10068
Volinia, S, 7065
Volk, C, 10079
Vollmer Jr., CM, 2344
Vollmer, J-Y, 4261
Volovitz, I, 6435
Volpert, OV, 10651, 5144
Volz, K, 5144
von der Maase, H, 34
von Herbay, A, 11361
von Horsten, HH, 2162
von Knebel Doeberitz, M, 6418, 8072
von Mensdorff-Pouilly, S, 7880
von Rahden, BHA, 5038
Vonderhaar, BK, 7509
Voo, KS, 1577
Vormoor, J, 1442
Vortmeyer, AO, 10847
Vos, MD, 3117
Vosseler, S, 1294
Vostal, JG, 7370
Votaw, J, 967
Voutsadakis, IA, 2914
Voz, M, 4544
Vozhilla, N, 9056
Vrieling, H, 10298

- Vrotsos, KM, 1180, 8766
 Vu, BT, 1918
 Vujanovic, N, 8461
 Vujaskovic, Z, 5163, 8853
 Vujcic, M, 5890
 Vukosavljevic, T, 1277
- Waaga-Gasser, AM, 4320
 Wada, K, 2846
 Wada, K, 2251
 Wada, S, 4939
 Wadsworth, PF, 4389
 Waelkens, E, 2441
 Wagner, A, 6321
 Wagner, BA, 6346
 Wagner, EF, 6409
 Wagner, R, 8072
 Wagner, WR, 533
 Wahl, AF, 8331
 Waidyanatha, S, 9574
 Wajapeyee, N, 8628
 Wakabayashi, T, 7573
 Wakada, M, 5662, 6364
 Wakayama, M, 546
 Wakazono, K, 2610
 Wakefield, JK, 4645
 Wakumoto, Y, 4817
 Waldeck, K, 4929
 Waldman, SA, 11129
 Walker, AM, 7509
 Walker, EC, 6139
 Walker, F, 3273
 Walker, M, 4389
 Walker, RL, 9226
 Walker, RC, 5778
 Walker, V, 2474
 Walker, WF, 3236
 Wall, ME, 4448
 Walls, CD, 9406
 Walser, B, 11001
 Walsh, MJ, 9216
 Walsh, PC, 1213
 Walter, KA, 4663
 Walters, DK, 4500
 Waltham, MC, 4929
 Waltham, M, 6139
 Waltregny, D, 2224
 Waltz, SE, 1285
 Walz, C, 2662
 Wan, D, 6843
 Wan, T, 4947
 Wan, X, 2406
 Wang, A, 7809
 Wang, A, 1164
 Wang, B, 4947
 Wang, C, 2542
 Wang, C, 246
 Wang, C, 6557
 Wang, C, 3781
 Wang, C-X, 8548
 Wang, C-Y, 5063
 Wang, DW, 4707
 Wang, D, 8158
 Wang, D, 1822, 3735
 Wang, H, 1822
 Wang, H, 9126
 Wang, H, 2705
 Wang, H, 493
 Wang, H, 8613
 Wang, H, 8604
 Wang, H, 8200
 Wang, H, 4020
 Wang, H-F, 957
 Wang, J, 246
 Wang, J, 925
 Wang, J, 5835, 6601
 Wang, J, 1433
 Wang, J, 177
 Wang, J, 2147, 11146
 Wang, J, 3100
 Wang, K-K, 7856
 Wang, K, 5628
 Wang, L, 7635
 Wang, L, 10289
- Wang, L, 11071
 Wang, L, 6071
 Wang, L, 2746, 4809
 Wang, L-X, 9547, 10569
 Wang, L, 4614
 Wang, M, 11501
 Wang, M-N, 1514
 Wang, M, 4020
 Wang, M, 9406
 Wang, N-d, 10330
 Wang, Q, 1450
 Wang, Q, 9868
 Wang, R, 9216
 Wang, R-F, 1577
 Wang, R-A, 5571
 Wang, R, 10716
 Wang, SH, 8022
 Wang, S, 5063
 Wang, S, 1089
 Wang, S, 7993
 Wang, S, 7370
 Wang, T-L, 331, 1994
 Wang, T, 10338
 Wang, TC, 2770, 10709
 Wang, V, 3299, 10750
 Wang, W, 5535
 Wang, W, 6017
 Wang, X, 8613
 Wang, X, 1450, 5153
 Wang, X-F, 8853, 11276
 Wang, X, 2554
 Wang, X, 5674
 Wang, XW, 10255
 Wang, X, 3410, 6976
 Wang, X, 727
 Wang, X-P, 10024
 Wang, X, 7052
 Wang, X, 10394
 Wang, YA, 8747
 Wang, Y, 8613
 Wang, YC, 9388
 Wang, Y, 1615
 Wang, Y, 130
 Wang, Y, 1523
 Wang, Y, 8747
 Wang, Y, 92
 Wang, Y, 11553
 Wang, Y, 7541
 Wang, Y, 722
 Wang, Y, 9406
 Wang, Z, 8224
 Wang, Z, 11694
 Wang, Z-w, 3877
 Wang, Z, 9064
 Wang, Z, 10450
 Wani, MC, 4448
 Warburton, HE, 6498
 Ward, BD, 1425
 Ward, BE, 10096
 Ward, MR, 925, 7612
 Ward, R, 4031
 Ware, CB, 6631
 Waring, PM, 4031
 Warner, BW, 8655
 Warner, K, 5063
 Warrington, NM, 11392
 Washida, M, 5864
 Washington, S, 11026
 Wasik, MA, 7800
 Wassef, M, 4544
 Watabe, H, 10822
 Watanabe, M, 7628
 Watanabe, M, 7874
 Watanabe, N, 11
 Watanabe, T, 9159
 Watanabe, T, 157
 Watanabe, T, 7628
 Watkins, SC, 10059
 Watmore, A, 2662
 Watowich, SS, 6701
 Watson, DK, 6228, 7205, 11581
 Watson, MA, 7121
 Watson, MA, 99
 Watson, PM, 6228
- Watson, PH, 5696, 10265
 Watson, PA, 11565
 Watson, R, 3218
 Watt, K, 5399
 Wattel, E, 1234
 Waxenecker, G, 7934
 Waxman, S, 1117, 7847, 7856
 Wazer, D, 4747
 Webb, A, 7591
 Weber, BL, 925, 7591, 7612
 Weber, B, 6557
 Weber, HC, 9934
 Weber, JD, 2755, 9843
 Weber, MJ, 3108
 Weber, M, 379, 6919
 Weber, W, 9741
 Wedel, T, 10486
 Wedemeyer, H, 2457
 Wedge, SR, 4389
 Wee, A, 10330
 Weeks, BR, 887
 Weems, C, 8905
 Wei, C, 11297
 Wei, D, 2746, 4809
 Wei, L-H, 4827
 Wei, L, 6601
 Wei, M, 10692
 Wei, N, 5835
 Wei, Q, 722
 Wei, S, 465, 5020
 Wei, W-Z, 8471
 Wei, Y, 338
 Wei, Z-L, 3950
 Weichel, A, 8504
 Weichselbaum, RR, 3146, 9479
 Weidmann, E, 3937
 Weigel, NI, 7959
 Weigelt, B, 9155
 Weihrauch, MR, 5516
 Weihua, Z, 11529
 Weitzen, S, 4554
 Weil, RJ, 7674
 Weill, B, 948
 Weinberg, OK, 11287
 Weinberg, RA, 6130
 Weinberg, RS, 9574
 Weiner, J, 7533
 Weiner, LM, 4993
 Weinshilboum, RM, 11071
 Weinstein, IB, 8442
 Weinstein, JN, 10255
 Weir, BA, 5561
 Weiss, L, 9735
 Weiss, RM, 3531
 Weiss, SJ, 6543
 Weiss, WA, 3617
 Weissenborn, SJ, 1394
 Weissfeld, JL, 8034
 Weissleder, R, 6330, 8324, 9253
 Weissman, BE, 3542, 10192
 Weitz, J, 10079
 Weitzel, J, 805
 Weitzman, JB, 5096
 Weksler, BB, 664
 Welch, D, 5991
 Welch, DR, 713, 3586, 7370
 Welch, R, 9574
 Welch, WR, 2162
 Weldon, RH, 698
 Wellenreuther, R, 7733
 Weller, GER, 533
 Wells, G, 3911
 Wells, S, 3538
 Wells, V, 1631
 Welsh, K, 210
 Wen, M-L, 3781
 Wen, W, 5015
 Wen, X, 9807
 Wen, Y, 2287
 Wendt, P, 417
 Wenger, RH, 11094
 Wennerberg, J, 1271
 Werndl, J, 805
 Wesley, UV, 1325
- Wessels, LFA, 822
 Wessendorf, S, 439
 Wessner, LL, 11001
 West, KL, 6711
 West, KA, 8423
 West, M, 4051
 West, S, 7591
 Westermark, B, 2065
 Westermark, U, 11597
 Westhoff, M-A, 10502
 Westhouse, RA, 3781
 Weston, A, 1251
 Westphal, G, 5857
 Westphal, H, 4506
 Westra, WH, 758
 Westwell, AD, 3911
 Wetherill, YB, 54
 Wetmur, JG, 1606
 Wetter, SK, 9038
 Wetterwald, A, 7682
 Wewer, UM, 4754
 Wey, JS, 3664
 Weyant, MJ, 1097
 Weyer, S, 10830
 Whalen, PM, 957
 Whang, YE, 3404, 10514
 Whang, YM, 3682
 Whang-Peng, J, 6943
 Whartenby, K, 2026
 Whary, MT, 10709
 Whary, M, 10912
 Wheaton, WW, 10164
 Wheeler, JJ, 1497
 Wheelock, MJ, 483
 White, JT, 3081
 White, JG, 8766
 Whitelegge, J, 6159
 Whiteside, TL, 11146
 Whiting, A, 2097
 Whitman, SP, 1277
 Wickramarachchi, D, 6022
 Wickremasinghe, RG, 2373
 Widaa, S, 7591
 Widschwendter, M, 1141
 Wieben, ED, 11071
 Wiederkum, S, 7934
 Wielinga, P, 2577, 4425
 Wiemann, S, 7733
 Wiemer, EAC, 5835
 Wiench, M, 1587
 Wierzbicki, A, 3410
 Wiesener, MS, 4598
 Wiesner, M, 9377
 Wiessler, M, 6305
 Wijnga, C, 10188
 Wijnholds, J, 4425
 Wijnhoven, SWP, 8166
 Wikman, FP, 34
 Wilczynski, SP, 92
 Wilder, ET, 9923
 Wilderman, MJ, 8379
 Wildes, F, 10801
 Wiley, EL, 246
 Wiley, EL, 11429
 Wiley, KE, 1213
 Wilhelm, E, 8754
 Wilkes, MC, 10431
 Willebrand, R, 2560
 Willems, L, 1234
 Willems, PHGM, 8801
 Williams, ARW, 7707
 Williams, A, 7533
 Williams, BO, 8250
 Williams, BRG, 2592
 Williams, CR, 4789
 Williams, ES, 5544
 Williams, EA, 9923
 Williams, L, 967
 Williams, LE, 5907, 622
 Williams, M, 8017
 Williams, NS, 8209
 Williams, O, 9245
 Williams, SV, 66
 Williams, SA, 4902

- Williamson, M. 6593
Wilson, A.J. 10170
Wilson, C. 10179
Wilson, J.B. 8826
Wilson, J.L. 10355
Wilson, S.M. 3396
Wilson, T. 8951
Wimberger, P. 2882
Wimmer-Kleikamp, S. 6745
Windhofer, F. 4020
Wing, M.R. 9883
Winnard, P.T. 10801
Winters, M.E. 3853
Wirth, T. 7393
Wirthner, R. 11094
Wirtzfeld, L.A. 5231, 6337
Wiseman, C.L. 7950
Wislez, M. 11478, 3226
Wissing, J. 379, 6919
Wistuba, H. 1642, 3226, 7568, 11478
Witt, M. 1316
Witte, D. 166
Witte, L. 1514
Wittman, M. 3781
Wiuf, C. 34
Wloch, Jan. 1587
Wlodarczyk, W. 5872
Wlodarski, P. 7800
Woda, B. 6425
Woerner, B.M. 11392
Woerner, S.M. 6418, 8072, 10170
Woetmann, A. 11136
Wohlfiahrt, J. 8567
Wolf, C.R. 2644, 4211
Wolf, J. 5516
Wolfe, M.M. 2251
Wolff, R.K. 6063
Woller, N. 7393
Wondergem, J. 3100
Wong, A. 8912
Wong, C.-M. 8861
Wong, F. 10330
Wong, H.P.S. 5272
Wong, J. 3883
Wong, J.Y.C. 5907
Wong, K.-K. 7096
Wong, K.-K. 76, 8142
Wong, M.K.K. 533
Wong, S. 9294
Wong, S.Y. 9789
Wong, T.W. 3781
Wong, W.H. 10602
Wong, Y.C. 1450
Wong, Y.-C. 5153
Wongvipat, J. 11565
Wonsey, D.R. 5181
Woo, M.M.M. 2234
Wood, C.G. 8406
Wood, M. 5690
Wood, N. 11721
Wood, W.C. 1909
Woodell, J. 6631
Woodruff, T.K. 7968
Woods, R.G. 1670
Wooster, R. 7591
Worden, B. 7071
Workman, P. 3356, 4918, 10686
Wortham, N. 11361
Wright, E.G. 3527, 5668
Wright, E. 4211
Wright, W.E. 7866
Wrobel, C.N. 11572
Wrobel, G. 439
Wrutniak-Cabello, C. 4282
Wu, A.M. 622, 5907
Wu, C.-C. 427
Wu, C.-L. 3030
Wu, D.Y. 2795
Wu, F. 758
Wu, G. 6337, 758
Wu, J.M. 7902
Wu, J. 8433
Wu, K. 417
Wu, K. 3462
Wu, L. 2825
Wu, L. 9261
Wu, L. 4633
Wu, M.H. 46
Wu, M. 7370
Wu, Q. 246
Wu, Q. 5917
Wu, Q.-L. 6504
Wu, S. 6380
Wu, T.-C. 309
Wu, T.T. 4809
Wu, T.-T. 2746
Wu, W. 7509
Wu, W.-W. 6901
Wu, W. 6
Wu, W.K.K. 5272
Wu, X. 6660
Wu, X. 6676
Wu, X. 349
Wu, X.X. 3487
Wu, X.-R. 1150, 3531
Wu, Y. 3185
Wu, Y. 4947
Wu, Y. 7635
Wu, Y. 11486
Wu, Y. 9073
Wurtzel, L. 5063
Wust, P. 5872
Wyatt, C.A. 11101
Wyckoff, J.B. 5278
Wynshaw-Boris, A. 8736
Xerri, L. 2170
Xi, L. 2147
Xia, G. 4623
Xia, J.-T. 1909
Xia, L. 7847
Xia, S. 5248
Xia, W. 338
Xia, Z. 8671
Xia, Z. 10050
Xian, M.J. 4417
Xiang, C. 7301
Xiang, J. 4955
Xiang, L. 8698
Xiang, R. 553, 3419, 8784
Xiang, Y.-Y. 6245
Xiao, A. 5172
Xiao, D. 9934
Xiao, W. 6255
Xiao, X. 4707
Xie, D. 6504
Xie, J. 1361
Xie, J. 9762
Xie, K. 2746, 4809
Xie, L. 6843
Xie, L. 3967
Xie, S. 9807
Xie, T. 3081
Xie, Y. 713
Xie, Z. 2303
Xing, M. 758
Xing, S.W. 8442
Xing, Y. 5925
Xiong, H. 5009
Xiong, W. 7194
Xiong, Y. 11354
Xiong, Y. 2684
Xu, H. 10024, 7421
Xu, J. 1213
Xu, J. 7993
Xu, J. 10692
Xu, K. 7856
Xu, L. 5711
Xu, L. 3470
Xu, L. 2947
Xu, M. 4246
Xu, R. 1687
Xu, R.-h. 613
Xu, S. 4955
Xu, W. 9294
Xu, W.-S. 7832
Xu, X.-C. 3462
Xu, X. 130
Xu, X. 9328
Xu, X. 5792
Xu, X.-M. 4614
Xu, Y. 1027
Xu, Y. 10810
Xu, Y. 3319, 9269
Xu, Z. 743
Xu, Z.-X. 3671
Xuan, J.-A. 2846, 8397
Xuan, J.W. 6337
Xue, R. 7635
Xue, S.-A. 1523
Yabashi, M. 4998
Yacoub, A. 6022
Yadav, S. 6022, 991
Yaden, B. 6593
Yagan, D. 4554
Yagi, Y. 828
Yagisawa, J. 2778
Yagita, H. 10783
Yagyu, T. 10464
Yahalom, J. 11061
Yakar, S. 6864
Yakushiji, H. 8736
Yam, G. 9294
Yam, J.W.-P. 8861
Yamabuki, T. 5638
Yamada, H. 9628
Yamada, T. 4417
Yamada, T. 8836, 10613
Yamada, Y. 10464
Yamagata, H. 157
Yamagata, K. 1655
Yamaguchi, K. 8706
Yamaguchi, Y. 4653
Yamamoto, A. 4368
Yamamoto, H. 10170
Yamamoto, K. 11704
Yamamoto, M. 8706
Yamamoto, M. 10154
Yamamoto, N. 4246
Yamamoto, S. 828
Yamamura, K. 4998
Yamane, K. 4362
Yamano, T. 1800
Yamasaki, Y. 6337
Yamashiro, J. 9495
Yamashita, K. 4963
Yamashita, S. 2610
Yamashita, Y. 5925
Yamauchi, H. 3389
Yamauchi, K. 4998
Yamauchi, K. 4246
Yamaura, A. 5190
Yamazaki, K. 10776
Yamazoe, M. 11704
Yamochi, T. 1973, 6950
Yamochi, T. 1973, 6950
Yamori, T. 5864
Yan, H. 919
Yan, J. 7976
Yan, L. 3193
Yan, L. 8766
Yan, X. 3081
Yan, Y. 3986
Yanagawa, T. 7546
Yanagihara, K. 2115
Yanagisawa, K. 226, 9628
Yanaihara, N. 2526
Yang, A. 7775
Yang, C.-S. 6943
Yang, C.-C. 1561
Yang, C.-H. 6943
Yang, C.-Y. 4827
Yang, C.S. 8049, 10623
Yang, C. 5172
Yang, F. 4947, 8887
Yang, G.-y. 10623
Yang, G. 10569
Yang, H. 1918
Yang, H.H. 2542
Yang, H.-S. 10016
Yang, J.-O. 9347
Yang, J. 939
Yang, J.-M. 3806
Yang, J. 6660
Yang, J. 9137
Yang, J. 5493
Yang, K. 8662
Yang, L. 8671
Yang, L. 1909
Yang, M. 2337, 4246, 5352
Yang, M. 8487
Yang, N. 925
Yang, P.-C. 6943
Yang, P. 6189, 8442, 10113, 11486
Yang, Q. 1223, 2526
Yang, S.-C. 5211
Yang, S. 5769
Yang, S. 4614
Yang, S. 6843
Yang, S. 4707
Yang, S. 9991
Yang, W.C. 9363
Yang, W. 9982
Yang, X. 8671
Yang, X. 879
Yang, X.J. 5628
Yang, X. 1761
Yang, X.P. 7071
Yang, X. 7338
Yang, X.L. 11486
Yang, X. 5263
Yang, Y.-M. 8538, 8548
Yang, Y. 10401
Yang, Y.H. 5272
Yang, Y. 7699, 8784
Yang, Z.F. 219
Yang, Z. 3179, 7724
Yang, Z. 9126
Yaniv, M. 3542, 5096
Yano, T. 7743
Yao, G. 6843
Yao, J.C. 2746
Yao, J. 4809
Yao, J. 9807
Yao, M. 4598
Yao, M. 6843
Yao, S. 5761
Yao, T.-P. 3883
Yao, Y. 9164
Yao, Z. 8274, 10921
Yap, R. 5144
Yarchon, R. 3299
Yasuda, K. 203
Yasui, H. 7478
Yasumoto, K. 5945
Yasunami, Y. 2979
Yatabe, Y. 9628, 10680
Yates, A. 7591
Yau, C.Y.E. 1497
Yau, T.-O. 8861
Yazaki, P.J. 5907, 622
Yazici, S. 3707, 3716
Yazici, Y.D. 4716
Ye, F. 5358
Ye, R. 1670
Ye, Y.N. 5272
Yea, S. 9216
Yeager, M. 9574
Yeatman, T.J. 1814
Yeatman, T. 7169
Yee, C. 1570
Yee, D. 10123
Yee, H. 6178
Yeger, H. 2592, 7267
Yeh, N.T. 7071
Yeh, S. 9807
Yemin, A.Y. 10149
Yen, Y. 6622, 10338
Yeoh, K.G. 7743
Yeudall, W.A. 4782
Yeung, S.-C.J. 3671, 9109
Yi, C. 5835
Yi, E.C. 3081
Yi, S. 9751
Yi, Y. 2755, 9843

- Yigitbasi, OG, 4716
 Yim, D, 1035
 Yim, HW, 1952
 Yin, C, 5172, 8218
 Yin, D, 4762
 Yin, G, 2979
 Yin, JA, 2662
 Yin, L, 10413
 Yin, S, 9574
 Yin, X, 9991
 Yin, Y, 9807
 Yin, Y, 3950
 Ying, L, 9132
 Yip, L, 427
 Yla-Herttuala, S, 4739
 Ylstra, B, 9510, 10208
 Yoda, K, 4683
 Yokoi, K, 10371, 3716
 Yokoi, M, 5720
 Yokomizo, K, 1868
 Yokote, A, 7276
 Yokoyama, KK, 546
 Yoneda, T, 2130
 Yonemitsu, Y, 7241
 Yong, ASM, 8912
 Yoo, BC, 3162
 Yoo, H, 686
 Yoo, NJ, 815
 Yoo, YD, 3682
 Yoon, P, 9029
 Yoon, SS, 5881
 Yoon, S-O, 2761
 Yoon, S-R, 8662
 Yoon, Y, 6811
 Yoon, Y, 967
 Yordy, JS, 11581
 Yore, MM, 4789
 Yorioka, N, 9771
 Yoshida, H, 1541
 Yoshida, J, 7573
 Yoshida, K, 157
 Yoshida, K, 10776
 Yoshida, S, 10159
 Yoshida, T, 5662, 6364
 Yoshida, T, 2115
 Yoshida, T, 9611
 Yoshikai, Y, 10032
 Yoshikawa, M, 1541
 Yoshiki, T, 2617
 Yoshimura, M, 11704
 Yoshino, I, 7241
 Yoshino, K, 8640
 Yoshioka, H, 4578
 Yoshioka, K, 157
 Yoshizaki, T, 8640
 You, HJ, 6811
 You, H, 8049
 You, K-H, 4485
 You, K-R, 2804, 6312
 You, L, 743
 You, M, 8158, 92
 You, S, 9132
 You, XJ, 3243
 You, nans, A, 3044
 Youn, C-K, 6811
 Younes, MN, 4716
 Young, BD, 375, 8597, 9137, 9152
 Young, IJT, 10113
 Yu, A, 331
 Yu, C, 8372
 Yu, D, 5498
 Yu, D, 1858
 Yu, D, 1904, 5454
 Yu, H-J, 8455
 Yu, JS, 2554
 Yu, J, 1647
 Yu, J, 1277
 Yu, JY, 3861
 Yu, JL, 8878
 Yu, M, 1719
 Yu, Q, 9012
 Yu, S, 9294
 Yu, WC, 219
 Yu, Y, 6701
 Yu, Z, 9566
 Yuan, F, 7541
 Yuan, H, 6199, 10854
 Yuan, H, 5163
 Yuan, J, 6042
 Yuan, L, 7421
 Yuan, LXH, 8406, 11118
 Yuan, M, 1523
 Yuan, Z-R, 10716
 Yuan, Z-M, 6734
 Yudina, A, 9253
 Yue, P, 6354, 7052, 9169
 Yuen, ST, 7591
 Yuen, ST, 9200
 Yule, K, 5133
 Yu-Lee, L-y, 7984
 Yumoto, H, 4998
 Yun, I, 2520
 Yun, J-M, 11203
 Yun, YS, 9501
 Yung, I, 9735
 Yung, R, 9566
 Yung, WKA, 1678, 1934
 Yuspa, SH, 562
 Yuste, L, 6801
 Yuza, Y, 7096
 Zgraggen, K, 10079
 Zabaleta, J, 3044
 Zabel, BU, 840
 Zacharek, SJ, 11354
 Zaffaroni, N, 5506
 Zagazdon, R, 2840
 Zagzag, D, 6178
 Zaichuk, TA, 5144
 Zaika, A, 6583
 Zajac, E, 6022
 Zakharov, A, 7603
 Zalatan, F, 11174
 Zalberg, J, 4031
 Zafra, E, 835
 Zambelli, D, 3868
 Zamburno, G, 432
 Zanca, C, 6668
 Zanca, P, 587
 Zanchi, C, 2364
 Zanesi, N, 6576
 Zang, Q, 8209
 Zannettino, ACW, 1700
 Zanon, C, 11227, 632
 Zanon, M, 632, 3428
 Zapata, JM, 210, 4799
 Zaridze, DG, 5076
 Zasloff, M, 4228
 Zauberman, Y, 6858
 Zaugg, K, 6685
 Zea, AH, 3044
 Zeeberg, BR, 10255
 Zeh, HJ, 9991
 Zehetmeier, C, 1887
 Zeineldin, R, 9280
 Zeitlin, B, 5063
 Zelcer, N, 4425
 Zeldin, DC, 4707
 Zelent, A, 1117, 7847, 7856, 8754
 Zender, L, 7393
 Zeng, W, 10847
 Zeng, Y, 6504
 Zenner, HP, 11613
 Zerilli, M, 6668
 Zeschmigg, M, 10634
 Zhai, Y, 6543
 Zhan, X, 10214
 Zhan, Y, 9190
 Zhang, B, 6054, 7283
 Zhang, B, 11118
 Zhang, D, 9287
 Zhang, H, 6843, 9073
 Zhang, H, 1961
 Zhang, H, 1136
 Zhang, H, 2085
 Zhang, H-L, 4844
 Zhang, H, 605
 Zhang, H, 8530
 Zhang, J, 7856
 Zhang, J, 8274, 8818, 10921
 Zhang, J, 6692
 Zhang, J, 11478
 Zhang, J, 7059
 Zhang, J, 4633
 Zhang, J, 8671
 Zhang, J, 8372
 Zhang, L, 2465, 4238
 Zhang, L, 7561, 8017
 Zhang, L, 1678
 Zhang, L, 7790
 Zhang, L, 6380
 Zhang, L, 4020
 Zhang, L, 925
 Zhang, L, 457, 6159
 Zhang, L, 10716
 Zhang, L, 9574
 Zhang, L, 4614
 Zhang, M, 9807
 Zhang, M, 5493
 Zhang, M, 4947
 Zhang, N, 1433
 Zhang, Q, 1761
 Zhang, Q, 4554
 Zhang, Q, 5544
 Zhang, R, 2526
 Zhang, R, 5428
 Zhang, RH, 8111
 Zhang, R, 8200
 Zhang, S, 9185
 Zhang, S-P, 10838
 Zhang, S, 7169
 Zhang, W, 3562
 Zhang, W, 1459
 Zhang, W, 1783
 Zhang, W, 1554
 Zhang, X, 5153
 Zhang, X, 317
 Zhang, X, 9445
 Zhang, X, 722, 9582
 Zhang, X-F, 10838
 Zhang, Y-P, 1941
 Zhang, Y, 2676
 Zhang, Y, 6054
 Zhang, Y, 3596
 Zhang, Y, 5544
 Zhang, Y, 3877, 9064
 Zhang, Z, 9751
 Zhang, Z, 605
 Zhang, Z, 92
 Zhang, Z, 1114
 Zhang, Z, 6601, 8200
 Zhao, H, 7169
 Zhao, H, 6864
 Zhao, H, 349
 Zhao, H, 2482, 9868
 Zhao, J, 5009
 Zhao, M, 758, 7763
 Zhao, W, 7635
 Zhao, X, 2125
 Zhao, X, 5561
 Zhao, X-Y, 2846
 Zhao, X, 7717
 Zhao, X, 4309
 Zhao, Y, 5498
 Zhao, Y, 1401, 3745
 Zhao, HE, 2303
 Zheng, D, 1687
 Zheng, H, 3562
 Zheng, SL, 1213
 Zheng, W, 5015
 Zheng, X, 2537, 6080
 Zheng, X, 10183
 Zheng, X, 2269
 Zheng, X, 4431
 Zheng, Y-L, 349, 9566
 Zhong, C, 4623, 5769
 Zhong, X-S, 9080
 Zhou, B, 6622
 Zhou, BP, 3257
 Zhou, C, 5153
 Zhou, D, 3081
 Zhou, H-J, 7976
 Zhou, H, 3419, 553
 Zhou, H, 9876
 Zhou, J, 6089
 Zhou, J, 6207
 Zhou, J-n, 10623
 Zhou, J, 657
 Zhou, J, 3883
 Zhou, J, 5544
 Zhou, R, 1839
 Zhou, S, 4520
 Zhou, W, 605
 Zhou, X, 4947
 Zhou, X, 1079
 Zhou, X, 427
 Zhou, Y, 613
 Zhou, Y, 3762
 Zhou, Y, 8101
 Zhou, Y, 7635
 Zhou, Y, 5848
 Zhou, Y, 10394
 Zhou, Z, 1124
 Zhou, Z, 6354, 7052
 Zhou, Z, 787
 Zhou, J, 9906
 Zhu, BT, 387, 5802
 Zhu, F, 3596
 Zhu, G, 1089
 Zhu, J, 9126
 Zhu, K, 4902
 Zhu, L, 5211
 Zhu, S, 861
 Zhu, S, 4623
 Zhu, T, 317
 Zhu, Y, 4520
 Zhu, Y, 8397
 Zhu, Y, 6151
 Zhu, Z, 1514, 3185
 Zhu, Z, 7023
 Zhuang, L, 9012
 Zhuang, M, 9363
 Zhuang, Z, 10847
 Zhurkin, VB, 10255
 Zi, X, 3479, 9762
 Zieger, K, 34
 Zielenkiewicz, P, 6305
 Zielinski, JF, 8471
 Ziel-van der Made, AC, 5730
 Ziffra, J, 6282
 Zigrino, P, 4134
 Zijlstra, A, 10959
 Zimmer, SG, 6957
 Zimmerman, MA, 2412
 Zimmermann, K, 3781
 Ziouta, Y, 10079
 Zips, D, 5374
 Zirgib, RA, 3518
 Zirroli, J, 10006
 Zitron, C, 7127
 Zitzvogel, L, 6409
 Zlobin, A, 4554
 Zongaro, S, 11411
 Zou, C, 4747
 Zou, L, 465, 5020
 Zou, W, 465, 5020
 Zucker, S, 4162
 Zucco, V, 2364
 Zudaire, E, 4181
 Zukowska, Z, 1719
 Zunino, F, 2364
 Zuzel, M, 7328
 Zwart, E, 3610, 8166
 Zweitig, DR, 4993
 Zyss, D, 10872

Volume 65

- [^{99m}TcOAAADT]-(CH₂)₂-NEt₃**
for malignant melanoma imaging, 4979
- ABCB5**
doxorubicin transport and resistance mediated by, in malignant melanoma, 4320
- ABCC drug efflux pumps**
in gliomas, 11419
- ABCG2**
harboring Gly482 mutation, antifolate resistance and, 8414
inhibition of, by chrysin derivatives, 4852
mitoxantrone resistance dependent on, extracellular vesicles mediating, 10952
in prevention of cytotoxic effect of Iressa, 1770
tumorigenicity of, 6207
- Aberrant crypt foci**
flat dysplastic, colon tumorigenesis and, rat model, 121
- ABL oncogenes**
phosphoinositide 3-kinase signaling and, 2047
- ACA (1'-Acetoxychavicol acetate)**
apoptosis induced by, in multiple myeloma, 4417
- 1'-Acetoxychavicol acetate (ACA)**
apoptosis induced by, in multiple myeloma, 4417
- Acetyl-CoA carboxylase- α gene**
RNA interference-mediated silencing of, apoptosis of prostate cancer cells induced by, 6719
- Ack1**
prostate tumorigenesis promoted by, 10514
- Actin cytoskeleton**
remodeled, in colon cancer cells, *K-RAS* and, 1244
- Actinin-4**
association of, with β -catenin, E-cadherin regulating, 8836
- Actinium-225 *in vivo* generators, targeted**
errant products of, control of, 4888
- Activated leukocyte cell adhesion molecule (ALCAM)**
MMP-2 activation by, 8801
- Activator protein 1 (AP-1)**
accelerating dihydropyrimidine dehydrogenase gene transcription in cancer cells, 1055
- Activator protein 2 α**
as chemosensitivity determinant, 8628
in melanoma, quantitative analysis of, 11185
- Activin A**
antitumor activity of, 1877
growth and cell cycle arrest induced by, in breast cancer cells, 7968
- Acute lymphoblastic leukemia. See Leukemia, acute lymphoblastic (ALL)**
- Acute myelogenous leukemia. See Leukemia, acute myelogenous (AML)**
- Acute myeloid leukemia. See Leukemia, acute myeloid (AML)**
- ADAM9**
carcinoma invasion promoted by, 4728
in prostate cancer in mouse, 9312
- ADAM12**
in breast tumor progression and stromal cell apoptosis, 4754
- Adeno-associated virus**
gene transfer of soluble VEGFR-3 mediated by, in lymphogenous metastasis inhibition, 6901
- Adenocarcinoma**
esophageal, progression of Barrett's metaplasia to, 3146
lung, *HER2* mutation in, 1642
mammary, in Fanconi anemia, *Trp53* and, 85
pancreatic ductal, *RAB6KIFL* and *DLG5* in, 105
prostate, *NKX3.1* suppressor gene in, 1164
- Adenocarcinoma gastric cells**
resistance of, to diallyl disulfide, GSH and ERK 1/2 in, 11735
- Adenoma(s)**
in *APC^{Min}* mice, molecular profiling of, 166
colorectal, meat intake and, 8034
formation of, carnosol preventing, 1097
- Adenomatous polyposis coli protein**
molecular organization of, 5195
threshold level of, for mouse intestinal tumorigenesis, 8622
- Adenoviral vector expressing IFN- β**
for orthotopic lung cancer model, 8379
- Adenovirus(es)**
conditionally replicating, *survivin*-responsive, 5284
E1a and *E4* gene expression of, PSES enhancer controlling, in prostate cancer therapy, 1941
E1-deleted, decreased replication ability of, increased brain tumor malignancy and, 8936
infection from, ionizing radiation-induced, dynamin 2-mediated, 5493
oncolytic, tissue inhibitor of metalloproteinase-3 expression from, 9398
oncolytic therapy mediated by, combined with immunostimulatory tumor therapy, 4343
REIC/Dkk-3 overexpression mediated by, apoptosis induced by, 9617
replicating, targeting colon cancer, 6882
replication of, noninvasive visualization of, 10154
secretable glucose-regulated protein 94/gp96 expression, radiation therapy enhanced by, 9126
targeted, armed with carboxypeptidase G2, in systemic GDEPT for hepatocellular carcinoma, 5003
virus-associated RNA I-deleted, as oncolytic agent, 1523
- Adenylate cyclase**
recombinant, tumor therapy with, 641
- 3 β -Adiol (5 α -Androstane-3 β , 17 β -diol)**
prostate cancer cell migration inhibited by, 5445
- Adipogenesis**
stromelysin-3 as negative regulator of, 10862
- Adjuvant therapy**
efficacy of, monitoring of, circulating tumor-specific DNA in, 1141
- Adoptive immunotherapy**
with tumor-reactive transforming growth factor- β -insensitive CD8⁺ T cells for prostate cancer, 1761
- ADPRT gene**
polymorphisms in, lung cancer risk and, 722
- β -Adrenoceptors**
NNK stimulating colon cancer via, 5272
- Adrenocortical tumors**
 β -catenin mutations in, 7622
- Adrenomedullin**
expression of, IL-1 β inducing, through hypoxia inducible factor 1, 4690
- Adriamycin**
with docetaxel, dosing time-dependent effects of, 8448
senescence induced by, Src inhibiting, through p21waf1 down-regulation, 8927
- AEE788**
in targeted therapy of colon cancer, 3/16
- Aflatoxin**
carcinogenesis induced by, susceptibility to, 1265
- AF4p12**
as *MLL* fusion partner, oncogenic activation and, 6521
- African Americans**
lung cancer risk in, less efficient G₂-M checkpoint associated with, 9566
- Aged. See Geriatric patients**
- Aggressive tumor variants (ATVs)**
immune selection and emergence of, Fas-mediated cytotoxicity causing, 4376
- Akl**
activation of
constitutive, in AML, 9643
HIN-1 and, 9659
rapamycin in, 7052
- temozolomide-induced G₂ arrest and senescence and, 4861
- brain-derived neurotrophic factor/TrkB protection of neuroblastoma cells mediated by, 2070
- chemoresistance in breast cancer cells dependent on, PED mediating, 6668
- Pdcd4 tumor suppressor protein phosphorylated and regulated by, 11282
- signaling activity of
HIV protease inhibitors blocking, 8256
SV40-dependent, mesothelioma and, 5256
single-chain antibodies against, proapoptotic activity of, 2815
- Tall phosphorylated and regulated by, 4515
- ALCAM (activated leukocyte cell adhesion molecule)**
MMP-2 activation by, 8801
- Alcohol**
perillyl, calcium-dependent constitutive nuclear factor- κ B pathway inhibited by, 8558
- ALDH1a2**
as tumor suppressor in prostate cancer, 8118
- Alendronate**
inhibiting intraperitoneal dissemination in ovarian cancer model, 540
- 3-Alkyladenine-DNA glycosylase (AAG)**
suppression of, siRNA in, 10472
- Alkylating agents**
cell killing by, mitochondrial-targeted MGMT and, 3319
- ALL. See Leukemia, acute lymphoblastic (ALL)**
- Allelic imbalance**
in bladder tumors, single nucleotide polymorphism analysis of, 34
- 17-Allylamine-demethoxygeldanamycin (17-AAG)**
bone metastasis potentiated by, 4929
HSP70 induction by, 10536
- 17-Allylamine-demethoxygeldanamycin (17-AAG) hydroquinone**
formation of, by NAD(P)H:quinone oxidoreductase 1, 10006
- 17-Allylamine-17-demethoxygeldanamycin**
B-Raf as target of, 10686
- Alternating reading frame (ARF)**
p14, DNA damage triggering, 9834
- Alternative splicing**
of *CYP11A1*, ovarian carcinogenesis and, 3726
of fibroblast growth factor receptor 3, 10441
of *Irf45* in gliomas, 3562
of *KLF6* gene, increased prostate cancer risk and, 1213
- Alveolar rhabdomyosarcoma (ARMS)**
genetic modeling of, new tactics in, 7530
- AME (AML1/MDS1/EV11)**
multiple domains of, hematopoiesis disrupted by, 7603
- Amifostine**
in radioprotection of parotid gland, 10486
synergistic anticancer effects of paclitaxel and, on endometrial cancer, 9517
- γ -Aminobutyric acid (GABA)**
cholangiocarcinoma growth regulated by, 11437
- γ -Aminobutyric acid type A receptor associated protein**
characterization of, in breast cancer, 394
- AML. See Leukemia, acute myelogenous (AML); Leukemia, acute myeloid (AML)**
- AML1/MDS1/EV11 (AME)**
multiple domains of, hematopoiesis disrupted by, 7603
- AMN107**
in vitro activity of, 4500
- Amphipathic peptide**
killing of leukemic cells by, 2373
- Amphiregulin**
serum increase in, predicting poor response to gefitinib, 9176

- transcription of, tobacco smoke stimulating, in oral epithelial cells, 5982
- AN-207**
in targeting of LHRH receptor in melanoma, 5857
- Anaphase-promoting complex/cyclosome and Cdh1, Aurora B degradation mediated by, 8730**
- Anastellin**
as angiogenesis inhibitor, 3967
G₁ arrest in microvessel endothelial cells from, 148
- Androgen(s)**
insulin-like growth factor-I receptor in prostate cancer up-regulated by, 1849
prostate cancer cells responsive to, molecular target of vitamin D in, 4762
resistance to, increased Hsp27 inducing, 11083
reversion of androgen-independent to androgen-stimulated prostate tumors by, 2082
thrombospondin-1 production in prostate repressed by, 300
- Androgen receptor (AR)**
in breast cancer, response to medroxyprogesterone acetate and, 8487
emodin down-regulating, 2287
HER-2/neu kinase inhibition impairing, 3404
loss of, in prostate cancer cells, 4836
post-transcriptional regulation by, by mammalian target of rapamycin, 2547
signal cascade mediated by, DOC-2/DAB2 modulating, 9906
status of, xenoestrogen action in prostate cancer and, 54
variation in, ovarian cancer and, 5974
- Androgen receptor gene**
in prostate cancer, 8514
- 5 α -Androstane-3 β ,17 β -diol (3 β -Adiol)**
prostate cancer cell migration inhibited by, 5445
- Anemia**
Fanconi
generation of head and neck squamous cell carcinoma cell lines in, 1271
mammary adenocarcinoma in, *Trp53* and, 85
radiation therapy efficacy in, darbepoietin alfa potentiating, 284
- Aneuploidy**
centromere protein H overexpression inducing, in colorectal cancer, 4683
chromosomal, cancer transcriptome and, WAVES and, 186
Ckap2 regulating, 6685
suppression of, ATM and p21 cooperating in, 8747
- Angiogenesis**
blockade of, by *Gax*, 1414
calcitonin stimulating, 8519
connective tissue growth factor promoting, 8887
CP-673,451 blocking, 957
immunotherapy against, using VEGFR2, 4939
induction of, 15(S)-hydroxyicosatetraenoic acid in, 7283
inflammatory, chemoprevention of, 10637
inhibition of
adenovirus-delivered anti-Tie-2 intrabody in, 972
anti-JAM-C in, 5703
drugs causing (See **Antiangiogenic drugs**)
endogenous factors in, 3967
IL-6R-specific peptide in, 4827
increased microtubule dynamics in, 2433
in murine gliomas, TSP-2 inhibiting, 9338
4-(N-(S-glutathionylacetyl)amino)phenylarsenozide in, 11729
stromal cell-derived factor-1/CXCR4 blockade in, 5864
thymosin β_{10} in, 137
vascular endothelial growth factor receptor-2 blockade in, 1294
of melanoma, cyclin E and, 692
of neuroblastoma cells, activin A suppressing, 1877
oncogenes and, 8878
in ovarian cancer
CXCL12 and vascular endothelial growth factor synergistically inducing, 465
interleukin-6 in, 10794
in pancreatic cancer
COX-2 inhibitors and, 982
SPA blocking, 2738
PEDF functional epitopes blocking, 5144
regulation of, Tid-1 interacting with von Hippel-Lindau protein in, 2520
Src regulation of IL-8 expression in pancreatic tumor cells and, 7214
suppression of
headpin in, 11501
in lung tumor eradication, DNA vaccine against survivin in, 553
- tumor**
BMK1 required for, 7699
extracellular matrix metalloproteinase inducer in, 3193
fastatin in regulation of, 4153
hypoxia and, 5498
in nestin-GFP mice, 2337, 5352
RAS-dependent, real-time MRI in *in vivo* assessment of, 8324
ultrasonic imaging of, targeted microbubbles in, 533
in vitro, MT1-MMP and $\alpha_v\beta_3$ critical for, 9377
- Angiogenic behaviors**
Axl regulating, 9294
- Angiogenin**
in HeLa cell proliferation, 1352
- Angiography**
magnetic resonance, in abnormal tumor vasculature visualization, 8218
- Angiopoietin 1**
mitogenic activity of, for cultured endothelial cells, 6820
- Angiostatin**
as angiogenesis inhibitor, 3967
- Angiotensin II type 2**
deficiency of, lung tumorigenesis and, 7660
- Animal models. See also Mouse models; Rat models**
- ANLN pathways**
in lung cancer, 11314
- Anoikis**
in hepatocellular carcinoma cells, peroxisome proliferator-activated receptor γ inhibition causing, 2251
in reactive prostate tumors, 11230
resistance to
neurotrophic receptor TrkB in, 7033
of prostate cancer metastasis precursor cells, XIAP protein contributing to, 2378
- Anoxia**
for tumor cell toxicity caused by low-oxygen environment, 3171
- Anterior gradient 2 (AGR2)**
as metastasis inducer in breast cancer, 3796
- Anthracyclines**
inactivation of, by cellular peroxidase, 6346
- Antiangiogenesis**
chemotherapy and radiation combined with, 3643
- Antiangiogenic activity of CP-673,451, 957**
- Antiangiogenic drugs**
chemotherapy combined with, coagulation marker for, 5365
drug resistance induced by, 5785
- Antibody(ies)**
Akt, intracellular, proapoptotic activity of, 2815
anti-CEACAM6, metastasis inhibited by, 8809
anti-EphA3, and ephrin-A5, concurrent binding of, amplifying EphA3 signaling, 6745
bispecific, for carcinoma treatment, 2882
against junctional adhesion molecule-C inhibiting angiogenesis, 5703
monoclonal (See **Monoclonal antibodies**)
to nerve growth factor for prostate tumor-induced bone pain, 9426
serum, to Huntingtin interacting protein-1, in prostate cancer, 4126
single-chain, tumor retention of, penetratin improving, 7840
- Antibody fragments**
Fv-Vc, manipulating half-life of, 622
- Antibody microarrays**
experimental design and analysis of, 2985
profiling of, revealing serum proteins in pancreatic cancer, 11193
- Antibody therapy**
of murine metastatic cancer, complement-mediated mechanisms in, 10562
- Anticancer drug**
nanoparticle targeting of, 5317
- Antifolate activity**
of tea catechins, 2059
- Antifolate resistance**
ABCG2 harboring Gly482 mutation conferring, 8414
MRP5-mediated, 4425
- Antiglioside GM2 monoclonal antibody**
for melanoma and small cell lung carcinoma xenografts, 6425
- Antigen(s)**
CH₂-appended, CTL differentiation by, 2930
early prostate cancer, in prostate cancer diagnosis, 4097
HLA class I, haplotype loss of, in lung cancer, 5945
prostate-specific membrane, in prostate cancer invasiveness suppression, 727
tumor
melanoma-associated, immunogenicity and, 632
MHC class II-restricted, discovery of, 10068
- Antigen loss variants**
of B16 melanoma, potent selection of, 2009
- Antigen-presenting cells (APCs)**
artificial, telomerase epitopes presented by, 5417
modification of, with siRNA *in vivo* to enhance DNA vaccine potency, 309
- Antiinflammatory drugs**
tumor radiosensitization by, 7911
- Antioxidant capacity**
of paclitaxel-treated cells, paclitaxel resistance and, 8455
- Antioxidant status**
prediagnostic, prostate cancer risk and, 2498
- Anti-p185^{HER2} antibody fragments**
for *in vivo* imaging, 5907
- Antiphosphatidylserine**
doxorubicin with, antitumor effect of, 4408
- Anti-prostate stem cell antigen (anti-PSCA) 1G8**
tumor growth inhibited by, 9495
- Antisense inhibition**
of hyaluronan synthase 2 inhibiting breast cancer, 6139
- Antitubulin agents**
synergism of, with 2-methoxyestradiol in breast cancer, 387
- Antitumor activity**
additive, of letrozole and fulvestrant, 5439
of carnosol, 1097
of CP-673,451, 957
of endostatin, 3656
- Antitumor immunity**
IL-12 and IL-18 interactions involving, 1063
- Antitumor mechanisms**
of IFN γ , uncoupling of, from counterregulatory mechanisms, 2906
- Antivascular endothelial growth factor**
pharmacology and pharmacodynamics of, 671
- Antivascular therapy**
of follicular thyroid cancer, 4716
- AP-1 (activator protein)**
accelerating dihydropyrimidine dehydrogenase gene transcription in cancer cells, 1055
- APCs. See Antigen-presenting cells (APCs)**
- Apolipoprotein E**
in ovarian cancer, 331
- Apoptin**
tumor cell-specific nuclear targeting of, 7059
- Apoptosis. See also Cell death**
in acute myelogenous leukemia, DIM derivative inducing, 2890
of breast cancer cells, synthetic triterpenoids with TRAIL inducing, 4799
of BxPC3 pancreatic cancer cells, induction of, ERPP inhibiting, 3877
of cancer cells, PUMA-induced ROS generation in, 1647
caspase-8- and caspase-9-mediated, suppression of, novel isoform of TUCAN expression in, 8706
CD95-induced, JNK suppressing, 6780
8-chloro-cyclic AMP-induced, 4896
cisplatin-induced, Siva-1 protein enhancing, 5301

- Ckap2 regulating, 6685
 cross talk of, with invasion signaling, caspase-3 activating, 9121
 decreased, sensitivity of *NQO1*-null mice to carcinogenesis and, 2054
 detachment-induced (See **Anoikis**)
 dexamethasone-induced
 MnSOD enhancing, 6255
 in multiple myeloma, GCS-100 enhancing, 8350
 drug-induced
 LY compounds sensitizing tumor cells to, 6264
 Rho GDP dissociation inhibitor inhibiting, 6054
 ETS1-induced, caspase-1 in, 7205
 Fas-dependent, sensitization of glioma cells to, by chemotherapy-induced oxidative stress, 5248
 Fas-mediated
 of androgen-sensitive prostate cancer cells, Lupeol inducing, 11203
 loss of, accelerating *Helicobacter*-induced gastric cancer, 10912
 fenretinide-induced, genes involved in, parthenolide and, 2804
 ginseng metabolite-mediated, COX-2 inhibiting, 1952
 of glioma cells, protein kinase C ϵ regulating, 7301
 hypoxia-inducible factor-1 in, 4147
 of hypoxic cells by diphtheria toxin A fused with oxygen-dependent degradation domain, 11622
 increased, carboxyaido-triazole combined with LM-1685 causing, anticancer effect and, 3853
 induction of
 bortezomib plus TRAIL in, 4902
 bovine herpesvirus 4 in, 9463
 caspase-1 α overexpression in, 8591
 CD7-restricted, in human T-cell acute lymphoblastic leukemia, 3380
 cell-permeable anti-Akt single-chain antibodies in, 2815
 checkpoint kinase 2 activation in, 6017
 chloride intracellular channel proteins and, 562
 in colon cancer cells
 DBPT in, 6380
 synergy of EGFR and erbB2 TKIs in, 5848
 by doxorubicin, in immature testis, 9999
 excitatory amino acid transporter-2 in, 1934
 flavokawains in, 3479
 glutathione *S*-transferase inhibitors in, 3751
 kringle 5 in, through GRP78, 4663
 in multiple myeloma cells, FTY720 in, 7478
 N-benzyladriamycin-14-valerate in, 10016
 nitric oxide in, in colon cancer cells, β -catenin overexpression blocking, 8604
 nuclear factor- κ B activated by 3-C1-ANPC in, 4909
 in primary meningioma cultures by fenretinide, 1547
 REIC/Dkk-3 overexpression in, 9617
 by roscovitine in Ewing's sarcoma family tumor cells, 9320
 ST1926 combined with ZD1839 in, 2364
 targeting PBR by photodynamic therapy in, 11051
 TRAIL in (See **Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)**, apoptosis induced by)
 WT1 in, through proapoptotic Akt, 8174
 inhibition of, after ionizing radiation, casein kinase II mediating, 4362
 in leukemia cells
 benzodithiophenes inducing, 7847
 coadministration of perifosine and histone deacetylase inhibitors inducing, 2422
 lung tumor cell, induction of, DNA vaccine against survivin in, 553
 medulloblastoma, ERK5 and MEK2 in, 5683
 modulation of, by CD44, 1887
 in multiple myeloma
 ACA-induced, 4417
 dexamethasone-induced, GCS-100 enhancing, 8350
 nitric oxide-induced, in lymphoblastoid and fibroblast cells, 6097
 nuclear PTEN regulating, 8096
 oxidative stress in, 203
 parthenolide-induced, susceptibility of cholangiocarcinoma cells to, 6312
 p53-dependent
 in colorectal cancer, GSK-3 β inactivation promoting, 9012
 transactivation-independent mechanism of, 2108
 p53/PKC-induced, matrix metalloproteinases 9 and 10 inhibiting, 4261
 p53 up-regulated modulator of (See **PUMA (P53 up-regulated modulator of apoptosis)**)
 p73 β -mediated, p57^{MDM2} induction and IEX-1 inhibition in, 2186
 p73-dependent, through death receptor, 2787
 prevention of
 in cancer promotion, 1655
 FLT3 internal tandem duplication mutation in, via PKA and RSK1, 7338
 prostate cancer cell
 decursin-induced, 1035
 induction of, CKIs in, 7717
 NF- κ B-mediated induction of, by CD437, 6354
 REIC/Dkk-3 overexpression inducing, 9617
 RNA interference-mediated silencing of *acetyl-CoA carboxylase- α* inducing, 6719
 thiazolidinediones mediating, 1561
 regulation of, serum and glucocorticoid-inducible protein kinase in, 457
 resistance to, CTCF overexpression in breast cancer cells and, 5112
 STI571-induced, survivin sensitizing Bcr-abl-positive cells to, 8224
 stromal cell, ADAM12 in, 4754
 sulforaphane-induced, Bax and Bak in, 2035
 T-cell, glioblastoma multiforme induced, 5428
 in thyroid PCCL3 cells, conditional BRAF^{V600E} expression inducing, 2465
 TRAIL-induced (See **Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)**, apoptosis induced by)
 caspase-mediated p65 cleavage promoting, 6111
 tumor, nitric oxide sensitization to, 8461
 tumor-selective, of acute myeloid leukemia, retinoid-cAMP induced, 8754
 UV-induced, caspase-3 activation in, BRCA2 phosphorylation regulating, 10657
ARL. See Androgen receptor (AR)
Arachidonic acid pathway
 inhibitors of, in lung cancer growth inhibition, 4181
Arf
 in mouse gliomagenesis, 2065
Arginase
 myeloid suppressor cells producing, in renal cell carcinomas, 3044
ARMS (alveolar rhabdomyosarcoma)
 genetic modeling of, new tactics in, 7530
Aromatase
 expression of
 in breast cancer, prostaglandin E₂ and, 657
 in cervical cancer, induction of, 11164
 liver receptor homologue-1 coactivated with, 11762
 gene resequencing and functional genomics in study of, 11071
 inhibitors of, in lung cancer therapy, 11287
Array-based comparative genomic hybridization
 of hereditary breast cancer, 7612
 in identification
 of cyclin D1 as target oncogene in nasopharyngeal cancer, 8125
 of glioblastoma subtypes, 1678
 of mouse breast tumors, 9695
Array-based gene expression profiles
 in identifying glioblastoma subtypes, 1678
Arresten
 as angiogenesis inhibitor, 3967
Arsenic genotoxicity of mitochondria and, 3236
Arsenic trioxide
 against myeloid leukemia, 2488
Arsenite
 cellular sensitivity to, PARP-1 deficiency and, 10977
 cyclin D1 induction through I κ B kinase β /nuclear factor- κ B pathway by, 9287
Asbestos
 epithelial cell proliferation induced by, 9670
 exposure to
 malignant mesothelioma risk from, SV40 enhancing, 3049
 mesothelial cell transformation after, SV40-dependent AKT activity driving, 5256
 lung inflammation induced by, 9670
ASH1 gene
 as therapeutic target for lung cancer, 10680
Asthma
 polymorphisms associated with, glioblastoma and, 6459
Astrocytes
 K-RAS activation in, glioma formation in neurofibromatosis 1 and, 236
Astrocytoma
 morphology, motility, and invasion of, Rho-kinase inhibition inducing, 8792
 preclinical, Pten loss in, 5172
Astrocytomas
 CXCR4 activation in, 11392
 juvenile pilocytic, expression analysis of, 76
Ataxia telangiectasia
 chromosomal breaks in, repair of, checkpoint abrogation in G₂ compromising, 11292
Ataxia telangiectasia mutated (Atm) mutations
 loss of *Brca1* and, in mammary gland cancer, 8736
ATM
 down-regulation of deficiency in catalytic subunit of DNA-dependent protein kinase causing, 1670
 haploinsufficiency for, 933
 p21 cooperating with, to suppress aneuploidy, 8747
Atomic bomb survivors
 cancer risk in, somatic mutation and, 5462
Atp2a2
 haploinsufficiency of, cancer and, 8655
ATP synthase
 decreased, in 5-FU-resistant colon cancer cells, 3162
ATR
 DNA damage response dependent on, NFB1/Mdc1 mediating, 1158
 mutations of, heterozygous, in mismatch repair-deficient cancer cells, 7091
ATVs (aggressive tumor variants)
 immune selection and emergence of, Fas-mediated cytotoxicity causing, 4376
AURKA expression
 inhibition of, chemosensitivity to taxane in pancreatic cancer induced by, 2899
Aurora B kinase
 degradation of, anaphase-promoting complex/cyclosome and Cdh1 mediating, 8730
Aurora kinases
 inhibition of, by JNJ-7706621, effects of, 9038
Autoimmune thyroiditis
 in Treg-depleted mice, 8471
Autophagy
 in glioma, DNA-PK inhibition inducing, 4368
Axl
 in tumor formation, 9294
AZD2171
 as vascular endothelial growth factor receptor-2 inhibitor, 4389
B7-1
 oncolytic herpes simplex virus double-armed with IL-18 and, 10663
Bacterial artificial chromosome array-based methylated CpG island amplification (BAMCA)
 identification of NR1/2 silencing by, 10233
Bacterial exotoxin
 domains of, fusion protein vaccine by, 9089
Ba/F3 cells
 transformation of, by signaling in EGFR mutants, 8968
Bak
 proapoptotic, WT1 regulating, 8174
 in sulforaphane-induced apoptosis, 2035
BAMCA (bacterial artificial chromosome array-based methylated CpG island amplification)
 identification of NR1/2 silencing by, 10233
BARD1
 BRCA1 bound to, ubiquitin ligase activity of, CDK2 and, 6
Barrett's esophagus
 progression of, to adenocarcinoma, 3146

Basal cell carcinoma

uniparental disomy in, single nucleotide polymorphism microarray unveiling, 8597

Base excision repair

temozolomide sensitivity and, 6394

Bax

in sulforaphane-induced apoptosis, 2035

BAX-5

as novel leukemia tumor antigen, gene expression profiling identifying, 10050

B cell lymphomas

anti-CD40 monoclonal antibody-based therapy of, cyclophosphamide inhibiting, 7493
motexafin gadolinium and zinc inducing oxidative stress responses in, 11676

Bcl-2

elevated levels of, cisplatin resistance in breast cancer and, 5301
invasion and lung metastasis promoted by, 5554
overexpression of, tumor-specific T-cell survival enhanced by, 2001
as proangiogenic signaling molecule, 5063

Bcl-2/adenovirus E1B 19 kDa interacting protein-3 (Bnip-3)

in metastatic breast cancer, 11689

Bcl-2 antisense oligonucleotide

in overcoming resistance to *ELA* gene therapy, 8406

Bcl-2-interacting mediator (Bim)

low-level expression of, in chronic myeloid leukemia, 9436

Bcl-XL

depletion of, in pancreatic cancer cells, 2344

BCL-ABL

Bim down-regulated by, in chronic myeloid leukemia, 9436

dendritic cell-mediated NK cell activation promoted by, 6409

expression of, imatinib resistance in CML and, 8912
survival up-regulated by, 8224

BCRP. See Breast cancer resistance protein (BCRP) BCRP/ABCG2. See Breast cancer resistance protein/ABCG2 (BCRP/ABCG2)**BEHAB/brevican**

tumor-specific isoforms of, in malignant gliomas, 6726

Benzenes

exposure to, hemotoxicity and, 9574

Benzo(a)pyrene

p53 knock-in murine fibroblasts exposed to, P53 mutations in lung tumors and, 2583

Benzodithiophenes

differentiation and apoptosis in leukemia cells induced by, 7847

retinoic acid receptor α activity potentiated by, 7856

N-Benzyladriamycin-14-valerate (AD198)

apoptosis induced by, through PKC- δ and PL3 phosphorylation, 10016

Bevacizumab

pharmacology and pharmacodynamics of, 671

BGC 945, 11721**B7-H1**

in resistance to cancer immunotherapy, 1089

BHAP

targeting HER-2, mitochondria and, 6891

Bicalutamide

prostate tumor growth promoted by, 9611

Big mitogen-activated protein kinase 1 (BMK1)

in tumor-associated angiogenesis, 7699

Biliary tract cancer

gene therapy of, 546

Bim (Bcl-2-interacting mediator)

low-level expression of, in chronic myeloid leukemia, 9436

Biogenesis

microRNA, cancer and, 3509

Bispecific T-cell engager (BiTE)

in tumor eradication, 2882

Bisphenol A

action of, in prostate cancer, 54

Bisphosphonates

cancer-induced bone disease and, 4971

Bladder cancer

allelic imbalance in, single nucleotide polymorphism analysis of, 34

apoptosis in

bortezomib plus TRAIL inducing, 4902

flavokawain A inducing, 3479

behavior of, cell cycle regulators and, 1150

BLCA-4 in, mechanistic analysis of, 7145

COX-2 overexpression and, 1808

DOC-2/DAB2 gene regulation in, 6089

8p depletion in, 66

gefitinib resistance in, 10524

HYAL1 hyaluronidase functions in, tumor-promoting, 2243

invasive, *SFRP* methylation and TP53 alteration in, 7081

murine, 2-acetylaminofluorene-induced, develop-

ment of, lack of p53 Ser389 phosphorylation

predisposing to, 3610

RUNX3 inactivation in, 9347

survival in, thromboxane synthase and, 11581

TRAIL-induced apoptosis in, galectin-3 inhibiting,

7546

BLCA-4

in bladder cancer, mechanistic analysis of, 7145

BLM helicase

disrupted type II telomere lengthening and, 5520

Mus81 endonuclease activity in human cells

facilitated by, 2526

Blood-tumor barrier

membrane transporters in gliomas and, 11419

Blood vessels

drug regimens targeting, drug resistance and, 5785

hair follicle-derived, vascularizing skin tumors in

mice, 2337

new, formation of (See **Angiogenesis**)

remodeling of, tumor growth and, 913

tumor

abnormal, visualization of, MRA in, 8218

delta-like 4 ligand up-regulation of, 8690

irradiated, vascular endothelial growth factor

receptor tyrosine kinase inhibition and, 5374

mosaic, 5740

in neuroblastoma, contribution of bone marrow-

derived cells to, 3200

pericytes and, 9741

plexin D as marker of, 8317

rapid accessibility of $\alpha_3\beta_1$ on, 2712

recombinant human erythropoietin α targeting,

with chemotherapy in human xenograft

models, 7186

suppression of, K5-engineered glioma cells in, 8359

targeted delivery of IFN γ to, 2906

Bloom syndrome

BLM helicase in, facilitating Mus81 endonuclease

activity in cells, 2526

B lymphocytes

receptor for, translocation of, in chronic lymphocytic

leukemia, 7328

transformed, mTOR activation in, 7800

BMP. See Bone morphogenic protein (BMP)**BMS-354825**

in vitro activity of, 4500

Bnip-3 (Bcl-2/adenovirus E1B 19 kDa interacting protein-3)

in metastatic breast cancer, 11689

Bnip3L

up-regulation of, breast cancer cells chemosensi-

tized through, 8151

Bombesin

cyclin D1 expression regulated by, via Egr-1 in

prostate cancer, 9934

Bone

disease of, cancer-induced, bisphosphonates and,

4971

metastasis to

17-allylamino-17-demethoxy gefamycin

potentiating, 4929

bone marrow mesenchymal stem cells in, 1129

of breast cancer, mouse model of, 6130

of follicular thyroid cancer, EGFR and VEGFR

inhibition in, 4716

interference with bone microenvironment

impairing, 7682

of prostate cancer

antivascular therapy of, 3707

osteoblastic

BMP promoting, 8274

through Wnts, 7554

VEGF promoting, 10921

osteoprotegerin in, 1710

microenvironment of, interference with, impairing

bone metastasis, 7682

pain in, prostate tumor-induced, anti-NGF therapy

for, 9426

resorption of

cancer cells and, 11001

heparanase expression by breast tumors

promoting, 5778

Bone marrow

cells derived from, contribution of, to tumor

vasculature in neuroblastoma, 3200

mesenchymal stem cells derived from (See **Mesenchymal stem cells**, bone marrow-derived)

mononuclear cells of, IL-6 production of, DHEA

inhibiting, 2269

pancreatic cancer-reactive T cells in, 10079

Bone morphogenic protein (BMP)

osteoblastic prostate cancer bone metastases

promoted through, 8274

overexpression of, in malignant melanoma, 448

in prostate cancer, biologic effects of, 5769

Bone sialoprotein

Isoimmunoreactivity of prostate cancer cells mediated by,

2303

Bortezomib (Velcade)

cytotoxicity of, in myeloma cell lines, Ca^{2+} disre-

gulation as critical determinant of, 3828

in differential regulation of Noxa, 6294

effects of, on proteasomes in multiple myeloma

cells, 7896

NOXA-mediated apoptosis in melanoma and myeloma

cells triggered by, 6282

proteotoxicity induced by, 11510

resistance to, in multiple myeloma, GCS-100

overcoming, 8350

sensitizing pancreatic cancer cells to endoplasmic

reticulum stress, 11658

TRAIL, plus, apoptosis induced by, 4902

BRAC1-19

anticancer activity of, 1489

B-Raf

as HSP90 client protein, 10686

V599E, mutant, inhibition of, in malignant melanoma,

2412

V600E

expression of

in papillary thyroid cancer, 4238

in thyroid PCCL3 cells, 2465

in mouse model, 11493

BRCA1 gene mutations

ovarian tumors with, MAPK inhibition in, 1994

V600E, poor survival in colon cancer associated

with, 6063

Brain

endothelial cells in, tumor-associated, IL-8 regulating,

10347

penetration of, by imatinib, Bcrp1-mediated, 2577

Brain-derived neurotrophic factor

in hepatocellular carcinoma, 219

Brain-derived neurotrophic factor/TrkB

in protection of neuroblastoma cells, Akt mediating,

2070

Brain tumor(s)

glial (See also **Glioma(s)**)

genetic alterations in, high-resolution genome-

wide mapping of, 4088

juvenile pilocytic astrocytomas as, expression analysis

of, 76

malignancy of, E1-deleted adenovirus replication in,

8936

nestin-driven oncolytic virus for, 2832

neurofibromatosis 1-associated, mTOR hyperactivation

in, 2755

BRCA1 gene

BARD1 bound to, ubiquitin ligase activity of, CDK2

and, 6

and c-Myc in psoriasis expression repression, 10265

estrogen receptor α repression by, cyclin D1

antagonizing, 6557

expression of, down-regulation of, by hypoxia, 11597

- homologous recombination regulated by, 11384
loss of, *Atm* heterozygosity with, in mammary gland cancer, 8736
methylation of, in sporadic breast cancer, 10692
phosphorylation of, caspase-3 activation regulated by, in UV-induced apoptosis, 10657
RAD51 function regulated by, 11384
sporadic breast cancer risk and, haplotype-based case-control study of, 7516
- BRCA1-related breast cancer**
BRCA2-related breast cancer and, comparative genomic hybridization profiles in, 822
- BRCA2 gene**
cell proliferation suppressed by, via stabilizing MAGE-D1, 4747
deficiency of, sensitizing cells to PARP inhibition, 10145
homologous recombination regulated by, in response to DNA damage, 4117
unclassified variants, functional evaluation and cancer risk assessment, 417
- BRCA2-related breast cancer**
BRCA1-related breast cancer and, comparative genomic hybridization profiles in, 822
- Breast(s).** See also **Mammary entries in animal models**
cells of, metabolic mapping of, via multiphoton fluorescence lifetime imaging of coenzyme NADH, 8766
epithelial cells of, motility and morphology of, R-Ras altering, 507
tissue microenvironment of, low-dose ionizing radiation-induced perturbation of, 6734
tumors in
progression of, psoriasis in, 11326
suppression of
FBX021 in, 11304
spleen tyrosine kinase in, 10289
- Breast cancer**
aggressive, biomarker of, protein kinase C α as, 8366
aggressive phenotype of, Cx43 regulating, 2705
aminoflavone for, DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by, 5325
androgen receptor in, response to medroxyprogesterone acetate and, 8487
antibody suppression of HER2 for, 650
antitense inhibition of hyaluronan synthase 2 inhibiting, 6139
apoptosis in
3,3'-diindolylmethane-induced, mechanism of, 364
synthetic triterpenoids with TRAIL inducing, 4799
BRCA1- and BRCA2-related, comparative genomic hybridization profiles in, 822
cell cycle in
arrest of, MAPK pathway and DFMO-induced, 11026
CaM-K in, 5408
cells in
chemoresistance in, AKT-dependent, PED mediating, 6668
chemosensitization of, through Bnip3L up-regulation, 8151
drug-resistant, *WTH3* methylation in, 10024
FIP200 in, cell cycle regulation by, 6676
invasiveness of, neutrophil-derived oncostatin M and, 8896
migration of, lysyl oxidase regulating, 11429
mitosis in, centrosomal Syk kinase and, 10872
motility and migration of, CXCR4-mediated, down-regulation of, by CHK, 2840
nuclear factor- κ B activation in, CK2-induced IKK-1/IKK ϵ in, 11375
SDF-1 α transactivation of HER2-neu in, 6493
survival of, integrin-mediated, 10970
ZR-75-1, insensitivity of, to 2-methoxyestradiol, 5802
cell surface markers for, identification of, 8209
cellular proliferation in, imaging of, with FLT-PET, 10104
chemoprevention, RXR-selective retinoids with antiestrogens in, 3462
chemotaxis of, ECF-induced, PKC ζ in, 1433
choline kinase suppression in, 11034
cisplatin resistance in, elevated Bcl-2 levels and, 5301
clinical markers in, *PIK3CA* mutations and, 2554
CTCF overexpression in, resistance to apoptosis and, 5112
deregulated estrogen receptor α expression in mammary epithelial cells of transgenic mice and, 681
EGF signaling in, steroid receptor regulation of, 10585
epidermal growth factor-induced gene regulation in, 6120
ErbB2-dependent, antitumor activity of rapamycin in, 5325
ErbB2-driven tumorigenesis in, premature senescence and, 840
ErbB2 overexpression in, masking of, in JIMT-1, 473
estrogen receptor signaling in, selenium disrupting, 3487
estrogen-signaling pathway in, tumor-stromal interaction through, 4653
galectin-3 activating K-Ras in, 7292
 γ -aminobutyric acid type A receptor associated protein characterization in, 394
GATA3 expression as prognostic marker, 11259
genomic imbalances in, 439
growth factor receptor pathways in, long-term estrogen deprivation and, 3903
growth inhibition and cell cycle arrest in, activin A mediating, through Smads, 7968
growth of
light-induced melanin suppression and, 11174
regulated by cleavable ErbB4 isoform, 1384
heparanase expression in, bone resorption promoted by, 5778
hereditary, genomic profiles in, 7612
homeobox D10 as tumor suppressor gene for, 7177
HSP-27 expression in, Brn-3b transactivating, 3072
human growth hormone as oncogene in, 317
HuR expression in, prognosis and, 2157
inflammatory, molecular subtypes of, gene expression profiling identifying, 2170
invasive
mtDNA G10398A polymorphism and, 8028
RING E3 ubiquitin ligase in, 10401
invasiveness of
suppression of, E124/PIG8 in, 2125
via CSF-1/EGF paracrine loop, 5278
JAG1 and NOTCH1 coexpressed in, 8530
liver receptor homologue-1 expression in, prostatic glandin E $_2$ and, 657
loss of X chromosome inactivation in, 2139
luminal to myoepithelial switch in, progestins initiating, 9779
MCF-7 cells in, Tn antigen expression in, MUC6 in, 7880
medullary, infiltration in, cyclin E and, 9727
memory T-cell response against, 3419
metastasis of
to bone
17-allylamino-17-demethoxy geldanamycin potentiating, 4929
mouse model of, 6130
DLC-1 suppressing, 6042
genes associated with, xenograft model of, 5578
induction of, AGR in, 3796
to lung, Sema3E inducing, 6167
osteonectin/SPARC/BM-40 inhibiting, 7370
postsurgical, dietary genistein in reduction of, 3396
silencing of *CXCR4* blocking, 967
Src activation of, 1858
in subpopulations, proliferation predicting, 4059
suppression of, by breast cancer metastasis suppressor I, 713
metastatic
Bnip-3 in, 11689
cyclin E transactivating calpain 2 in, 10700
postmenopausal, letrozole for, sEGFR concentrations in, 3059
prognostic signatures preservation and, 9155
telopeptide removal from fibrillar collagen I promoting, 5674
TREC complex and, 3011
microRNA gene expression deregulation in, 7065
multidrug resistance in, glucosylceramide synthase contributing to, 3861
murine model of
array CGH analyses of, 9695
Ron and, 1285
neuregulin and ErbB2 activation in, 6801
nuclear epidermal growth factor receptor in, prognostic value of, 338
nuclear factor- κ B and osteolytic activity in, 3209
PELP1 in, altered subcellular localization of, 7724
PIK3CA mutations associated with, activation of, 10992
p14 in, nucleolar localization of, 7223
postmenopausal, additive antitumor effect of letrozole and fulvestrant in, 5439
premenopausal, with *cyclin D1* gene amplification, adjuvant tamoxifen in, adverse effects of, 8009
prevention of, tamoxifen-associated, phytoestrogen and, 879
prognosis of
perinucleolar compartment prevalence and, 246
protein expression profiling predicting, 767
progression of
ADAM12 in, 4754
CD44 attenuation of metastatic invasion during, 6755
prosurvival pathways in, *S100A7* stimulating, 5696
proteasome activity in, increased, 5599
Rad9 amplification and methylation in, 8646
radiation resistance in, peroxiredoxin II in, 10338
A Ras homologue member 1 inhibiting STAT3 in, 6701
recurrent, endocrine therapy for, response to, DNA methylation and, 4101
risk of
folate and B vitamins and, 1606
MTHFR polymorphisms and, 1606
sporadic, *BRCA1* and, haplotype-based case-control study of, 7516
TGF- β pathway variants and, 3454
signaling essentials in, 2511
Slx1 overexpression in, gene amplification and, 2668
sleep duration and, 9595
spontaneous feline mammary carcinoma as model of, 907
sporadic, *BRCA1* promoter methylation in, 10692
survival of, genetic polymorphisms in *VEGF* gene associated with, 5015
survival expression in, regulation of, by HER2 and EGFR, 11018
syndecan-1 expression in, omega-3 polyunsaturated fatty acids regulating, 4442
synergism between 2-methoxyestradiol and antitubulin agents in, 387
tamoxifen responsiveness in, lapatinib and, 18
therapy of
adjuvant, monitoring efficacy of, circulating tumor-specific DNA in, 1141
oncolytic herpes simplex virus for, 1532
positron, with ^{18}F -2-deoxy-2-fluoro-D-glucose, 698
survival after, reactive oxygen species formation and, 1105
targeting β -transducin repeat-containing protein in, 1904
transcriptome correlation map of, 1376
trastuzumab resistance in, IGF-IR/HER-2 contributing to, 11118
tumor formation in, STAT3 knockdown blocking, 2532
tumorigenesis of
MAGE-D1 suppression and, 4747
neu-induced, cyclin-dependent kinase 4 and, 10174
tumorigenic cells in, *in vitro* propagation of, 5506
Twist overexpression in, tumor growth promoted by, 10801
ubiquitin-conjugating enzymes in, increased, 5599
YB-1 provoking, 4078
zonula occludens-1 regulating membrane-type 1 matrix metalloproteinase expression in, 7691
Breast cancer-associated gene 2 (BCA2)
in invasive breast cancer, 10401

- Breast cancer metastasis suppressor 1 (BRMS1)**
breast cancer metastasis suppression by, 713
nuclear factor- κ B negatively regulated by, 3586
- Breast cancer resistance protein (BCRP)**
brain penetration of imatinib and, 2577
expression of, in putative prostate stem cells, 66-60
- Breast cancer resistance protein/ABCG2 (BCRP/ABCG2)**
drug resistance mediated by
gefitinib reversing, 1541
estrogen-mediated post transcriptional
down-regulation of, 596
inhibition of, by chrysin derivatives, 4852
- Breast cancer resistance protein 1 (Bcrp1)**
imatinib mesylate transport mediated by, 2577
- BRMS1. See Breast cancer metastasis suppressor 1 (BRMS1)**
- Bru-3b transcription factors**
HSP-27 transactivated by, in breast cancer cells, 3072
- Burkitt lymphoma**
cells of, overexpression of tripeptidyl-peptidase II in, 1361
translocation in, murine model of, 1306
- B vitamins**
intake of, breast cancer risk and, 1606
- C-1027**
cell cycle alterations and telomere dysfunction
induced by, 5344
- Cachexia**
protein degradation in, reduction of, by β -hydroxy- β -methylbutyrate, 277
- E-Cadherin**
association of β -catenin and actinin-4 regulated by, 8836
in differential response to calcium in culturing
normal vs. malignant prostate cells, 9269
phosphorylation of, by protein kinase D1, in
prostate cancer, 483
- P-Cadherin**
promoting cell-cell adhesion and counteracting
invasion in melanoma, 8774
- P-Cadherin/CD133**
overexpression of, promoting pancreatic cancer cell
motility, p120ctn interacting with, 3092
- Calcitonin**
angiogenesis stimulated by, 8519
- Calcitriol**
prostaglandin metabolism regulated by, 7917
- Calcium**
constitutive nuclear factor- κ B pathway dependent
on, perillyl alcohol inhibiting, 8558
1,25-dihydroxyvitamin D₃ interaction with, in colon
cancer, 493
response of normal vs. malignant prostate cells to,
Notch-1 and E-cadherin affecting, 9269
- Calcium/calmodulin-dependent kinase I (CaM-K)**
in breast cancer cell cycle, 5408
- Calcium sensing receptor (CaSR)**
in colon cancer, 493
- Calpain 2**
expression of, cyclin E transactivating, 10700
- Camptothecin**
cells treated by, effect of histone deacetylase
inhibitors on, scheduling and, 6957
radiosensitization induced by, Ku86 in, 9194
topoisomerase I-DNA complex inhibited by, 3894
- Cancer**
emerging role of RAB GTPases in, 2516
EMP3 epigenetic inactivation in, 2565
epithelial, diagnosis of, multiphoton microscopy in,
1180
gene expression in, wavelet transforms and, 186
human, *JPO1/CDCA7* overexpression in, 5620
hydra phenomenon of, 2997
microRNA biogenesis and, 3509
prenatal origin of, stem cells and, 358
promotion of, by pathogenic mitochondrial DNA
mutations, 1655
risk of
in atomic bomb survivors, somatic mutation
and, 5462
BRCA2 unclassified variants and, 417
of unknown primary (CUP), expression diagnostic
for, 4031
- Cancer cells**
alternative lengthening of telomeres in, 2730
bone resorption and, 11001
colorectal, apoptosis of, PUMA-induced ROS
generation in, 1647
cytotoxicity toward, with siRNA-mediated polo-like
kinase 1, 2698
deformation of, dual-color imaging of, 4246
downstream mutation in, growth arrest function of
mouse double minute-2 disabled by, 1839
dual-color, *in vivo* real-time imaging of, 4246
effects of clioquinol on, 3389
folate receptor α expression in, enhancement of, 4-31
gene expression in, real-time detection of, using
molecular beacon imaging, 1909
glycolysis in, inhibition of, 613
growth and invasiveness of, furin impairing, 4162
HER2-overexpressing, multi-epitope HER2-targeted
photoimmunotherapy of, 6371
invasiveness of, ADAM9 promoting, 4728
lines of, malignant stem cells in, 8944
MDA-MB-435, resistance to 2-methoxyestradiol in,
9406
methionine metabolism on, 1554
methylation replication in, 11
migration of
dual-color imaging of, 4246
matrix metalloproteinase-2 and, 130
RafA ad RafB in, 7111
migratory potential of, Tld1 regulating, 8784
mismatch repair-deficient, ATR mutations in, 7091
mitochondria of, cytotoxicity of jasmonates for, 1984
multidrug resistant, gefitinib reversing resistance in,
6943
neoplastic phenotype of, cytochrome P450 2J2
promoting, 4707
proliferation of, p90 ribosomal S6 kinase in, 1027
selective targeting of, by docetaxel, 4401
sensitization of, to chemotherapy, genistein in, 6934
signaling intricacies in, 2511
transcription in
dihydropyrimidine dehydrogenase gene, activator
protein accelerating, 1055
NF- κ B-dependent, chemotherapeutic drugs blocking,
4273
tumorigenic, stem-like, side population enriched in,
6207
- Cancer stem cells (CSCs)**
side population enriched by, 6207
- Cancer/testis antigen expression**
in mesenchymal stem cells, 2207
- Cancer-testis gene**
CTCF/BORIS binding sites regulating, 7751
in lung cancer cells, BORIS and NY-ESO-1 expression
and, 7763
- Cannabinoid receptor**
as target for prostate cancer treatment, 1635
- Canstatin**
as angiogenesis inhibitor, 3967
efficacy and mechanism of action of, 4353
- Carboxyaido-triazole (CAI)**
LM-1685 combined with, apoptosis increased by,
anticancer effect and, 3853
- Carboxyl-terminal Src kinase homologous kinase (CHK)**
CXCR4 regulation by, breast cancer cell migration
and, 2840
- Carboxypeptidase G2**
targeted adenovirus with, systemic GDEPT for
hepatocellular carcinoma using, 5003
- Carcinoembryonic antigen (CEA)**
cell adhesion molecule 1st-4L related to, hepatocel-
lular cancer suppressed by, 11010
expression of, by thymic epithelial cells, 6443
immune responses against, induction of, by oral
vaccine, 6990
tumor-specific glycosylation of, dendritic cells
recognizing, on colorectal cancer cells, 5935
expression of, SOX9 inhibiting, in colon cancer
cells, 2193
tolerance to, in CEA-transgenic mice, breaking, 1925
- Carcinogenesis**
aflatoxin-induced, susceptibility to, 1265
cervical, Wnt signaling in, 6199
colon, folate transport gene inactivation and, 887
esophageal squamous cell, microarray analysis of,
in rat, 401
gastric, MNU-induced, PPAR γ and, 4769
haploinsufficiency for ATM and RAD9 and, 933
mammary
in AIB1/SRC-3 null mice, 7993
2-deoxyglucose and, 7023
peroxisome proliferator-activated receptor and,
3950
melanotroph, suppression of, accelerated progres-
sion of pituitary and thyroid tumors and, 787
nonautonomous effect of p53 tumor suppressor in,
1627
ovarian, cytochrome P450 1A1 overexpression in,
3726
pancreatic, K-ras oncogene in, 5045
prostatic
oxidative damage in, loss-of-function of *Nkx3.1*
promoting, 6773
oxidative stress and, 2498
pulmonary
ANLN pathways in, 11314
human trna-dihydrouridine synthase and, 5638
reactive oxygen species in, 948
RhoA-induced, choline kinase potentiating, 5647
skin
mouse, pRb in, 9678
Perp deficiency suppressing, 6551
protein kinase C α deficiency and, 7356
reduction of, antioxidant approach to, 1401
sensitivity to, 2054
susceptibility to, chronic UVB exposure and, 6006
UVB-induced, DDB2 in protection against, 10298
- Carcinoma**
basal cell, uniparental disomy in, single nucleotide
polymorphism microarray unveiling, 8597
 β -catenin activation in, tissue-type plasminogen
activator in, 526
hepatocellular (See **Hepatocellular carcinoma (HCC)**)
renal cell (See **Renal cell carcinoma (RCC)**)
squamous cell (See **Squamous cell carcinoma (SCC)**)
- Carney complex**
mouse model for, 4506
- Carnesol**
preventing adenoma formation, 1097
- Casein kinase II (CK2)**
apoptosis inhibited by, after ionizing radiation, 4362
- CaSm**
cellular transformation mediated by, altered gene
expression and mRNA stability associated
with, 6228
- Caspase**
activation of, in TRAIL-resistant colon carcinoma
cell lines, ROS regulating, 7436
p65 cleavage mediated by, TRAIL-induced apoptosis
promoted by, 6111
in prostate cancer therapy, 4309
second mitochondria-derived activator of, sensi-
tization for γ -irradiation induced by, 10502
- Caspase-1**
ETS1 transactivating, in ETS1-induced apoptosis,
7205
- Caspase-1 α**
down-regulation of, in ovarian cancer, 8591
- Caspase-3**
activation of, in UV-induced apoptosis, BRCA1
phosphorylation regulating, 10657
cross talk between apoptosis and invasion signaling
activated by, 9121
- Caspase-8**
somatic mutations of, gastric carcinomas and, 815
- CaSR (calcium sensing receptor)**
in colon cancer, 403
- CAST (Escherichia coli ampicillin secretion trap)**
in breast cancer marker identification, 8209
- CAT25**
as marker for microsatellite instability in colorectal
cancer, 8072

- Catalase (CAT)**
breast cancer survival and, 1105
- Catalytic topoisomerase II inhibitors**
purine-based, 7470
- Catechins, tea**
antifolate activity of, 2059
intestinal tumorigenesis inhibited by, 10623
- Catenin**
p120, localization of, in colon cancer, 10938
- β -Catenin**
association of, with actinin-4, E-cadherin regulating, 8836
degradation of, GSK3 β -mediated, MUC1 blocking, 10413
mutations of, in adrenocortical tumors, 7622
overexpression of, nitric-oxide-induced apoptosis in colon cancer cells blocked by, 8604
- γ -Catenin**
regulation of, in prostate cancer, 2130
- Cathepsin D**
serum, in glioma patients, 5190
- Cat model**
spontaneous breast cancer in, as model of human breast cancer, 907
- CCAAT/enhancer binding protein**
expression of, decreased, in macrophages, tumor evasion and, 10578
- CCAAT/enhancer binding protein α (C/EBP α) expression**
loss of, in skin squamous cell carcinoma, 861
- CCAAT/enhancer binding protein α knock-in mice**
reduced hepatocellular carcinoma susceptibility in, 10330
- CCAAT/enhancer binding protein δ**
vitamin D and, 4762
- CCAAT/enhancer-binding protein homologous protein (CHOP)**
MG132 inducing DR5 through, 5662
- 3-C1-ANPC**
nuclear factor- κ B activated by, apoptosis induced by, 4909
- C-C chemokine receptor 5 (CCR5)**
pulmonary metastasis promoted by, 3374
- C-C chemokine receptor 7 (CCR7) expression**
on melanoma cells, epigenetic up-regulation of, 1800
- CCI-779**
effects of, on prostate cancer xenografts, 2825
- CCN1 (cysteine-rich 61)**
plasmin proteolysis of, 9705
- CCR5 (C-C chemokine receptor 5)**
pulmonary metastasis promoted by, 3374
- CCR7 (C-C chemokine receptor 7) expression**
on melanoma cells, epigenetic up-regulation of, 1800
- CD4⁺**
CD4⁺CD25⁺ regulatory lymphocytes
intestinal tumor regression induced by, 3998
CD4⁺CD25⁺ T cells, regulatory
depleted, mice with, tumor regression and autoimmunity in, 8471
in hepatocellular carcinoma, 2457
EBV-encoded nuclear antigen 1-specific, 1577
- CD4⁺ melanoma-reactive T cells**
engineering, 1570
- CD4⁺ T cell-mediated antigen-specific immunotherapy**
of cervical cancer, 2018
- CD8⁺**
high-TCR density, sensitivity of, to CH₂-appended antigen, 2930
- CD8⁺ melanoma-reactive T cells**
engineering, 1570
- CD8⁺ T cells**
epitopes defined by, tumor antigen-directed expression of, 6002
responses of, to renal cell carcinoma antigens, 1079
transforming growth factor- β -insensitive, for prostate cancer, 1761
- CD9**
down-regulation of, in ovarian cancer cell, peritoneal dissemination and, 2617
- CD20**
Myc down-regulating, in B lymphoma, 5454
- CD24**
expression of, tumor growth and metastasis and, 10783
- CD25⁺ regulatory T cells**
IL-10 and, in control of antitumor CD8 T cells, 8479
- CD26**
cell adhesion and tumorigenicity regulated by, 6950
- CD26/dipeptidyl peptidase IV**
regulating p38 phosphorylation and topoisomerase II α expression, 1973
- CD30-extracellular signal-regulated kinase 1/2**
mitogen-activated protein kinase signaling
CD30 promoter induced by, 7628
- CD30 promoter**
induction of, by CD30-ERK1/2-JunB, 7628
- CD34⁺CD19⁺ cells**
in high-risk acute lymphoblastic leukemia, 1442
- CD34⁺ cells**
expansion of, by valproic acid, 1505
- CD40**
mantle cell lymphoma cell proliferation induced by, retinoic acid and, 587
monoclonal antibodies directed against, anti-multiple myeloma activity of, 5898
- CD44**
bridging of MMP-9 to, in colon cancer cells, 11545
fibroblast growth factor 2 binding to, laminin peptide blocking, 10494
on LS174T colon cancer cells, E-selectin ligand activity of, 5812
metastatic invasion during breast cancer progression attenuated by, 6755
modulation of apoptosis by, 1887
v6-containing isoforms of, Met- and Ron-dependent cell migration inhibited by, 6105
- CD44 receptor**
P-glycoprotein interacting with, cell invasion and, 6660
- CD70**
glioblastomas inducing T-lymphocyte death by, 5428
- CD95**
apoptosis induced by, JNK suppressing, 6780
- CD153/PVR**
glioma cell dispersal enhanced by, 10930
- CD437**
apoptosis induction by, NF- κ B-mediated, 6354
- CDCA**
mutations of, and CIN in colorectal cancer, 11361
- Cdc42**
down-regulation of, by *N-myc*, 3136
- CDDO**
heme oxygenase-1 and Nrf2-ARE signaling activated by, 4789
- CDK2**
in BRCA1-BARD1 ubiquitin ligase down-regulation, 6
- Cdk4**
cooperation between p27^{Kip1} and, in tumor development, 3846
- CDK4 gene alterations**
in mantle cell lymphoma, 2199
- CDKN2A**
common variants of, melanoma risk and, 835
- CDNA microarray analysis**
of esophageal carcinogenesis, 401
- CD8⁺ T cells**
function of, in ovarian cancer, monitoring of, 7000
- CDX2**
polymorphisms and expression of, colorectal cancer risk and, 5488
- CEA. See Carcinoembryonic antigen (CEA)**
- CEACAM6**
antibodies against, metastasis inhibited by, 8809
- Celecoxib**
enhancing photodynamic therapy, 9473
radiosensitivity enhancement by, 9501
in ω -3 polyunsaturated fatty acid-rich diet in colon cancer prevention, 8022
- Cell(s)**
energy status of, low, blocking tumor cell anabolism, 2441
growth of, 4-HPR suppressing, 9555
life span of, glycolytic enzymes modulating, 177
malignant transformation of, transcriptional programs of, 4530
migration of
RASSF1A controlling, 7653
SSX down-regulation impairing, 2207
- Mus81 endonuclease activity of, BLM helicase facilitating, 2526
neoplastic transformation of
histone h3 phosphorylation in, 5818
STAT3 required for, 5828
proliferation of
breast cancer metastasis in subpopulations predicted by, 4059
EG-1 stimulating, 6159
survival of, p53CSV mediating, 1197
- Cell competition**
Myc and, 6485
- Cell cycle**
arrest of
activin A mediating, 7968
G₂/M, JNK inducing, 6780
MAPK pathway and DFM0-induced, 11026
BCR-ABL-mediated regulation of, in CML, 3264
breast cancer, CaM-K in, 5408
checkpoints in
cryptochrome and circadian cycle and, cancer anc, 6828
lung cancer risk and, 349
deregulation of, therapeutic approaches to, 3846
dysregulation of, in multiple myeloma, cdk4/cyclin D1 and cdk6/cyclin D2 pairing promoting, 11345
hepatic, pRB loss and, 4568
modulation of, cIAP1 in, 210
nuclear PTEN regulating, 8096
pancreatic cancer, arrest of, through induced p27^{Kip1} expression, 4870
progression of
anastellin inhibiting, 148
C-1027 altering, 5344
RASSF1A inhibiting, 3682
regulation of
Ckap2 in, 6685
by FIP200 in breast cancer cells, 6676
mouse p10 in, 3249
p27(ARID1A/SMARCF1) subunit of mammalian SWI/SNF in, 9236
rapamycin-mediated, glycogen synthase kinase 3 β in, 1961
regulators of, bladder tumor behavior and, 1150
restarting of, when checkpoint arrests, 7037
tumor relevant modulators of, functional profiling of, 7733
- Cell death. See also Apoptosis**
in glioblastoma, RAS inhibition inducing, 999
regulation of, in oncogenesis, 8069
- Cellular adhesion molecules**
polymorphisms in, benzene exposure and, 9475
- Cellular peroxidase**
in anthracycline inactivation, 6346
- Cellular retinoic acid-binding protein II signaling**
proapoptotic genes as targets for, 8193
- Cellular senescence**
accelerated, escape from, in lung cancers, 2795
- Cellular stress**
in imprinted gene inactivation, 26
- Central nervous system tumors**
embryonal, c-Met pathway in, 9355
- Centromere protein H**
overexpression of, in colorectal cancer, aneuploidy induced by, 4683
- Centrosome(s)**
abnormalities of
in multiple myeloma, hyaluronan-mediated motility receptor affecting, 850
in tumor endothelial cells, 2507
amplification of, FoxM1 loss causing, 5181
duplication errors in, in cells overexpressing tripeptidyl-peptidase II, 1361
oncogenic tyrosine kinase targeting, 7231
Syk tyrosine kinase localized to, breast cancer cell mitosis and, 10872
- Ceratinamines**
cellular effects of, 3040
- Cervical cancer**
aromatase expression in, induction of, 11164
human papillomavirus and, vaccination against, 641
immunotherapy of, CD4⁺ T cell-mediated antigen-specific, 2018

- metastasis of, *LAMP3/TSC403/DC-LAMP* overexpression promoting, 8640
- progression of
- membrane type 1 matrix metalloproteinase in, 6543
 - Wnt signaling in, 6199
- tumor-infiltrating lymphocytes in, NKR expression on, 2921
- Cervical lymph nodes**
- molecular staging of, in head and neck cancer, 2147
- Cetuximab**
- EGFR down-regulation by, 3003
- Checkpoint (Chk) pathways**
- abrogation of, CNDAC-induced G₂ arrest and, 6874
 - cyclin-dependent kinase inhibition and, 780
 - DNA damage-induced arrest of, restarting cell cycle after, 7037
 - regulators of, RNA silencing of, in chemosensitization of p53-defective prostate cancer cells, 2872
- Checkpoint kinase 1 (Chk1)**
- in homologous recombination cell repair, Fhit opposing, 8613
 - in preventing premature mitosis in response to gemcitabine, 6835
- Checkpoint kinase 2 (Chk2)**
- activation of, anticancer activity of, 6017
 - hypoxia-induced phosphorylation of, 10734
- Chemical carcinogenesis**
- polycyclic aromatic hydrocarbon in, 1251
 - skin, in *NQO1*-null mice, 2054
- Chemoprevention**
- of breast cancer, RXR-selective retinoids with antiestrogens in, 3462
 - D-type cyclins and, 6476
 - of gastric cancer, PPAR γ in, 4769
 - NSAIDs in, 1868
 - 11p27^{del} in tumorigenesis and, 9363
 - of tumor inflammatory angiogenesis, 10637
 - of UV light-induced skin tumorigenesis, EGFR inhibition in, 3958
- Chemoresistance**
- in breast cancer cells, AKT-dependent, PED mediating, 6668
 - cancer, *SLC7A11* in, 7446
 - control of, *sirt1* in, 10183
 - in malignant melanoma, ABCB5-mediated, 4320
 - in pancreatic cancer
 - Bcl-XL in, 2344
 - nuclear factor- κ B activation and, 1316 - in pediatric osteosarcoma, 1748
- Chemosensitivity**
- activator protein 2 α determining, 8628
 - cancer, *SLC7A11* in, 7446
 - high motility group A2 potentiating, 6622
 - p53 regulation of decoy receptor 2 and, 9169
 - rapamycin-mediated, glycogen synthase kinase 3 β in, 1961
 - taxane, in pancreatic cancer, 2899
- Chemosensitization**
- of breast cancer cells through Bnip3L up-regulation, 8151
 - to cisplatin in nasopharyngeal carcinoma, mitotic arrest deficient 2 expression inducing, 1450
 - of p53-defective prostate cancer cells, 2872
- Chemotaxis**
- EGF-induced, PKC ζ in, 1433
- Chemotherapy**
- alkylating agents in, mitochondrial-targeted MGMT and, 3319
 - antiangiogenic drug combinations with, coagulation marker for, 5365
 - combined with tumor-debulking surgery and adjuvant immunotherapy, 7580
 - cross-linking agents in, tolerance to, multiple repair pathways mediating, 11704
 - cytotoxic, leveraging tumor vaccine activity with, 8059
 - cytotoxicity induced by, disruption of hexokinase II-mitochondria binding potentiated by, 10545
 - deoxynucleotide depletion and E2F-1 elevation in, 7809
 - immunotherapy combined with, 8065
 - metronomic, 7045
- multidrug resistance in (See **Multidrug resistance (MDR)**)
- for neuroblastoma, Akt inhibitors in, 2070
- oxidative stress induced by, sensitization of glioma cells to Fas-dependent apoptosis by, 5248
- radiation and antiangiogenesis combined with, 3643
- resistance of hepatocellular carcinomas to, virotherapy overcoming, 7393
- response to, prediction of, expression profiles of osteosarcoma in, 8142
- sensitizing cancer cells to, genistein in, 6934
- triple, tumor necrosis factor-related apoptosis-inducing ligand-based, for pancreatic cancer, 2344
- tumor response to, [¹⁸F]FLT-PET in early monitoring of, 4202
- Children. See Pediatric patients**
- Chimerism**
- mixed, renal cancer treatment with, 10032
- CHIR-12.12**
- anti-multiple myeloma activity of, 5898
- Chk pathways. See Checkpoint (Chk) pathways**
- Chloride intracellular channel proteins**
- antisense suppression of, in apoptosis induction and tumor growth inhibition, 562
- 8-Chloro-cyclic AMP**
- growth inhibition and apoptosis induced by, 4896
- Cholangiocarcinoma**
- growth of, GABA regulating, 11437
- Cholangiocarcinoma cells**
- susceptibility of, to parthenolide-induced apoptosis, 6312
- Choline**
- metabolism of, in ovarian tumor progression, 9369
- Choline kinase**
- RhoA-induced carcinogenesis potentiated by, 5647
 - suppression of, in breast cancer, 11034
- Chondromodulin-1**
- as angiogenesis inhibitor, 3967
- CHOP (CCAAT/enhancer-binding protein homologous protein)**
- MC132 inducing DR5 through, 5662
- Chromatin**
- in remodeling of hTR and hTERT gene promoters, telomerase gene expression and, 7585
 - structure of, valproic acid altering, 3815
- Chromatin immunoprecipitation**
- allele-specific, glutathione S-transferase M3 promoter SNP and, 99
- Chromosome(s)**
- aberrations of
 - C-1027 inducing, 5344
 - gemcitabine selecting for, 10208 - abnormalities of
 - genome-wide mapping of, in glial brain tumors, 4088
 - in tumor endothelial cells, 2507 - amplifications of, in lung cancer, 5561
 - aneuploidy of, cancer transcriptome and, WAVES and, 186
 - instability of (CIN)
 - in breast cancer, Twist overexpression and, 10801
 - CDC4* mutations and, in colorectal cancer, 11361 - epithelial tumor development by *p53-Fbxw/Cdc4* pathway and, 6488
 - genetic disruption of cytosine DNA methyltransferase enzymes inducing, 8635
 - hydroquinone-induced, 3527
 - oncogenic transformation by SEI-1 associated with, 6504
 - in *Rad51d*-deficient mouse cells, 2089
 - in thyroid PCCL3 cells, conditional BRAF^{V600E} expression inducing, 2465
 - from *in vivo* bystander effect of γ radiation, 5668
 - loci on, affecting spontaneous lung cancer, 8158
 - as transcriptome correlation maps, 1376
- Chromosome 1q23**
- genetic mapping of Li-Fraumeni syndrome predisposition locus to, 427
- Chromosome 3p**
- FHIT* on, genetic linkage of, to prostate cancer risk, 805
- Chromosome 8p11-p12**
- deletion of, in bladder cancer, 66
- Chromosome 10 (PTEN) nuclear import**
- major vault protein-mediated, 4108
- Chromosome 17 aneusomy**
- BRCA1* methylation associated with, 10692
- Chrysin derivatives**
- ABCG2 inhibition by, 4852
- CI-1040**
- taxol efficacy enhanced by, 2854
- CIAP1**
- localization and cell cycle functions of, 210
- Ciglitazone**
- in lung cancer growth inhibition, 4181
- CIMP (CpG island methylator phenotype)**
- neuroblastoma prognosis and, 828
- CIN. See Chromosome(s), instability of (CIN)**
- Circadian cycle**
- cryptochrome and cell cycle checkpoints and, cancer and, 6828
- Circulating tumor cells (CTCs)**
- global gene expression profiling of, 4993
- Cis-Diamminedichloro-platinum(II) treatment**
- element array by scanning X-ray fluorescence microscopy after, 4998
- Cisplatin**
- apoptosis induced by, Siva-1 protein enhancing, 5301
 - effect of, on fibrosarcoma tumor model, monitoring of, 4202
 - resistance to
 - genes mediating, 5890
 - in ovarian cancer, ErbB receptor signaling in, 6789 - sensitivity to, kinase suppressor of Ras1 enhancing, 3986
 - sensitization to, in nasopharyngeal carcinoma, mitotic arrest deficient 2 expression inducing, 1450
 - tolerance to, polymerase η in, 9799
- CK2**
- inducible I κ B kinase/I κ B kinase ϵ expression induced by, activating NF- κ B in breast cancer cells, 11375
- Ckap2 (cytoskeleton associated protein 2)**
- tetraploidy checkpoint regulated by, 6685
- CL-387,785**
- gefitinib resistance overcome by, 7096
- Class complement pathway**
- tachyplesin activating, 4614
- Claudin-3**
- expression of, in ovarian epithelial cells, function of, 7378
 - in human cancer, 9603
- Claudin-4**
- expression of, in ovarian epithelial cells, function of, 7378
 - in human cancer, 9603
 - induction of, NSAIDs in, 1868
- Clear cell renal cell carcinoma**
- stromal cell-derived factor-1 α and CXCR4 expression in, 6178
- Clioquinol**
- anticancer activity of, 3389
- Clonal expansion**
- high degree of, in premalignant clones, 1234
- Clones**
- pre-malignant, fate of, before tumor onset, 1234
- Clostridium perfringens enterotoxin**
- intraperitoneal, for chemotherapy-resistant ovarian cancer, 4334
- c-Met pathway**
- in embryonal CNS tumors, 9355
- c-Met receptor**
- therapeutic inhibition of, in non-small cell lung cancer, 1479
- CML. See Leukemia, chronic myeloid (CML)**
- c-Myc**
- and *BRCA1* in psoriasis expression repression, 10265
 - immortalization of HPrEC by, 2179
 - insertion of, into *Igh* inducing B-cell and plasma cell tumors in mice, 1306
 - targeted destruction of, by engineered E3, 7874
 - target genes of, with overlapping functions, c-Myc-independent restoration of multiple phenotypes by, 2097

- Colitis**
retinoblastoma protein hyperphosphorylation and E2F1 activation promoted by, 9132
- Collagen**
cancer cell migration on, MMP-2 and, 130
fibrillar, lack of telopeptides in, breast tumor cell invasion promoted by, 5674
- Colon**
mucosa of, hyperproliferation of, gastrin precursors signaling, 2770
tumor of, xenograft models of, growth of, SKI-606 inhibiting, 5358
- Colon cancer**
aberrant crypt foci and, rat model, 121
AEE788 in targeted therapy of, 3716
antitumor effects of KITTENIN siRNA on, 8993
apoptosis in
 nitric oxide-induced, β -catenin overexpression blocking, 8604
 thiazolidin compound inducing, 6380
 β_1 integrin hypersialylation in, cell motility and, 4645
calcium sensing receptor in, 493
cells in
 changes in, maintaining, oncogenic *K-RAS* in, 1244
 growth of, retinol inhibiting, 9923
 HCT116, tumorigenicity in, glutathione *S*-transferase π 1 promoting, 9485
 LS174T, CD44 on, E-selectin ligand activity of, 5812
 sensitization of
 to TRAIL, 7436
 to TRAIL-induced apoptosis by COX-2 inhibition, 11447
cystostasis of, guanylyl cyclase C-induced, 11129
development of
 cytoplasmic phospholipase A₂ deletion enhancing, 2636
 folate transport gene inactivation and, 887
 doxorubicin resistance in, nitric oxide reverting, 516
Dukes B, Wnt-5a protein expression in, prognosis and, 9142
5-FU-resistant, decreased ATP synthase in, 3162
genetic instability in, gene expression signature of, 9200
inflammation and, CysLT₁ receptor in adenocarcinoma cell nucleus and, 732
invasiveness of, dentin matrix protein 2 enhancing, 11545
microsatellite-stable, *BRAF* V600E mutation in, poor survival and, 6063
NNK stimulating, via β -adrenoceptors, 5272
p120 catenin localization in, 10938
prevention of, celecoxib in, in α -3 polyunsaturated fatty acid-rich diet, 8022
progression of, intrinsic mitochondrial membrane potential linked to, 9861
protein kinase G up-regulating 15-LOX-1 expression in, 8442
RAD001 with oncolytic virus for, 6882
rTS signaling mimic in, 5-fluorouracil sensitivity enhanced by, 5917
SOX9 in, carcinoembryonic antigen gene expression inhibited by, 2193
Src-FAK signaling in, 1335
STAT3 in, trefoil factors and vascular endothelial growth factor and, 195
synergy of EGFR and ErbB2 TKIs in, 5848
tumor immune evasion in, Fas ligand in, 9817
xenografts of
 antiangiogenic effects in, early, detection of, 9253
 growth of, enzastaurin suppressing, 7462
- Colony-stimulating factor-1 (CSF-1)**
epidermal growth factor paracrine loop with, breast cancer invasiveness and, 5278
in epithelial ovarian cancer, 3762
- Colorectal adenoma**
meat intake and, 8034
- Colorectal cancer (CRC)**
CDX4 mutations and CIN in, 11361
cells of, senescence of, human telomerase reverse transcriptase expression rescuing, 2321
centromere protein H overexpression in, aneuploidy induced by, 4683
dendritic cells interacting with, 5935
ELF and Smad4 in, 4228
EPHB2 inactivation in, mechanisms of, 10170
Fas-mediated apoptosis in, p53 status and STAT1 and, 8951
gene expression in, overlapping with fetal mouse intestine development, 8715
gene targets dysregulated in, identification of, 166
inflammatory bowel disease-associated, mesalazine in chemoprevention, 3993
JNK-dependent Smad2/3L phosphorylation in, 157
K-ras mutations in, tumor microenvironment and, 8134
microsatellite instability in
 CAT25 as marker for, 8072
 HLA class I antigen machinery in, 6418
 impairment of stromelysin-1 transcriptional activity by promoter mutations in, 3811
p53-dependent apoptosis in, GSK-3 β inactivation promoting, 9012
PIK3CA gene mutations in, functional analysis of, 4562
risk of
 CDX2 variants and expression in, 5488
 CYP7A1 and, 2979
tumor-derived heat shock protein 96 for, natural killer activity in, 3942
tumorigenesis in, lipoxigenases and, 11486
two noncoding repeat mutations in, 4607
- Comparative genomic hybridization, array**
of hereditary breast cancer, 7612
at tiling-path resolution, microalterations in oral cancer detected by, 7561
- Compensatory proliferation, Myc and, 6485**
- Complement**
in antibody therapy of murine metastatic cancer, 10562
- Computed tomography**
single-photon emission, small-molecule, for metastatic melanoma imaging, 4979
- Conditionally replicating adenovirus (CRAd)**
for biliary tract cancers, 5-FU resistance and, 546
- Connective tissue growth factor (CTGF)**
angiogenesis and prostate cancer tumorigenesis promoted by, 8887
- Connexin 43 (Cx43)**
down-regulation of, by retroviral delivery of small interfering RNA, aggressive breast cancer cell phenotype and, 2705
expression of, suberoylanilide hydroxamic acid enhancing, 9771
- Constitutively photomorphogenic 1 (COP1)**
major vault protein with, in cancer progression, 5835
- Contortrostatin**
drug resistance induced by, 5785
- Convection-enhanced drug delivery, 6858**
- COP1 (constitutively photomorphogenic 1)**
major vault protein with, in cancer progression, 5835
- Copy number detection**
using oligonucleotide arrays, 6071
- Cortactin**
overexpression of, EGFR down-regulation inhibited by, 3273
- COX-2, See Cyclooxygenase-2 (COX-2)**
- CP-673,451 antiangiogenic and antitumor activity of, 957**
- CpG**
methylation patterns of, replication of, in cancer cells, 11
- CpG island methylation**
of DNA damage response genes in ovarian cancer, 8061
- CpG island methylator phenotype (CIMP)**
neuroblastoma prognosis and, 828
- CpG-oligodeoxynucleotides**
therapeutic synergism of, with gemcitabine in orthotopic human pancreatic carcinoma xenograft, 6388
- CRAd (conditionally replicating adenovirus)**
for biliary tract cancers, 5-FU resistance and, 546
- C-RAF**
mutations of, in cancer, 9719
- CRC, See Colorectal cancer (CRC)**
- C19ORF5**
antitumor activities of, 4191
specificity of RASSF1A determined by, 1830
- Cryptochrome**
circadian cycle and cell cycle checkpoints and, cancer and, 6828
- CTCF**
overexpression of, in breast cancer cells, resistance to apoptosis and, 5112
- CTCF/BORIS binding**
cancer-testis genes regulated by, 7751
to NY-ESO-1 promoter, in lung cancer, 7763
- CTCs (circulating tumor cells)**
global gene expression profiling of, 4993
- CTL epitopes**
for prostate cancer immunotherapy, 6435
- CTLs**
antitumor responses of, CD4⁺ T cells suppressing, 6984
differentiation of, by CH₂-appended antigen, 2930
- Cutaneous T-cell lymphomas (CTCL)**
NAV3 gene deletion/translocation in, 8101
- C-X-C chemokine receptor 4 (CXCR4) expression, See CXCR4 (C-X-C chemokine receptor 4) expression**
- CXC chemokines**
Bcl-2 acting in proangiogenic signaling pathway through, 5063
up-regulation of, in fibroblasts by low dose ionizing radiation, 10159
- CXCL12**
vascular endothelial growth factor and, inducing neoangiogenesis in ovarian cancer, 465
- CXCL12/stromal cell-derived factor-1 α**
HER2-neu transactivated by, in breast cancer cells, 6493
- CXCR4 (C-X-C chemokine receptor 4)**
activation of, in astrocytomas, 11392
expression of
 in BCR-ABL-expressing cells and chronic myeloid leukemia, 2676
 in hemangioblastoma and clear cell renal cell carcinoma, 6178
 interaction of, with stromal cell-derived factor-1, blockade of, in tumor neoangiogenesis, 5864
 stromal-derived factor-1 α up-regulating, 9891
on melanoma cells, epigenetic up-regulation of, 1800
negative regulation of, by kisspeptin signaling, 10450
in ovarian cancer, TNF- α up-regulating, 10355
prostate cancer invasion induced by, YM529 inhibiting, 8818
regulation of, by CHK, breast cancer cell migration and, 2840
silencing of, blocking breast cancer metastasis, 967
tumor cells expressing, enhanced targeting of, by transducible anticancer peptides, 10646
- CY15**
phenotypical similarity of, to immature dendritic cells, 2560
- 2'-C-cyano-2'-deoxy-1- β -D-arabino-pentofuranosyl-cytosine**
G₂ arrest induced by, checkpoint abrogation and, 6874
- Cyclic AMP/CREB regulated genes**
aberrant activation of, Mect1-Maml2 fusion oncogene linked to, 7137
- Cyclin(s)**
D-type
 dysregulation of, protein kinase A disruption causing, 10307
 negative regulation of TSC1-TSC2 by, 11354
 retinoid targeting of, through chemopreventive mechanisms, 6476
- Cyclin A2**
transcriptional regulation of, by RASSF1A via p120^{CAS}, 2690
- Cyclin D**
induction of, through I- κ B kinase β /nuclear factor- κ B pathway by arsenite, 9287
- Cyclin D1**
bombesin-induced activation of, via Egr-1, 9934

- BRCA1 repression of estrogen receptor α** antagonized by, 6557
- cyclin-dependent kinase 4 with, and cdk6/cyclin D2** promoting cell cycle dysregulation in multiple myeloma, 11345
- gene amplification of** in nasopharyngeal cancer, 8125
- premenopausal breast cancer with, tamoxifen in,** 8009
- Cyclin D2**
cyclin-dependent kinase 6 with, and cdk4/cyclin D1 promoting cell cycle dysregulation in multiple myeloma, 11345
- Cyclin-dependent kinase 4 (Cdk4)**
neu-induced breast tumorigenesis and, 10174
- Cyclin-dependent kinase 4 (cdk4)**
cyclin D1 with, and cdk6/cyclin D2 promoting cell cycle dysregulation in multiple myeloma, 11345
- Cyclin-dependent kinase 6 (cdk6)**
cyclin D2 with, and cdk4/cyclin D1 promoting cell cycle dysregulation in multiple myeloma, 11345
- Cyclin-dependent kinases (Cdk)**
inhibition of
checkpoint pathways and, 780
by [N]-7706621, effects of, 9038
- Cyclin E**
calpain 2 transactivating, 10700
infiltration in breast cancer and, 9727
melanoma angiogenesis and metastasis and, 692
- Cyclooxygenase-1 (COX-1)**
in prevention and treatment of ovarian epithelial cancer, 3735
- Cyclooxygenase-2 (COX-2)**
differential levels of, cancer cells expressing, radio-sensitivity enhancement in, by celecoxib, 9501
expression of, RXR-selective retinoid inhibiting, via AP-1 crosstalk, 3462
ginseng metabolite-mediated apoptosis inhibited by, 1952
inhibition of
colon cancer cells sensitized to TRAIL-induced apoptosis by, 11447
T regulatory activities in lung cancer reduced by, 5211
inhibitors of, in pancreatic cancer, 982
lysophosphatidic acid as inducer of, in ovarian cancer, 2234
mammary hyperplasia mediated by, EP2 required for, 4496
in oral mucosa of smokers, epidermal growth factor receptor and, 664
overexpression of, bladder cancer and, 1808
p38 regulating, in MNEC and DCIS, 1792
prostaglandin E_2 from, promoting tumor growth, 1822
Rb/E2F pathway regulating, 3633
- Cyclooxygenases**
coexpression of vascular endothelial growth factors with, in esophageal adenocarcinoma, 5038
- Cyclophilin A**
suppression in, lung cancer growth diminished by *in vivo*, 8853
- Cyclophosphamide**
anti-CD40 inhibited by, 7493
dose reduction of virotherapy and, 11255
immunostimulatory effects of, controlled by inducible nitric oxide synthase, 5027
intermittent bolus-dose, with metronomic chemotherapy as long-term treatment strategy, 7045
oncolytic virus combined with, for glioma, 6850
pharmacokinetics of, 4211
- CYP1A1 polymorphisms**
in estrogen activation, 2973
- CYP2B1**
herpes simplex virus type 1 expressing, in brain tumor oncolysis, 6850
- CysLT₂ receptor**
in colorectal adenocarcinoma cell nucleus, inflammation and, 732
- Cystatin C**
overexpression of, in host, metastasis reduced by, 8608
- Cysteine-rich 61 (CCN1)**
plasmin proteolysis of, 9705
- Cysteine switch**
inactivating, in protein kinase C ϵ , 10478
- Cytochrome P450 1A1**
overexpression of, in ovarian cancer cells, 3726
- Cytochrome P450 7A1**
colorectal cancer risk and, 2979
- Cytochrome P450 1B1**
variants of, functional analysis of, 5105
- Cytochrome P450 2J2**
expression of, in human tumors, 4707
- Cytochrome P450s**
in cyclophosphamide pharmacokinetics, 4211
- Cytokines**
angiogenic, hepatocyte growth factor inducing, through Egr-1, 7071
polymorphisms in, benzene exposure and, 9574
production of, yonellis inhibiting, 2964
- Cytomegalovirus infection**
p73-dependent apoptosis impaired by, 2787
- Cytoplasmic domain**
of proforms of epidermal growth factor in thyroid cancer, 1343
- Cytoplasmic phospholipase A₂ deletion**
colon tumorigenesis enhanced by, 2636
- Cytosine DNA methyltransferase enzymes**
genetic disruption of, chromosomal instability induced by, 8635
- Cytoskeleton associated protein 2 (Ckap2)**
tetraploidy checkpoint regulated by, 6685
- Cytosols**
hepatic, 3-nitrobenzanthrone activated by, 2644
- Cytotoxic chemotherapy**
leveraging tumor vaccine activity with, 8059
- Cytotoxic gene therapy**
with immunostimulation for glioma, 7194
- Cytotoxicity**
cancer cell, with siRNA-mediated polo-like kinase 1, 2698
cancer-selective, MBD3 mediating, by HDIs, 11400
chemotherapy-induced, disruption of hexokinase II-mitochondria binding potentiated by, 10545
of dihydroartemisinin to papillomavirus-expressing epithelial cells, 10854
of histone deacetylase inhibitors, mutant p53 depletion and, 7386
synergistic
of ST1926 and ZD1839, 2364
of temozolomide with IFN- β on glioma cells, 7573
of velcade in myeloma cell lines, Ca²⁺ dysregulation as critical determinant of, 3828
- Darbopoietin alfa (DA)**
potentiating radiotherapy efficacy in anemic mice, 284
- Darpp-32**
in upper gastrointestinal carcinomas, 6583
- Dasatinib**
action of, in prostate cancer, 9185
- DCIS (ductal carcinoma *in situ*)**
COX-2 expression in, p38 regulating, 1792
- DDB2**
in protection against carcinogenic effects of UVB, 10298
- DDT (dichlorodiphenyltrichloroethane)**
exposure to, cancer mortality and, 9588
- Death receptor**
p73-dependent apoptosis through, 2787
regulation of, in apoptosis modulation by CD44, 188
- Death receptor 5 (DR5)**
MG132 induced by, through CHOP, 5662
- Decitabine**
for glioblastoma multiforme, 11469
in myelodysplastic syndrome, complex effects of, 7086
- Decoy receptor 2 (Dcr2)**
as p53 target gene regulating chemosensitivity, 9169
- Decursin**
in prostate carcinoma cell inhibition, 1035
- Dedifferentiation**
in thyroid PCCL3 cells, conditional BRAF^{V600E} expression inducing, 2465
- Dehydroepiandrosterone (DHEA)**
effects of, on myeloma cells, 2269
- Delta-like-1**
in glioma cell survival and proliferation, 2353
- Delta-like 4 ligand**
up-regulation of, in tumor vasculature, 8690
- Dendritic cells**
activated, antigens to, targeting of, for metastatic melanoma, 7007
apoptosis mediated by, nitric oxide sensitizing tumor cells to, 8461
colorectal cancer cells interacting with, 5935
naive, intratumoral injection of, in murine lymphoma, 5958
natural killer cells and, crosstalk between, adjuvant hsp70 and, 7942
NK cell activation mediated by, BCR/ABL promoting, 6409
plasmacytoid, CD8⁺ regulatory T cells induced by, in ovarian cancer, 5020
protein transduction of, for NY-EAO-1-based immunotherapy of myeloma, 10041
tumor-infiltrating, suppressive or protective immune responses induced by, 4955
in tumor rejection, 3437
type-1 polarized, tumor immunity induced by, 10059
- Dentin matrix protein 2**
colon cancer invasiveness enhanced by, 11545
- ¹⁸F-2-Deoxy-2-fluoro-D-glucose**
positron therapy with, for breast cancer, 698
- 2-Deoxyglucose**
mammary carcinogenesis and, 7023
- Deoxynucleotide**
depletion of, in chemotherapy, 7809
- Dexamethasone**
apoptosis induced by
MnSOD enhancing, 6255
in multiple myeloma, GCS-100 enhancing, 8350
- DHEA (dehydroepiandrosterone)**
effects of, on myeloma cells, 2269
- Diallyl disulfide (DADS)**
resistance of adenocarcinoma gastric cells to, GSH and ERK 1/2 in, 11735
- Dichlorodiphenyltrichloroethane (DDT)**
exposure to, cancer mortality and, 9588
- Differentiation therapy, 1117**
- α -Difluoromethylornithine (DFMO)**
and MAPK pathway, cell cycle arrest induced by, in breast cancer cells, 11026
- Dihydroartemisinin (DHA)**
cytotoxicity of, to papillomavirus-expressing epithelial cells, 10854
- Dihydropyrimidine dehydrogenase gene (DPYD)**
transcription of, in cancer cells, 1055
- 5-(2,4-Dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin (DBPT)**
apoptosis induced by, in colon cancer cells, 6380
- 1,25-Dihydroxyvitamin D₃**
in androgen-responsive prostate cancer cells, 4762
calcium interaction with, in colon cancer, 493
- Diindolylmethane, 1,1-bis[3-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane**
inducing apoptosis in acute myelogenous leukemia, 2890
- Diindolylmethane derivative, novel**
inducing apoptosis in acute myelogenous leukemia, 2890
- 3,3'-Diindolylmethane (DIM)**
breast cancer cell apoptosis induced by, mechanism of, 364
- 5,6-dimethylxanthone-4-acetic acid (DMXAA)**
activating tumor macrophages and T cells, 11752
- Dipeptidyl peptidase IV (DPP-IV)**
basic fibroblast growth factor signaling pathway blocked by, in prostate cancer, 1325
- Disease**
emerging role of RAB GTPases in, 2516
- Disomy, uniparental**
in acute myeloid leukemias, 375
homozygous gene mutation associated with, 9152
SNP microarray unveiling, in basal cell carcinoma, 8597
- DLCL1 gene**
breast cancer metastasis suppressed by, 6042

- in hepatocellular carcinoma, functional characteristics of, 8861
- DLG5 gene**
with *RAB6KIFL*, pancreatic cancer and, 105
- DNA**
synthesis of, inhibition of, human exonuclease 1b degradation and, 3604
tumor-specific, circulating, in monitoring adjuvant therapy, 1141
- DNA adducts**
lung cancer risk and, 8042
- DNA damage**
apoptosis and cell death induced by, signaling through IRF-5 and, 7403
cellular response to
ATR-dependent, NFB1/Mdc1 mediating, 1158
p53/CSV as cell-survival mediator in, 1197
cyclin-dependent kinase inhibition activating, 780
farnesyltransferase inhibitors inducing, by reactive oxygen species, 3671
homologous recombination in response to, BRCA2 regulating, 4117
in melanocytes, melanocortins and endothelin-1 reducing, 4292
recognition of, phosphorylated p53 and, 10810
repair of (See **DNA repair**)
response to, p53 in, 7666
subnuclear redistribution of, p14ARF triggered by, 9834
valosin-containing protein phosphorylation after, 7533
- DNA damage response genes**
CpG island methylation of, in advanced ovarian cancer, 8961
- DNA-dependent protein kinase (DNA-PK)**
catalytic subunit of, deficiency in, in ATM down-regulation, 1670
inhibition of, autophagy in glioma induced by, 4368
nontoxic radiation-sensitizing drugs targeting, 4987
- DNA double-strand breaks**
postreplicative joining of, 10223
- DNA ligase III**
in nonhomologous end joining, 4020
- DNA methylation**
in breast cancer, 8646
effects of, on Galectin-3 expression in pituitary tumors, 1136
response to endocrine therapy for recurrent breast cancer and, 4101
RUNX3 inactivation in bladder tumors by, 9347
SWI/SNF chromatin-remodeling factors inducing changes in, 3542
- DNA methyltransferase(s)**
cytosine, genetic disruption of, chromosomal instability induced by, 8635
inhibitor of, small-molecule, 6305
- DNA methyltransferase 3A**
interaction of, with Mbd3 and Brg1 in mouse lymphosarcoma cells, 10891
- DNA methyltransferase-3B (DNMT3B)**
down-regulation of, by histone deacetylase inhibitors, 2684
- DNA methyltransferase 1 (DNMT-1)**
interplay of *RUNX1/MTG8* with, in acute myeloid leukemia, 1277
regulation of, by pRb/E2F1 pathway, 3624
- DNA microarray**
in esophageal carcinogenesis analysis, 401
- DNA polymerase α**
excess of, genetic instability and tumorigenesis and, 325
- DNA repair**
from aflatoxin damage, tissue-specific differences in, 1265
base excision, temozolomide sensitivity and, 6394
cross-link, in vertebrate cells, 11704
inhibition of, by HSV, glioblastoma radiosensitivity and, 5310
lung cancer risk and, 349
mismatch (MMR)
cancer cells deficient in, ATR mutations in, 7091
lack of, predisposing to hematologic malignancy, 2626
- Mlh3* and *Pms2* and, 8662
Mutl homologue hMLH3 in, 10759
in p53-deficient keratinocytes, 8723
- DNA vaccine(s)**
with GD2 ganglioside mimetic peptides, protective GD2 cross-reactive antibody responses induced by, 3410
potency of, enhancing, coadministration with small interfering RNA in, 309
against survivin in lung tumor eradication, 553
targeting Fos-related antigen 1 enhanced by IL-18, memory T-cell response induced by, 3419
xenogeneic, autoimmunity induced by, in mammary cancer inhibition, 1071
- DNMT-1. See DNA methyltransferase 1 (DNMT-1)**
- DOC-2/DAB2 gene**
androgen receptor-mediated signal cascade modulated by, 9906
expression of, in transitional cell carcinoma, 6089
- Docetaxel**
with adriamycin, dosing time-dependent effects of, 8448
antiphosphatidylserine with, antitumor effect of, 4408
selective targeting of cancer cells by, 4401
- Dog breeds**
lymphoproliferative disease phenotypes in, 5654
- Doxorubicin**
apoptosis induced by, in immature testis, 9999
hair follicle-derived blood vessels inhibited by, 2337
nuclear factor- κ B-dependent transcription blocked by, 4273
resistance to, in colon cancer cells, nitric oxide reverting, 516
sensitivity to, CD26/dipeptidyl peptidase IV associated with, 1973
transport and resistance to, ABCB5-mediated, in malignant melanoma, 4320
- DPPIV (dipeptidyl peptidase IV)**
basic fibroblast growth factor signaling pathway blocked by, in prostate cancer, 1325
- Drosophila Eyes Absent Homologue 2 (EYA2)**
in ovarian cancer, 925
- Drosophila model**
furry gene of, *AF4p12* in humans and, 6521
Myc, cell competition, and compensatory proliferation in, 6485
for type 2 MEN and papillary thyroid cancer, RET isoforms in, ZD6474 suppressing, 3538
- Drug(s)**
anticancer
efficacy of, EGFR-targeted immunoliposomes enhancing, 11631
nanoparticle targeting of, 5317
delivery of, convection-enhanced, 6858
metabolic response to, targeted drug development and, 9633
- Drug resistance**
BCRP-mediated, gefitinib reversing, 1541
GRP78 overexpression and, 5785
in multiple myeloma cells, overcoming, FTY720 in, 7478
overcoming, by glycolysis inhibition, 613
- Ductal carcinoma in situ (DCIS)**
COX-2 expression in, p38 regulating, 1792
- Dust**
urban exposure to, gene expression alterations from, 1251
- Dynamin 2**
ionizing radiation-induced adenovirus infection mediated by, 5493
- EIAF/PEA3**
Rho/ROCK pathway activated by, in non-small-cell lung cancer cells, 10776
- EIA gene therapy**
for ovarian cancer, resistance to, Bcl-2 antisense oligonucleotide overcoming, 8406
- E2F**
hypoxia-induced down-regulation of *BRCA1* expression by, 11597
topoisomerase II regulated by, 4067
- E2F1**
activation of, chronic inflammation promoting, 9231
- elevation of, in chemotherapy, 7809
- E3**
engineered, targeted destruction of c-Myc by, 7874
- E5 oncogene**
hyperplasia induced by, EGFR requirements for, 6534
- E7 protein**
of cutaneous HPV8 inducing invasion of keratinocytes, 2216
- Early growth response 1 (Egr1)**
hepatocyte growth factor inducing angiogenic cytokines through, 7071
in p53 regulation *in vivo*, 5133
- Early prostate cancer antigen (EPCA)**
in prostate cancer diagnosis, 4097
- EBAG9. See Estrogen receptor-binding fragment-associated antigen 9 (EBAG9)**
- EBV-associated tumors**
VAI-deleted adenovirus targeting, 1523
- EBV-encoded nuclear antigen 1 (EBNA1)-specific regulatory T cells, 1577**
- E-cadherin**
suppression of, carcinoma progression accelerated by, 1783
- Echinomycin**
HIF-1 DNA-binding activity inhibited by, 9047
- Editorial**
It Is Time for a Human Genome Project, 11229
Message from the Editor-in-Chief, 1
- Editorial Note**
Genetics and Latinos: Proceedings of a National Summit, 2996
- EEF1A translation factor**
increased, in breast cancer, 5599
- Effector pathways**
multiple, for Rac3-mediated transformation, 9883
- EG-1**
cellular proliferation stimulated by, 6159
- EGF. See Epidermal growth factor (EGF)**
- Egr-1. See Early growth response 1 (Egr-1)**
- Elderly. See Geriatric patients**
- ELF**
in colorectal cancer, 4228
- EIF4E survival pathway**
rapamycin activating, 7052
- Embryonal carcinoma**
developmental biology of, 5588
- Embryonal CNS tumors**
c-Met pathway in, 9355
- EMMPRIN (extracellular matrix metalloproteinase inducer)**
in tumor angiogenesis, 3193
- Emodin**
prostate cancer cell growth inhibited by, 2287
- EMP3**
epigenetic inactivation of, in cancer, 2565
- Endocrine therapy**
for recurrent breast cancer, response to, DNA methylation and, 4101
- Endometrial cancer(s)**
microsatellite instability, gene expression profiling of, 5031
PIK3CA and *PTEN* mutations coexisting in, 10669
synergistic anticancer effects of paclitaxel and amifostine on, 9517
tamoxifen-stimulated, trastuzumab therapy for, 8504
targeting of, lysophosphatidic acid acyltransferase- β in, 9415
- Endometrial cells**
DNA methyltransferase activity in, *de novo*, down-regulation of, 2684
- Endometrioid ovarian carcinomas**
HE4 overexpression in, 2162
- Endoplasmic reticulum stress**
bortezomib sensitizing pancreatic cancer cells to, 11658
in pancreatic cancer cells, bortezomib inducing apoptosis via, 11510
selenium and, 9073
- Endorepellin**
as angiogenesis inhibitor, 3967
- Endostatin**
as angiogenesis inhibitor, 3967

- antitumor activity of, 3656
therapeutic efficacy of, biphasic dose-response curve for, 11044
- Endothelial cells**
apoptosis of, krigle 5 inducing, through GRP78, 4663
calcitonin acting on, angiogenesis stimulated by, 8519
canstatin acting on, efficacy of, 4353
cultured, mitogenic activity of angiotensin I for, 6820
delta-like 4 ligand function in, 8690
microtubule dynamics in, increased, antiangiogenic concentrations of paclitaxel inducing, 2433
microvessel, G_i arrest in, anastellin causing, 148
sprouting of, electrostatic signaling of, 11529
transformation of, by Kaposi's sarcoma-associated herpesvirus, 5084
- tumor**
chromosome and centrosome abnormalities in, 2507
vascular
integrin $\alpha_5\beta_1$ overexpression on, 2712
mosaic structure of, 5740
tumor-associated, IL-8 regulating, 10347
vascular, measles virus targeting, 5292
- Endothelial-derived gene 1 (EG-1)**
cellular proliferation stimulated by, 6159
- Endothelial precursor cells**
pericytes and, 9741
- Endothelin-1**
down-regulation of, *RhoGDI2* suppressing metastasis by, 7320
epithelial-mesenchymal transition promoted by, in ovarian cancer cells, 11649
survival effects of, 4292
- Energy**
cellular, anabolic activity and, 2441
- Environment**
low-oxygen, tumor cell toxicity caused by, anoxia for, 3171
- Environmental pollution**
3-nitrobenzanthrone in, activation of, by human NQO1, 2644
- Enzastaurin**
human tumor xenograft growth suppressed by, 7462
- Enzymes**
glycolytic, cellular life span and, 177
- EOC (epithelial ovarian carcinomas)**
HE4 overexpression in, 2162
- EP2**
COX-2-mediated mammary hyperplasia and, 4496
- EPCA (early prostate cancer antigen)**
in prostate cancer diagnosis, 4097
- EphA2**
gene therapy targeting, *in vivo* siRNA-mediated, 6910
- EphA3**
tumor-targeting reagents specific for, 6745
- EphB2**
inactivation of, in colorectal tumors, mechanisms of, 10170
- EphB4**
in prostate cancer, expression of, 4623
- Ephrin-A5**
and anti-EphA3 antibody, concurrent binding of, amplifying EphA3 signaling, 6745
- Epidermal growth factor (EGF)**
chemotaxis induced by, PKC ζ in, 1433
colony-stimulating factor-1 paracrine loop with, breast cancer invasiveness and, 5278
gene regulation in breast cancer induced by, 6120
proforms of, cytoplasmic domain of, in thyroid cancer, 1343
signaling by, steroid receptor regulation of, 10585
- Epidermal growth factor receptor (EGFR)**
auto-oxidation of (-)-epigallocatechin-3-gallate inactivating, 8049
blockade of, chemosensitizing breast cancer cells through Bnip3L up-regulation, 8151
COX-2 in oral mucosa of smokers and, 664
down-regulation of, cortactin overexpression inhibiting, 3273
- dynamics of, influencing response to EGFR targeted agents, 3003
genetic heterogeneity of, in lung cancers, 7276
immunoliposomes targeting, enhancing efficacy *in vivo*, 11631
inhibition of
in chemoprevention of UV light-induced skin tumorigenesis, 3958
enhanced radiation response following, 3328
in follicular thyroid cancer bone metastasis, 4716
in HIF-2-dependent renal cancer prevention, 5221
for pancreatic cancer, 10371
sensitivity of NSCLC to, epithelial-mesenchymal transition as determinant of, 9455
inhibitors of, in lung cancer, 226
leptin transactivating, JAK2 and ERK1/2 activation in gastric cancer and, 9159
mutant, in non-small cell lung cancer sensitivity to geldanamycins, 6401
mutations of
cancer-derived, signaling in, Ba/F3 cells trans formed by, 8968
gefitinib resistance caused by, overcoming, 7096
in lung cancer, 7525
neuroblastoma proliferation mediated by, 9868
prognostic value of, in breast cancer, 338
regulation of, single nucleotide polymorphisms in, 46
requirement of, for E5-induced hyperplasia, 6534
serum concentrations of, in letrozole-treated meta-static breast cancer patients, 3059
signaling by, ABCG2 protecting, 1770
synergy of, with ErbB2 TKIs in colon cancer cells, 5848
targeting estrogen receptor and, for non-small cell lung cancer, 1459
truncated, ovarian cancer suppression with, 3243
- Epidermal growth factor receptor 2 (EGFR2)**
coexpression of, with HER2, survivin expression regulated by, 11018
- Epidermal growth factor receptor (EGFR) tyrosine kinase domain**
mutations of, in lung cancer, 7568
- Epidermal growth factor receptor-related protein (ERRP)**
pancreatic cancer growth inhibited by, 3877
- Epidermal growth factor receptor variant III (EGFRvIII)**
integrin α_5 down-regulated by, aberrant cell spreading and focal adhesion formation induced by, 9280
- (-)-Epigallocatechin-3-gallate**
auto-oxidation of, inactivating EGFR, 8049
intestinal tumorigenesis inhibited by, 10623
- Epigenetic modeling**
of origins of multidrug-resistant cells in sarcoma cell line, 9388
- Epigenetic modifier**
of intestinal tumor risk, loss of imprinting of *IGF2* as, 11236
- Epigenetics, 1117**
in CCR7 and CXCR4 up-regulation in melanoma cells, 1800
in *EMIP3* inactivation in cancer, 2565
in γ -catenin regulation in prostate cancer, 2130
genes silenced in prostate cancer identified by, 4218
in inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in renal cell carcinoma, 4598
in regulation of *WTH3* in drug-resistant breast cancer cells, 10024
in *SLC5A8* silencing in gliomas, 3617
in transdifferentiation of normal melanocytes by metastatic melanoma microenvironment, 10164
in tumor suppressor gene reactivation by small-molecule DNA methyltransferase inhibitor, 6305
- Epimorphism**
overexpression of, in mouse mammary gland, 8617
- Epithelial cells**
breast, motility and morphology of, R-Ras aP'ering, 507
cancer, growth and survival of, SIRT1 enabling, 10457
conversion of, into mesenchymal cell lineages in neoplasia, 5991, 5996
- Snail inducing, 6237
malignant transformation of, galectin-3 phosphorylation and, 10767
- mammary
breast cancer-associated *PIK3CA* mutations oncogenic in, 10992
oncogenic transformation of, human growth hormone and, 317
migration and invasion of, PDEF in, 11572
oral, tobacco smoke stimulating amphiregulin transcription in, 5982
ovarian, claudin-3 and claudin-4 expression in, function of, 7378
papillomavirus-expressing, dihydroartemisinin cytotoxicity to, 10854
proliferation of, asbestos-induced, 9670
prostate
c-Myc immortalizing, 2179
p38 MAPK invasion in, geistin inhibiting, 3470
thymic, CEA expression by, 6443
- Epithelial-mesenchymal signaling**
MMP-7 and, 7363
- Epithelial-mesenchymal transition (EMT)**
in carcinoma invasion and metastasis
Snail inducing, 6237
in carcinoma invasion and metastasis, 5991, 5996
in ovarian cancer cells, endothelin-1 promoting, 11649
sensitivity of NSCLC to EGFR inhibition determined by, 9455
signaling and, 3179
- Epithelial ovarian carcinomas (EOC)**
HE4 overexpression in, 2162
- Epithelial tumor(s)**
in Fanconi anemia, *Trp53* and, 85
p53-Fbxw7/Cdc4 pathway in development of, 6488
therapeutic response in, nanoparticle targeting of anticancer drug improving, 5317
- Epithelioid sarcomas**
SMARCB1 inactivation in, 4012
- EP2 receptor**
in skin tumor development, 9304
- Epstein-Barr virus**
latent membrane protein 1 of, TGF α induced by, 8826
- ErbB**
and their ligands, gefitinib sensitivity and, 11478
- ErbB receptor signaling**
altered, in resistant ovarian cancer, 6789
- ErbB2**
activation of, in breast cancer, neuregulin and, 6801
breast cancer dependent on, antitumor activity of rapamycin in, 5325
overexpression of
in breast cancer, masking of, in JIMT-1, 473
PIK3CA mutations correlated with, in breast cancer, 2554
Src synthesis and stability promoted by, 1858
tumorigenesis driven by, in breast cancer, premature senescence and, 840
- ErbB2 kinase inhibitor**
synergy of, with EGFR in colon cancer cells, 5848
- ErbB3**
expression of, tumor cell radiosensitization induced by Hsp90 inhibition predicting, 6967
- ErbB4**
isoforms of, cleavable, in breast cancer cells, 1384
WW domain-containing proteins interacting with, 6764
- ERG**
in megakaryoblastic leukemias, 7596
- Erk**
activation of, EGFR-independent, 6275
- Erlotinib (Tarceva)**
EGFR inhibition by, enhanced radiation response following, 3328
EGFR up-regulation by, 3003
- ERRP (epidermal growth factor receptor-related protein)**
pancreatic cancer growth inhibited by, 3877
- Erythropoietin α**
recombinant human, with chemotherapy in human xenograft models, 7186

- Escherichia coli ampicillin secretion trap (CAST)**
in breast cancer marker identification, 8209
- Esophageal cancer**
coexpression of cyclooxygenases and vascular endothelial growth factors in, 5038
expression profile of, 7127
failure of TGF- β to degrade SnoN in, 4782
growth inhibition in, EGFR inactivation and, 8049
risk of, STK15 haplotypes associated with, 3548
squamous cell
development of, microarray analysis of, in rat, 401
genome-wide association study in, 2542
PGP.5 promoter methylation in, 4963
risk of, *P53* and *MDM2* polymorphisms and, 9582
- Esophagus**
Barrett's, progression of, to adenocarcinoma, 3146
precancerous rat, gene expression profiling of, 7790
- Estradiol**
activation of, by CYP1A1 allelic variants, 2973
- Estrogen**
activation of, by CYP1A1 allelic variants, 2973
in down-regulation of breast cancer resistance protein/ABCG2, 596
endogenous, cervical cancer cell proliferation and, 11164
receptor for
 α
BRCA1 repression of, cyclin D1 antagonizing, 6557
functions of, LIM domain only 4 protein in regulation of, 10594
breast cancer cell growth regulated by, cleavable ErbB4 isoforms in, 1384
ligands of, in regulation of gene expression in non-small cell lung cancer, 1598
PIK3CA mutations correlated with, in breast cancer, 2554
signaling, selenium disrupting, 3487
targeting epidermal growth factors and, for non-small cell lung cancer, 1459
Tsc mouse liver hemangioma enhanced by, 2474
- Estrogen deprivation**
breast cancer cells adapted to, growth factor receptor pathways in, 3903
- Estrogen receptor-binding fragment-associated antigen 9 (EBAG9)**
as tumor-promoting factor for renal cell carcinoma, 3700
- Estrogen-related receptors**
EGF-induced signaling in breast cancer cells regulated by, 6120
- Estrogen-signaling pathway**
in breast cancer, tumor-stromal interaction through, 4653
- Estrone**
activation of, by CYP1A1 allelic variants, 2973
- Etoposide-induced gene 24/p53-induced genes (E24/PIG8)**
in suppression of breast cancer invasiveness, 2125
- ETS1**
apoptosis induced by, caspase-1 in, 7205
- Eukaryotic elongation factor-2 kinase (eEF-2 kinase)**
stability of, ubiquitination of, 3806
- Eukaryotic translation elongation factor 2 (eEF2)**
phosphorylation of, farnesyltransferase inhibitor inducing, 5841
- Ewing's family of tumors**
neural phenotype of, EWS-FLI1 expression and, 4633
- Ewing's sarcoma**
development of, from primary bone marrow-derived mesenchymal progenitor cells, 11459
EWS/FLI-1-dependent, murine, 8698
metastatic, tumor growth in, EWS-FLI1 siRNA inhibiting, 8984
NVP-AEW541 activity against, 3868
tumor cell plasticity in, 11520
- Ewing's sarcoma family tumor cells (ESFT)**
roscovetine-induced apoptosis in, 9320
- EWS-FLI1**
expression of, neural phenotype of Ewing's family of tumors and, 4633
knockdown of, by siRNA, metastatic Ewing's sarcoma tumor growth inhibited by, 8984
- Excitatory amino acid transporter-2 (EAAT-2)**
glioma proliferation controlled by, 1934
- Exonuclease 1b**
human, degradation of, DNA synthesis inhibition and, 3604
- Expression array analysis**
of acquired gemcitabine resistance, chromosomal aberrations and, 10208
- Extracellular matrix metalloproteinase inducer (EMMPRIN)**
in tumor angiogenesis, 3193
- Extracellular signal-regulated kinase (ERK)**
antibody suppression of, 650
farnesyl transferase inhibitor-induced STAT3 inhibition for pancreatic cancer with, 2861
papillomavirus E2 regulating MMP-9 through, 11613
- Extracellular signal-regulated kinase 1/2 (ERK1/2)**
activation of, leptin-induced, in gastric cancer, 9159
in AGS resistance to DADS, 11735
- Extracellular signal-regulated kinase 5 (ERK5)**
in medulloblastoma cell death, 5683
- Extravascular fluid transport**
of macromolecules, MRI of, 1425
- EYA2 (Drosophila Eyes Absent Homologue 2)**
in ovarian cancer, 925
- Ezrin**
metastatic behavior in osteosarcoma mediated by, rapamycin inhibiting, 2406
- FA. See Fanconi anemia (FA)**
- FAK. See Focal adhesion kinase (FAK)**
- Familial medullary thyroid cancer (FMT)**
STAT3 activation in, by RET, 1729
- Familial pheochromocytoma syndrome**
novel susceptibility loci for, 9651
- Familial risk**
of nasopharyngeal carcinoma, 8567
- Fanconi anemia (FA)**
generation of head and neck squamous cell carcinoma cell lines in, 1271
mammary adenocarcinoma in, *Trp53* and, 85
- Fanconi anemia complementation group C mutations**
pancreatic cancer and, 383
- FAP (fibroblast activation protein)**
tumor immunotherapy targeting, 11156
- Farnesyltransferase inhibitors (FTIs)**
antineoplastic mechanisms of, 9109
eukaryotic translation elongation factor 2 phosphorylation induced by, 5841
pancreatic cancer radiosensitivity and, 8433
reactive oxygen species-mediated DNA damage induced by, 3671
STAT3 targeted by, 2861
- Fas**
apoptosis dependent on, sensitization of glioma cells to, by chemotherapy-induced oxidative stress, 5248
apoptosis mediated by
of androgen-sensitive prostate cancer cells, Lupeol inducing, 11203
in colorectal cancer, p53 status and STAT1 and, 8951
loss of, accelerating *Helicobacter*-induced gastric cancer, 10912
cytotoxicity mediated by, immunoselection resulting from, 4376
with intercellular adhesion molecule-1 in tumor progression, 1045
- Fas ligand**
in tumor immune evasion in colon cancer, 9817
- Fas signaling**
MDA-7/IL-24-mediated, in ovarian cancer cell death, 3017
- Fastatin**
in tumor angiogenesis regulation, 4153
- Fatty acids**
 ω -3 polyunsaturated, syndecan-1 expression in breast cancer cells regulated by, 4442
- FBXO31**
as breast tumor suppressor candidate, 11304
- FdUMP[10]**
thymineless death induced by, 4844
- Fenretinide**
apoptosis induced by, genes involved in, parthenolide and, 2804
inducing apoptosis in meningioma, 1547
- Fetal hormone levels**
cancer risk and, 358
- Fetuin-A**
Lewis lung carcinoma tumorigenesis promoted by, 499
- FEZ1/LZTS1 gene**
reduced expression of, outcome prediction in lung cancer and, 1207
- FHIT**
on chromosome 3p, genetic linkage of, to prostate cancer risk, 805
- Fibroblast(s)**
clustering of, hepatocyte growth factor/scatter factor induced by, tumor cell invasiveness and, 9914
cross-talk of, with melanoma, gene expression profiling revealing, 4134
dermal, transformation of, mitochondrial activity inducing, 4282
metabolic phenotypes in, K-ras codon-specific mutations producing, 5512
mouse embryonic, DNA-PKcs-deficient, postreplicative joining of DSBs in, 10223
neoplastic transformation of, 11411
nitric oxide-induced apoptosis in, 6097
normal, thrombospondin-1 down-regulation in, 8878
up-regulation of CXCL chemokines in, by low dose ionizing radiation, 10159
UVB-induced response of, transcription-coupled repair in, 432
- Fibroblast activation protein (FAP)**
tumor immunotherapy targeting, 11156
- Fibroblast growth factor**
basic, signaling, dipeptidyl peptidase IV blocking, in prostate cancer, 1325
- Fibroblast growth factor 2 (FGF2)**
binding of, to CD44, laminin peptide blocking, 10494
- Fibroblast growth factor receptor 3 (FGFR3)**
expression of, in normal and tumor-derived urothelium, 10441
- Fibrosarcoma(s)**
cells in, intravasation and metastasis of, MMP down-regulation and, 10959
effect of cisplatin on, monitoring of, 4202
glucose consumption in, heterogeneity of, 5163
lung metastasis from, cystatin C overexpression in host reducing, 8608
tumorigenic activity of, syndecan-2-mediated, focal adhesion kinase regulating, 9899
- Fibulins**
as angiogenesis inhibitor, 3967
- FIP200**
cell cycle regulation by, in breast cancer cells, mechanism of, 6676
- Flavokawain A**
in apoptosis induction, 3479
- FLT3 gene**
antibodies against, in AML therapy, 1514
internal tandem duplications in, in constitutive Akt activation in AML, 9643
- FLT3 internal tandem duplication mutation**
in apoptosis prevention via PKA and RSK1, 7338
- Fludolone**
for tumor xenografts, 9445
- Fluorescence imaging**
of adenovirus replication, 10154
whole-body, on pancreatic cancer, MRI compared with, 9892
- Fluorescence lifetime imaging (FLIM)**
multiphoton, metabolic mapping of breast cells via, 8766
- Fluorescence-mediated tomographic (FMT) mapping**
of tumor targets, 6330
- [¹⁸F]fluorothymidine-positron emission tomography imaging**
of proliferation in breast cancer, 10104
- 5-Fluorouracil (5-FU)**
resistance to

- in colon cancer, decreased ATP synthase in, 3162
CRAd for biliary tract cancers and, 546
sensitivity to, enhancement of, by rTS signaling, 5917
- Focal adhesion kinase (FAK)**
aggressive melanoma phenotype promoted by, 9851
in malignant transformation, STAT3 mediating maintenance of, 5828
in mammary adenocarcinoma lung metastasis formation, 4698
Src-dependent phosphorylation of, in colon cancer, 1335
tumorigenic activity of syndecan-2 in fibrosarcoma regulated by, 9899
- Folate**
intake of, breast cancer risk and, 1606
- Folate receptor α (FR- α)**
BGC 945 targeted to, 11721
expression of, enhanced, in tumor cells, 4431
- Formalin-fixed, paraffin-embedded (FFPE) tumors**
LOH detection in, with SNP arrays, 10188
- Fos-related antigen 1 enhanced by IL-18**
DNA vaccine targeting, memory T-cell response induced by, 3419
- FoxM1**
loss of, centrosome amplification and mitotic catastrophe from, 5181
- Fps/fes**
tumor suppressor role of, 3518
- Fragile histidine triad (FHIT) gene**
in homologous recombination cell repair, CHK1 opposing, 8613
- Frequently deleted in liver cancer (DLC1)**
in hepatocellular carcinoma, functional characteristics of, 8861
- Frizzled-related protein 3, Frzb/secreted (sFRP3)**
prostate cancer and, 9762
- FTY720**
anti-multiple myeloma activity of, 7478
- 5-FU. See 5-Fluorouracil (5-FU)**
- Fulvestrant**
with gefitinib for non-small cell lung cancer, 1459
and letrozole, additive antitumor effect of, 5439
- Functional idiotype, 6002**
- Functional profiling**
in discerning cancer relevant modulators of cell cycle, 7733
- Furin**
cancer cell growth inhibition mediated by, 4162
- Fusion protein complementation imaging, 7413**
- Fusion protein vaccine**
by domains of bacterial exotoxin, 9089
- Fusokine interleukin-2/interleukin-18 as immune stimulator, 9536**
- IGF8**
tumor growth inhibited by, 9495
- G₂**
checkpoint abrogation in, radiosensitivity in ataxia telangiectasia and, 11292
- G₂ arrest**
CNDAC-induced, checkpoint abrogation and, 6874
- GABA (γ -aminobutyric acid)**
cholangiocarcinoma growth regulated by, 11437
- β -Galactoside binding protein (β GBP)**
in circumventing multidrug resistance, 1631
- α (1,3)-Galactosyl isotypes**
vaccines expressing, for melanoma, 10555
- Galectin-3**
expression of, in pituitary tumors, DNA methylation and, 1136
K-Ras activated by, in breast cancer cells, 7292
phosphorylation of, malignant transformation and, 10767
TRAIL-induced apoptosis inhibited by, 7546
in Wnt signaling, 3535
- Galectin-7**
in T cell lymphoma, 5205
- Gangliosides**
glioblastomas inducing T-lymphocyte death by, 5428
- Gastric cancer**
CASPASE-8 mutation in, 815
expression profile of, 7127
- Helicobacter pylori-induced, loss of Fas-mediated apoptosis accelerating, 10912**
- hypomethylation of R-RAS gene in, 2115**
- Krüppel-like factor 4 expression in, 2746**
- leptin-induced JAK2 and ERK1/2 activation in, 9159**
- loss of RUNX3 expression and, 4809**
- in mice, MNU-induced, peroxisome proliferator-activated receptor γ and, 4769**
- p21/CIP1 in, sonic hedgehog-Gli1 signaling regulating, 10822**
- RUNX3 inactivation in, 7743**
- Gastric intraepithelial neoplasia**
Helicobacter pylori inducing, in mice, 10709
- Gastric tumors**
hyperplastic
TNF- α -dependent inflammation causing, 9147
- Gastrin**
precursors of
mice overexpressing, colonic hyperproliferation in, 2770
- Gastrointestinal tract**
cancer of
Sd⁺ carbohydrate expression in, metastasis inhibited by, 6220
stromal tumor of, mouse model of, 6631
upper, cancer of, *Darpp-32* in, 6583
- GATA6**
DOC-2/DAB2 gene regulation in bladder cancer in presence of, 6089
- GATA binding protein 3 (GATA3)**
as breast cancer prognostic marker, 11259
- Gax gene**
angiogenesis and nuclear factor- κ B inhibited by, 1414
- GBM. See Glioblastoma multiforme (GBM)**
- GD2 ganglioside mimotope**
DNA vaccine expressing, protective GD2 cross-reactive antibody responses induced by, 3410
- Gefitinib (Iressa)**
cellular targets of, 379
cytotoxic effect of, prevention of, ABCG2 in, 1770
with fulvestrant for non-small cell lung cancer, 1459
multidrug resistant cancer cell resistance reversed by, 6943
poor response to, predictors of, 9176
resistance to
in bladder cancer cells, 10524
CL-387,785 overcoming, 7096
reversing BCRP-mediated drug resistance, 1541
sensitivity to
ErbB and their ligands in, 11478
HER2 overexpression and, 4253
- Gelatinase**
inhibitor of, antimetastatic activity of, 3523
- Geldanamycin**
sensitivity of lung cancer to, mutant EGFRs and, 6401
- Gemcitabine**
in combined therapy of pancreatic therapy, 10371
for pancreatic cancer, gemistein potentiating, 9064
premature mitosis in response to, checkpoint kinase 1 in prevention of, 6835
resistance to
acquired, chromosomal aberrations and, 10208
ribonucleotide reductase and, 9510
therapeutic synergism of, with CpG-oligodeoxynucleotides in orthotopic human pancreatic carcinoma xenograft, 6388
- Gemistein**
gemcitabine potentiated by, for pancreatic cancer, 9064
- Gene(s)**
activation of, differential, by HIF-1 α and HIF-2 α , 3299
associated with breast cancer metastasis, xenograft model of, 5578
cancer-relevant, functional profiling in identification of, 7733
cancer-testis, CTCF/BORIS binding sites regulating, 7751
conferring cisplatin resistance, identification of, 5890
imprinted, inactivation of, stress and tumorigenesis in, 26
RAB6KIFL and DLG5, pancreatic cancer and, 105
- resequencing of, in study of aromatase, 11071
- SDHC, mutated, in mice, apoptosis and tumorigenesis and, 203**
- silenced**
in prostate cancer, epigenetic identification of, 4218
restoring expression of, halogenated thymidines in, 6927
tumor suppressor, *RASSF1A* as, 92
- Gene amplification**
Six1, overexpression and, in breast cancer, 2668
- Gene-directed enzyme prodrug therapy, systemic of hepatocellular carcinoma, 5003**
- Gene expression**
adenovirus *E1a* and *E4*, PSES enhancer controlling, in prostate cancer therapy, 1941
alterations in
CaSm-mediated cellular transformation associated with, 6228
from urban dust exposure, 1251
autocrine PDGF-dependent, in glioblastoma cells, 5523
BRMS1-regulated, nuclear factor- κ B in, 3586
in cancer cells
real-time detection of, using molecular beacon imaging, 1909
wavelet transforms and, 186
classifier of, radiation sensitivity prediction using, 7169
endogenous, regulation of, in non-small cell lung cancer, 1598
in fetal mouse intestine development overlapping with colorectal cancer, 8715
Hox, MLL-ENL, induced, in maintaining hematopoietic progenitor cell immortalization, 9245
in melanoma, effects of IFN- γ on, 8869
microRNA, in breast cancer, 7065
in pancreatic intraepithelial neoplasia, 1619
radiation-induced changes in, orthotopic growth of glioma cells and, 10389
in sarcomas, hypoxia-related, RNA interference of vascular endothelial cell growth factor A in, 5881
as signature for primary Wilms tumor relapse, 2592
STAT3 driving, 939
- Gene expression profiling**
array-based, in identifying glioblastoma subtypes, 1678
BAX- δ identified by, as novel leukemia tumor antigen, 10050
in cancer diagnosis and prognosis, 4031
of colon cancer, gene expression signature in, 9200
of esophageal and gastric lesions, 7127
glioblastoma survival and, 4051
global, of circulating tumor cells, 4993
of human clinically nonfunctional pituitary adenomas, 10214
of human embryonal carcinomas, 5588
of human sarcomas, 9226
of lung cancer, 3063
melanoma-fibroblast cross-talk revealed by, 4134
of microsatellite instability endometrial cancers, 5031
molecular subtypes of inflammatory breast cancer identified by, 2170
of oligodendrogliomas, treatment response and, 11335
of osteosarcoma in chemotherapy response prediction, 8142
of papillary thyroid cancer, 1587
of precancerous rat esophagus, 7790
of serous ovarian tumors, 10602
- Gene mapping**
susceptibility, in prostate cancer, 2610
- Gene polymorphism(s)**
asthma-associated, glioblastoma and, 6459
CDX2, colorectal cancer risk and, 5488
in cellular adhesion molecules, benzene exposure and, 9475
in cytochrome P450 7A1, colorectal cancer risk and, 2979
in cytokines, benzene exposure and, 9574
G691S RET, pancreatic cancer and, 11536
in *MDM2* gene, single nucleotide, 5481
in oxidative stress mechanism, survival after breast cancer and, 1105

- single nucleotide, in STK15, esophageal cancer risk increased by, 3548
- in *VEGF* gene, association of, with breast cancer survival, 5015
- vitamin D receptor, sun exposure and, advanced prostate cancer risk and, 5470
- Generators**
targeted *in vivo*, errant products of, control of, 4888
- Gene therapy**
of biliary tract cancers, 546
ELA, resistance to, Bcl-2 antisense oligonucleotide overcoming, 8406
of glioma, cytotoxic, with immunostimulation, 7194
intrapulmonary IFN- β , with adenoviral vector for orthotopic lung cancer model, 8379
of prostate cancer, PSES enhancer in, 1941
synthetic vector system for, 8079
virus-based, in solid tumors, novel delivery method for, 7541
- Genetic events**
in tumorigenesis induction, 9892
- Genetic heterogeneity**
of EGFR in lung cancers, 7276
- Genetic instability**
in colon cancer, gene expression signature of, 9200
DNA polymerase α excess and, 325
in premalignant clones, 1234
- Genetic markers**
in glioblastoma survival, gene expression profiling and, 4051
- Genetic modeling**
of origins of multidrug-resistant cells in sarcoma cell line, 9388
of rhabdomyosarcoma, 4490
alveolar, new tactics in, 7530
- Genetic regulation**
of γ -catenin in prostate cancer, 2130
- Genetic signature**
of STAT3 in tumors, 5054
- Genetic variants**
clinical significance of, 10096
- Gene transfer vectors**
in intracellular toxin delivery, 254
- Genistein**
cancer cells sensitized to chemotherapy by, 6934
dietary, in postsurgical metastasis reduction, 3396
MDM2 inhibited by, 8200
p38 MAPK cell invasion in prostate inhibited by, 3470
- Genital cancers**
HPV, mechanisms of amplification in, 1174
- Genome**
defective, destruction of, C19ORF5 mediating, 4191
- Genome research**
dissecting cancer through, 8587
- Genome-wide association study**
in esophageal cancer, 2542
- Genome-wide mapping**
high-resolution, of genetic alterations in glial brain tumors, 4088
single nucleotide polymorphism microarray, unveiling uniparental disomy in basal cell carcinoma
- Genomic amplification**
of *Orthodenticle* homologue 2 in medulloblastomas, 703
- Genomic analysis**
of disease-perturbed networks in prostate cancer cells, 3081
identifying *NDRG2* in aggressive meningiomas, 7121
of lung cancer with SNP arrays, 5561
novel pheochromocytoma susceptibility loci identified by, 9651
- Genomic homozygosity**
germ cell tumor development and, 9137
- Genomic hybridization, comparative**
comprehensive DNA copy number profiling of meningiomas using, 2653
of hereditary breast cancer, 7612
in identifying cyclin D1 as target oncogene in nasopharyngeal cancer, 8125
profiles from, in BRCA1- and BRCA2-related breast cancer, 822
- Genomic imbalances**
in breast cancer, 439
- Genomic profiling**
of hereditary breast cancer, 7612
- Genotoxicity**
of arsenic, mitochondria and, 3236
high mobility group A2 potentiating, 6622
- Geriatric patients**
prostate cancer in, susceptibility gene mapping and, 2610
- Germ cell tumor**
nonseminomatous, development of, genomic homozygosity and, 9137
- Ginseng**
metabolite of, apoptosis mediated by, COX-2 inhibiting, 1952
- Gleevec. See Imatinib mesylate (Gleevec)**
- Glioblastoma**
autocrine PDGF-dependent genes in, 5523
Lyn kinase activity in, elevated, 5535
microRNA-21 as antiapoptotic factor in, 6029
molecular subtypes of, DNA and RNA alterations in, 1678
radiosensitivity of, DNA repair inhibited by HSV and, 5310
survival of, gene expression profiling and, 4051
tissue factor regulation in, hypoxia and PTEN in, 1406
xenografts of, growth of, enzastaurin suppressing, 7462
- Glioblastoma multiforme (GBM)**
aberrant Stat3 activation in, 2956
asthma polymorphisms and, 6459
cell death in, Ras inhibition inducing, 999
decitabine and TRAIL for, 11469
Ras signaling in, 8250
T-cell apoptosis induced by, 5428
- Glioma(s)**
aberrant Stat3 activation in, 2956
activity of myxoma virus against, 9982
alternative splicing of *Ilp45* in, 3562
autophagy in, DNA-PK inhibition inducing, 4368
bone marrow-derived mesenchymal stem cells for, 3307
cells in
apoptosis and survival of, protein kinase C- ϵ regulating, 7301
human, motility of, hyaluronic acid induction of osteopontin enhancing, 686
orthotopic growth of, radiation-induced changes in gene expression influenced by, 10389
sensitization of, to Fas-dependent apoptosis by chemotherapy-induced oxidative stress, 5248
survival and proliferation of, Notch-1, Delta-like-1 and Jagged-1 in, 2353
development of, *Ink4a* and *Arf* in, 2065
EMP3 epigenetic inactivation in, 2565
formation of, in neurofibromatosis 1, K-RAS activation and, 236
genetic alterations in, high-resolution genome-wide mapping of, 4088
growth of
excitatory amino acid transporter-2 decreasing, 1934
tumor necrosis factor reducing, 3928
malignant
TIMP-3 expression from oncolytic adenovirus in, 9398
tumor-specific isoforms of BEHAB/brevican identified in, 6726
membrane transporters in, 11419
migration of, CD155/PVR enhancing, 10930
model of, macroscopic, long-term survival in, 7194
murine, angiogenesis in, thrombospondin-2 inhibiting, 9338
network analysis in, 8679
neurofibromatosis 1-associated, dysregulation of methionine aminopeptidase-2 expression in, 9843
oncolytic viruses for, 6850
nestin-driven, 2832
prognosis of, cathepsin D as serum marker for, 5190
proteomic-based prognosis of, 7674
rapamycin-induced autophagy in, synergistic augmentation of, 3336
SLC5A8 silencing in, 3617
- synergistic cytotoxicity of temozolomide and IFN- β on, 7573
therapy of, perifosine and temozolomide in, 7429
- Glucocorticoid receptor gene**
mutations of, in childhood ALL, 9712
- Glucocorticoid receptor (GR)**
folate receptor α expression up-regulated by, in tumor cells, 4431
- Glucose**
consumption of, in solid tumors, 5163
- Glucosephosphate isomerase**
cellular life span and, 177
- Glucose-regulated protein 78 (GRP78)**
kringle 5 inducing apoptosis through, 4663
- Glucose-regulated protein 94/gp96**
immunogene therapy based on, radiation therapy and, 9126
- Glutathione**
in AGS resistance to DADS, 11735
metabolism of, in tumors, imaging of, 10149
- Glutathione S-transferase inhibitors**
new, proapoptotic activity of, 3751
- Glutathione S-transferase M3 promoter**
single nucleotide polymorphism in, allele-specific chromatin immunoprecipitation and, 99
- Glutathione S-transferase π 1**
tumorigenicity in HCT116 colon cancer cells promoted by, 9485
- 4-(N-(S-glutathionylacetyl)amino)phenylarsenozide**
in angiogenesis inhibition, 11729
- Glycoform engineering**
improving effector functions of IG3N11 by, 7934
- Glycogen synthase kinase 3 β (GSK-3 β)**
 β -catenin degraded by, MUC1 blocking, 10413
inactivation of, promoting p53-dependent apoptosis in colorectal cancer, 9012
kinase-inactive, in mammary tumorigenesis, 5792
in pancreatic cell survival regulation, 2076
in rapamycin-mediated cell cycle regulation and chemosensitivity, 1961
- Glycolysis**
in cancer cells, inhibition of, 613
- Glycolytic enzymes**
cellular life span and, 177
- P-Glycoprotein**
CD44 receptor interacting with, cell invasion and, 6660
down-regulation of, multidrug resistance and, 3861
inhibitors of, brain penetration of imatinib and, 2577
- Glycosylation**
of gp96, prostate cancer prevention and, 6466
RECK-mediated suppression of tumor cell invasion regulated by, 7455
- Gly482 mutation**
ABCG2 harboring, antifolate resistance and, 8414
- Glypican-3**
hepatocellular carcinoma growth promoted by, 6245
as hepatocellular carcinoma serum marker, 372
- G₂-M checkpoint**
less efficient, increased lung cancer risk in African Americans and, 9566
- GM-CSF. See Granulocyte macrophage colony-stimulating factor (GM-CSF)**
- Gold(III) porphyrin 1a**
action of, on mitochondria, 11553
- gp96**
glycosylation of, prostate cancer prevention and, 6466
- GPR54**
kisspeptin-10-induced signaling of, CXCR4 negatively regulated by, 10450
- G-Quadruplex ligand**
in vivo anticancer activity of, 1489
- Graft-versus-leukemia (GVL)**
pretransplant effects of, 9735
- Granulocyte macrophage colony-stimulating factor (GM-CSF)**
monoclonal anti-idiotypic antibody 6G6.C4 fused to, anti-CEA response and, 1925
tumor vaccines secreting, IFN- α augmenting, 2449
- Granulocyte macrophage colony-stimulating factor tumor cell vaccine**

- CD8⁺ T-cell responses to renal cell carcinoma antigens and, 1079
- Granulosa cell tumorigenesis**
genetic control of, 1259
- Green tea catechins**
antifolate activity of, 2059
intestinal tumorigenesis inhibited by, 10623
- GRN163L**
lung cancer inhibited by, *in vivo*, 7866
- Growth factor**
epidermal (See **Epidermal growth factor (EGF)**)
- Growth factor receptor pathways**
in breast cancer cells adapted to long-term estrogen deprivation, 3903
- Growth hormone**
human, as oncogene in breast cancer, 317
- GRP78**
overexpression of, drug resistance and, 5785
- G₁-S arrest**
phenoxodiol inducing, 3364
- GSK-3 β** . See **Glycogen synthase kinase-3 β (GSK-3 β)**
- Guanosine 3',4'-monophosphate, cyclic**
interruption of homologous desensitization in, restoring colon cancer cystostasis, 11129
- GVL (graft-versus-leukemia)**
pretransplant effects of, 9735
- Gynecologic cancer**
targeting of lysophosphatidic acid acyltransferase- β in, 9415
- Halogenated thymidines**
as antisilencing agents, 6927
- Haploinsufficiency**
for ATM and RAD9, 933
of *Atp2a2*, cancer and, 8655
functional, PP2A A α -induced, 8183
for *Vhl*, lung cancer susceptibility and, 6576
- Haplotype loss of HLA class I antigen**
in lung cancer, 5945
- HBDLTF1**
targeting tumor angiogenic microenvironment, 11109
- HCC**. See **Hepatocellular carcinoma (HCC)**
- HIDACIs**. See **Histone deacetylase inhibitors (HDACIs)**
- HDM2**
stabilization of, aberrantly spliced form of HDMX in, 9687
- HDMX**
aberrantly spliced form of, 9687
- Head and neck squamous cell carcinoma (HNSCC)**
cell line in, generation of, in Fanconi anemia patients, 1271
cE2 phosphorylation in, farnesyltransferase inhibitor inducing, 5841
hepatocyte growth factor inducing angiogenic cytokines through Egr-1 in, 7071
HPV-specific T cells in, 11146
metastasis of, novel markers of, 2147
rapamycin for, antitumor activity of, 9953
transcriptome analysis of, 1693
- Headpin**
in angiogenesis suppression, 11501
- Heart**
disease of, radiation-induced, mast cells and, 3100
radiation damage to, early radiation-induced lung function loss from, 6509
- Heat shock proteins (HSPs)**
gp96, glycosylation of, prostate cancer prevention and, 6466
- HSP27**
expression of, in breast cancer, Bm-3b transactivating, 3072
increased, after androgen ablation facilitating androgen-independent prostate cancer progression, 11083
- HSP70**
adjuvant, DC-NK crosstalk and, 7942
induction of, by HSP 90 inhibitors, 10536
tumor exosomes positive for, natural killer cells activated by, 5238
upregulation of, by Δ Np63 α in human cancer, 758
HSP70-like protein 1 fusion protein, CEA-specific CD8⁺ CTL response enhanced by, 4947
- HSP90**
inhibition of
17-AAG hydroquinone in, 10006
radiosensitization induced by, ErbB3 preventing, 6967
inhibitors of
bimodal effects of, on HIF system, 11094
HSP70 induction by, 10536
HSP90 client protein, activated B-RAF as, 10686
HSP96, in colorectal cancer therapy, natural killer activity in, 3942
photodynamic therapy and, 1018
- Hedgehog signaling**
effects of, on pancreatic ductal epithelial cells, 1619
GLI in prostate cancer, 2990
sonic
glioma-associated oncogene 1 pathway of, regulating p21/CIP1 in gastric carcinoma cells, 10822
small-molecule inhibitors of, for medulloblastoma, 4975
- HE4 (human epididymis protein 4)**
overexpression of, in ovarian cancer, 2162
- HEK293T cells**
differential gene activation by HIF-1 α and HIF-2 α in, 3299
- HeLa cells**
proliferation of, angiogenin in, 1352
- Helicobacter pylori**
gastric cancer induced by, loss of Fas-mediated apoptosis accelerating, 10912
gastric intraepithelial neoplasia induced by, in mice, 10709
- Hemangioblastoma**
stromal cell-derived factor-1 α and CXCR4 expression in, 6178
- Hemangioma**
Tsc mouse liver, estrogen and tamoxifen in, 2474
- Hematologic malignancy**
lack of DNA mismatch repair predisposing to, 2626
- Hematopoiesis**
multiple domains of AME disrupting, 7603
suppression of, in myelodysplastic syndromes, p38 MAPK and, 9029
- Hematopoietic cells**
Raf-transformed, treatment of, *in vivo* model of, 9962
- Hematopoietic progenitor cells**
immortalization of, MLL-ENL induced Hox gene expression in maintaining, 9245
- Hematopoietic stem cells (HSCs)**
cytokine-induced expansion of, valproic acid enhancing, 1505
proliferation of, valproic acid stimulating, 2637
- Heme oxygenase-1**
synthetic triterpenoids activating, 4789
- Hemopoietic cells**
malignant, killing of, by targeted peptide, 2373
- Hemostasis**
in early cancer development, 8579
- Hemotoxicity**
benzene exposure and, 9574
- HEN2**
LOM3 interacting with, in neuroblastoma, 4587
- Heparanase**
expression of, by breast tumors, bone resorption promoted by, 5778
- Heparin-binding epidermal growth factor-like growth factor**
oxidative stress and, 8242
- Hepatic cytosols**
3-nitrobenzanthrone activated by, 2644
- Hepatitis C virus core protein**
PML function suppressed by, in hepatoma cells, 10830
- Hepatocellular carcinoma (HCC)**
anoikis in, peroxisome proliferator-activated receptor γ inhibition causing, 2251
brain-derived neurotrophic factor in, 219
DLCL1 in, functional characteristics of, 8861
drug resistance of, virotherapy overcoming, 7393
growth of
glypican-3 promoting, 6245
PTK787/ZZK222584 inhibiting, 3691
siRNA inhibiting, 6843
metastasis of, siRNA inhibiting, 6843
rat, CEACAM1⁺-4L suppressing, 11010
reduced susceptibility to, in knock-in of C/EBP α , 10330
regulatory T cells in, 2457
serum marker for, glypican-3 as, 372
systemic gene-directed enzyme prodrug therapy of, 5003
- Hepatocyte growth factor activator inhibitor type 2/SPINT2**
epigenetic inactivation of, in renal cell carcinoma, 4598
- Hepatocyte growth factor/scatter factor**
angiogenic cytokines induced by, through Egr-1, 7071
induction of, by fibroblast clustering, tumor cell invasiveness and, 9914
- Hepatoma cells**
fenretinide-induced apoptosis in, 2804
hepatitis C virus core protein suppressing PML function in, 10830
sodium valproate-treated, natural killer cell lysis of, 6321
- HER2 gene**
coexpression of, with EGFR, survivin expression regulated by, 11018
overexpression of
BHAP targeting, mitochondria and, 6891
breast cancer prognosis and, 907
in HIF activation, 3257
sensitivity to gefitinib increased by, 4253
somatic mutations of, in lung adenocarcinoma, 1642
- HER2/neu**
in breast cancer cells, CXCL-12/stromal cell-derived factor-1 α transactivating, 6493
mammary tumorigenesis and angiogenesis induced by, decreased, in Cox-2 knockout mice, 10113
phosphorylation of, antibody suppression of, 650
tumors expressing, outgrowth of, HER2 virus-like particles preventing, 5953
- HER2/neu kinase**
inhibition of, androgen receptor impaired by, 3404
- HER2-positive tumor xenografts**
immuno-PET imaging of, 1471
- HER2-targeted photoimmunotherapy**
multipeptide, 6371
- Herpes simplex virus (HSV)**
DNA repair inhibited by, glioblastoma radiosensitivity and, 5310
oncolytic
for breast cancer therapy, 1532
double-armed with IL-18 and soluble B7-1, 10663
- Herpes simplex virus 1 (HSV-1)**
ionizing radiation activated by, 9479
oncolytic, for gliomas, 2832, 6850
- Herpesvirus 4**
bovine, oncoapoptosis induced by, 9463
- Herpesvirus, Kaposi's sarcoma-associated**
novel oncogenes for, 5084
viral IFN regulatory factor 1 encoded by, transforming growth factor- β signaling inhibited by, 1738
- HERV-K (human endogenous retrovirus K)**
in melanomas, 4172
- Heterozygosity**
loss of
in childhood ALL, SNP microarray analysis of, 3053
in tobacco smoke-induced non-small cell lung cancer, 1664
- Hexokinase II**
binding of, to mitochondria, disruption of, chemotherapy-induced cytotoxicity potentiated by, 10545
- HIF-1**. See **Hypoxia-inducible factor 1 (HIF-1)**
- HIF-2 α** . See **Hypoxia-inducible factor 2 α (HIF-2 α)**
- High mobility group A1 (HMGAI)**
as molecular target for MYCN in neuroblastoma, 8308
- High motility group A2**
chemosensitivity potentiated by, 6622
- HIN-2**
Akt activation and, 9659
- Histamine signaling**
supporting malignant melanoma progression, 4458

- Histiocytic tumor**
dendritic cell-like, CY15 as, 2560
- Histone deacetylase inhibitors (HDACIs)**
antileukemic synergism between perifosine and, 2422
cytotoxicity of, mutant p53 depletion and, 7386
DNMT3B down-regulated by, 2684
DOC-2/DAB2 gene regulation in bladder cancer in presence of, 6089
effect of, on camptothecin-treated cells, scheduling and, 6957
exposure to, susceptibility of cancer cells to NK cell killing after, 11136
MBD3 mediating cancer-selective cytotoxicity by, 11400
polyploidy induction by, 7832
- Histone H3**
interaction of, with ribosomal S6 kinase 2, tumor suppressor p53 protein contributing to, 3596
phosphorylation of, at serine 10 in neoplastic cell transformation, 5818
- HIV protease inhibitors**
Akt signaling inhibited by, 8256
- HLA. See under Human leukocyte antigen (HLA) entries**
- HLA-G proteins**
in cancer, 10139
- HMEC (human mammary epithelial cells)**
COX-2 expression in, p38 regulating, 1792
- HMGNI**
tumorigenicity and, 6711
- HNSCC. See Head and neck squamous cell carcinoma (HNSCC)**
- Hodgkin's disease**
thymus and activation-related chemokine in, 5516
- Homeobox D10**
as tumor suppressor gene for breast cancer, 7177
- Homeobox gene Gax**
angiogenesis and nuclear factor- κ B inhibited by, 1414
- Homeobox Mx1**
as p53 regulator, 749
- Homocysteine**
as junction enzyme in cancer cells, 1554
- Homologous recombination**
in response to DNA damage, BRCA2 regulating, 4117
- Homozygous mutation**
in acute myeloid leukemias, uniparental disomy associated with, 9152
- Hormones**
islet and N-nitrosomorpholine, cocarcinogenic effects of, 7013
prostate cancer cell line progression refractory to, 11565
- Hox gene expression**
MLL-ENL induced, in maintaining hematopoietic progenitor cell immortalization, 9245
- HPV. See Human papillomavirus (HPV)**
- H-Ras**
genetic alterations in, in malignant transformation, 4530
oncogenic, Ku80 expression up-regulated by, 6811
- HSC (hematopoietic stem cells)**
cytokine-induced expansion of, valproic acid enhancing, 1505
- HSNF5 gene**
loss of, inactivating replicative senescence, 10192
- HSP. See Heat shock proteins (HSP)**
- hTERT (human telomerase reverse transcriptase)**
regulation of, STAT3 in, 6516
- Human endogenous retrovirus K (HERV-K)**
in melanomas, 4172
- Human epidermal growth factor receptor 2. See HER2**
- Human epididymis protein 4 (HE4)**
overexpression of, in ovarian cancer, 2162
- Human Epigenome Project**
Human Epigenome Workshop, 11241
- Human leukocyte antigen (HLA) class I antigen**
haplotype loss of, in lung cancer, 5945
machinery defects in, in microsatellite unstable colorectal cancers, 6418
- Human mammary epithelial cells (HMEC)**
COX-2 expression in, p38 regulating, 1792
- Human papillomavirus (HPV)**
E5 oncogene of, hyperplasia induced by, EGFR requirements for, 6534
genital cancers from, mechanisms of amplification in, 1174
T cells specific for, in head and neck squamous cell carcinoma, 11146
- Human papillomavirus 8**
cutaneous, E7 protein of, inducing invasion of keratinocytes, 2216
mice transgenic for, skin tumor development in, 1394
- Human papillomavirus 16**
recombinant adenylate cyclase carrying, in tumor eradication, 641
- Human papillomavirus 16 E6**
oncogenic potential of, PDZ domain interactions and, 8266
- Human papillomavirus E2**
in MMP-9 regulation through ERK, 11613
- Human prostate epithelial cells (HPrEC)**
immortalization of, by c-Myc, 2179
- Human T-cell leukemia virus type 1 (HTLV-1)**
at age 25, progress report, 4467
- Human telomerase reverse transcriptase (hTERT) expression**
reconstitution of, rescuing colorectal cancer cells from senescence, 2321
in telomerase-positive to telomerase-negative cell conversion, 2778
- Huntingtin interacting protein-1 (HIP1)**
serum antibodies to, in prostate cancer, 4126
- hull**
cytoplasmic, in invasive ductal breast cancer prognosis, 2157
- HYAL1 hyaluronidase**
in prostate cancer, 7782
tumor-promoting functions of, in bladder cancer, 2243
- Hyaluronan synthase 3**
antisense-mediated suppression of, inhibiting breast cancer, 6139
- Hyaluronic acid**
osteopontin induction by, 686
- Hyaluronidase**
HYAL1-type
in prostate cancer, 7782
tumor-promoting functions of, in bladder cancer, 2243
in ovarian tumors, MRI of, 10316
- Hydra phenomenon of cancer, 2997**
- Hydrogen peroxide**
intracellular production of, drug-induced apoptosis and, 6264
- Hydroquinone**
chromosome instability induced by, 1527
- β -Hydroxy- β -methylbutyrate (HMB)**
protein degradation in cancer cachexia reduced by, 277
- 15(S)-Hydroxyeicosatetraenoic acid**
in angiogenesis induction, 7283
- Hypersensitivity**
regional, pulmonary radiation injury and, 3568
- Hyperthermia**
regional, noninvasive MR thermography for, in recurrent rectal cancer, 5872
- Hypoxia**
BRCA1 expression down-regulated by, 11597
checkpoint kinase 2 phosphorylation induced by, 10734
Rab11 trafficking induced by, carcinoma invasion promoted by, 2761
radiation-induced signaling pathways and, 579
RNA interference of vascular endothelial cell growth factor A and, in sarcomas, 5881
in tissue factor regulation in glioblastoma, 1406
tumor, monitoring, noninvasive approach to, 6151
tumor angiogenesis and, 5498
up-regulation of metastasis-promoting gene products induced by, 2387
- Hypoxia-inducible factor-1 (HIF-1)**
activation of
HER2/P1-3K/Akt involved in, 3257
tumor angiogenesis and, 5498
DNA-binding activity of, echinomycin inhibiting, 9047
- IL-1 β inducing adrenomedullin through, 4690
novel small molecule inhibitors of, 4918
small-molecule inhibitor of, identification of, 605
in tumor growth, apoptosis, and insulin pathway, 4147
- Hypoxia-inducible factor-1 α (HIF-1 α)**
as cancer therapeutic target, evaluation of, 7249
differential gene up-regulation by, in HEK293T cells, 3299
inhibition of, taxanes and microtubule-disrupting drugs in, 9021
reduced expression of, in perinecrotic regions of solid tumors, 7259
topotecan blocking, in neuroblastoma cells, 4775
VEGF/Flt1 autocrine loop interacting with, in neuroblastoma, 7267
- Hypoxia-inducible factor-2 α (HIF-2 α)**
differential gene up-regulation by, in HEK293T cells, 3299
transactivation of, Nox4 for, in VHL-deficient renal cell carcinoma, 9190
tumor growth promoted by, 2277
- Hypoxia-inducible factor (HIF) system**
induction of, by low levels of HSP90 inhibitors, 11094
- Hypoxia-inducible protein 2 (HIG2)**
as renal cell carcinoma marker and therapeutic target, 4817
- Hypoxic cells**
apoptosis of, by DT-A/ODD, 11622
- ICP34.5**
oncolytic HSV-1 mutant expressing, for gliomas, 2832
- Idiotypes, functional, 6002**
- IDN5390**
targeting of class III β -tubulin by, in overcoming paclitaxel resistance, 2397
- IEE-1**
inhibition of, p73 β -mediated apoptosis requiring, 2186
- IFN. See Interferon entries**
- IFN regulatory factor-5 (IRF-5)**
DNA damage signaling through, 7403
- IGF-1 (insulin-like growth factor 1)**
VEGF induced by, in prostate epithelial cells, activated Ras enhancing, 2085
- IGF-IR. See Insulin-like growth factor-1 receptor (IGF-IR)**
- IGN311**
improved effector functions of, 7934
- I κ B kinase β /nuclear factor- κ B pathway**
cyclin D induction through, by arsenite, 9287
- ILK (integrin-linked kinase)**
inhibition of, in pancreatic cancer, 1497
- IL-13 α 2**
in aberrant Stat3 signaling in malignant glioma cells, 2956
- Imaging**
of cellular proliferation in breast cancer with FLT-PET, 10104
fusion protein complementation, 7413
magnetic resonance (See **Magnetic resonance imaging (MRI)**)
ultrasound (See **Ultrasound imaging; Ultrasound microimaging**)
in vivo, anti-p185^{HER2} antibody fragments for, 5907
- Imatinib mesylate (Gleevec)**
Bcrp1-mediated transport of, 2577
CML refractory to, AMN107 and BMS-354825 for, 4500
Leydig cell tumor growth inhibited by, 1897
resistance to, in chronic myeloid leukemia, kinetics of, 8912
therapeutic effects of, against bone metastasis of prostate cancer, zoledronate enhancing, 3707
- Immortal cell lines**
reversible conversion of, from telomerase-positive to telomerase-negative, 2778
- Immortal DNA strand cosegregation**
in cells undergoing asymmetric self-renewal, 3155
- Immortalization**
protein kinase A disruption causing, 10307
- Immune privilege**
in colon cancer, Fas ligand mediating, 9817

Immune response

against CEA, induction of, by oral vaccine, 6990
 suppressive or protective, tumor-infiltrating dendritic
 cell subsets inducing, 4955
 to tumor growth, cell-mediated, mathematical
 modeling of, 7950

Immune surveillance

against metastasis, M2 macrophages and myeloid
 suppressor cells blocking, 11743
 toll-like receptors on tumor cells facilitating evasion
 of, 5009

Immune therapy. See Immunotherapy**Immunity**

altered, in prostate dysplasia progression, 2947
 antitumor
 IL-12 and IL-18 interactions involving, 1063
 in Treg-depleted mice, 8471
 tumor, DC1-induced, 10059

Immunogene therapy

GRP94-based, radiation therapy enhanced by, 9126

Immunogenicity

of anti-idiotypic monoclonal antibody MK2-23 by
 fusion with IL-2, enhancement of, 6976
 melanoma antigen and, 632

Immunoliposomes

EGFR-targeted, enhancing efficacy *in vivo*, 11631

Immunomodulatory drug therapy

with immune therapy for multiple myeloma, 11712

Immuno-positron emission tomography

for HER2-positive tumor xenograft imaging, 1471

Immunostimulation

conditional cytotoxic gene therapy combined with,
 for glioma, 7194
 fusokine interleukin-2/interleukin-18 in, 9536

Immunostimulatory effects

of cyclophosphamide controlled by inducible nitric
 oxide synthase, 5027

Immunostimulatory tumor therapy

adenovirus-mediated oncolytic therapy combined
 with, 4343

Immunotherapy

adjuvant, combined with tumor-debulking surgery
 and chemotherapy, 7580
 alpha-particle, errant products in, efforts to control,
 4888

antiangiogenic, using VEGFR2, 4939

antitumor, vaccination with 5-Aza in, 2009
 based on killing of *Salmonella*-infected tumor cells,
 3920

of cervical cancer, CD4⁺ T cell-mediated antigen-
 specific, 2018

chemotherapy combined with, 8065

with immunomodulatory drug therapy for multiple
 myeloma, 11712

janus-activated kinase 2/signal transducers and
 activators of transcription 3 pathways inhibi-
 tion and, 9525

of myeloma, NY-ESO-1 protein transduction for,
 10041

of prostate cancer, human CTL epitopes in, 6435
 resistance to, B7-H1 in, 1089

with targeted virus replication for pancreatic cancer,
 9056

T cell adoptive, host lymphodepletion augmenting,
 9547
 tumor, targeting fibroblast activation protein, 11156

Indinethacin

claudin-4 induced by, 1868

Inflammation

cancer promotion dependent on, targeting myelo-
 monocytic cells to revert, 9113
 chronic, p53 as key responder in, 10255
 colon cancer and, CysLT₁ receptor in adenocarci-
 noma cell nucleus and, 732
 in genesis and perpetuation of cancer, 8583
 tumor necrosis factor- α -dependent, gastric
 hyperplasia caused by, 9147

Inflammatory angiogenesis

chemoprevention of, 10637

Inflammatory breast cancer (IBC)

molecular subtypes of, gene expression profiling
 identifying, 2170

Inhibitor of apoptosis protein

cIAP1, localization and cell cycle functions of, 210

Ink4a gene

alterations in, in malignant transformation, 4530
 in mouse gliomagenesis, 2065

Inositol pentakisphosphate

antitumor properties of, 8339

Insulin-like growth factor binding protein-3 (IGFBP-3)

Δ Np63 α regulating, 2314

Insulin-like growth factor binding protein-5 (IGFBP-5)

as matrix metalloproteinase-7 target, 7363

Insulin-like growth factor 2 (IGF2)

loss of imprinting of, as epigenetic modifier of
 intestinal tumor risk, 11236

Insulin-like growth factor 1 (IGF-I)

VEGF induced by, in prostate epithelial cells,
 activated Ras enhancing, 2085

Insulin-like growth factor-1 receptor (IGF-IR)

inhibitor of, antitumor activity of, 3868
 as therapeutic target in cancer, 10123
 transgenic expression of, tumor development by, 3781
 up-regulation of, by androgens in prostate cancer,
 1849

Insulin-like growth factor-1 receptor (IGF-IR)/

human epidermal growth factor receptor 2
 contributing to trastuzumab resistance of breast
 cancer cells, 11118

Insulin receptor substrate (IRS)

phosphoinositide 3-kinase activated by, in pancreatic
 cancer, 9164

Insulin-signaling pathway

hypoxia-inducible factor-1 in, 4147

Integrin(s)

bridging of MMP-9 to, in colon cancer cells, 11545

 α_2 Integrin

EGFRvIII down-regulating, aberrant cell spreading
 and focal adhesion formation induced by,
 9280

 $\alpha_6\beta_4$ Integrin

breast cancer cell survival mediated by, 10970

 $\alpha_4\beta_3$ Integrin

in murine mammary carcinoma growth and
 metastasis, 10324

for *in vitro* angiogenesis, 9377

 $\alpha v\beta_5$ Integrin

in murine mammary carcinoma growth and
 metastasis, 10324

 β_1 Integrin

clustering of, glycosphingolipid-dependent, 8233
 hypersialylation of, in colon cancer, cell motility
 and, 4645

overexpression of, on tumor blood vessels, 2712

 β_{1A} Integrin

expression and role of, in prostate cancer, 6692

 β_2 Integrin

Met tyrosine kinase tumorigenesis unleashed by, 10674

Integrin-linked kinase (ILK)

inhibition of, in pancreatic cancer, 1497

Intercellular adhesion molecule-1 (ICAM-1)

with Fas in tumor progression, 1045

Interferon (IFN)

as angiogenesis inhibitors, 3967
 unresponsiveness of LNCaP cells to, from lack of
IAK1 gene expression, 3447

Interferon- α (IFN- α)

GM-CSF-secreting tumor vaccines augmented by,
 2449

Interferon- β (IFN- β)

intrapulmonary, using adenoviral vector for ortho-
 topic lung cancer model, 8379

synergistic cytotoxicity of temozolomide with, on
 glioma cells, 7573

Interferon- γ (IFN- γ)

antimetastatic effect of, gene expression changes
 associated with, 8869

production of, by natural killer cells, SHIP1
 negatively regulating, 9099

susceptibility of NK lysis of BCR/ABL targets and,
 2914

tumor vascular targeting with, 2906

Interleukin(s)

as angiogenesis inhibitors, 3967

Interleukin-1 β (IL-1 β)

adrenomedullin expression induced by, through
 hypoxia inducible factor 1, 4690

Interleukin-2 (IL-2)

antitumor response of, in isolated limb perfusion,
 4300

fusion with, enhancement of immunogenicity of
 anti-idiotypic monoclonal antibody MK2-23
 by, 6976

Interleukin-4 (IL-4)

aberrant Stat3 signaling by, in malignant glioma
 cells, 2956

mantle cell lymphoma cell proliferation induced by,
 retinoic acid and, 587

receptor for, ovarian cancer therapy targeting, 8388

Interleukin-6 (IL-6)

autocrine pathways of, MnSOD disrupting, 6255

inhibitor of, renal cell carcinoma and, 2
 ovarian cancer angiogenesis and, 10794

p53 promoter methylation maintained by, 4673
 production of bone marrow mononuclear cell by,
 DHEA inhibiting, 2269

Interleukin-6 receptor (IL-6R)

peptide binding to, inhibiting angiogenesis and
 tumor growth, 4827

Interleukin-7 (IL-7)

expansion and persistence of anti-tumor T cells
 dependent on, in lymphodepleted mice,
 tumor regression and editing from, 10569

Interleukin-8 (IL-8)

in pancreatic tumor cells, Src regulating, 7214

production of, Td1 inhibiting, cancer cell motility
 and, 8784

tumor-associated endothelial cells regulated by,
 10347

tumor-derived, osteolysis stimulated by, 11001

Interleukin-10 (IL-10)

and CD25⁺ regulatory T cells, antitumor CD8 T-cell
 response inhibition by, 8479

Interleukin 10 receptor (IL-10R)

Myc down-regulating, in B lymphoma, 5454

Interleukin-12 (IL-12)

in prostate cancer therapy, 4309

synergistic effects of, with IL-18 in antitumor
 immunity, 1063

Interleukin-18 (IL-18)

Fos-related antigen 1 enhanced by, DNA vaccine
 targeting, memory T-cell response induced by,
 3419

oncolytic herpes simplex virus double-armed with
 soluble B7-1 and, 10663

synergistic effects of, with IL-12 in antitumor
 immunity, 1063

Interleukin-24 (IL-24)

Fas signaling mediated by, in ovarian cancer cell
 death, 3017

Internal tandem duplications

in *Flt3* gene in constitutive Akt activation in AML,
 9643

Interstitial fluid transport

of macromolecules, MRI of, 1425

Intestinal tumorigenesis

EGCG inhibiting, 10623

p27^{del} in, 9363

Intestinal tumors

regression of, CD4⁺CD25⁺ regulatory lymphocytes
 inducing, 3998

risk of, loss of imprinting of *IGF2* as epigenetic
 modifier of, 11236

Intracellular toxin delivery

pre-mRNA segmental *trans*-splicing in, 254

Invasion inhibitory protein 45 (Iip45)

alternative splicing of, in gliomas, 3562

Invasion signaling

cross talk of, with apoptosis, caspase-3 activating,
 9121

Iressa. See Gefitinib (Iressa)**IRF-1**

N-ras-induced myeloid cell growth suppression
 mediated by, 797

Irinotecan

oncolytic virus combined with, for glioma, 6850

Irradiation. See also Radiation; Radiotherapy

total body, T-cell proliferation and, 9547

IRS (insulin receptor substrate)

phosphoinositide 3-kinase activated by, in
 pancreatic cancer, 9164

Islet hormones

N-nitrosomorpholine and, cocarcinogenic effects of, 7013

Isolated limb perfusion

antitumor response of IL-2 and melphalan in, 4300

Isoilybin B

in prostate cancer, 4448

JAB1

VDUP1 inhibiting, 4485

JAG1

NOTCH1 coexpressed with, in breast cancer, 8530

Jagged-1

in glioma cell survival and proliferation, 2353

JAK2/STAT3 (janus-activated kinase 2/signal

transducers and activators of transcription 3) pathways

inhibition of, immunotherapy and, 9525

Janus-activated kinase 1 (JAK1) gene expression

lack of, in LNCaP cells, 3447

Janus-activated kinase 2 (JAK2)

activation of, leptin-induced, in gastric cancer, 9159
PCMI fused to, in leukemia, 2662

Janus-activated kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathways

inhibition of, immunotherapy and, 9525

Jasmonates

cytotoxicity of, on human cancer cell mitochondria, 1984

JIMT-1

masking of overexpression of ErbB2 in breast cancer in, 473

JN-7706621

as dual inhibitor of CDK and Aurora kinases, effects of, 9038

JNK. See c-Jun NH₂-terminal kinase (JNK)**JPO2**

in medulloblastoma, 5607

JPO1/CDC47

overexpression of, in human cancers, 5620

JunB

CD30-ERK1/2 MAPK signaling induced by, 7628

C-Jun NH₂-terminal kinase (JNK)

BAD Ser¹²⁸ not phosphorylated by, 8372

and MKK7, metastasis suppression by, 10984

RASSF1A suppressing, 3682

Smad2/3L phosphorylation induced by, in colorectal cancer, 157

C-Jun-N-terminal-kinase

inhibition of, sensitizing tumor cells to CD95-induced apoptosis, 6780

Junctional adhesion molecule-C (JAM-C)

antibody against, inhibiting angiogenesis, 5703

Juvenile pilocytic astrocytomas

expression analysis of, 76

Kaiso

expression and nuclear location of, regulated by tumor microenvironment, 2224

Kaposi's sarcoma

herpesvirus associated with, novel oncogenes for, 5084

Kaposi's sarcoma-associated herpesvirus (KSHV)

viral IFN regulatory factor 1 encoded by, transforming growth factor- β signaling inhibited by, 1738

Keratinocytes

invasion of, HPV8 E7 inducing, 2216

p-53 deficient, DNA repair in, 8723

survival and proliferation of, after UV irradiation, epidermal STAT3 in, 5720

UVB-induced response of, transcription-coupled repair in, 432

Kidney(s)

cancer of, treatment of, with mixed chimerism, 10032
transplantation of, skin cancer and, 1755

Kinase(s)

mammalian sterile 20-like, in tumor suppression, 5485

Kinase suppressor of Ras1 (KSR1)

cisplatin sensitivity enhanced by, 3986

Kisspeptin-10-induced signaling

of GPR54, CXCR4 negatively regulated by, 10450

KITENIN

siRNA targeting, colon tumors suppressed by, 8993

KIT gene

testicular germ cell tumor progression and, 8065

KLF4. See Krüppel-like factor 4 (KLF4) protein**KLF6 gene**

alternative splicing of, increased prostate cancer risk and, 1213

KLF6 (Krüppel-like factor 6)

tumor suppressor activity of, acetylation regulating, 9216

KLF6 SV1

prostate cancer cell growth and spread suppressed by, 5761

km23 dynein light chain alterations

in ovarian cancer, 6216

K-Ras

activation of, in astrocytes, glioma formation in neurofibromatosis 1 and, 236

galectin-3 activating, in breast cancer cells, 7292
gliomagenesis in mice induced by, *Ink4a* and *Arf* in, 2065

mutations of

codon-specific, metabolic phenotypes induced by, 5512

in colorectal cancer, tumor microenvironment and, 8134

in lung cancer, smoking and, 5076

ovarian tumors with, MAPK inhibition in, 1994
oncogenic, in maintaining cellular changes in colon cancer, 1244

pancreatic cancer radiosensitivity and, 8433

K-ras oncogene

in pancreatic carcinogenesis, 5045

K-ras signaling

in glioblastoma maintenance, 8250

Kringle 5 (K5)

angiostatic and antimacrophage properties of, 8359
apoptosis induced by, through GRP78, 4663

Krüppel-like factor 4 (KLF4) protein

destabilization of, ubiquitin-proteasome pathway and, 10394

expression of, in gastric cancer, 2746

Krüppel-like factor 6 (KLF6)

tumor suppressor activity of, acetylation regulating, 9216

Ku80

expression of, up-regulation of, by oncogenic H-Ras, 6811

Ku86

in camptothecin-induced radiosensitization, 9194

*******Lactosylceramide**

β_1 -integrin clustering and endocytosis regulated by, 8233

Laminin

PI3K/Akt/mTOR pathway activated by, in small cell lung cancer, therapeutic resistance and, 8423

Laminin peptide

FGF2 binding to CD44 blocked by, 10494

LAMP3/TSC403/DC-LAMP

overexpression of, cervical cancer metastasis promoted by, 8640

Lapatinib

tamoxifen responsiveness and, 18

L-Asparaginase

in acute lymphoblastic leukemia, *in vitro* response to, 291

Latent membrane protein 1 (LMP1)

TGF α induced by, 8826

LATS1

human, in mitotic exit network, 6568

Lenalidomide

SGN-40 combined with, for multiple myeloma, 11712

Leptin

EGFR transactivated by, JAK2 and ERK1/2 activation in gastric cancer and, 9159

Letrozole

and fulvestrant, additive antitumor effect of, 5439
MAPK activation and, 5380

for postmenopausal metastatic breast cancer, sEGFR concentrations in, 3059

Letters to the Editor

re: A. Cristaudo *et al.*, 65:3049-52, 10121

re: A. Nesterov *et al.*, 64:3922-7, 1615

re: A. Takahashi *et al.*, 64:8839-45, 10632

re: D. Rubio *et al.*, 65:3035-9, 9601

re: E. Navarro-Perán *et al.*, 65:2059-64, 8573

re: G.P. Adams *et al.*, 64:6200-6, 2044

re: K.A. Vito *et al.*, 64:873-7, 2983

re: L.H. Saal *et al.*, 65:2554-9, 11227

re: L.L. Chen *et al.*, 1115

re: P. Parrella *et al.*, 63:8507-10, 10634

re: Y. Hippo *et al.*, 64:2418-23, 372

re: Y. Wang *et al.*, 64:4105-11, 1112

re: Z. Zhang *et al.*, 64:5882-90, 1114

Leukemia(s)

acute, PCMI-JAK2 in, 2662

BCR-ABL, PI3K isoforms and downstream targets for, 2047

cells in

apoptosis in, coadministration of perifosine and histone deacetylase inhibitors inducing, 2422

killing of, by targeted amphipathic peptide, 2373

chronic, PCMI-JAK2 in, 2662

graft-versus, pretransplant effects of, 9735

megakaryoblastic, ERG in, 7596

OLIG2 inducing, with LMO1, 7151

Leukemia, acute lymphoblastic (ALL)

BAX- δ as novel tumor antigen in, gene expression

profiling identifying, 10050

defective p38 MAPK signaling in, 3290

high-risk, leukemic stem cells in, 1442

L-asparaginase in, *in vitro* response to, 291

pediatric

glucocorticoid receptor mutations in, 9712

loss of heterozygosity in, ANP microarray in

analysis of, 3053

treatment response in, MTHFR polymorphisms

and, 2482

T-cell

CD7-restricted apoptosis induction in, 3380

Tall in, 4515

virotherapy for, 3347

Leukemia, acute myelogenous (AML)

anti-FLT3 antibodies as therapeutic agents in, 1514

apoptosis in, DIM derivative inducing, 2890

TEL/PTPRR cloning and characterization in, with

inv(12)(p13q13), 6612

Leukemia, acute myeloid (AML)

Akt in, constitutive activation of, 9643

blast apoptosis in, retinoid-cAMP induced, 8754

charged pocket in BTB/POZ domain and, 6080

hematopoietic stem cell proliferation in, valproic

acid stimulating, 2637

interplay of RUNX1/MTG8 and DNA methyltrans-

ferase 1 in, 1277

paricalcitol and arsenic trioxide against, 2488

uniparental disomy in, 375

with homozygous mutation, 9152

Leukemia, acute promyelocytic (APL)

benzodithiophenes in

differentiation and apoptosis induced by, 7847

retinoic acid receptor α activity potentiated by,

7856

Leukemia, chronic lymphocytic (CLL)

B-cell receptor translocation and signaling in, 7328

Leukemia, chronic myelogenous (CML)

imatinib-refractory, AMN107 and BMS-354825 for,

4500

Skp2 and p27^{Kip1} regulation in, 3264

Leukemia, chronic myeloid (CML)

BCR/ABL in, NK cell-mediated lysis of, 2914

CXCR4 expression in BCR-ABL-expressing cells and,

2676

imatinib mesylate resistance in, kinetics of, 8912

low-level expression of Bcl-2-interacting mediator

in, 9436

Leukemia virus

human T-cell, type 1, at age 25, progress report, 4467

Leukotrienes

in inflammation-induced colon carcinogenesis, 732

Lewis lung carcinoma

tumorigenesis in, fetuin-A promoting, 499

Leydig cell tumor growth

imatinib mesylate inhibiting, 1897

LFS (Li-Fraumeni syndrome)

predisposition locus for, genetic mapping of, 427

Lidocaine

in radioprotection of parotid gland, 10486

Li-Fraumeni syndrome (LFS)

predisposition locus for, genetic mapping of, 427

LIGHT/TNFSF14

expression and function of, on melanoma, 3428

LIM domain only 4 (LMO4) protein

in estrogen receptor α regulation, 10594

LIM-only protein 3 (LMO3)

oncogenic potential of, in neuroblastoma, 4587

Linkage analysis

of susceptibility genes, 2610

15-Lipoxygenase-1

expression of, protein kinase G inducing, in lung cancer, 8442

5-Lipoxygenase (5-LOX)

as marker for early pancreatic intraepithelial neoplastic lesions, 6011

Lipoxygenases

colon tumorigenesis and, 11486

Liver

cancer of

multiple portal venous injections in therapy of, mouse models for, 3823

metastasis to

preclinical, ultrasound evaluation of, 5231

Liver receptor homologue-1

in breast cancer, prostaglandin E_2 and, 657

coactivation of, with aromatase expression, 11762

Lkb1 gene mutation

with p53 mutation in tumorigenesis, 11297

LM-1685

carboxyaido-triazole combined with, apoptosis increased by, anticancer effect and, 3853

LMO1

OLIG2 contributing to leukemogenesis with, 7151

LMO3 (LIM-only protein 3)

oncogenic potential of, in neuroblastoma, 4587

LNcap cells

IFN unresponsiveness in, from lack of *IAK1* gene expression, 3447

Lonafarnib

combined with paclitaxel, tubulin acetylation enhanced by, 3883

Loss of heterozygosity (LOH)

detection of, in FFPE tumors with SNP arrays, 10188

somatic, in *Tsc1*^{-/-} mice, 10179

in tobacco smoke-induced non-small cell lung cancer, 1664

5-LOX (5-lipoxygenase)

as marker for early pancreatic intraepithelial neoplastic lesions, 6011

LOX (lysyl oxidase)

breast cancer cell migration regulated by, 11429

LPA (lysophosphatidic acid)

COX-2 induction by, in ovarian cancer, 2234

Lung(s)

cells of, growth-stimulated, apoptosis in, *N*-acetylcysteine conjugate of phenethyl isothiocyanate enhancing, 8538

early radiation-induced functional loss in,

radiation damage to heart enhancing, 6509

inflammation of, asbestos-induced, 9670

metastasis to

Bcl-2 promoting, 5554

CCRS promoting, 3374

from fibrosarcoma, cystatin C overexpression

in host reducing, 8608

RhoGDI2 suppressing, by down-regulating

endothelin-1, 7320

Sema3E inducing, 6167

radiation injury to, regional hypersensitivity

associated with, 3568

Lung adenocarcinoma

HER2 mutation in, 1642

Lung cancer

aromatase inhibitors for, 11287

ASH1 as therapeutic target for, 10680

EGFR mutations in, 7568

epidermal growth factor receptor inhibitors in, 226

escape from accelerated cellular senescence in,

2795

gefitinib sensitivity in, ErbB and their ligands in,

11478

genome analysis of, with SNP arrays, 5561

GRN163L inhibiting, *in vivo*, 7866

growth of

inhibition of, arachidonic acid pathway

inhibitors and peroxisome

proliferator-activated receptor ligands in,

4181

Notch signaling pathways in, 3555

haplotype loss of HLA class I antigen in, 5945

human tRNA-dihydrouridine synthase and, 5638

mammalian target of rapamycin inhibition and, 3226

MBD3 mediating cancer-selective cytotoxicity

by HDIs in, 11400

miR-17-92 overexpression in, 9628

murine

antitumor immune response in, induction of, 11752

effects of mutant p53 alleles on, 10280

orthotopic model of, adenoviral vector

expressing IFN- β in therapy of, 8379

spontaneous, loci affecting, 8158

mutations in, smoking and, 5076

non-small cell (NSCLC)

advanced, poor response to gefitinib in,

predictors of, 9176

ANLN pathways in, 11314

atypical protein kinase C γ as oncogene in, 8905

cyclophilin A as molecular target in, 8853

EGFR mutations in, 7525

endogenous gene expression in, regulation of, 1598

genetic heterogeneity of *EGFR* in, 7276

MAPK/Erk activation in, *EGFR*-independent, 6275

metastasis-associated receptor tyrosine kinases

in, identification of, 1778

plakophilin 3 oncogene as therapeutic target in,

7102

progesterone receptor in, 6450

Rho/ROCK pathway activated by E1AF in, 10776

sensitivity of

to *EGFR* inhibition, epithelial-mesenchymal

transition as determinant of, 9455

to geldanamycins, mutant *EGFRs* and, 6401

therapeutic inhibition of c-Met in, 1479

therapy for, combined targeting of estrogen

receptor and epidermal growth factor

receptor in, 1459

tobacco smoke-induced, loss of heterozygosity

patterns in, 1664

VEGF expression in, PDGF-AA as regulator of,

7241

outcome prediction in, reduced FEZ1/LZTS1

expression and, 1207

primary and metastatic, distinguishing between,

gene expression profiling of, 3063

progression of, isothiocyanates inhibiting, 8548

protein kinase mutations in, 7591

risk of

in African Americans, less efficient G $_2$ -M

checkpoint associated with, 9566

cell cycle checkpoints and, 349

cytochrome P450 1B1 variants and, 5105

DNA adducts and, 8042

DNA damage/repair and, 349

polymorphisms in DNA base excision repair

genes *ADPRT* and *XRCC1* and, 722

sensitivity to gefitinib in, *HER2* and, 4253

small cell (SCLC)

laminin-mediated activation of PI3K/Akt/mTOR

pathway in, therapeutic resistance and,

8423

xenografts of, antiangiogenic GIM2 monoclonal

antibody for, 6425

susceptibility to, *Vhl* haploinsufficiency and, 6576

TAP1 expression in, survival increased by, 7926

telomerase expression preceding, 9623

TRAIL gene therapy for, 1687

T regulatory activities in, COX-2 inhibition reducing,

5211

tumor growth in, fetuin-A promoting, 499

Lung tumors

development of, angiotensin II AT $_2$ deficiency and,

7660

eradication of, DNA vaccine against survivin in, 553

p53 mutations in, benzo(a)pyrene-exposed p53

knock-in murine fibroblasts correlating with,

2583

taxol enhanced by CI-1040 for, 2854

Lupol

Fas-mediated apoptosis of androgen-sensitive

prostate cancer cells induced by, 11203

Luteinizing hormone releasing hormone (LHRH)

receptor

targeting of, in malignant melanoma, 5857

Luteolin

TRAIL-induced apoptosis sensitized by, 7815

LY compounds

apoptosis-sensitizing activity of, 6264

Lymphangiogenesis

peritumoral, VEGF-A promoting, 9261

prostate cancer, metastasis and, 9789

Lymphatic vessel metastasis

VEGF-A promoting, 9261

VEGFR-3 signals in, 4739

Lymph node(s)

cervical, molecular staging of, in head and neck

cancer, 2147

metastasis to, *PIK3CA* mutations correlated with, in

breast cancer, 2554

tumor-draining, intravital microscopy of, 11639

Lymphoblastic leukemia, acute. See Leukemia,

acute lymphoblastic (ALL)

Lymphoblastoid cells

MT1, mismatch repair defect in, 4525

nitric oxide-induced apoptosis in, 6097

radiation-induced signals in, hypoxia and, 579

Lymphocytes

marrow-infiltrating, activated, anti-myeloma

activity of, 2026

regulatory, CD4⁺CD25⁺, intestinal tumor regression

induced by, 3998

Lymphoid malignancy

asymptomatic phase preceding, fate of

pre-malignant clones during, 1234

Lymphoid tumors

apoptosis in, TRAIL signaling, 11265

Lymphoma(s)

B, Myc down-regulating IL 10R and CD20 ub, 5454

B cell

anti-CD40 monoclonal antibody-based therapy

of, cyclophosphamide inhibiting, 7493

motexafin gadolinium and zinc inducing

oxidative stress responses in, 11676

Burkitt

cells of, overexpression of tripeptidyl-peptidase II

in, 1361

translocation in, murine model of, 1306

development of

germinal center-associated nuclear protein

RNA-primase expression associated with,

5925

Notch suppression of p53 in, 7159

Hodgkin, Reed-Sternberg cells of, CD30 promoter

activation in, 7628

large cell

anaplastic, CD30 promoter activation in, 7628

T-anaplastic, tumorigenicity of, CD26 regulating,

6950

mantle cell

CD40-induced cell proliferation in, retinoic acid

and, 587

CDK4 and *MDM2* alterations in, 2199

murine, therapeutic vaccination against, 5958

non-Hodgkin's

risk of, organochlorines in plasma and, 11214

rituximab inhibiting NF- κ B signaling pathway in,

264

transformed, loss of *SMRT* in, 4554

p14 in, nucleolar localization of, 7223

relapsed, aberrant transcription of *MDR-1* in, 11694

SGN-40 activity against, 8331

T-cell

cutaneous, *NAV3* gene deletion/translocation in,

8101

galectin-7 in, 5205

Lymphomagenesis

of p53 null mice, PTPIB regulating, 10088

- Lymphoproliferative diseases**
canine, breed-restricted phenotypes of, 5654
- Lymphosarcoma cells**
mouse, interaction of Dnmt3a with Mbd3 and Brg1 in, 10891
- Lyn kinase activity**
elevated, in glioblastoma, 5535
- Lysophosphatidic acid acyltransferase- β (LPAAT- β)**
targeting of, in gynecologic cancer, 9415
- Lysophosphatidic acid (LPA)**
COX-2 induction by, in ovarian cancer, 2234
- Lysosomal death pathways**
as targets for cancer therapy, 2993
- Lysosomal leakage**
antitumor activity of siramesine and, 8975
- Lysosomes**
as targets for cancer therapy, 2993
- Lysyl oxidase (LOX)**
breast cancer cell migration regulated by, 11429
- MACE-D1**
suppression of, breast cancer tumorigenesis and, 4747
- Macromolecules**
interstitial fluid transport of, MRI of, 1425
- Macrophage inhibitory cytokine 1 (MIC-1)**
stores of, prostate cancer outcomes and, 2330
- Macrophages**
breast cancer invasiveness promoted by, 5278
differentiation of, yondelis inhibiting, 2964
diminished expression of NF- κ B and C/EBP in, tumor evasion and, 10578
M2, in immune surveillance against metastasis, 11743
recruitment of, tumor necrosis factor in, 3928
tumor, DMXAA activating, 11752
tumor-associated, migration of, K5-engineered glioma cells blocking, 8359
in tumor rejection, 3437
- Magnetic resonance angiography (MRA)**
in abnormal tumor vasculature visualization, 8218
- Magnetic resonance imaging (MRI)**
contrast materials for, in *in vivo* mapping of tissue transglutaminase activity, 1369
in convection-enhanced drug delivery monitoring, 6858
of hyaluronidase in ovarian tumors, 10316
of interstitial fluid transport of macromolecules, 1425
on pancreatic cancer, whole-body fluorescence imaging compared with, 9892
real-time, in RAS-dependent tumor angiogenesis assessment *in vivo*, 8324
in tumor response assessment, 7041
- Magnetic resonance spectroscopy (MRS)**
in imaging of glutathione metabolism in tumors, 10149
in MAPK signaling monitoring, 3356
tissue, in prostate cancer characterization, 3030
- Magnetic resonance thermography**
of recurrent rectal carcinoma, 5872
- Major vault protein (MVP)**
constitutively photomorphogenic 1 with, in cancer progression, 5835
PTEN nuclear import mediated by, 4108
- Malignancy**
lymphoid, asymptomatic phase preceding, fate of premalignant clones during, 1234
- Malignant transformation**
testis promoting, 868
transcriptional programs of, 4530
- Mammalian sterile 20-like kinases**
in tumor suppression, 5485
- Mammary. See Breast entries in humans**
- Mammary cancer**
Atm heterozygosity with loss of *Brca1* increasing severity of, 8736
development of, in A1B1/SRC-3 null mice, 7993
epimorphin overexpression in mouse mammary gland promoting, 8617
growth of, suppression of, by retinoic acid, 8193
inhibition of, induction of autoimmunity by xenogeneic DNA vaccination in, 1071
lung metastasis formation in, FAK in, 4698
murine, in integrin-deficient mice, 10324
p14 in, nuclear localization of, 7223
- Mammary carcinoma susceptibility loci, 9637**
- Mammary epithelia**
type II TGF- β receptor knockout in, 2296
- Mammary gland**
epimorphin overexpression in, 8617
- Mammary hyperplasia**
COX-2-mediated, EP2 required for, 4496
- Mammary tumors**
development of
decreased, in Cox-2 knockout mice, 10113
in p53.R270H/WAPCre mice, 8166
transforming acidic coiled coil 1 promoting, 10363
Wnt-1-induced, PTEN inhibiting, 6864
feline, as model of human breast cancer, 907
metastasis of, VEGF-C inhibition and, 9004
murine
development of, tamoxifen inhibiting, 3493
formation and metastasis of, Ron receptor signaling augmenting, 1285
oncolytic HSV for, 1532
mutations of *Apc* and *p53* synergizing to promote, 410
- Manganese superoxide dismutase (MnSOD)**
autocrine IL-6 pathways disrupted by, 6255
breast cancer survival and, 1105
inactivation of, p53 translocation to mitochondria and, 3745
polymorphism of, prostate cancer risk and, 2498
in skin carcinogenesis reduction, 1401
- Mantle cell lymphoma (MCL)**
CD40-induced cell proliferation in, retinoic acid and, 587
CDK4 and *MDM2* alterations in, 2199
- MAPK. See Mitogen-activated protein kinase (MAPK)**
- Marrow-infiltrating lymphocytes (MILs)**
activated, anti-myeloma activity of, 2026
- Mass spectrometry**
matrix-assisted laser desorption/ionization, brain tumor prognosis based on, 7674
- Mast cells**
radiation-induced heart disease and, 3100
- Maternal embryonic leucine zipper kinase (MELK)**
as therapeutic target, 9751
- Matrix-assisted laser desorption/ionization mass spectrometry**
brain tumor prognosis based on, 7674
- Matrix metalloproteinase (MMP)**
down-regulation of, vascular intravasation of tumor cells and, 10959
inducer of, extracellular, in tumor angiogenesis, 3193
membrane type 1
in cervical cancer progression, 6543
expression of, regulated by zonula occludens-1 in breast cancer cells, 7691
p53/PKC-induced apoptosis inhibited by, 4261
- Matrix metalloproteinase-1 (MMP-1)**
inhibition of, in MDA-231 cells, short hairpin RNA-mediated, 11101
membrane-type 1, for *in vitro* angiogenesis, 9377
- Matrix metalloproteinase-2 (MMP-2)**
activity of
ALCAM controlling, 8801
claudin-3 and claudin-4 expression in ovarian epithelial cells and, 7378
cancer cell migration and, 130
expression of, SXX down-regulation impairing, 2207
induction of, Bcl-2 promoting invasion and lung metastasis by, 5554
- Matrix metalloproteinase-3 (MMP-3) promoter mutations**
microsatellite instability colorectal tumors impaired by, 3811
- Matrix metalloproteinase-7 (MMP-7)**
insulin-like growth factor binding protein-5 as target of, 7363
- Matrix metalloproteinase-9 (MMP-9)**
bridging of, to integrins and CD44, in colon cancer cells, 11545
- contribution of bone marrow-derived cells to tumor vasculature in neuroblastoma dependent on, 3200
latent membrane protein 1 inducing, 8826
regulation of, by papillomavirus E2 through ERK, 11613
- MBP-1**
carboxyl-terminal repressor domain of, prostate tumor regression and, 718
- MCF7 cells**
in breast cancer, Tn antigen expression in, MUC6 in, 7880
irradiated, mTOR pathway inhibition in, 11061
multidrug-resistant and sensitive, *W713* regulation in, 7421
tumorigenicity of, MCT-1 oncogene contributing to, 10651
- MCL. See Mantle cell lymphoma (MCL)**
- Mcl-1**
down-regulation of, in multiple myeloma by seliciclib, 5399
- MCS5, 9637**
- MCT-1 oncogene**
contributing to tumorigenicity of MCF7 cells, 10651
- Mda-7/IL-24**
as "magic bullet" for cancer, 10128
- MDM2. See Mouse double minute 2 (MDM2)**
- MDR. See Multidrug resistance (MDR)**
- Measles virus**
targeted to vascular endothelium, 5292
- Meat intake**
colorectal adenoma and, 8034
prostate cancer risk and, 11779
- Mect1-Maml2 fusion oncogene**
aberrant activation of cyclic AMP/CREB regulated genes, 7137
- Medroxyprogesterone acetate**
response to, androgen receptor in breast cancer and, 8487
- Medulloblastoma**
cell death in, ERK5 and MEF2 in, 5683
genomic amplification of *Orthodenticle homologue 2* in, 703
JPO2 in, 5607
oncogene for, *OTX2* as, 919
targeting, 4975
- Meeting Reports**
Eight Beatson International Cancer Conference, 11247
Inflammation and Cancer Think Tank Meeting, 8583
International Conference on Tumor Progression and Therapeutic Resistance, 4475
National Cancer Institute Division of Cancer Biology Think Tanks, 9117
Oncogenomics Conference, 8587
Seventeenth Annual Pezcoller Symposium, 11251
Tenth International Conference on Differentiation Therapy, 1117
- Megakaryoblastic leukemias**
ERG in, 7596
- Melanocortins**
survival effects of, 4292
- Melanocyte(s)**
DNA damage in, melanocortins and endothelin-1 reducing, 4292
inflammatory killing of, potent selection of antigen loss variants after, 2009
normal, epigenetic transdifferentiation of, by metastatic melanoma microenvironment, 10164
- Melanoma**
activator protein-2 α in, quantitative analysis of, 11185
angiogenesis and metastasis of, cyclin E and, 692
antioxidant enzyme in, immunogenicity and, 632
B16, antigen loss variants of, potent selection of, 2009
cross-talk of, with fibroblasts, gene expression profiling revealing, 4134
development of, E2F regulation of topoisomerase II repression and, 4067
gene expression in, effects of IFN- γ on, 8869
human endogenous retrovirus K expression in, 4172
LIGHT/TNFSF14 expression and function on, 3428
malignant
aggressive phenotype of, focal adhesion kinase promoting, 9851

- bone morphogenic protein expression in, 448
cell-cell adhesion and invasion in, P-cadherin and, 8774
cutaneous, CCR7 and CXCR4 expression in, epigenetic up-regulation of, 1800
doxorubicin transport and resistance in, ABCB5-mediated, 4320
LHRH receptor targeting in, 5857
mutant γ -B-Raf inhibition in, 2412
progression of, histamine signaling supporting, 4458
- metastasis of**
mda-9/syntenin as regulator of, 10901
- metastatic**
microenvironment of, epigenetic transdifferentiation of normal melanocytes by, 10164
[99m TcOAAADT]-(CH₂)₂-NEt₂ for imaging of, 4979
NOXA-mediated apoptosis in, proteasome inhibitors triggering, 6282
targeting of antigens to activated dendritic cells for, 7007
transgenic N-ras and, 4005
risk of, *CDK24* common variants and, 835
senescence in, maintaining proliferation and suppression of, Tbx2 in, 2260
SPARC in, antitumor activity and, 5123
stage IV, intratumoral T-cell infiltrates and MHC class I expression in, 3937
stem cell subpopulation in, 9328
T cells reactive to, engineering of, 1570
tumor growth in, endogenous retrovirus promoting, 2588
vaccines expressing α (1,3)-galactosyl isotopes for, 10555
vascularization of, tumor-induced vascular remodeling in, 913
xenografts of, antiangiogenic GM2 monoclonal antibody for, 6425
- Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24)**
as "magic bullet" for cancer, 10128
- Melanoma differentiation-associated gene-7 (mda-7)**
Fas signaling mediated by, in ovarian cancer cell death, 3017
- Melanoma differentiation-associated gene-9 (mda-9)/syntenin**
as melanoma metastasis regulator, 10901
- Melanotransferrin helper T-cell epitope**
identification of, 10065
- Melatonin**
suppression of, light-induced, breast cancer growth and, 11174
- MELK (maternal embryonic leucine zipper kinase)**
as therapeutic target, 9751
- Melphalan**
antitumor response of, in isolated limb perfusion, 4300
- Meningioma(s)**
aggressive, *NDRG2* in, 7121
apoptosis in, fenretinide inducing, 1547
chromosome 1 array-CGH analysis of, 2653
Notch activation in, 5070
- Mesalazine**
replication fidelity improved by, in cultured colorectal cells, 3993
- Mesenchymal stem cells**
bone marrow-derived
in bone invasion, 1129
Ewing's sarcoma development from, 11459
in glioma therapy, 3307
cancer/testis antigen expression in, 2207
telomerase-immortalized, cultures of, cancer stem cells from, 3126
transformation of, spontaneous, 3035
- Mesothelioma**
 β -catenin-deficient, *SPFP4* silencing in, 743
malignant
mouse model of, 8090
risk of, SV40 enhanced by, 3049
murine models of, antitumor immune response in, induction of, 11752
SV40 and, 2602
Akt signaling as therapeutic target for, 5256
- Messenger RNA**
interleukin 6, renal cell carcinoma and, 2
transcription elongation linked to, in breast cancer metastasis, 3011
- Metabolic mapping, of breast cells via multiphoton FLIM, 8766**
- Metastasis**
to bone
17-Allylamino-17-demethoxy geldanamycin potentiating, 4929
bone marrow mesenchymal stem cells in, 1129
of follicular thyroid cancer, EGFR and VEGFR inhibition in, 4716
interference with bone microenvironment impairing, 7682
of prostate cancer, osteoblastic BMP promoting, 8274
VEGF promoting, 10921
- breast cancer**
Bnip-3 in, 11689
to bone, mouse model of, 6130
CD44 attenuation of, 6755
DLC-1 suppressing, 6042
genes associated with, xenograft model of, 5578
induction of, AGR in, 3796
osteonectin/SPAR/BM-40 inhibiting, 7370
postmenopausal, letrozole for, sEGFR concentrations in, 3059
postsurgical, dietary genistein in reduction of, 3396
prognostic signatures preservation and, 9155
silencing of *CXCR4* block, 967
Src activation for, 1858
in subpopulations, proliferation predicting, 4059
suppression of, by breast cancer metastasis suppressor 1, 713
telopeptide removal from fibrillar collagen I promoting, 5674
TREX complex and, 3011
CD24 expression and, 10783
of cervical cancer, *LAMP3/TSC403/DC-LAMP* over expression promoting, 8640
epithelial-mesenchymal transition in, 5991, 5996
head and neck cancer, novel markers of, 2147
host-tumor interactions in, melanoma-fibroblast cross-talk and, 4134
immune surveillance against, M2 macrophages and myeloid suppressor cells blocking, 11743
inhibition of
anti-CEACAM in, 8809
by ATP6L siRNA, 6843
Sd¹ carbohydrate expression in, 6220
to liver, preclinical, ultrasound evaluation of, 5231
to lung
Bcl-2 promoting, 5554
CCR5 promoting, 3374
from fibrosarcoma, cystatin C overexpression in host reducing, 8608
RhoGDI2 suppressing, by down-regulating endothelin-1, 7320
Sema3E inducing, 6167
lung cancer, non-small cell, receptor tyrosine kinases associated with, identification of, 1778
lymphatic
VEGF-A promoting, 9261
VEGFR-3 signals in, 4739
to lymph nodes
PIK3CA mutations correlated with, in breast cancer, 2554
rAAV-sVEGFR3-mediated gene transfer inhibiting, 6901
mammary tumor
to lung, formation of, FAK in, 4698
Ron receptor signaling augmenting, 1285
TGF- β signaling absence and, 2296
- melanoma**
cyclin E and, 692
mda-9/syntenin as regulator of, 10901
[99m TcOAAADT]-(CH₂)₂-NEt₂ for imaging of
MMP-2 and, on collagen, 130
of murine mammary carcinomas, integrins in, 10324
neurotrophic receptor TrkB in, 7033
osteosarcoma
ezrin-mediated, rapamycin inhibiting, 2406
ostertoxin inhibiting, 1124
- ovarian cancer, colony-stimulating factor-1 overexpression and, 3762
particle irradiation suppressing, 113
prostate cancer
anoikis in, 11230
to bone
antivascular therapy of, 3707
osteoprotegerin in, 1710
reduction by, host cystatin C overexpression in, 8608
spontaneous, rejection of, surrogate antigen-based tumor vaccines in, 2938
suppression of, by JNK1 and MKK7, 10984
suppression of, in *S100A4(mts-1)*-deficient mice, 3772
synuclein- γ gene as molecular indicator of, 7635
of T cell lymphoma, galectin-7 in, 5205
tumor bed effect and, 2387
VEGF-C inhibition and, 9004
- Metastasis, prostate cancer lymphangiogenesis and, 9789**
- Met-dependent cell migration**
CD44 v6 peptides inhibiting, 6105
- Methionine**
metabolism of, in cancer cells, 1554
- Methionine aminopeptidase-2 (MetAP2)**
expression of, dysregulation of, in neurofibromatosis 1-associated glioma, 9843
- 2-Methoxyestradiol**
as angiogenesis inhibitor, 3967
insensitivity of ZR-75-1 breast cancer cells to, 5802
resistance to, in MDA-MB-435 cancer cells, 9406
synergism of, with antitubulin agents in breast cancer, 387
- Methylation replication**
in cancer cells, decreased fidelity in, 11
- Methyl CpG-binding domain protein 3 (MBD3)**
cancer-selective cytotoxicity by HDIs mediated by, 11400
- Methylenetetrahydrofolate reductase (MTHFR) polymorphisms**
breast cancer risk and, 1606
therapy response in pediatric acute lymphoblastic leukemia and, 2482
- O⁶-Methylguanine DNA methyltransferase (MGMT)**
mitochondrial targeting of, cell killing by alkylating agents and, 3319
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)**
colon cancer stimulated by, via β -adrenoceptors, 5272
tobacco-specific, lung tumorigenesis and, 7660
- Metronomic chemotherapy, 7045**
- Met tyrosine kinase**
tumorigenesis of, β_4 integrin unleashing, 10674
- MG132**
death receptor 5 induced by, through CHOP, 5662
- MGUS (monoclonal gammopathy of undetermined significance) plasma cells**
MICA expression in, 7502
- MHC class I expression**
in stage IV melanoma, 3937
- MHC class II-restricted tumor antigens**
discovery of, 10068
- MICA**
expression of, by multiple myeloma and MGUS plasma cells, 7502
- Microarrays**
antibody, experimental design and analysis of, 2985
cDNA, in esophageal carcinogenesis analysis, 401
comparative genomic hybridization based on candidate genes in breast cancer revealed by, 439
comprehensive DNA copy number profiling of meningiomas using, 2653
for genome-wide typing of single nucleotide polymorphisms in analysis of loss of heterozygosity in ALL, 3053
hypomethylation of *R-RAS* gene in gastric cancer discovered by, 2115
melanoma tissue, activator protein-2 α expression in, quantitative analysis of, 11185
in prognostic signatures analysis in breast cancer, 9155
Src-regulated gene activity identified by, 1814
in susceptibility gene mapping analysis, 2610

- Microcyst**
formation of, tumor necrosis factor in, 3928
- MicroRNA-21**
as antiapoptotic factor in glioblastoma cells, 6029
- MicroRNA biogenesis**
cancer and, 3509
- MicroRNA expression**
in breast cancer, 7065
- Microsatellite instability (MSI)**
in colorectal cancer, CAT25 as marker for, 8072
of endometrial cancers, gene expression profiling of, 5031
- Microscopy**
intravital, of tumor-draining lymph node, 11639
scanning X-ray fluorescence, element array by, after *cis*-diamminedichloro-platinum(II) treatment, 4998
- Microtubules**
agents disrupting
HIF-1 α inhibited by, 9021
synergism of, with 2-methoxyestradiol in breast cancer, 387
dynamics of, in endothelial cells, increased, antiangiogenic concentrations of paclitaxel inducing, 2433
stabilization of
ceratamides in, 3040
C19ORF5 in, 4191
- Migration stimulating factor (MSF)**
expression of, mRNA 3'-untranslated region truncation controlling, 10742
- Milk thistle**
in prostate cancer, 4448
- MILs (marrow-infiltrating lymphocytes)**
activated, anti-myeloma activity of, 2026
- Mindin/RG-1**
in human monoclonal antibody radioimmunotherapy, 8397
- Mir-17-92**
overexpression of, in lung cancer, 9628
- Mismatch repair (MMR) defect**
in colorectal cancer cells, 4607
in lymphoblastoid MT1 cells, 4525
- Mitochondria**
action of gold(III) porphyrin Ia on, 11553
activity of, p43 overexpression stimulating, 4282
aggregation of, C19ORF5 supporting, 4191
BHAP targeting HER-2 and, 6891
bonding of hexokinase II to, disruption of, chemotherapy-induced cytotoxicity potentiated by, 10545
damage to
in canstatin activity, 4353
mediating genotoxicity of arsenic, 3236
human cancer cell, cytotoxicity of jasmonates for, 1984
membrane lipids of, TRAIL altering, 8286
membrane potential of, of colonic cancer cells, tumor progression linked to, 9861
oxidative stress from, in apoptosis and tumorigenesis, 203
p53 translocation to, manganese superoxide dismutase inactivation and, 3745
targeting of, by *O*⁶-methylguanine DNA methyltransferase, cell killing by alkylating agents and, 3319
- Mitochondrial aggregation and genome destruction (MAGD)**
C19ORF5 mediating, 4191
- Mitochondrial DNA (mtDNA)**
G10398A polymorphism, invasive breast cancer and, 8028
pathogenic mutations in, in cancer promotion, 1655
- Mitogen-activated protein kinase (MAPK)**
activation of, letrozole and, 5380
big, in tumor-associated angiogenesis, 7699
cell proliferation, transformation and tumorigenesis up-regulated by, Spz1 mediating, 4041
inhibition of, in ovarian cancer, 1994
Notch3 receptor inhibiting lung cancer growth and, 3555
p38
defective signaling through, in ALL cells, 3290
prostate epithelial cell invasion by, genistein inhibiting, 3470
signaling
activation of, EGFR-independent, 6275
inhibition of, magnetic resonance spectroscopy monitoring of, 3356
in skin tumorigenesis, ornithine decarboxylase and, 572
- Mitogen-activated protein kinase (MAPK) pathway**
and DFMO, cell cycle arrest induced by, in breast cancer cells, 11026
- Mitogenic activity**
of angiopoietin1 for cultured endothelial cells, 6820
- Mitosis**
aberrant, in cells overexpressing tripeptidyl-peptidase II, 1361
inhibitors of, MDM2 antagonists in protection against, 1918
integrity of, in multiple myeloma, hyaluronan-mediated motility receptor affecting, 850
premature, in response to gemcitabine, checkpoint kinase 1 in preventing, 6835
- Mitotic arrest deficient 2 expression**
inducing sensitization to cisplatin in nasopharyngeal carcinoma, 1450
- Mitotic catastrophe**
FoxM1 loss causing, 5181
- Mitotic exit network**
human LATS1 in, 6568
- Mitoxantrone**
resistance to, extracellular vesicles mediating, 10952
- MK885**
in lung cancer growth inhibition, 4181
- MKK7**
JNKK1 and, metastasis suppression by, 10984
- Mlh3**
DNA mismatch repair and tumor suppression and, 8662
MutLII homologue, in DNA mismatch repair, 10759
- MIL-ENL expression**
Hox gene expression induced by, in maintaining hematopoietic progenitor cell immortalization, 9245
- MLL fusion proteins**
transcriptional activation by, 11367
- MM. See Multiple myeloma (MM)**
- M2 macrophages**
in immune surveillance against metastasis, 11743
- MMP. See Matrix metalloproteinase (MMP)**
- MMR. See DNA repair, mismatch (MMR)**
- MMR defect. See Mismatch repair (MMR) defect**
- MMTV. See Mouse mammary tumor virus (MMTV)**
- MnSOD. See Manganese superoxide dismutase (MnSOD)**
- Molecular beacon imaging**
for gene expression in cancer cells, 1909
- Molecular classification**
of papillary renal cell carcinoma, 5628
- Molecular therapy**
of human cancer, 1117
for renal cell carcinoma, hypoxia-inducible protein 2 as target of, 4817
- Monoclonal antibody(ies)**
anti-CD40
anti-multiple myeloma activity of, 5898
humanized, antilymphoma activity of, 8331
anti-FLT3, in AML therapy, 1514
antiganglioside GM2, for melanoma and small cell lung cancer xenografts, 6425
anti-idiotypic, 6G6.C4 fused to GM-CSF, anti-CEA response and, 1925
B7-H1 and PD-1 blockade by, cancer immunotherapy potentiated by, 1089
in HER2 suppression, 650
MK2-23, anti-idiotypic, immunogenicity of, enhancement of, by fusion with IN-2, 6976
- Monoclonal gammopathy of undetermined significance (MGUS) plasma cells**
MICA expression in, 7502
- Mononuclear cells**
bone marrow, IL-6 production of, DHEA inhibiting, 2269
- Mosaicism**
somatic, cancer and, 8514
- Mosaic tumor vessels, 5740**
- Motexafin gadolinium**
oxidative stress responses induced by, in B-cell lines, 11676
zinc metabolism disrupted by, 3837
- Mouse double minute 2 (MDM2)**
antagonists of, p53 activation by, in chemoprotection, 1918
gene for, alterations of, in mangle cell lymphoma, 2199
genetic polymorphisms in
risk of esophageal squamous cell carcinoma and, 9582
single nucleotide, 5481
genistein inhibiting, 8200
growth arrest function of, disabling of, in cancer cells, 1839
- Mouse mammary tumor virus (MMTV)**
human cells infected by, 6651
p14 of, in lymphomagenesis and mammary carcinogenesis, 7223
- Mouse model(s)**
abnormal tumor vasculature in, MRA visualization of, 8218
adenoma formation in, carnosol preventing, 1097
adriamycin/docetaxel combination in, dosing time-dependent effects of, 8448
aflatoxin DNA repair in, 1265
AIB1/SRC-2 null, mammary carcinogenesis in, 7993
of alveolar rhabdomyosarcoma, genetic tactics for, 7530
anemic, radiation therapy in, darbepoietin alfa potentiating, 284
Apc^{min/+}
intestinal tumorigenesis in, polyamine catabolism and, 5390
intestinal tumor regression in, CD4⁺CD25⁺ regulatory lymphocytes inducing, 3998
APC^{Min}, adenomas in, molecular profiling of, 166
athymic, lack of DNA mismatch repair in, hematologic malignancy and, 2626
B6129, *Helicobacter pylori* inducing gastric intraepithelial neoplasia in, 10709
B-cell and plasma cell tumors in, insertion of *c-Myc* in *Igh* inducing, 1306
bladder cancer in, apoptosis in, flavokawain A inducing, 3479
of breast cancer metastasis to bone, 6130
for Carney complex tumor syndrome, 4506
CEA-transgenic, anti-CEA response in, 1925
cervical cancer in, immunotherapy of, CD4⁺ T cell-mediated antigen-specific, 2018
C57/6J-scld, X-linked dominant growth suppression in, 5690
colon carcinogenesis in, folate transport gene inactivation and, 887
control of genomic instability and epithelial tumor development in, 6488
Cox-2 knockout, decreased mammary tumorigenesis in, 10113
CuZn-superoxide dismutase-deficient, mutation accumulation in, 11271
CY15 in, phenotypical similarity of, to immature dendritic cells, 2560
deregulated estrogen receptor α expression in mammary epithelial cells of, ductal carcinoma *in situ* and, 681
epimorphin overexpression in, promoting mammary cancer, 8617
EWS/FLI-1-dependent Ewing's sarcoma in, 8698
Fancd2^{-/-}/Trp53^{+/+}, epithelial tumor formation in, 85
Fhit-deficient, Vhl haploinsufficiency in, lung cancer susceptibility and, 5576
ganp-Tg, lymphomagenesis in, 5925
gastric cancer in
Helicobacter-induced, loss of Fas-mediated apoptosis accelerating, 10912
MNU-induced, peroxisome proliferator-activated receptor γ and, 4769
gastrin precursors overexpressed in, 2770
of gastrointestinal stromal tumor, 6631
gliomagenesis in, *Ink4a* and *Arf* in, 2065

- HRN, cyclophosphamide pharmacokinetics in, 4211
human breast tumors in, antitumor effect of docetaxel plus antiphenanthridine on, 4408
hyperplastic gastric tumors in, TNF- α -dependent inflammation causing, 9147
immunocompetent, STAT3 knockdown blocking breast tumor formation in, 2532
immunodeficient
 AML in, anti-FLT3 antibodies as therapeutic agents in, 1514
 tumor eradication from, bispecific antibody for, 2882
iMyc^{hi} plasma cell tumors in, 7644
integrin-deficient, mammary gland tumors in, 10324
intestinal tumorigenesis in, threshold level of adenomatous polyposis coli protein for, 8622
Leydig cell tumor growth in, imatinib mesylate inhibiting, 1897
lung cancer in
 effects of mutant p53 alleles on, 10280
 spontaneous, loci affecting, 8158
 TRAIL gene therapy for, 1687
lung tumors in, taxol enhanced by CI-1040 for, 2854
lymphodepleted, tumor regression and editing in, 10569
lymphosarcoma cells in, interaction of Dnm13a with Mbd3 and Brg1 in, 10891
mammary cancer in
 Apc and p53 mutations synergizing to promote, 410
 development of, peroxisome proliferator-activated receptor and, 3950
 inhibition of
 induction of autoimmunity by xenogeneic DNA vaccination in, 1071
 tamoxifen in, 3493
mammary epithelia in, type II TGF- β receptor knockout in, 2296
mammary hyperplasia in, COX-2-mediated, EP2 required for, 4496
mammary tumor formation and metastasis in, Ron receptor signaling augmenting, 1285
melanoma in
 progression of, histamine signaling supporting, 4458
 tumor growth in, endogenous retrovirus promoting, 2588
of mesothelioma, 8090
metastatic cancer in, complement in antibody therapy of, 10562
metastatic carcinoma in, TAP deficiency in, mechanisms underlying, 7485
metastatic melanoma in, therapy of, anti-DEC targeting in, 7007
mismatch repair and tumor suppression in, by *Mlh3* and *Pms2*, 8662
mouse p10 in cell cycle regulation and transformation, 3249
for multiple portal venous injections for liver malignancies, 3823
mutated *SDHC* gene in, apoptosis and tumorigenesis and, 203
myeloperoxidase-null, asbestos effects on, 9670
NQO1-null, sensitivity of, to skin carcinogenesis, 2054
nude
 colon cancer in, AEE788 in targeted therapy of, 3716
 NOK tumorigenesis in, mutagenic study of, 10838
 transgenic, nestin-linked green fluorescent protein, for tumor angiogenesis imaging, 2337, 5352
Ogg1 knockout, skin photocarcinogenesis in, 6006
orthotopic
 lung cancer in, adenoviral vector expressing IFN- β in therapy of, 8379
renal cell carcinoma in, blocking PDGF-D/PDGFR β inhibiting, 5711
of osteosarcoma, ezrin-mediated metastatic behavior in, rapamycin inhibiting, 2406
osteosarcoma tumor growth and metastasis in, osterix inhibiting, 1124
ovarian cancer in
 alendronate inhibiting intraperitoneal dissemination in, 540
 chemotherapy-resistant, CPE-mediated therapy for, 4334
ovarian granulosa cell tumorigenesis in, genetic control of, 1259
PACE4 expression in basal keratinocytes of, tumor progression enhanced by, 7310
pancreatic tumor growth in, uPAR inhibition blocking, 7775
p53 null, lymphomagenesis of, PTP1B regulating, 10088
p53.R270H/WAPCre, mammary tumor development in, 8166
prostate cancer in
 ADAM9 in, 9312
 autologous, eradication of, 1761
 Pten inactivation and, 5730
 sphingosine kinase-1 as chemotherapy sensor in, 11667
prostate dysplasia in, immune function alterations in, 2947
prostate tumor regression in, carboxyl-terminal repressor domain of MBP-1 and, 718
protein kinase C α deficiency in, skin carcinogenesis and, 7356
Rad51d-deficient cells of, extensive chromosomal instability in, 2089
Rassf1a, tumor susceptibility of, 92
renal cancer treatment with mixed chimerism in, 10032
SI0044(*mtsl-1*)-deficient, tumor development in, 3772
skin carcinogenesis in, pRb in, 9678
skin tumorigenesis in, Smad4 and, 8671
skin tumor susceptibility in, *Odc* gene overexpression and, 1146
transgenic
 bladder tumor behavior in, cell cycle regulators and, 1150
 breast cancer of, ErbB2-dependent, antitumor activity of rapamycin in, 5325
 for human papillomavirus type 8, skin tumor development in, 1394
 human *TERT* gene promoter fragment regulation in, 1187
 IGF-IR expression in, tumor development by, 3781
 K5.COX-2, bladder cancer in, 1808
 mammary tumors in, oncolytic HSV for, 1532
 nestin-GFP, tumor angiogenesis in, 2337
 N-Ras^{Q61R}, metastatic melanoma and, 4005
 papillary thyroid cancer in, BRAF expression causing, 4238
 prostate cancer in, preclinical studies in, new ultrasound microimaging technology for, 6337
 salivary gland tumors in, targeted *PLAG1* proto-oncogene overexpression in, 4544
Treg-depleted, tumor regression and autoimmunity in, 8471
Tsc, liver hemangioma in, estrogen and tamoxifen in, 2474
Tsc1^{-/-}, renal tumor induction and somatic LOH in, 10179
tumor suppression in, p53 Ser389 phosphorylation in, 3610
UVB-induced skin patches in, tumor p53 mutations in, 3577
vault poly(ADP-ribose) polymerase-deficient, increased tumorigenesis in, 8846
 vsmc
 B-raf, 11493
 with wild-type p53 alleles, tumorigenicity of MCF7 breast cancer cells in, 1627
MPLSM (multiphoton laser scanning microscopy)
 in differentiation of normal, precancerous, and cancerous squamous epithelia, 1180
MRP5
 resistance to antifolates mediated by, 4425
MRPs (multidrug resistance proteins)
 resistance to antifolates mediated by, 4425
MRS, See **Magnetic resonance spectroscopy (MRS)**
MT1 cells
 lymphoblastoid, mismatch repair defect in, 4525
MTHFR (methylenetetrahydrofolate reductase) polymorphisms
 therapy response in pediatric acute lymphoblastic leukemia and, 2482
MUC4
 in JIMT-1, masking of overexpression of ErbB2 in breast cancer in, 473
MUC6
 in Tn antigen expression in MCF-7 cells, 7880
MUC1 oncoprotein
 GSK3 β -mediated β -catenin degradation blocked by, 10413
Multidrug resistance gene *mdr1*
 aberrant transcription of, 11694
 control of, by *sirt1*, 10183
Multidrug resistance (MDR)
 CD44 interacting with P-glycoprotein and, 6660
 circumventing, by β -galactoside binding protein, 1631
 gefitinib reversing, 6943
 glycosylceramide synthase blockade contributing to, 3861
 impaired nitric oxide synthesis and, 516
 in MCF7 cells, *WTH3* regulation in, 7421
 in sarcoma cell lines, origins of, modeling of, 9388
 splicing factor SPF45 and, 6593
Multidrug resistance protein-1 (MDR-1)
 inhibition of, in restoring paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells, 10381
Multidrug resistance proteins (MRPs)
 resistance to antifolates mediated by, 4425
Multiphoton fluorescence lifetime imaging
 metabolic mapping of breast cells via, 8766
Multiphoton laser scanning microscopy (MPLSM)
 in differentiation of normal, precancerous, and cancerous squamous epithelia, 1180
Multiple endocrine neoplasia (MEN) syndromes, type 2
 RET isoforms in, ZD6474 suppressing, 3538
Multiple myeloma (MM)
 apoptosis in
 ACA inducing, 4417
 dexamethasone-induced, GCS-100 enhancing, 8350
 autocrine IL-6 stimulation in, MnSOD disrupting, 6255
 bortezomib resistance in, GCS-100 overcoming, 8350
 cell cycle dysregulation in, cdk4/cyclin D1 and cdk6/cyclin D2 pairing promoting, 11345
 cells of
 FTY720 activity against, 7478
 growth of, VEGFR-1 promoting, 3185
 centrosome abnormalities in, hyaluronan-mediated motility receptor affecting, 850
 CHIR-12.12 activity against, 5898
 DHEA effects on, 2269
 immunotherapy of, NY-ESO-1 protein transduction for, 10041
 lenalidomide with SGN-40 for, 11712
 Mcl-1 down-regulation in, by seliciclib, 5399
 MICA expression by, 7502
 NOXA-mediated apoptosis in, proteasome inhibitors triggering, 6282
 NOXA regulation in, by proteasome inhibition, 6294
 osteolytic bone disease in, stromal-derived factor-1 α mediating, 1700
 proteasomes in, effects of PS-341 on, 7896
 resveratrol for, 9943
Multiple portal venous injection
 for liver malignancies, mouse models for, 3823
Muscle wasting
 protein degradation in, reduction of, by β -hydroxy- β -methylbutyrate, 277
Musculoskeletal tumors
 NVP-AEW541 activity against, 3868
Mus81 endonuclease activity
 in human cells, BLM helicase facilitating, 2526
Mutagenesis
 bystander, low LET-induced, 9876
Mutation rate
 quantitative measurement of, 8111
Mutation(s)
 accumulation of, in CuZn-superoxide dismutase-deficient mice, 11271

- Apc**, synergy of, with *p53* mutation to promote mammary neoplasia, 410
- β -catenin**, in adrenocortical tumors, 7622
- BRAF**, ovarian tumors with, MAPK inhibition in, 1994
- BRCA2**, functional evaluation and cancer risk assessment, 417
- CDC4**, and CIN in colorectal cancer, 11361
- C-RAF**, in cancer, 9719
- EGFR**, in lung cancer, 7525
- EGFR** tyrosine kinase domain, in lung cancer, 7568
- erythrocyte glycoprotein A gene**, in atomic bomb survivors, cancer risk and, 5462
- FANCC** and **FANCG**, pancreatic cancer and, 383
- Glucocorticoid receptor** gene, mutations of, in childhood ALL, 9712
- homozygous**, in acute myeloid leukemias, uniparental disomy associated with, 9152
- K-Ras**
codon-specific, metabolic phenotypes induced by, 5512
ovarian tumors with, MAPK inhibition in, 1994
- K-Ras**
in colorectal cancer, tumor microenvironment and, 8134
- Lhl1** and **p53** in tumorigenesis, 11297
- in lung cancer, smoking and, 5076
- mitochondrial DNA, in cancer promotion, 1655
- p53**
in benzo(a)pyrene-exposed human -53 knock-in murine fibroblasts, 2583
synergy of, with *Apc* mutation to promote mammary neoplasia, 410
- PKC α**
in anaplastic thyroid cancer, 10199
breast cancer-associated, activation of, 10992
clinical markers in breast cancer and, 2554
in colorectal cancer, functional analysis of, 4562
- point, **RUNX3** inactivation in bladder tumors by, 9347
- protein kinase, in lung cancer, 7591
- β -tubulin, associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells, 9406
- in two short noncoding mononucleotide repeats in colorectal cancers, 4607
- MutL homologous hMLH3**
in DNA mismatch repair, 10759
- MVP**, See **Major vault protein (MVPP)**
- Myc**
cell competition and, 6485
compensatory proliferation and, 6485
IL 10R and CD20 down-regulated by, in B lymphomas, 5454
insertion of, in *Igh* accelerating peritoneal plasmacytomas, 7644
- MYC inactivation**
tumor dormancy and, 4471
- MYCN**
HMGA1 as molecular target for, in neuroblastoma, 8308
- Myelodysplastic syndrome**
decitabine in, complex effects of, 7086
- Myelodysplastic syndromes**
hematopoietic suppression in, p38 MAPK in, 9029
- Myelofibrosis**
idiopathic, nuclear factor- κ B pathway in, 3281
- Myeloid cells**
growth suppression of, *N-ras*-induced, IRF-1 mediating, 797
- Myeloid leukemia, acute**, See **Leukemia, acute myeloid (AML)**
- Myeloid suppressor cells**
arginase-producing, in renal cell carcinomas, 3044
in immune surveillance against metastasis, 11743
- Myeloma**
activity activated marrow-infiltrating lymphocytes against, 2026
multiple (See **Multiple myeloma (MM)**)
- Myeloma cell lines**
velcade cytotoxicity in, Ca^{2+} dysregulation as critical determinant of, 3828
- Myelomonocytic cells**
targeting, to revert inflammation-dependent cancer promotion, 9113
- Myeloperoxidase (MPO)**
breast cancer survival and, 1105
- Myeloproliferative disorders (MPD)**
oncogenic tyrosine kinase targeting centrosome in, 7231
- Myocyte enhancer factor 2 (MEF2)**
in medulloblastoma cell death, 5683
- Myoepithelial cells**
in breast cancer, increase in, progestins initiating, 9779
- Myxoma virus**
antitumor activity of, against gliomas, 9982
- N-acetylcysteine conjugate of phenethyl isothiocyanate**
apoptosis in growth-stimulated lung cells enhanced by, 8538
lung cancer progression inhibited by, 8548
- NAD(P)H:Quinone oxidoreductase 1 (NQO1)**
17-allylamino-demethoxygeldanamycin hydroquinone formed by, 10006
in 3-nitrobenzanthrone activation, 2644
- Nanoparticle targeting**
of anticancer drug, 5317
- Nasopharyngeal cancer**
cyclin D1 amplification in, 8125
family risk of, 8567
sensitization to cisplatin in, mitotic arrest deficient 2 expression inducing, 1450
- Natural killer activity**
in HSP96-treated colon cancer, 3942
- Natural killer (NK) cells**
activation of, dendritic cell-mediated, BCR/ABL promoting, 6409
dendritic cells, crosstalk between, adjuvant hsp70 and, 7942
HSP70-positive tumor exosomes activating, 5238
IFN- γ production by, SHIP1 negatively regulating, 9099
in lysis
of BCR/ABL targets, IFN γ signaling and, 2914
of sodium valproate-treated hepatoma cells, 6321
susceptibility of cancer cells to killing by, after histone deacetylase inhibitor exposure, 11136
- Natural killer (NK) receptors**
expression of, on tumor-infiltrating T cells, 2921
- Navelbine (vinorelbine)**
resistance to, RLP176 mediating, 991
synergism of, with 2-methoxyestradiol in breast cancer, 387
- NAI3 gene**
deletion or translocation of, in cutaneous T-cell lymphomas, 8101
- NBS1**
lack of, inducing hypermutability, telomere instability and, 5544
- NDRG2**
in aggressive meningioma, 7121
- Nephroblastoma**, See **Wilms tumor**
- Nerve growth factor**
antibody to, for prostate tumor-induced bone pain, 9426
- Network analysis**
in human glial brain tumors, 8679
- Neural crest-derived tumors**
neuropeptide Y in, 1719
- Neuregulin**
ErbB2 activation by, in breast cancer, 6801
- Neuroblastoma(s)**
bone metastasis of, bone marrow mesenchymal stem cells in, 1129
brain-derived neurotrophic factor/TrkB protection of, Akt mediating, 2070
EMP3 epigenetic inactivation in, 2565
high mobility group A1 as molecular target for MYCN in, 8308
malignant transformation of, activin A suppressing, 1877
N-myc, *Cdc42*, and *nm23* genes in, 3136
oncogenic potential of LMO3 in, 4587
prognosis in, CpG island methylator phenotype and, 828
proliferation of, mediated by EGFR, 9868
- topotecan blocking HIF-1 α and VEGF in, 4775
- tumor vasculature in, contribution of bone marrow-derived cells to, 3200
- VEGF/Flt1 and HIF-1 α autocrine loop in, 7267
- Neuroendocrine cancer**
neuropeptide Y in, 1719
- Neuroendocrine features**
lung cancers with, *ASH1* as therapeutic target for, 10680
- Neuroendocrine transdifferentiation**
of prostate cancer, protocadherin-PC inducing, 5263
- Neurofibromatosis**
glioma formation in, K-RAS activation and, 236
- Neurofibromatosis 1**
brain tumors associated with, mTOR hyperactivation in, 2755
glioma associated with, dysregulation of methionine aminopeptidase-2 expression in, 9843
- Neuropeptide Y (NPY)**
in neuroendocrine cancer, 1719
- Neuropilin-1**
pancreatic tumor growth suppressed by, 3664
- Neurotrophic receptor TrkB**
in anoikis resistance and metastasis, 7033
- Neutrophils**
oncostatin M produced by, breast cancer cells stimulating, 8896
- NFBD1/Mdc1**
ATR-dependent DNA damage response mediated by, 1158
- NF- κ B**, See **Nuclear factor- κ B (NF- κ B)**
- NH $_2$ -terminal fragments**
of adenomatous polyposis coli protein, tumor-associated, regulation of, 5195
- N-(4-Hydroxyphenyl)retinamide (4-HPR)**
invasion, osteoclastogenesis, and cell growth inhibited by, 9555
- Nitric oxide**
apoptosis induced by, in colon cancer cells, β -catenin overexpression blocking, 8604
synthesis, doxorubicin resistance and, 516
tumor cells sensitized to apoptosis by, 8461
- Nitric oxide synthase, inducible**
expression of, prolactin down-regulating, 7984
immunostimulatory effects of cyclophosphamide controlled by, 5027
- 3-Nitrobenzanthrone (3-NBA)**
activation of, by human NQO1, 2644
- N-nitrosomorpholine**
islet hormone and, cocarcinogenic effects of, 7013
- Nkx3.1**
loss-of-function of, promoting increased oxidative damage in prostate carcinogenesis, 6773
- NKX3.1 suppressor gene**
in human prostate cancer, 1164
- Nm23 genes**
expression of, in neuroblastoma, 3136
- N-myc genes**
Cdc42 down-regulated by, 3136
- NNK**, See **4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)**
- NOK**
tumorigenesis abrogated by, mutagenic study of, 10838
- Non-Hodgkin's lymphoma (NHL)**
risk of, organochlorines in plasma and, 11214
rituximab inhibiting NF- κ B signaling pathway in, 264
transformed, loss of *SMRT* in, 4554
- Nonhomologous end joining**
DNA ligase III in, 4020
- Nonsteroidal anti-inflammatory drugs (NSAIDs)**
claudin-4 induced by, 1868
tumor radiosensitization by, 7911
- Notch**
suppression of *p53* by, in lymphomagenesis, 7159
- Notch1**
in differential response to calcium in culturing normal vs. malignant prostate cells, 9269
in glioma cell survival and proliferation, 2353
JAG1 coexpressed with, in breast cancer, 8530
- Notch3 receptor**
in tumorigenesis, 3555

- Notch signaling pathway**
activation of, in meningiomas, 5070
- Nox4**
for hypoxia-inducible factor 2- α transactivation in VHL-deficient renal cell carcinoma, 9190
- NoxA**
apoptosis mediated by, in melanoma and myeloma cells, proteasome inhibitors triggering, 6282
differential regulation of, by proteasome inhibition, 6294
- Δ Np63 α**
in HSP70 upregulation in human cancer, 758
IGFBP-3 regulated by, 2314
- NPY (neuropeptide Y)**
in neuroendocrine cancer, 1719
- N-Ras**
myeloid cell growth suppression induced by, IRF-1 mediating, 797
- N-Ras^{Q61K}**
activated, expression of, on INK4a-deficient back ground, metastasizing melanoma formation caused by, 4005
- Nr-CAM**
shed ectodomain of, cell motility and tumorigenesis stimulated by, 11605
- Nrf2-ARE signaling**
synthetic triterpenoids activating, 4789
- NS-398**
enhancing photodynamic therapy, 9473
- NSAIDs (nonsteroidal anti-inflammatory drugs)**
claudin-4 induced by, 1868
- NSC-134734**
hypoxia-inducible factor-1 inhibited by, 4918
- NSC-643735**
hypoxia-inducible factor-1 inhibited by, 4918
- NRX1**
proximity of, to *TPR* in cell nuclei, 2572
- Nuclear factor- κ B (NF- κ B)**
activation of
in breast cancer cells, CK2-induced IKK- α /IKK- β in, 11375
chemoresistance in pancreatic cancer and, 1316
activity of, in differentiating PC-3 cells, 11588
apoptosis induction mediated by, by CD437, 6354
Bcl-2 acting in proapoptogenic signaling pathway through, 5063
breast cancer metastasis suppressor 1 negatively regulating, 3586
calcium-dependent, perillyl alcohol inhibiting, 8558
3-CI-ANPC-activated, apoptosis induced by, 4909
expression of, decreased, in macrophages, tumor evasion and, 10578
gene transcription of, in pancreatic cancer, glycogen synthase kinase-3 β and, 2076
inhibition of
3,3'-diindolylmethane-induced breast cancer cell apoptosis and, 364
Gax in, 1414
mechanisms in breast cancer cells dependent on, regulating tumor burden, 3209
signaling pathway of, inhibition of, by rituximab in non-Hodgkin's lymphoma, 264
transcription in cancer cells dependent on, chemotherapeutic drugs blocking, 4273
in transforming growth factor- β 1 production in idiopathic myofibrosis, 3281
- Nuclear receptor 1/2 gene**
silencing of, identification of, by BAMCA, 10233
- Nucleotide excision repair**
in p53-deficient keratinocytes, 8723
- Nucleus of cells**
dynamics of, dual-color imaging of, 4246
- NVP-AEW541**
antitumor activity of, in musculoskeletal tumors, 3868
- NY-FSO-1**
immunotherapy of myeloma based on, protein transduction of dendritic cells for, 10041
- NY-ESO-1 promoter**
CTCT/BORIS binding to, in lung cancer, 7763
- Octamer binding transcription factor Oct-1**
as stress sensor, 10750
- OLIG2**
contributing to leukemogenesis with LM01, 7151
- Oligo array comparative genomic hybridization**
of acquired gemcitabine resistance, chromosomal aberrations and, 10208
- Oligodendrogliomas**
treatment response in, gene expression profiles and, 11335
- Oligonucleotide arrays**
copy number detection using, 6071
- Omega-3 polyunsaturated fatty acids**
syndecan-1 expression in breast cancer cells regulated by, 4442
- Oncogene(s)**
angiogenesis and, 8878
breast cancer, YB-1 as, 4078
fms/fes as, 3518
K-ras, in pancreatic carcinogenesis, 5045
medulloblastoma, *OTX2* as, 919
- Oncogenesis**
HPV16 E6, PDZ domain interactions and, 8266
regulation of cell death in, 8069
unphosphorylated STAT3 in, 939
- Oncolytic adenovirus**
tissue inhibitor of metalloproteinase-3 expression from, 9398
- Oncolytic herpes simplex virus**
double-armed with IL-18 and soluble B7-1, 10663
- Oncolytic therapy**
immunostimulatory tumor therapy combined with, 4343
viral, dose reduction of, cyclophosphamide allowing, 11255
- Oncolytic vaccinia**
replicating, tumor-selectivity of, 9991
- Oncolytic virus**
for gliomas, 2832, 6850
RAD001 with, or colon cancer, 6882
- Oncopoptosis**
bovine herpesvirus 4 inducing, 9463
- Oncoprotein TAF-13/SET**
phosphorylation of, prostate cell growth through, 4578
- Oncostatin M**
neutrophil-derived, breast tumor invasiveness and, 8896
- 103D5R**
as hypoxia-inducible factor 1 inhibitor, 605
- OPG (osteoprotegerin)**
in prostate cancer bone metastasis, 1710
- Oral cavity**
cancer of, multiple microalterations in, detected at high frequency, 7561
lesions of, premalignant, toluidine blue staining in identification of, 8017
- Organic anion uptake transporters**
in gliomas, 11419
- Organochlorines**
in plasma, risk of non-Hodgkin's lymphoma and, 11214
- Ornithine decarboxylase**
in skin tumorigenesis, 572
- Ornithine decarboxylase (*Odc*) gene**
overexpression of, skin tumor susceptibility and, 1146
- Orthodenticle homologue 2**
genomic amplification of, in medulloblastomas, 703
- Osteoblastic bone metastasis(es)**
of prostate cancer
BMP promoting, 8274
VEGF promoting, 10921
prostate cancer cells promoting, through Wnts, 7554
- Osteoblasts**
differentiation of, resveratrol promoting, 9943
- Osteocalcin**
osteomimicry of prostate cancer cells mediated by, 2303
- Osteoclastogenesis**
4-HPR suppressing, 9555
- Osteoclasts**
activity of, increased, in multiple myeloma, 1700
formation of, resveratrol preventing, 9943
- Osteolytic bone disease**
breast cancer and, 3209
- in multiple myeloma, stromal-derived factor-1 α mediating, 1700
- Osteonectin/SPAR/BM-40**
in breast cancer metastasis inhibition, 7370
- Osteopontin**
hyaluronic acid inducing, 686
- Osteoprotegerin (OPG)**
in prostate cancer bone metastasis, 1710
- Osteosarcoma**
expression profiles of, in chemotherapy response prediction, 8142
ezrin-mediated metastatic behavior in, rapamycin inhibiting, 2406
pediatric, chemotherapy-resistant, 1748
tumor growth and metastasis of, osterix inhibiting, 1124
- Osterix**
osteosarcoma tumor growth and metastasis inhibited by, 1124
- OTX2**
as medulloblastoma oncogene, 919
- Ovarian cancer**
adrenomedullin expression in, through HIF-1, 4690
advanced
chemotherapy in, recovery of CD8⁺ T-cell function during, 7000
CpG island methylation of DNA damage response genes in, 8961
angiogenesis of, interleukin-6 in, 10794
apolipoprotein E in, 331
apoptosis in, Fas signaling and MDA-7/IL-24 mediating, 3017
caspase-1 α down-regulated in, 8591
chemotherapy-resistant, CPE-mediated therapy for, 4334
CXCR4 in, tumor necrosis factor- α up-regulating, 10355
cytochrome P450 1A1 overexpression in, 3726
dissemination of, suppression of, thalidomide in, 10464
Drosophila Eyes Absent Homologue 2 in, 925
EIA gene therapy for, resistance to, Bcl-2 antisense oligonucleotide overcoming, 8406
epithelial
colony-stimulating factor-1 and, 3762
prevention and treatment of, COX-1 in, 3735
epithelial-mesenchymal transition in, endothelin-1 promoting, 11649
granulosa cell
genetic control of, 1259
misregulated Wnt/ β -catenin signaling in, 9206
HE4 overexpression in, 2162
hyaluronidase in, MRI of, 10316
interleukin-4 receptor targeting for, 8388
km23 dynein light chain alterations in, 6526
LPA induction of COX-2 in, 2234
malignant transformation of, testis promoting, 868
mitogen-activated protein kinase pathway inactivation in, 1994
neovascularization in, CXCL12 and vascular endothelial growth factor synergistically inducing, 465
paclitaxel-resistant, restoring paclitaxel sensitivity in, 10381
peritoneal dissemination of, CD9 down-regulation in, 2617
plasmacytoid dendritic cells inducing CD8⁺ regulatory T cells in, 5020
progression of, choline metabolism in, 9369
A Ras homologue member 1 inhibiting STAT3 in, 6701
resistant, ErbB receptor signaling in, 6789
risk of, androgen receptor variation and, 5974
SEI-1 in, 6504
stem and progenitor-like cells in, 3025
targeting of lysophosphatidic acid acyltransferase- β in, 9415
tumorigenicity of, suppression of, with truncated EGFR, 3243
in vivo model of, alendronate inhibiting intraperitoneal dissemination in, 540
- Ovarian epithelial cells**
claudin-3 and claudin-4 expression in, function of, 7378

- Ovarian tumors**
serous, expression profiling of, 10602
- Oxidative stress**
antitumor activity of siramesine and, 8975
in apoptosis and tumorigenesis, 203
chemotherapy-induced, sensitization of glioma cells to Fas-dependent apoptosis by, 5248
in prostate carcinogenesis, loss-of-function of *Nkx3.1* promoting, 6773
prostatic carcinogenesis and, 2498
responses to
metexalin gadolinium and zinc inducing, in B-cell lines, 11676
nuclear HB-EGF in, 8242
- Oxygen deprivation**
cells exposed to, cell death and, 3171
- p14 alternating reading frame**
subnuclear redistribution of, DNA damage triggering, 9834
- p16**
latent membrane protein 1 inducing, 8826
- p21**
ATM cooperating with, to suppress aneuploidy, 8747
transcriptional repression of, 3980
- p21/cyclin-dependent kinase-interacting protein 1**
in gastric carcinoma cells, sonic hedgehog signaling pathway regulating, 10822
- p21^{WAF1/CIP1}**
induction of, phenoxodiol inducing G₁-S arrest by, 3364
- p27^{Kip1}**
cooperation between Cdk4 and, in tumor development, 3846
degradation of, BCR-ABL-mediated, in CML, 3264
expression of, induced, pancreatic cancer cell proliferation inhibited by, 4870
in intestinal tumorigenesis, 9363
- p38**
cyclooxygenase-2 regulated by, in HMEC and DCIS, 1792
phosphorylation of, CD26/dipeptidyl peptidase IV regulating, 1973
- p38 MAPK**
defective, in ALL cells, 3290
genistein inhibiting, 3470
hematopoietic suppression in myelodysplastic syndromes and, 9029
HL60 cells activated by, 8-chloro-cyclic AMP-induced growth inhibition and apoptosis mediated by, 4896
- p43**
overexpression of, mitochondrial activity stimulated by, 4282
- p53(s)**
activation of, by MDM2 antagonists in chemo protection, 1918
apoptosis mediated by
in colorectal cancer, GSK-3 β inactivation promoting, 9012
matrix metalloproteinases 9 and 10 inhibiting, 4261
in chronic inflammatory stress, 10255
decoy receptor 2 as target gene of, chemosensitivity regulated by, 9169
effect of, on colorectal cancer, 8951
genetic alterations in, in malignant transformation, 4530
gene transcription regulated by, in ionizing radiation response, 7666
homeobox *Mis1* as regulator of, 749
keratinocytes deficient in, DNA repair in, 8723
loss of, with *Fbxw7* gene loss, epithelial tumor development and, 6488
lower induction of, sensitivity of *NQO1*-null mice to carcinogenesis and, 2054
modulating RPA-dependent and RPA-independent WRN helicase activity, 1223
mutant
depletion of, cytotoxicity of histone deacetylase inhibitors and, 7386
transcriptional and apoptotic activities of, 2108
mutations of
in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts, 2583
effects of, on murine lung cancer, 10280
with *Lkb1* mutation in tumorigenesis, 11297
tumor, in UVB-induced mouse skin patches, 3577
phosphorylated, DNA damage recognition and, 10810
phosphorylation and activation of, nitric oxide-induced apoptosis dependent on, 6097
PTEN expression and, 601
regulation and function of, in renal cell carcinoma, 6498
regulation of, *in vivo*, early growth response 1 in, 5133
in ribosomal S6 kinase 2 and histone H3 interaction, 3596
signaling pathways and, 6601
suppression of, by Notch in lymphomagenesis, 7159
in tetraploidy checkpoint regulation, 6685
topoisomerase I degradation dependent on, 8920
translocation of, to mitochondria, manganese superoxide dismutase inactivation and, 3745
tumor suppressor activities of, *in vivo*, 9971
- p53 and DNA damage-regulated IQ motif protein (PIQ)**
cloning and characterization of, 10725
- p53 network**
novel genes in, 5096
- p53 polymorphisms**
risk of esophageal squamous cell carcinoma and, 9582
- p53CSV**
in cell-survival pathway, 1197
- p53-defective prostate cancer cells**
chemosensitization of, 2872
- p53/IMPDH-dependent immortal DNA strand regulation**
in adult stem cells, 3155
- p53 Ser389 phosphorylation**
in tumor suppression, 3610
- p53 tumor suppressor**
nonautonomous effects of, in carcinogenesis, 1627
- p53 tumor suppressor gene**
R270H mutation of, mice expressing, mammary tumor development in, 8166
- p53 tumor suppressor gene promoter**
methylation of, maintenance of, interleukin 6 supporting, 4673
- p57^{Kip2}**
induction of, p73 β -mediated apoptosis requiring, 2186
- p65**
cleavage of, caspase-mediated, TRAIL-induced apoptosis promoted by, 6111
- p73**
apoptosis dependent on, through death receptor, 2787
- p73 β**
apoptosis mediated by, p57^{Kip2} induction and IEX-1 inhibition in, 2186
- p90 ribosomal 6 kinase**
in cancer cell proliferation, 1027
- p120^{EAP}**
cyclin A2 regulation by *RASSF1A* via, 2690
- p210^{BCR-ABL}**
SDF-1 chemotactic response inhibited by, via CXCR4 signaling alterations, 2676
- p270 (ARID1A/SMARCF1) subunit**
of mammalian SWI/SNF in cell cycle regulation, 9236
- p300**
modulating nuclear morphology in prostate cancer, 708
prostate-specific antigen activation in prostate cancer and, 5965
- p300/CBP**
inactivation of, to bypass senescence, 8298
- PACE4**
expression of, enhancing tumor progression, 7310
- Paclitaxel**
antiangiogenic concentrations of, inducing increased microtubule dynamics in endothelial cells, 2433
- combined with lonafarnib, tubulin acetylation enhanced by, 3883
resistance to
antioxidant capacity and, 8455
targeting of class III β -tubulin by IDN5390 in overcoming, 2397
synergism of, with 2-methoxyestradiol in breast cancer, 387
synergistic anticancer effects of amifostine and, on endometrial cancer, 9517
therapeutic effects of, against bone metastasis of prostate cancer, zoledronate enhancing, 3707
- PAH (polycyclic aromatic hydrocarbon)**
exposure to, altered gene expression from, 1251
- Pain**
bone, prostate tumor-induced, anti-NGF therapy for, 9426
- Pancreatic cancer**
angiogenesis in, SPA blocking, 2738
Bcl-XL depletion in, 2344
cells in
motility of, P-cadherin promoting, p120ctn interacting with, 3092
proliferation of, inhibition of, through induced p27^{Kip1} expression, 4870
sensitization of, to endoplasmic reticulum stress, bortezomib in, 11658
survival of, glycogen synthase kinase 3 β regulating, 2076
chemoresistance in, nuclear factor- κ B activation and, 1316
COX-2 inhibitor in, 982
development of, K-ras oncogene in, 5045
effects of ILK inhibition on, 1497
FANCC and FANCG mutations and, 383
farnesyl transferase inhibitor-induced STAT2 inhibition in, 2861
growth of
ERRP inhibiting, 3877
neuropilin-1 suppressing, 3664
SPA blocking, 2738
G691S RET polymorphism and, 11536
IL-8 in, SRC regulating, 7214
insulin receptor substrate activating phosphoinositide 3-kinase in, 9164
5-lipoxygenase as marker for, 6011
orthotopic model of
comparison of whole-body fluorescence imaging and MRI on, 9892
gemcitabine potentiated by gemistein for, 9064
plasma protein profiling in detection of, 10613
poor survival in, S100A6 and, 3218
RAB6KIFL and *DLG5* in, 105
radiosensitivity of, K-Ras in, 8433
serum proteins in, antibody microarray profiling revealing, 11193
targeted therapy of, 10371
targeted virus replication plus immunotherapy for, 9056
taxane chemosensitivity in, 2899
tumor growth in, urokinase plasminogen activator receptor inhibition blocking, 7775
tumor-reactive T cells in, 10079
xenograft of, gemcitabine with CpG-oligodeoxynucleotides for, 6388
- Pancreatic intraepithelial neoplasia (PanIN)**
gene expression profiles in, 1619
- PanIN (pancreatic intraepithelial neoplasia)**
gene expression profiles in, 1619
- Papillomavirus, human. See Human papillomavirus (HPV)**
- Paracrine loop**
colony-stimulating factor-1/epidermal growth factor, breast cancer invasiveness and, 5278
- Paricalcitol**
against myeloid leukemia, 2488
- Parotid gland**
radioprotection of, 10486
- PARP-1 (poly(ADP-ribose) polymerase-1)**
lack of, cellular sensitivity to arsenite and, 10977

- Parthenolide**
apoptosis induced by, susceptibility of cholangiocarcinoma cells to, 6312
apoptosis-related genes and, 2804
- Particle irradiation**
in metastasis suppression, 113
- Paclitaxel**
sensitivity to, restoring, in paclitaxel-resistant ovarian cancer cells, 10381
- PC-3 cells**
CXCR4 expression in, up-regulation of, by stromal-derived factor-1 α , 9891
- PCOTH**
overexpression of, in prostate cancer, 4578
- PDEF (prostate derived Ets factor)**
in epithelial migration and invasion, 11572
- PDGF**. See **Platelet-derived growth factor (PDGF)**
- PDT**. See **Photodynamic therapy (PDT)**
- PED**
AKT-dependent chemoresistance in breast cancer cells mediated by, 6668
- Pediatric patients**
leukemia in, treatment response in, MTHFR polymorphisms and, 2482
osteosarcoma in, chemotherapy-resistant, 1748
Wilms tumor in, primary, relapse of, molecular signature for, 2592
- PELPI (proline-, glutamic acid-, and leucine-rich protein-1)**
in STAT activation, 5571
- Penetratin**
tumor retention of single-chain Rvs enhanced by, 7840
- Pericentriolar material (PCMI)**
JAK2 fused to, in leukemia, 2662
- Pericytes**
endothelial precursor cells, 9741
- Perifosine**
antileukemic synergism between histone deacetylase inhibitors and, 2422
in glioma therapy, 7429
- Perillyl alcohol**
calcium-dependent constitutive nuclear factor- κ B pathway inhibited by, 8558
- Perinuclear compartment (PNC)**
prevalence of, breast cancer prognosis and, 246
- Peripheral benzodiazepine receptor (PBR)**
targeting of, by photodynamic therapy, apoptosis induced by, 11051
- Peritoneum**
dissemination of ovarian cancer in, CD8 down-regulation in, 2617
- Peroxidase, cellular**
in anthracycline inactivation, 6346
- Peroxiredoxin II**
in radiation-resistant MCF-7 breast cancer cells, 10338
- Peroxisome proliferator-activated receptor γ (PPAR γ)**
anoikis in hepatocellular carcinoma cells caused by, 2251
MNU-induced gastric carcinogenesis and, 4769
- Peroxisome proliferator-activated receptor ligands**
in lung cancer growth inhibition, 4181
- Peroxisome proliferator-activated receptor (PPAR)**
carcinogenesis and, 3950
- Perp**
deficiency of, skin carcinogenesis suppressed by, 6551
- PET**. See **Positron emission tomography (PET)**
- PEX**
as angiogenesis inhibitor, 3967
- PGP.5 promoter methylation**
in esophageal squamous cell carcinoma, 4963
- Pharmacokinetics**
of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments, 622
- Phenethyl isothiocyanate**
N-acetylcysteine conjugate of
apoptosis in growth-stimulated lung cells enhanced by, 8538
lung cancer progression inhibited by, 8548
- Phenotype(s)**
c-Myc, multiple, restoration of, by c-Myc target genes with overlapping functions, 2097
malignant, low energy mimicry suppressing, 2441
tumor, reversion of, by VEGFR-2 blockade, 1294
- Phenoxodiol**
G $_1$ -S arrest induced by, p21^{WAF1} induction in, 3364
- Phenochromocytomas**
novel susceptibility loci for, 9651
- Phosphatase and tensin homologue deleted on chromosome 10**. See **PTEN**
- Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway**
laminin-mediated activation of, in small cell lung cancer, therapeutic resistance and, 8423
- Phosphatidylinositol-3 kinase/Akt pathway**
hypoxia-independent hypoxia-inducible factor-1 activation of, in HER2 overexpressing cells, 3257
- Phosphatidylinositol 3-kinase/Akt pathway**
inhibition of, antitumor effects of, 8339
- Phosphatidylinositol 3-kinase (PI3K)**
activation of, transforming growth factor- β in, 10431
- Phosphatidylinositol 3-kinase/protein kinase B inhibitors**
in synergistic augmentation of rapamycin-induced autophagy in glioma cells, 3336
- Phosphoglycerate mutase**
cellular life span and, 177
- Phosphoinositide 3-kinase (PI3K)**
insulin receptor substrate activating, in pancreatic cancer, 9164
in signaling, ABL oncogenes and, 2047
- Phosphoinositide 3-kinase (PI3K) pathway**
inhibition of, TAO suppressing prostate cancer cell growth by, 9807
- Phospholipid scramblase 3 (PLS3)**
PKC- δ -induced phosphorylation of, AD198 inducing apoptosis through, 10016
- Phosphoserine aminotransferase**
DNA methylation of, response to endocrine therapy for recurrent breast cancer and, 4101
- Photodynamic therapy (PDT)**
celecoxib and NS-398 enhancing, 9473
heat shock proteins and, 1018
hexaminolevulinate-mediated, targeting PBR by, apoptosis induced by, 11051
- Photoimmunotherapy**
multipeptide HER2-targeted, 6371
- Phytoestrogen**
tamoxifen-associated breast cancer prevention and, 879
- Pigment epithelial-derived factor (PEDF)**
functional epitopes of, in prostate cancer, 5144
- PI3K**. See **Phosphoinositide 3-kinase (PI3K)**
- PIK3CA gene mutations**
in anaplastic thyroid cancer, 10199
breast cancer-associated, activation of, 10992
clinical markers in breast cancer and, 2554
in colorectal cancer, functional analysis of, 4562
PTEN gene mutations coexisting with, in endometrial cancer, 10669
- Pilocarpin**
in radioprotection of parotid gland, 10486
- Pilocytic astrocytomas**
juvenile, expression analysis of, 76
- PIQ (p53 and DNA damage-regulated IQ motif protein)**
cloning and characterization of, 10725
- Pituitary adenomas**
human clinically nonfunctional, 10214
- Pituitary cancer**
PKC α -D294G in, fails to transduce extracellular signals, 4520
- Pituitary tumors**
accelerated progression of, melanotroph carcinogenesis suppression and, 787
galectin-3 expression in, DNA methylation and, 1136
- PI3K-Akt-mTOR-S6K1 signaling**
activation of, 15(S)-HETE inducing angiogenesis via, 7283
- Plakophilin 3 oncogene**
as target for lung cancer treatment, 7102
- Plasma coagulation**
in glioblastoma, regulation of, 1406
- Plasmacytomas**
peritoneal, insertion of Myc into Igh accelerating, 7644
- Plasma protein profiling**
in pancreatic cancer detection, 10613
- Plasmin**
proteolysis of CCN1 by, 9705
- Plasminogen activator**
tissue-type, β -catenin activated by, 526
urokinase-type, receptor for, inhibition of, blocking pancreatic tumor growth, 7775
- Platelet-derived growth factor (PDGF)**
autocrine gene expression dependent on, in glioblastoma cells, 5523
- Platelet-derived growth factor-AA (PDGF-AA)**
as VEGF regulator in lung cancer, 7241
- Platelet-derived growth factor-d/platelet-derived growth factor receptor β signaling**
blocking of, renal cell carcinoma inhibited by, 5711
- Platelet-derived growth factor receptor (PDGFR) signaling**
inhibition of, for pancreatic cancer, 10371
- Platelet factor-4**
as angiogenesis inhibitor, 3967
- Pleomorphic adenoma gene 1 (PLAG1)**
proto-oncogene
overexpression of, in salivary gland tumors in transgenic mice, 4544
- Plexin D1**
expression of, tumor-specific, 8317
- PLZF/RAR α**
leukemia-associated, charged pocket in BTB/POZ domain and, 6080
- Pms2**
DNA mismatch repair and tumor suppression and, 8662
- Point mutations**
RUNX3 inactivation in bladder tumors by, 9347
- Pokemon**
in cancer pathogenesis, 8575
- Poliovirus vaccines**
oral, contamination of, with infectious SV40, 10273
- Pollution, environmental**
3-nitrobenzanthrone in, activation of, by human NQO1, 2644
- Polo-like kinase 1 (PLK1)**
depletion of, small interfering RNA-mediated, cytotoxicity toward cancer cells with, 2698
- Poloxamer 407**
in viral gene delivery in solid tumors, 7541
- Poly(ADP-Ribose) polymerase-1 (PARP-1)**
camptothecin sensitivity and, 3894
lack of, cellular sensitivity to arsenite and, 10977
- Poly(ADP-Ribose) polymerase (PARP) inhibition**
Brca2 deficiency sensitizing cells to, 10145
- Polyamine**
catabolism of, intestinal tumorigenesis and, 5390
- Polycyclic aromatic hydrocarbon (PAH)**
exposure to, altered gene expression from, 1251
- Polymerase η in cisplatin tolerance**, 9799
- Polymorphisms, gene**. See **Gene polymorphism(s)**
- Polyomavirus middle T (PyVmt) antigen**
tumor formation and metastasis induced by, TGF- β receptor knockout and, 2296
- Polyomavirus VP1/VP2Her2 virus-like particles**
outgrowth of HER-2/*neu*-expressing tumors prevented by, 5953
- Polyplodidy**
induction of
by histone deacetylase inhibitor, 7832
- Polyps**
intestinal, regression of, CD4⁺CD25⁺ regulatory lymphocytes inducing, 3998
- Positron emission tomography (PET)**
3-deoxy-3'-[¹⁸F]fluorothymidine, in early detection of tumor response to chemotherapy, 4202
[¹⁸F]fluorothymidine, in imaging of cellular proliferation in breast cancer, 10104
for HER2-positive tumor xenograft imaging, 1471
imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments by, 622

- Positron therapy**
for breast cancer with ^{18}F -2-deoxy-2-fluoro-D-glucose, 698
- PP2A A α**
cancer-associated, functional haploinsufficiency and tumorigenicity induced by, 8183
- PRAME (preferentially expressed antigen of melanoma)**
tumorigenicity reduced by, 7348
- PRb. See Retinoblastoma protein (pRb)**
- Precancer**
epithelial, diagnosis of, multiphoton microscopy in, 1180
- Precursor cells**
endothelial, pericytes and, 9741
- Preferentially expressed antigen of melanoma (PRAME)**
tumorigenicity reduced by, 7348
- Premalignant clones**
fate of, before tumor onset, 1234
- 6-Prenylchrysin**
ABCG2 inhibition by, 4852
- Proangiogenic signaling pathway**
Bcl-2 acting in, 5063
- Progenitor-like cells**
ovarian cancer behavior and, 3025
- Progesterone receptor(s)**
in lung cancer, 6450
PIK3CA mutations correlated with, in breast cancer, 2554
- Progestins**
luminal to myoepithelial switch in breast cancer initiated by, 9779
- Programmed cell death 4 (Pcdcd4)**
Akt phosphorylating and regulating, 11282
epidermal expression of, tumorigenesis suppressed by, 6034
- Prolactin**
16-kDa, p38 MAPK/Stat1/IRF-1 signaling to inducible nitric oxide synthase/nitric oxide inhibited by, 7984
- Prolactin fragment**
as angiogenesis inhibitor, 3967
- Prolactin signaling**
absence of, medullary thyroid cancer and, 8497
- Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1)**
altered subcellular localization of, in breast cancer cells, 7724
in STAT activation, 5571
- Promyelocytic leukemia bodies, ALT-associated, 2722**
- Promyelocytic leukemia (PML) function**
suppression of, by hepatitis C virus core protein in hepatoma cells, 10830
- Prostaglandin(s)**
metabolism of, calcitriol regulating, 7917
- Prostaglandin D synthase-derived products**
stromal cell, in prostate cancer growth suppression, 6189
- Prostaglandin E $_2$ (PGE $_2$)**
EP2 receptor for, in skin tumor development, 9304
inhibition of, T regulatory activities in lung cancer reduced by, 5211
intestinal tumor growth promoted by, signaling pathways responsible for, 1822
liver receptor homologue-1 expression in breast cancer and, 657
MAPK/Erk pathway signaling activated by, 6275
- Prostaglandin F $_{2\alpha}$ -FP receptor**
angiogenic role of, in endometrial adenocarcinomas, 7707
- Prostate cancer**
advanced, risk of, sun exposure and vitamin D receptor gene polymorphisms and, 5470
ALDH1a2 as candidate tumor suppressor in, 8118
androgen-independent, reversion of, to androgen-stimulated phenotype, androgen causing, 2082
androgen-independent progression in, increased Hsp27 facilitating, 11083
androgen receptor gene in, 8514
androgen receptor in, HER-2/neu kinase inhibition impairing, 3404
- androgen-responsive cells in, molecular target of vitamin D in, 4762
anoikis resistance in, XIAP protein contributing to, 2378
apoptosis in
induction of
bortezomib plus TRAIL in, 4902
CKIs in, 7717
decursin in, 1035
NF- κ B-mediated, by CD437, 6354
RNA interference-mediated silencing of *acetyl-CoA-carboxylase- α* , 6719
REIC/Dkk-3 overexpression inducing, 9617
thiazolidenediones mediating, 1561
 β_{1A} integrin expression in, 6692
blood test for, 4126
bone morphogenetic proteins and, 5769
bone pain induced by, anti-NGF therapy for, 9426
 γ -catenin gene regulation in, 2130
CCI-779 for, 2825
cells in
androgen-sensitive, Fas-mediated apoptosis of, Lupeol inducing, 11203
growth of
stromal cell PGDS suppressing, 6189
tocopherol-associated protein suppressing, 9807
migration of, 3β -adial inhibiting, 5445
proliferation of, ribosomal S6 kinase regulating, 3108
PSGL-1 and EL-1 expression on, 5750
cyclin D1 expression in, bombesin-induced, via *Egr-1*, 9934
dasatinib action in, 9185
detection of, EPCA in, 4097
development of, oxidative damage in, loss-of-function of *Nkx3.1* promoting, 6773
dipeptidyl peptidase blocking basic fibroblast growth factor signaling pathway in, 1325
DOC-2/DAB2 modulating androgen receptor-mediated signal cascade in, 9906
EGF signaling in, steroid receptor regulation of, 10585
emodin inhibiting growth of, 2287
EphB4 expression and biological significance in, 4623
epigenetic analysis of, 4218
Frzb/secreted frizzled-related protein 3 and, 9762
growth and spread of, KLF6 splicing and, 5761
growth stimulation in, calcitriol attenuating, 7917
hedgehog-Gli signaling in, 2990
HYAL1 hyaluronidase in, 7782
hyperthermia-induced proteasome inhibition in, 4836
IGF-I induction of VEGF in, activated Ras enhancing, 2085
immune function alterations in, 2947
immunotherapy for, human CTL epitopes in, 6435
insulin-like growth factor-I receptor in, androgens up-regulating, 1849
invasion in, CXCR-4-induced, YM529 inhibiting, 8818
invasiveness of, suppression of, prostate-specific membrane antigen in, 727
lymphangiogenesis in, metastasis and, 9789
macrophage inhibitory cytokine 1 stores in, 2330
metabolic characterization of, tissue magnetic resonance spectroscopy in, 3030
metastasis of, to bone
antivascular therapy of, 3707
osteoblastic
BMP promoting, 8274
through Wnts, 7554
osteoprotegerin in, 1710
milk thistle compounds in, 4448
murine
ADAM9 in, 9312
autologous, eradication of, 1761
network analysis of cells in, 3081
neuroendocrine transdifferentiation of, protocadherin-PC inducing, 5263
NKX3.1 suppressor gene in, 1164
osteoblastic activity mediated by, VEGF promoting, 10921
- osteomimicry of, osteocalcin and bone sialoprotein mediating, 2303
p300 and PSA activation in, 5965
PC-3 cells in, differentiation of, increased NF- κ B activity in, 11588
PCOTH overexpressed in, 4578
p53-defective cells in, chemosensitization of, 2872
pigment epithelial-derived factor functional epitopes in, 5144
p300 modulation of nuclear morphology in, 708
preclinical model of, tumor evolution in, 10243
prevention of, glycosylation of gp96 and, 6466
progression of, hormone-refractory, 11565
protein kinase D1 phosphorylating E-cadherin in, 483
PSA expression in, 8003
radioimmunotherapy of, tomeregulin-targeted, 2846
radiotherapy of, antibody-based, mindin/RG-1 as target of, 8397
reactive, anoikis in, 11230
regression of, carboxyl-terminal repressor domain of MBP-1 and, 18
risk of
alternative splicing of *KLF6* gene and, 1213
genetic linkage of, to *FHIT*, 805
manganese superoxide dismutase polymorphism and prediagnostic antioxidant status and, 2498
meat and meat mutagens and, 11779
short PRLR up-regulating VDR and p21/waf1 in, 7509
sphingosine kinase-1 as chemotherapy sensor in, 11667
SRC-3 in, 7976
SRC-1 in promotion of, 7959
stem cells in, tumorigenic, prospective identification of, 10946
stromal-to-epithelial signaling in, *SFRP1* as mediator of, 10423
susceptibility gene mapping in, 2610
susceptibility to, toll-like receptor 4 and, 11771
targeted elimination of, by genetically directed T lymphocytes, 9080
therapy of
cannabinoid receptor as target for, 1635
caspase and IL-12 in, 4309
gene, PSES enhancer in, 1941
TRAIL-induced apoptosis in, tunicamycin enhancing, 6364
in transgenic mouse model, preclinical studies in, new ultrasound microimaging technology for, 6337
tumorigenesis in
Ack1 promoting, 10514
connective tissue growth factor promoting, 8887
TWIST in, 5153
xenoestrogen action in, 54
xenografts of
effects of CCI-779 on, 2825
growth of, bicalutamide promoting, 9611
- Prostate derived Ets factor (PDEF)**
in epithelial cell migration and invasion, 11572
- Prostate gland**
epithelial cells of
c-Myc immortalizing, 2179
COX-2 expression and activity in, Rb/E2F regulating, 3633
normal vs. malignant, culture requirements for, 9269
p38 MAPK invasion in, genistein inhibiting, 3470
thrombospondin-1 production in, androgens repressing, 300
- Prostate-specific antigen (PSA)**
activation of, in prostate cancer, p300 regulating, 5965
expression of, in prostate cancer, 8003
- Prostate-specific membrane antigen (PSMA)**
in prostate cancer invasiveness suppression, 727
targeting of, by genetically directed human T cells, 9080
- Proteasomes**
activity of, increased, in breast cancer, 5599
inhibition of
hyperthermia-induced, in prostate cancer cells, 4836
NOXA regulation by, 6294

- in multiple myeloma cells, effects of PS-341 on, 7896
- Protein(s)**
bone morphogenic, overexpression of, in malignant melanoma, 448
heat shock (See **Heat shock proteins (HSP)**)
valosin-containing, phosphorylation of, after DNA damage, 7533
- Protein 1 fusion protein**
Hsp70-like, CEA-specific CD8⁺ CTL response enhanced by, 4947
- Protein 4**
secreted frizzled-related, methylation silencing of, WMT signaling in mesothelioma and, 743
- Protein expression profiling**
in predicting breast cancer prognosis, 767
- Protein kinase(s)**
DNA-dependent
catalytic subunit of, deficiency in, in ATM down-regulation, 1670
inhibition of, autophagy in glioma induced by, 4368
noncytotoxic radiation-sensitizing drugs targeting, 4987
mitogen-activated (See **Mitogen-activated protein kinase (MAPK)**)
serum and glucocorticoid-inducible, antiapoptotic effect of, 457
somatic mutations of, in lung cancer, 7591
targeted by gefitinib, 379
- Protein kinase A (PKA)**
disruption of, immortalization and dysregulation of D-type cyclins from, 10307
FLT3/ITD prevention of apoptosis via, 7338
- Protein kinase A signaling pathway**
cAMP-dependent, in prostate cancer cells, 2303
- Protein kinase C**
apoptosis potentiated by, matrix metalloproteinases 9 and 10 inhibiting, 4261
- Protein kinase C α**
deficiency of, impaired epidermal hyperplasia and tumor formation enhancement from, 7356
- Protein kinase C α (PKC α)-D294 mutant**
in pituitary and thyroid tumors fail to transduce extracellular signals, 4520
- Protein kinase C δ**
PLS3 phosphorylation induced by, AD198 inducing apoptosis through, 10016
- Protein kinase C ϵ**
apoptosis and survival of glioma cells regulated by, 7301
as breast cancer biomarker, 8366
inactivating cysteine switch in, 10478
- Protein kinase C γ**
atypical, as oncogene in lung cancer, 8905
- Protein kinase C ζ**
in EGF-induced chemotaxis, 1433
- Protein kinase DI**
E-cadherin phosphorylation by, in prostate cancer, 483
- Protein kinase G**
15-LOX-1 expression induced by, in colon cancer, 8442
- Protein molecular signatures**
in cancer tissues, 10642
- Protein-protein interactions**
small molecule-mediating, fusion protein complementation imaging of, 7413
- Protein tyrosine phosphatase 1B (PTP1B)**
lymphomagenesis of p53 null mice regulated by, 10088
- Proteolysis**
in cachexia, reduction of, by β -hydroxy- β -methylbutyrate, 277
of CCN1 by plasmin, 9705
- Proteomic analysis**
brain tumor prognosis based on, 7674
of disease-perturbed networks in prostate cancer cells, 3081
of gefitinib selectivity, 379
of human clinically nonfunctional pituitary adenomas, 10214
- Proteotoxicity**
bortezomib inducing, 11510
- Protocadherin-PC**
neuroendocrine transdifferentiation of prostate cancer induced by, 5263
- Protopanaxadiol saponins**
apoptosis mediated by, COX-2 inhibiting, 1952
- PS-341**. See **Bortezomib (Velcade)**
- PSA (prostate-specific antigen)**
expression of, in prostate cancer, 8003
- PSes enhancer**
adenovirus gene expression control by, in prostate cancer therapy, 1941
- Pseudopalisading necrosis**
in glioblastoma, regulation of, 1406
- PSMA (prostate-specific membrane antigen)**
in prostate cancer invasiveness suppression, 727
- Psoriasis**
in breast tumor progression, 11326
expression of, BRCA1 and c-Myc repressing, 10265
- PTEN**
expression of, p53 and, 6601
inactivation of, in mouse prostate cancer, 5730
loss of
in breast cancer, *PIK3CA* mutations correlating with, 2554
transforming growth factor β -mediated invasion increased by, 11276
nuclear, regulating cell cycle, 8096
overexpression of, Wnt-1-induced mammary tumorigenesis inhibited by, 6864
in tissue factor regulation in glioblastoma, 1406
in tumor suppression, 5172
- PTEN (chromosome 10) nuclear import**
major vault protein-mediated, 4108
- PTEN mutations**
PIK3CA gene mutations coexisting with, in endometrial cancer, 10669
- PTK787/ZK222584**
hepatocellular carcinoma growth arrested by, 3691
- PUMA (P53 up-regulated modulator of apoptosis)**
overexpression, of inducing reactive oxygen species generation in colorectal cancer cells, 1647
- Piwafl**
down-regulation of, Src inhibiting adriamycin-induced senescence through, 8927
- QLT0254**
tumor growth inhibition by, 1497
- Quinols**
antitumor, thioredoxin as target for, 3911
- RAB GTPases**
emerging role of, in cancer and human disease, 2516
- RAB6KIFL gene**
with *DLG5*, pancreatic cancer and, 105
- RAB25 overexpression**
in cancer, 2516
- Rab11 trafficking**
hypoxia-induced, carcinoma invasion promoted by, 2761
- Rac3-mediated transformation**
multiple effector pathways required for, 9883
- R3230Ac tumors**
glucose consumption in, heterogeneity of, 5163
- RAD001**
with oncolytic virus for colon cancer, 6882
- RAD9**
amplification of, DNA methylation and, in breast cancer, 8646
haploinsufficiency for, 933
- RAD51**
chromosomal stability and, 2089
function of, BRCA1 regulating, 11384
- Radiation**
antiangiogenesis and chemotherapy combined with, 3643
gamma
bystander effect of, *in vivo*, chromosome instability from, 5668
protecting cells from, oncogenic H-Ras up-regulating Ku80 expression in, 6811
sensitization for, second mitochondria-derived activator of caspase inducing, 10502
- gene expression changes induced by, in glioma cells, orthotopic growth and, 10389
heart damage from, early radiation-induced lung function loss from, 6509
heart disease induced by, mast cells and, 3100
ionizing
adenovirus infection, dynamin 2-mediated, 5493
CK2 inhibiting apoptosis after, 4362
herpes simplex virus 1 activated by, 9479
low-dose
CXC chemokines up-regulated by, in fibroblasts, 10159
perturbation of breast tissue microenvironment induced by, 6734
NBS1 mutation by, telomere instability and, 5544
response to, identification of novel p53 target genes in, 7666
sensitivity to, tumorigenicity and, HMG1 and, 6711
low linear energy transfer, bystander mutagenesis induced by, 9876
pulmonary injury from, regional hypersensitivity associated with, 3568
rapamycin-sensitive pathway inhibited by, in MCF-7 cells, 11061
resistance to (See **Radioreistance**)
response to, enhanced, after EGFR inhibition, 3328
sensitivity to (See **Radiosensitivity**)
toxicity induced by, resistance to, hypoxia in, 579
ultraviolet (See **Ultraviolet radiation; Ultraviolet radiation B (UVB)**)
- Radiation therapy**. See **Radiotherapy**
- Radioimmunotherapy**
of prostate cancer, tomogrelin-targeted, 2846
of solid tumors
penetratin in, 7840
ST1571 in, 7824
- Radioreistance**
in breast cancer cells, peroxiredoxin II in, 10338
in rectal cancer, survivin in, 4881
- Radiosensitivity**
in ataxia telangiectasia, G₂ checkpoint abrogation and, 11292
DNA topoisomerase I-mediated, Ku86 in, 9194
enhancement of, by celecoxib, 9501
of glioblastoma, DNA repair inhibited by HSV and, 5310
of lymphoblastoid cells, hypoxia and, 579
of malignant glioma cells, DNA-PK inhibition inducing, 4368
of pancreatic cancer, K-Ras and, 8433
prediction of, using gene expression classifier, 7169
RLP76 as major determinant of, 6022
tumor cell
antiinflammatory drugs and, 7911
HIV protease inhibitors enhancing, 8256
Hsp90 inducing, ErbB3 preventing, 6967
signaling inhibition and, 7902
- Radiotherapy**
DNA-PK inhibitor enhancing, 4987
enhancement of, adenovirus-mediated secreted glucose-regulated protein 94/gp96 in, 9126
particle, in metastasis suppression, 113
of prostate cancer, antibody-based, mindin/RG-1 as target of, 8397
protection of parotid gland during, 10486
- Raf proteins**
hematopoietic cells transformed by, treatment of, *in vivo* model of, 9962
- RalA and RalB**
in cancer cell migration, 7111
- Rapamycin**
Akt and eIF4E survival pathways activated by, 7052
antitumor activity of
in HNSCC, 9953
in transgenic mouse model of breast cancer, 5325
autophagy induced by, in malignant glioma cells, synergistic augmentation of, 3336
cell cycle regulation and chemosensitivity mediated by, glycogen synthase kinase 3 β in, 1961
ezrin-mediated metastatic behavior in osteosarcoma inhibited by, 2406
mammalian target of (mTOR)
activation of, in transformed B lymphocytes, 7800

- hyperactivation of, in neurofibromatosis
1-associated brain tumors, 2755
- inhibition of
in irradiated MCF-7 cells, 11061
lung cancer progression and, 3226
as molecular target in HNSCC, 9953
post-transcriptional regulation of androgen
receptor by, 2547
- Ras.** See also **H-Ras**; **K-Ras**; **N-Ras**; **R-Ras**
- Ras**
activated, insulin-like growth factor I-mediated
vascular endothelial growth factor production
enhanced by, 2085
inhibition of, glioblastoma cell death induced by,
999
interaction with thymosin β_{10} in angiogenesis
inhibition, 137
selective inhibition of, tumor radiosensitivity and,
7902
tumor angiogenesis dependent on, real-time MRI in
in vivo assessment of, 8324
- Ras-association domain family 1 (RASSF1) tumor
suppressor gene**, 3497
- Ras homologue member 1 (ARHI)**
STAT3 inhibited by, in breast and ovarian cancers,
6701
- Ras-mitogen-activated protein kinase signaling
cascade**
in PGE₂ regulation of COX-2 expression, 1822
- Ras-related tumor suppressor**
RRP22 as, 3117
- RASSF1A**
cell cycle progression inhibited by, 3682
in cell migration control, 7653
cyclin A2 regulation by, via p120^{F4E}, 2690
JNK pathway suppressed by, 3682
specificity of, cell death inducer C19ORF5
determining, 1830
- Ras^{V12G}**
ALT⁺ cells expressing, malignant transformation of,
6512
- Rat model(s)**
ACI/Seg, linkage and microarray analyses of
susceptibility genes in, 2610
aflatoxin DNA repair in, 1265
colon tumorigenesis in, aberrant crypt foci and, 121
esophageal squamous cell carcinogenesis in,
microarray analysis of, 401
esophagus in, precancerous, gene expression
profiling of, 7790
Fischer 344, solid tumors in, glucose consumption
heterogeneity in, 5163
hepatocellular carcinoma in
brain-derived neurotrophic factor in, 219
CEACAM1^{-4L} suppressing, 11010
mammary carcinoma susceptibility loci in, 9637
nude, breast cancer xenografts in, growth of, light-
induced melanin suppression and, 11174
prostate of, thrombospondin-1 production in,
androgens repressing, 300
soft tissue sarcoma-bearing, isolated limb perfusion
in, antitumor response of IL-2 and melphalan
in, 4300
streptozotocin-diabetic, intrahepatic
transplantation of pancreatic islets in, 7013
suppression of ovarian cancer with truncated ECFR
in, 3243
- Rb/E2F pathway**
disruption of, increased COX-2 expression and
activity in prostate epithelial cells from, 3633
- Rb family proteins**
inactivation of, to bypass senescence, 8298
- RCC.** See **Renal cell carcinoma (RCC)**
- Reactive oxygen species (ROS)**
action of gold(III) porphyrin 1a on mitochondria
related to, 11553
caspase activation regulated by, in TRAIL-resistant
colon carcinoma cell lines, 7436
direct induction of, by farnesyltransferase inhibitors,
9109
DNA damage by farnesyltransferase inhibitors
mediated by, 3671
formation of, by breast cancer treatments, survival
and, 1105
- generation of, in colorectal cancer cells, PUMA
overexpression inducing, 1647
production of, tuberin regulating, 10881
in tumor growth control, 948
- Receptor tyrosine kinases (RTKs)**
metastasis-associated, in non-small cell lung cancer,
identification of, 1778
tumorigenic signaling by, loci and genes in, 9695
- RECK**
tumor cell invasion suppression mediated by,
glycosylation regulating, 7455
- Recombinant adenylate cyclase**
tumor therapy with, 641
- Recombination**
homologous, in response to DNA damage, BRCA2
regulating, 4117
- Rectal cancer**
recurrent, magnetic resonance thermography of, 5872
survival as radioresistance factor in, 4881
- Reed-Sternberg cells**
of Hodgkin lymphoma, CD30 promoter activation
in, 7628
- REIC/Dkk-3**
overexpression of, apoptosis induced by, 9617
- Renal cancer**
treatment of, with mixed chimerism, 10032
- Renal cell carcinoma (RCC)**
antigens in CD8⁺ T-cell responses to, 1079
blocking PDGF-D/PDGF β inhibiting, 5711
clear cell, stromal cell-derived factor-1 α and CXCR4
expression in, 6178
estrogen receptor-binding fragment-associated
antigen 9 as tumor-promoting factor for, 3700
hepatocyte growth factor activator inhibitor type
2/SPINT2 in, epigenetic inactivation of, 4598
hypoxia-inducible protein 2 as marker for, and
therapeutic target, 4817
interleukin 6 inhibitor and, 2
myeloid suppressor cells in, 3044
papillary, molecular classification of, 5628
p53 regulation and function in, 6498
tumorigenesis in, HIF-2-dependent, EGFR
inhibition preventing, 5221
VHL-deficient, HIF2- α transactivation in, Nox4
for, 9190
- Renal tumors**
induction of, in *Tsc1*^{-/-} mice, 10179
- Replication protein A (RPA)**
interactions of, with WRN and p53, 1223
- Resveratrol**
for multiple myeloma, 9943
- RET**
activation of STAT3 by, in familial medullary thyroid
cancer, 1729
G691S polymorphism of, pancreatic cancer and,
11536
- Retinoblastoma protein (pRb)**
hyperphosphorylation of, chronic inflammation
promoting, 9231
liver-specific, loss of, consequences of, 4568
loss of function of, tumor evolution initiated by, in
preclinical prostate cancer model, 10243
in mouse skin carcinogenesis, unexpected roles for,
9678
- Retinoic acid**
inhibiting CD40-induced cell proliferation in mantle
cell lymphoma, 587
mammary carcinoma growth suppressed by, 8193
- all-trans-Retinoic acid**
for medulloblastoma, 919
- 13-cis-retinoic acid**
in lung cancer growth inhibition, 4181
- Retinoic acid receptor α**
activity of, benzodithiophenes potentiated by, 7856
- Retinoic acid receptor (RAR)**
proapoptotic genes as targets for, 8193
- Retinoid**
RXR-selective, inhibiting COX-2 expression via AP-1
crossstalk, 3462
- Retinol**
colon cancer cell growth inhibited by, 9923
- RET isoforms**
in *Drosophila* model for type 2 MEN and papillary
thyroid cancer, ZD6474 suppressing, 3538
- Retrovirus**
endogenous, in melanomas, 4172
endogenous, promoting tumor growth, 2588
- Rexinoid-cAMP induced AML blast apoptosis**, 8754
- RG108**
as DNA methyltransferase inhibitor, 6305
- Rhabdomyosarcoma**
alveolar, genetic modeling of, new tactics in, 7530
genetic modeling of, 4490
- RhoA**
carcinogenesis induced by, choline kinase
potentiating, 5647
- Rho GDP dissociation inhibitor**
drug-induced apoptosis inhibited by, 6054
- Rho-kinase**
inhibition of, astrocytoma morphology, motility, and
invasion induced by, 8792
- Rho/Rho-associated kinase pathway**
ELAF/PEA3 activated by, in non-small-cell lung
cancer cells, 10776
- Rho/Rho-kinase**
R-Ras altering breast epithelial cell motility and
morphology and, 507
SIP₂ regulation of, in inhibition of tumor cell
migration, 3788
- Ribonucleic acid (RNA).** See **RNA**
- Ribonucleotide reductase**
gemcitabine resistance and, 9520
- Ribosomal RNA transcription**
angiogenin in, 1352
- Ribosomal S6 kinase 1-mediated BAD phosphory-
lation at Serine 112**
FLT3/ITD prevention of apoptosis via, 7338
- Ribosomal S6 kinase (RSK)**
p90
in cancer cell proliferation, 1027
in prostate cancer cell proliferation regulation,
3108
- Ribosomal S6 kinase 2 (RSK2)**
interaction of, with histone H3, tumor suppressor
p53 protein contributing to, 3596
- RING Ee3 ubiquitin ligase**
in invasive breast cancer, 10401
- Rituximab**
NF- κ B signaling pathway inhibition by, in
non-Hodgkin's lymphoma, 264
- RLIP76**
as major determinant of radiation sensitivity, 6022
mediating vinorelbine resistance, 991
- RNA**
messenger
interleukin 6, renal cell carcinoma and, 2
stability of, CaSm-mediated cellular
transformation associated with, 6228
transcription elongation linked to, in breast
cancer metastasis, 3011
3' untranslated region truncation, MSF
controlled by, 10742
ribosomal, transcription of, angiogenin in, 1352
short hairpin (shRNA), MMP-1 inhibition in
MDA-231 cells mediated by, 11101
small interfering (siRNA)
in 3-alkyladenine-DNA glycosylase suppression,
10472
in c-Met inhibition for non-small cell lung
cancer, 1479
coadministration with DNA vaccines, 309
EWS-FLI1 knockdown by, metastatic Ewing's
sarcoma tumor growth inhibited by, 8984
in vivo anti-*EphA2* therapy mediated by, 6910
NBS1 knockdown by, hypermutability and
telomere instability induced by, 5544
polo-like kinase depletion mediated by,
cytotoxicity toward cancer cells with, 2698
protein kinase C ϵ inhibited by, 8366
retroviral delivery of, Cx43 down-regulated by,
aggressive breast cancer cell phenotype
and, 2705
targeting ATP6L, metastasis inhibited by, 6843
targeting KIFENIN, colon tumors suppressed
by, 8993
- RNA interference (RNAi)**
choline kinase suppression mediated by, in breast
cancer cells, 11034

- inducible, *in vivo*, in evaluating HIF-1 as therapeutic target, 7249
- silencing of *ACC-2* mediated by, apoptosis of prostate cancer cells induced by, 6719
- of VEGF-A in sarcomas, hypoxia and, 5881
- RNA-mediated interference**
- Src-regulated gene activity identified by, 1814
- TRNA dihydrouridine synthase**
- in lung cancer, 5638
- Ron-dependent cell migration**
- CD44 v6 peptides inhibiting, 6105
- Ron receptor signaling**
- augmenting mammary tumor formation and metastasis, 1285
- ROS. See Reactive oxygen species (ROS)**
- Roscovitine**
- apoptosis induced by, in Ewing's sarcoma family tumor cells, 9320
- R-Ras**
- breast epithelial cell motility and morphology altered by, 507
- hypomethylation of, in gastric cancer, 2115
- RRP22**
- tumor suppression potential of, 3117
- RSK. See Ribosomal S6 kinase (RSK)**
- RTS signaling**
- 5-fluorouracil sensitivity enhanced by, 5917
- RUNX3**
- expression of, gastric cancer and, 4809
- inactivation of, in gastric cancer, 7743
- RUNX1/MTGS**
- interplay of DNA methyltransferase 1 with, in acute myeloid leukemia, 1277
- S100A7**
- prosurvival pathways in breast cancer stimulated by, 5695
- Saccharomyces cerevisiae**
- cisplatin resistance in, genes mediating, 5890
- S100A6 expression**
- pancreatic cancer survival and, 3218
- Salivary glands**
- radioprotection of, 10486
- tumors of, targeted *PLAG1* proto-oncogene overexpression in, 4544
- Salmonella**
- tumor cells infected with, killing of, immunotherapy based on, 3920
- Sarco(endo)plasmic reticulum Ca²⁺-ATPase isoform 2 (SERCA2)**
- haploinsufficiency of, cancer and, 8655
- Sarcoma(s)**
- epithelioid, SMARCB1 inactivation in, 4012
- Ewing's (See **Ewing's sarcoma**)
- gene expression in, hypoxia-related, RNA interference of vascular endothelial cell growth factor A in, 5881
- gene expression profiling of, 9226
- Kaposi's (See **Kaposi's sarcoma**)
- NVP-AEW541 activity against, 3868
- Sarcoma cell line**
- multidrug-resistant cells in, origins of, modeling of, 9388
- Scanning X-ray fluorescence microscopy**
- element array by, after *cis*-diamminedichloro-platinum(II) treatment, 4998
- Scatter factor/hepatocyte growth factor, 9355**
- SCC. See Squamous cell carcinoma (SCC)**
- SCH66336**
- eukaryotic translation elongation factor 2 phosphorylation induced by, 5841
- Sd⁺ carbohydrate**
- expression of, metastasis inhibited by, 6220
- Second mitochondria-derived activator of caspase (Smac)**
- sensitization for γ -irradiation induced by, 10502
- Secreted frizzled-related protein 4 (SFRP4)**
- methylation silencing of, Wnt signaling in mesothelioma and, 743
- Secreted human intestinal carboxylesterase**
- herpes simplex virus type 1 expressing, in brain tumor oncolysis, 6850
- Secreted protein acidic and rich in cysteine (SPARC)**
- antitumor activity and, 5123
- Segmental trans-splicing**
- pre-mRNA, for intracellular toxin delivery, 254
- SEI-1**
- oncogenic transformation by, chromosomal instability and, 6504
- E-Selectin**
- expression of, on prostate tumor cells, 5750
- E-Selectin ligand activity**
- LS174T colon cancer cells possessing, 5812
- P-Selectin**
- expression of, on prostate tumor cells, 5750
- Selenium**
- endoplasmic reticulum stress and, 9073
- estrogen receptor signaling disrupted by, 3487
- Seliciclib**
- mcl-1 down-regulation in multiple myeloma by, 5399
- Sema3E**
- lung metastasis induced by, 6167
- Senescence**
- adriamycin-induced, Src inhibiting, through p21waf1 down-regulation, 8927
- cellular
- accelerated, escape from, in lung cancers, 2795
- Akt activation protecting against, 4861
- checkpoint kinase 2 activation in, 6017
- of colorectal cancer cells, human telomerase reverse transcriptase expression rescuing from, 2321
- in melanomas, maintenance of, Tbx2 in, 2260
- premature
- ERBB2-induced, in breast cancer, 840
- ras-induced, E1A rescuing, inactivation of p300/CBP and Rb family proteins in, 8298
- replicative, loss of *hSNF5* gene inactivating, 10192
- Ser¹²⁰**
- phosphorylation of, proapoptotic activity of BAD and, 8372
- Serous ovarian carcinomas**
- He4 overexpression in, 2162
- Serum and glucocorticoid-inducible protein kinase (SGK)**
- antiapoptotic effect of, 457
- SFRP1**
- as mediator of stromal-to-epithelial signaling in prostate cancer, 10423
- SFRP genes**
- epigenetic inactivation of, in bladder cancer, 7081
- SFRP4 (secreted frizzled-related protein 4)**
- methylation silencing of, Wnt signaling in mesothelioma and, 743
- SGK (serum and glucocorticoid-inducible protein kinase)**
- antiapoptotic effect of, 457
- SGN-40**
- antilymphoma activity of, 8331
- lenalidomide combined with, for multiple myeloma, 11712
- Shed ectodomain**
- of Nr-CAM, cell motility and tumorigenesis stimulated by, 11605
- Short 1b prolactin receptor (PRLR)**
- VDR and p21/waf1 up-regulated by, in prostate cancer cells, 7509
- Sialoprotein**
- bone, osteomimicry of prostate cancer cells mediated by, 2303
- Signaling**
- activation of
- p53 and, 6601
- cellular kinase, impact of SU6668 on, 6919
- in EGFR mutants, Ba/F3 cells transformed by, 8968
- electrostatic, of endothelial cell sprouting, 11529
- epithelial-mesenchymal, MMP-7 and, 7363
- epithelial-to-mesenchyme transition and, 3179
- hedgehog (See **Hedgehog signaling**)
- invasion, cross talk of, with apoptosis, caspase-3 activating, 9121
- kisspeptin, of GPR54, CXCR4 negatively regulated by, 10450
- phenotypic, in breast cancer cells, 2511
- P13K-Akt-mTOR-S6K1, activation of, 15(S)-HETE inducing angiogenesis via, 7283
- stromal-to-epithelial, in prostate cancer, *SFRP1* as mediator of, 10423
- through IFN regulatory factor-5, DNA damage, 7403
- Wnt (See **Wnt signaling**)
- Signal transducer and activator of transcription 1 (STAT1)**
- effect of, on colorectal cancer, 8951
- Signal transducer and activator of transcription 3 (STAT3)**
- activation of
- PELP1 in, 5571
- by RET in familial medullary thyroid cancer, 1729
- in colon cancer cells, trefoil factors and vascular endothelial growth factor and, 195
- epidermal, keratinocyte survival and proliferation after UV irradiation regulated by, 5720
- farnesyl transferase inhibitor targeting, 2861
- genetic signature of, in tumors, 5054
- in hTERT expression regulation, 6516
- knockdown of, blocking breast tumor formation, 2532
- malignant transformation depending on, 5828
- in oncogenesis and transcriptional regulation, 939
- Ras homologue member 1 inhibiting, in breast and ovarian cancers, 6701
- Signal transduction pathways**
- radiation-induced, hypoxia and, 579
- Silencing**
- of nuclear receptor 1/2 gene, identification of, by BAMCA, 10233
- Silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) gene**
- alteration of, in transformed non-Hodgkin's lymphomas, 4554
- Silybum marianum compounds**
- in prostate cancer, 4448
- Single nucleotide polymorphism(s)**
- in acute myeloid leukemias analysis, 375
- in allelic imbalance in bladder tumors analysis, 34
- in array analysis of lung cancer, 5561
- in epidermal growth factor receptor regulation, 46
- in genome-wide association study in esophageal cancer, 2542
- glutathione S-transferase M3 promoter, allele-specific chromatin immunoprecipitation and, 99
- high-density oligonucleotide arrays, copy number detection using, 6071
- in *MDM2* gene, 5481
- in STK15, esophageal cancer risk increased by, 3548
- Single nucleotide polymorphism (SNP) arrays**
- LOH detection in FFPE tumors with, 10188
- Single nucleotide polymorphism (SNP) microarray analysis**
- in basal cell carcinomas unveiling uniparental disomy, 8597
- of loss of heterozygosity in ALL, 3053
- Single-photon emission computed tomography**
- small-molecule, for metastatic melanoma imaging, 4979
- Siramesine**
- antitumor activity of, lysosomal leakage and oxidative stress and, 8975
- Sirt1**
- as cancer-specific survival factor, 10457
- in control of multidrug resistance gene and chemoresistance, 10183
- Siva-1 protein**
- cisplatin-induced apoptosis enhanced by, 5301
- Six1**
- overexpression of, in breast cancer, gene amplification and, 2668
- SKI-606**
- in colon tumor xenograft growth inhibition, 5358
- Skin**
- tumorigenesis in
- induction of, mitogen-activated protein kinase in, ornithine decarboxylase in, 572
- UV light-induced, chemoprevention of, EGFR inhibition in, 3958
- Skin cancer**
- chemical-induced, sensitivity to, 2054
- development of

- Perp* deficiency suppressing, 6551
programmed cell death 4 suppressed by, 6034
from donor cells in kidney transplant recipient, 1855
- Skin carcinogenesis**
mouse, pRb in, 9678
reduction of, antioxidant approach to, 1401
- Skin squamous cell carcinoma**
loss of C/EBP α expression in, 861
- Skin tumors**
development of
EP2 in, 9304
in HPV8-transgenic mice, 1394
susceptibility to, *Odc* gene overexpression and, 1146
- Skp2**
expression of, BCR-ABL-induced, in CML, 3264
- SL0101**
as P90 ribosomal S6 kinase inhibitor, 1027
- SLC7A11**
in cancer chemosensitivity and chemoresistance, 7446
- SLC5A8 expression**
silencing of, in gliomas, 3617
- Sleep duration**
breast cancer and, 9595
- Smad4**
in colorectal cancer, 4228
in skin tumorigenesis, 8671
- Smad2/3L**
phosphorylation of, JNK-dependent, in colorectal cancer, 157
- SMARCB1/INI1 tumor suppressor gene**
inactivation of, in epithelioid sarcomas, 4012
- SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) gene**
alteration of, in transformed non-Hodgkin's lymphomas, 4554
- Snail**
epithelial differentiation program modulated by, 6237
- SnoN**
failure of TGF- β to degrade, in esophageal cancer, 4782
- Sonic Hedgehog signaling pathway**
glioma-associated oncogene 1, regulating p21/CP1 in gastric carcinoma cells, 10822
in medulloblastoma, small-molecule inhibitors of, 4975
- SOX9**
in colon cancer cells, carcinoembryonic antigen gene expression inhibited by, 2193
- SIP₂**
Rho/Rho kinase pathway regulated by, in inhibition of tumor cell migration, 3788
- SPARC (secreted protein acidic and rich in cysteine)**
antitumor activity and, 5123
- Special Workshop Report**
Blueprint for a Human Epigenome Project: The AACR Human Epigenome Workshop, 11241
- Spectrometry**
mass, matrix-assisted laser desorption ionization, brain tumor prognosis based on, 7674
- Spectroscopy, magnetic resonance**. See **Magnetic resonance spectroscopy (MRS)**
- Sphingosine kinase-1**
as chemotherapy sensor in prostate cancer, 11667
- Spindle integrity**
in multiple myeloma, hyaluronan-mediated motility receptor affecting, 850
- Spleen tyrosine kinase**
in transcription repression and tumor suppression, 10289
- Splicing**
alternative (See **Alternative splicing**)
- Splicing factor SPF45 overexpression**
multidrug resistance and, 6593
- Sp1 protein**
overexpression of, reducing, inhibiting tumorigenicity, 1007
- Spz1**
cell proliferation, transformation and tumorigenesis mediated by, 4041
- Squamous cell carcinoma (SCC)**
esophageal (See **Esophageal cancer, squamous cell**)
- head and neck (See **Head and neck squamous cell carcinoma (HNSCC)**)
progression of, E-cadherin suppression accelerating, 1783
- skin**
loss of C/EBP α expression in, 861
p53 mutations in, UVB-induced mouse skin patches and, 3577
- Squamous epithelial cancers**
diagnosis of, multiphoton microscopy in, 1180
- Squamous epithelium**
IGFBP-3 regulation by Δ Np63 α in, 2314
- Src**
adriamycin-induced senescence inhibited by, through p21waf1 down-regulation, 8927
IL-8 in pancreatic tumor cells regulated by, 7214
tumor cell growth and, 1335
- Src-1**
in prostate cancer cell growth and progression, 7959
- Src-3**
in prostate cancer, 7976
- Src homology 2-containing inositol 5'-phosphatase 1 (SHIP1)**
natural killer cell IFN- γ production negatively regulated by, 9099
- Src kinase**
gene activity regulated by, invasive phenotype induced by, 1814
synthesis and stability of, eRBB2 promoting, 1858
- Src tyrosine kinase**
in restoring paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells, 10381
- SRG (survival-related gene)**
identification and characterization of, 10716
- SSX**
down-regulation of, cell migration and matrix metalloproteinase 2 expression impaired by, 2207
- ST1926**
interaction of, with ZD1839, 2364
- STAT1**. See **Signal transducer and activator of transcription 1 (STAT1)**
- STAT3**. See **Signal transducer and activator of transcription 3 (STAT3)**
- Stathmin**
degradation of, proteasome-mediated, PUMA overexpression inducing, 1647
- Stem cells**
asymmetric self-renewal associated with, p53/IMPDP-dependent immortal DNA strand regulation of, 3155
- cancer**
cloned, tumorigenic heterogeneity in, 3126
side population enriched by, 6207
- hematopoietic**
cytokine-induced expansion of, valproic acid enhancing, 1505
proliferation of, valproic acid stimulating, 2537
- leukemic, in childhood high-risk ALL, 1442**
- malignant, in cancer cell lines, 8944**
- mesenchymal (See Mesenchymal stem cells)**
- ovarian cancer behavior and, 3025**
- prenatal origin of cancer and, 358**
- prostate, putative, breast cancer resistance protein expression in, 6640**
- prostate cancer, tumorigenic, prospective identification of, 10946**
- tumorigenic subpopulation of, in melanomas, 9328**
- Steroid receptor**
in epidermal growth factor signaling regulation, 10585
- STI571**. See **Imatinib mesylate**
- apoptosis induced by, survivin sensitizing Bcr-abl-positive cells to, 8224**
- in radioimmunotherapy of solid tumors, 7824**
- STK15**
two functional coding single nucleotide polymorphisms in, esophageal cancer risk increased by, 3548
- Stomach**
cancer of (See **Gastric cancer**)
hyperplastic tumors of, TNF- α -dependent inflammation causing, 9147
- intraepithelial neoplasia of, *Helicobacter pylori* inducing, in mice, 10709
- Stress**
cellular, in imprinted gene inactivation, 26
endoplasmic reticulum (See **Endoplasmic reticulum stress**)
inflammatory, p53 as key responder in, 10255
oxidative (See **Oxidative stress**)
sensor of, Oct-1 as, 10750
- Stromal cell(s)**
apoptosis of, ADAM12 in, 4754
prostate, prostaglandin D synthase metabolites produced by, in prostate cancer growth suppression, 6189
tumor interaction with
ADAM9 promoting carcinoma invasion through, 4728
in breast cancer, 4653
- Stromal cell-derived factor-1 α**
in hemangioblastoma and clear cell renal cell carcinoma, 6178
osteolytic bone disease in multiple myeloma mediated by, 1700
- Stromal cell-derived factor-1/CXCR4**
blockade of, in tumor neoangiogenesis, 5864
- Stromal-derived factor-1 α**
CXCR4 expression in PC-3 cells increased by, 9891
- Stromal-to-epithelial signaling**
in prostate cancer, *SFRP1* as mediator of, 10423
- Stromal tumor**
gastrointestinal, mouse model of, 6631
normalization of, by VEGF-2 blockade, 1294
- Stromelysin-1 (ST1)**
transcriptional activity of, impairment of, by promoter mutations, colorectal tumor instability and, 3811
- Stromelysin-3 (ST3)**
in desmoplastic response, 10862
- SU6668**
cellular targets of, 6919
- SU11274**
in c-Met inhibition for non-small cell lung cancer, 1479
- Suberoylanilide hydroxamic acid (SAHA)**
connexin 43 expression enhanced by, 9771
- Substance P analogues**
growth and angiogenesis in pancreatic cancer blocked by, 2738
- Sulfonaphane**
apoptosis induced by, Bax and Bak in, 2035
N-acetylcysteine conjugate of, lung cancer progression inhibited by, 8548
- Sun exposure**
vitamin D receptor gene polymorphisms and, advanced prostate cancer risk and, 5470
- Superoxide**
in mitochondria, apoptosis and tumorigenesis and, 203
- Support vector machine (SVM) classifier**
in cancer diagnosis and prognosis, 4031
- Surgery**
tumor-debulking, combined with chemotherapy and adjuvant immunotherapy, 7580
- Survival-related gene (SRG)**
identification and characterization of, 10716
- Survivin**
Bcr-abl up-regulating, 8224
conditionally replicating adenovirus responsive to, 5284
DNA vaccine against, in lung tumor eradication, 553
expression of, HER2 and EGFR regulating, 11018
gene for, in tissue microenvironment regulation, 3531
as radioresistance factor in rectal cancer, 4881
- SV40**
infectious, oral poliovirus vaccines contaminated with, 10273
mesothelioma and, 2602
Akt signaling as therapeutic target for, 5256
risk of malignant mesothelioma enhanced by, 3049
- SV40 sequences**
at telomeres in alternative lengthening of telomeres cell lines, 2730
- SWI/SNF chromatin-remodeling factors**
DNA methylation changes induced by, 3542

- p270 (ARID1A/SMARCF1) subunit of, in cell cycle regulation, 9236
- Syk tyrosine kinase**
localized to centrosomes, breast cancer cell mitosis and, 10872
- Syndecan-1**
expression of, in breast cancer cells, omega-3 polyunsaturated fatty acids regulating, 4442
- Syndecan-2**
tumorigenic activity of fibrosarcoma mediated by, focal adhesion kinase regulating, 9899
- Synuclein- γ gene**
as molecular indicator of metastasis, 7635
- TACC1 (transforming acidic coiled coil 1)**
transformation and tumorigenesis promoted by, 10363
- Tachyplesin**
in classic complement pathway activation, 4614
- Tall**
phosphorylation and regulation of, Akt in, 4515
- Tamoxifen**
adjuvant, in premenopausal breast cancer, 8009
breast cancer prevention by, phytoestrogen and, 879
endometrial cancer stimulated by, trastuzumab therapy for, 8504
mouse mammary tumorigenesis inhibited by, 3493
responsiveness to, lapatinib restoring, 18
Tsc mouse liver hemangioma retarded by, 2474
- TAP (tocopherol-associated protein)**
prostate cancer cell growth inhibited by, 9807
- TAP (transporter associated with antigen processing)**
deficiency of, mechanisms underlying, in metastatic murine carcinomas, 7485
- Tarceva (erlotinib)**
EGFR inhibition by, enhanced radiation response following, 3328
- TARC (thymus and activation-related chemokine)**
in Hodgkin's disease, 5516
- Targeted actinium-225 *in vivo* generators**
errant products of, control of, 4888
- Targeted microbubbles**
in ultrasonic imaging of tumor angiogenesis, 533
- Targeted virus replication**
immunotherapy plus, for pancreatic cancer, 9056
- Taxane**
chemosensitivity to, in pancreatic cancer, 2899
- Taxanes**
HIF-1 α inhibited by, 9021
- Taxol**
efficacy of, enhanced by CI-1040, 2854
- Thx2**
overexpression of, in maintaining proliferation and suppression of senescence in melanoma, 2260
- T-cell acute lymphoblastic leukemia**
CD7-restricted apoptosis induction in, 3380
- T-cell engager**
bispecific, in tumor eradication, 2882
- T cell lymphoma**
galectin-7 in, 5205
- T-cell responses**
memory, against breast cancer, 3419
tumor reactive, IL-12 with IL-18 skewing, 1063
- TCH (transitional cell hyperplasia)**
COX-2 overexpression and, 1808
- TCR (transcription-coupled repair)**
in UVB-induced response of fibroblasts and keratinocytes, 432
- Tea**
catechins in
antifolate activity of, 2059
intestinal tumorigenesis inhibited by, 10623
- Tectochrysin**
ABCG2 inhibition by, 4852
- Telomerase**
artificial antigen-presenting cells transduced with, 5417
in cancer, 3513
expression of
fibroblast cell line immortalized by, neoplastic transformation of, 11411
preceding lung cancer development, 9623
- gene expression of, lack of, in ALT, chromatin and, 7585
interference with, BRACO-19 in, 1489
virotherapy dependent on, overcoming drug resistance of hepatocellular carcinomas, 7393
- Telomerase reverse transcriptase, human (hTERT)**
regulation of, STAT3 in, 6516
- Telomere(s)**
alternative lengthening of (ALT)
cell line with, SV40 sequence at telomeres in, 2730
lack of telomerase gene expression in, chromatin and, 7585
SV40-immortalized fibroblast cell lines with, not requiring hTERT for transformation, 6512
variant, telomere length maintained by, 2722
in cancer, 3513
dysfunction of, C-1027 inducing, 5344
instability of, *NBS1* knockdown inducing hypermutability and, 5544
type II, lengthening of, disrupted, BLM helicase and, 5520
- Telopeptides**
lack of, in fibrillar collagen I, breast tumor cell invasion promoted by, 5674
- TEL/protein tyrosine phosphatase receptor-type R**
cloning and characterization of, in AML with inv(12)(p13q13), 6612
- Temozolomide**
G₂ arrest induced by, Akt and, 4861
in glioma therapy, 7429
sensitivity to, base excision repair and, 6394
synergistic cytotoxicity of IFN- β with, on glioma cells, 7573
- TERT gene promoter fragment**
regulation of, in transgenic mice, 1187
- Testicular germ cell tumor**
progression of, *KIT* gene and, 8085
- Testis**
cancer of, developmental biology of, 5588
immature, doxorubicin-induced apoptosis in, 9999
- Testisin**
malignant transformation promoted by, 868
- Thalidomide**
urokinase receptor expression and invasion inhibited by, 10464
- Thiazolidenediones**
mediating apoptosis in prostate cancer cells, 1561
- Thioredoxin**
as target for antitumor quinols, 3911
- 3B-3CT**
as gelatinase inhibitor, antimetastatic activity of, 3523
- Thrombohemorrhagic syndrome**, 8579
- Thrombospondin(s)**
as angiogenesis inhibitor, 3967
- Thrombospondin-1**
down-regulation of, in normal fibroblasts, 8878
production of, in prostate, androgens repressing, 300
- Thrombospondin-2 (TSP2)**
angiogenesis inhibited by, in murine gliomas, 9338
- Thromboxane synthase**
bladder cancer survival and, 11581
- Thymidines**
halogenated, as antisilencing agents, 6927
- Thymineless death**
FdUMP[10] inducing, 4844
- Thymosin β_{10}**
angiogenesis inhibition by, 137
- Thymus**
epithelial cells of, CEA expression by, 6443
- Thymus and activation-related chemokine (TARC)**
in Hodgkin's disease, 5516
- Thyocytes**
human, proximity of *TPR* and *NTRK1* rearranging loci in, 2572
- Thyroid cancer**
anaplastic, *PIK3CA* gene mutation in, 10199
follicular, antivasculature therapy of, 4716
medullary
accelerated progression of, melanotroph carcinogenesis suppression and, 787
- familial, STAT3 activation in, by RET, 1729
prolactin signaling and, 8497
- papillary**
BRAF^{V600E} expression in, targeted, 4238
gene expression profile of, 1587
PCC13 cells in, conditional BRAF^{V600E} expression in, 2465
proximity of *TPR* and *NTRK1* rearranging loci in, 2572
RET isoforms in, ZD6474 suppressing, 3538
PKC α -D294G in, fails to transduce extracellular signals, 4520
proEGF cytoplasmic domain in, 1343
transcriptome analysis of, 1693
- Thyroiditis**
autoimmune, in Treg-depleted mice, 8471
- Tid1**
cancer cell motility regulated by, 8784
von Hippel-Lindau protein interacting with, angiogenesis regulated by, 2520
- Tie-2**
intrabody targeting, in angiogenesis inhibition, 972
- TILs (tumor-infiltrating lymphocytes)**
NKR expression on, 2921
- TIMPs (tissue inhibitors of metalloproteinase)**
apoptosis of breast epithelial cells inhibited by, 898
- Tissue factor (TF)**
expression of, in glioblastoma, regulation of, 1406
- Tissue inhibitor of metalloproteinase-3 expression**
from oncolytic adenovirus, 9398
- Tissue inhibitor of metalloproteinase (TIMP)**
apoptosis of breast epithelial cells inhibited by, 898
- Tissue microarrays**
in predicting breast cancer prognosis, 767
- Tissue-type plasminogen activator (tPA)**
 β -catenin activated by, 526
- T lymphocytes**
apoptosis of, glioblastomas inducing, 5428
CD4⁺, antitumor CTL responses suppressed by, 6984
CD8⁺
and CD4⁺ tumor-reactive, engineering, 1570
responses of, to renal cell carcinoma antigens, 1079
transforming growth factor- β -insensitive, for prostate cancer, 1761
DMXAA activating, 11752
genetically directed, in targeted elimination of prostate cancer, 9080
HPV-specific, in head and neck squamous cell carcinoma, 11146
proliferation of, total body irradiation and, 9547
regulatory
CD8⁺, plasmacytoid dendritic cells inducing, in ovarian cancer, 5020
CD25⁺, IL10 and, in antitumor CD8 T-cell response inhibition, 8479
CD4⁺CD25⁺
depleted, mice with, tumor regression and autoimmunity in, 8471
in hepatocellular carcinoma, 2457
regulatory, EBV-encoded nuclear antigen 1-specific, 1577
tumor-infiltrating, NKR expression on, 2921
tumor infiltration by, in stage IV melanoma, 3937
tumor-reactive, in bone marrow of pancreatic cancer patients, 10079
tumor-specific, survival of, Bcl-2 overexpression enhancing, 2001
- TNF (tumor necrosis factor)**
glioma growth reduced by, 3928
- Tobacco smoke**
amphiregulin transcription stimulated by, in oral epithelial cells, 5982
cyclooxygenase-2 and epidermal growth factor receptor and, 664
cytochrome P450 1B1 variants and, 5105
lung cancer induced by, progression of, isothiocyanates inhibiting, 8548
mutations in lung cancer and, 5076
NNK from
colon cancer stimulated by, via β -adrenoceptors, 5272
lung tumorigenesis and, 7660

- non-small cell lung cancer induced by, loss of heterozygosity patterns in, 1664
- Tocopherol-associated protein (TAP)**
prostate cancer cell growth inhibited by, 9807
- Toll-like receptors**
on tumor cells facilitating immune surveillance evasion, 5009
- Toll-like receptor 4 (TLR4)**
susceptibility to prostate cancer and, 11771
- Toluidine blue**
risk of premalignancy progression and, 8017
- Tomography**
fluorescence-mediated, in mapping of tumor targets, 6330
- Tomoregulin**
targeting of, for radioimmunotherapy of prostate cancer, 2846
- Topoisomerase I**
degradation of, topotecan-triggered, p53 activity and, 8920
- Topoisomerase I-DNA complex(es)**
camptothecin inhibiting, 3894
radiosensitization mediated by, Ku86 and, 9194
thymineless death with, FdUMP[10] inducing, 4844
- Topoisomerase II α**
expression of, CD26/dipeptidyl peptidase IV regulating, 1973
- Topoisomerase II β**
E2F regulating, 4067
- Topoisomerase II inhibitors**
catalytic, purine-based, 7470
- Topotecan**
hypoxia-inducible factor-1 α and vascular endothelial growth factor blocked by, in neuroblastoma cells, 4775
topoisomerase I degradation triggered by, p53 activity and, 8920
- Total body irradiation**
T-cell proliferation and, 9547
- Toxin**
intracellular delivery of, pre-mRNA segmental *trans*-splicing in, 254
- TP53 alteration**
in bladder cancer, 7081
- TP53 mutation**
in lung cancer, smoking and, 5076
- TPP II (tripeptidyl-peptidase II)**
cells overexpressing, aberrant mitosis in, 1361
- TPR**
proximity of, to *NTRK1* in cell nuclei, 2572
- Trabectedin (yondelis)**
macrophage differentiation inhibited by, 2964
- TRAIL. See Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)**
- Transcription**
activation of, MLL fusion proteins in, 11367
regulation of, unphosphorylated STAT3 in, 939
repression of
by Kaiso, 2224
spleen tyrosine kinase in, 10289
- Transcription-coupled repair (TCR)**
in UVB-induced response of fibroblasts and keratinocytes, 432
- Transcription elongation**
mRNA transport linked to, in breast cancer metastasis, 3011
- Transcription factor *Pokemon***
in cancer pathogenesis, 8575
- Transcriptome analysis**
large-scale, of head, neck, and thyroid cancer, 1693
- Transcriptome correlation map**
of breast cancer, 1376
- Transducible anticancer peptides**
enhanced targeting of CXCR4-expressing tumor cells by, 10646
- β -Transducin repeat-containing proteins**
augmenting antitumor drug effects in breast cancer, 1904
- Transforming acidic coiled coil 1 (TACC1)**
transformation and tumorigenesis promoted by, 10363
- Transforming growth factor α (TGF- α)**
latent membrane protein 1 inducing, 8826
- serum increase in, predicting poor response to gefitinib, 9176
- Transforming growth factor- β 1 production**
nuclear factor- κ B pathway regulating, in idiopathic myelofibrosis, 3281
- Transforming growth factor β (TGF- β)**
in activation of phosphatidylinositol 3-kinase, 10431
failure of, to degrade SnO α in esophageal cancer, 4782
tumor invasion mediated by, loss of PTEN increasing, 11276
in tumor suppression, 4228
- Transforming growth factor β (TGF- β) signaling**
Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibiting, 1738
pathways for, variants of, genetic assessment of, in breast cancer risk prediction, 3454
tumor-suppressive role of, in mammary gland tumorigenesis, 2296
- Transglutaminases**
tissue, activity of, mapping of, MRI contrast material for, 1369
- Transitional cell hyperplasia (TCH)**
COX-2 overexpression and, 1808
- Transplantation**
kidney, skin cancer and, 1755
- Transporter associated with antigen processing (TAP)**
deficiency of, mechanisms underlying, in metastatic murine carcinomas, 7485
- Transporters associated with antigen processing (TAP1)**
expression of, in lung cancer, survival increased by, 7926
- Transposons**
for cancer gene discovery, 9607
- Trans-splicing, segmental**
pre-mRNA, for intracellular toxin delivery, 254
- Trastuzumab**
resistance of breast cancer cells to, IGF-IR/HER-2 contributing to, 11118
for tamoxifen-stimulated endometrial cancer, 8504
- β TRCP1**
expression of, increased
nuclear factor- κ B activation and, chemoresistance in pancreatic cancer and, 1316
- Trefoil factors**
proinvasive activity of, STAT3 and, in colon cancer cells, 195
- TREX complex**
breast cancer metastasis and, 3011
- Trimodal cancer therapy, 3643**
- Tripeptidyl-peptidase II (TPP II)**
cells overexpressing, aberrant mitosis in, 1361
- Triterpenoids, synthetic**
activating heme oxygenase-1 and Nrf2-ARE signaling, 4789
TRAIL in breast cancer and, 4799
- TrkB**
anoikis resistance and, 7033
- Troglitazone**
inducing apoptosis in prostate cancer cells, 1561
- Troponin I**
as angiogenesis inhibitor, 3967
- TSC1-TSC2 complex**
negative regulation of, by D-type cyclins, 11354
- TSP-2 (thrombospondin-2)**
angiogenesis inhibited by, in murine gliomas, 9338
- Tuberin**
reactive oxygen species production regulated by, 10881
- Tuberous sclerosis complex (TSC)**
tuberin regulating ROS production and, 10881
- Tubulin**
acetylation of, lonafarnib and paclitaxel enhancing, 3883
- β -Tubulin**
class III, targeting of, by IDN5390 in overcoming paclitaxel resistance, 2397
mutations of, associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells, 9406
- TUCAN**
overexpression of, in cancer, 8706
- Tumor(s)**
aggressive behavior of, *survivin* gene signature predicting, 3531
angiogenic microenvironment of, HBDLTF1 targeting, 11109
bladder (See **Bladder cancer**)
blood vessels of (See **Blood vessels, tumor**)
brain (See **Brain tumor(s)**)
cytochrome P450 2J2 expression in, 4707
development of
cooperation between Cdk4 and p27^{Kip1} in, 3846
suppression of, in *S100A4(mts-1)*-deficient mice, 3772
dormancy of, MYC inactivation and, 4471
EBV-associated, VAI-deleted adenovirus targeting, 1523
eradication of, recombinant adenylate cyclase in, 641
Ewing's family of, neural phenotype of, EWS-FLI1 expression and, 4633
formation of, Ax1 in, 9294
glutathione metabolism in, imaging of, 10149
HER-2/*neu*-expressing, outgrowth of, HER2 virus-like particles preventing, 5953
HER2-positive, immuno-PET imaging of, 1471
intestinal, regression of, CD4⁺CD25⁺ regulatory lymphocytes inducing, 3998
invasiveness of
epithelial-to-mesenchyme transition and, 3179
hypoxic stimulation of, 2761
local spread and recurrence of, 2997
lung (See **Lung tumors**)
microenvironment of
Kaiso expression and nuclear location regulated by, 2224
MSH2 expression and, 8134
neural crest-derived, neuropeptide Y in, 1719
photodynamic therapy-treated, heat shock proteins and, 1018
progression of
Fas with intercellular adhesion molecule-1 in, 1045
PACE4 expression enhancing, 7310
SRC-1 in, 7959
regression of, from measles virus targeted to vascular endothelium, 5292
rejection of, macrophage and dendritic cells in, 3437
response of, to therapy, assessment of, MRI in, 7041
skin (See **Skin tumors**)
solid
apoptosis of hypoxic cells in, 11622
glucose consumption in, 5163
perinecrotic regions of, reduced HIF-1 α expression of, 7259
radioimmunotherapy of
penetratin in, 7840
STI571 in, 7824
viral gene delivery in, 7541
suppression of
hypermethylation-suppressed RASSF1A in, 1830
mammalian sterile 20-like kinases in, 5485
Mlh3 and *Pms2* and, 8662
p53 in, 9971
p53 Ser389 phosphorylation in, 3610
Pten, 5172
RRP22 in, 3117
spleen tyrosine kinase in, 10289
transforming growth factor- β in, 4228
susceptibility of *Rassf1a* knockout mice to, 92
therapy of, combined adenovirus-mediated oncolytic and immunostimulatory, 4343
- Tumor angiogenesis. See Angiogenesis**
- ultrasonic imaging of, targeted microbubbles in, 533**
- Tumor bed effect**
metastasis and, 2387
- Tumor cells**
apoptosis of, nitric oxide sensitization of, 8461
circulating, global gene expression profiling of, 4993
glioblastoma, *lyn* kinase activity in, elevated, 5535
growth of, fetuin-A promoting, 499
invasiveness of

- induction of hepatocyte growth factor/scatter factor by fibroblast clustering promoting, 9914
- RECK-mediated suppression of, glycosylation regulating, 7455
- Snail inducing, 6237
- killing of, classic complement pathway in, tachyplesin activating, 4614
- migration of, S1P₂ regulation of Rho/Rho kinase pathway inhibiting, 3788
- nuclear targeting of apoptin specific to, 7059
- plasticity of, in Ewing's sarcoma, 11520
- proliferation of, TRAIL-mediated, 7888
- radiosensitivity of, HIV protease inhibitors enhancing, 8256
- radiosensitization of
- antiinflammatory drugs in, 7911
 - by Hsp90 inhibition, ErbB3 preventing, 6967
 - signaling inhibition and, 7902
- toll-like receptors on, facilitating immune surveillance evasion, 5009
- Tumor growth**
- anti-JAM-C inhibiting, 5703
 - CD24 expression and, 10783
 - CD4⁺ T cells promoting, 6984
 - chloride intracellular channel proteins inhibiting, 562
 - control of, reactive oxygen species in, 948
 - docetaxel plus antiphenolipidylserine inhibiting, 4408
 - endogenous retrovirus promoting, 2588
 - HIF-2 α promoting, 2277
 - hypoxia-inducible factor-1 in, 4147
 - immune response to, cell-mediated, mathematical modeling of, 7950
 - inhibition of
 - 8-chloro-cyclic AMP-induced, 4896
 - IG8 in, 9495
 - IL-6R-specific peptide in, 4827 - of osteosarcoma, osteix inhibiting, 1124
 - in pancreatic cancer, SPA blocking, 2738
 - suppression of, X-linked dominant, 5690
 - tumor-induced remodeling of vasculature and, 913
- Tumorigenesis**
- aberrant crypt foci and, in rat colon, 121
 - breast cancer
 - antisense-mediated hyaluronan synthase 2 suppression inhibiting, 6139
 - cells in, *in vitro* propagation of, 5506
 - MAGE-D1 suppression and, 4747 - carcinogen-induced, increased, in Vpwr^{-/-} mice, 8846
 - colon
 - cytoplasmic phospholipase A₂ deletion enhancing, 2636
 - lipoxigenases and, 11486
 - cooperation of *Lkb1* and *p53* gene mutations in, 11297
 - DNA polymerase κ excess and, 325
 - fetuin-A promoting, 499
 - galectin-7 promoting, 5205
 - IGF-IR expression and, 3781
 - imprinted gene inactivation by, 26
 - induction of
 - DNA hypermethylation of CpG island-containing genes in, pRb pathway inactivation and, 3624
 - genetic events in, 9824 - intestinal
 - EGCG inhibiting, 10623
 - mouse, threshold level of adenomatous polyposis coli protein for, 8622
 - polyamine catabolism and, 5390 - intestinal, p27^{high} in, 9363
 - lung
 - angiotensin II AT₂ deficiency and, 7660
 - Notch signaling pathways in, 3555 - mammary
 - decreased, in Cox-2 knockout mice, 10113
 - ERBB2-driven, premature senescence and, 840
 - kinase-inactive glycogen synthase kinase 3 β and, 5792
 - Ron receptor signaling augmenting, 1285
 - tamoxifen inhibiting, 3493 - transforming acidic coiled coli 1 promoting, 10363
 - Wnt-1-induced, PTEN inhibiting, 6864
 - mechanisms of amplification in, 1174
 - melanoma, mutant V599R B-Raf in, 2412
 - Met tyrosine kinase, β_4 integrin unleashing, 10674
 - mouse skin, susceptibility to, *Odc* gene overexpression and, 1146
 - NOK, mutagenic study of, 10838
 - ovarian granulosa cell, genetic control of, 1259
 - oxidative stress in, 203
 - pancreatic, neuropilin-1 suppressing, 3664
 - programmed cell death 4 suppressed by, 6034
 - prostate cancer
 - Ack1 promoting, 10514
 - connective tissue growth factor promoting, 8887
 - shed ectodomain of Nr-CAM stimulating, 11605 - skin
 - EP2 receptor in, 9304
 - induction of, mitogen-activated protein kinase in, ornithine decarboxylase in, 572
 - Smad4 function and, 8671
 - UV light-induced, chemoprevention of, EGFR inhibition in, 3958
 - Spz1 regulating, 4041
 - subpopulation of stem cells in melanomas contributing to, 9328
 - in transgenic mice, human *TERT* promoter expression in, 1187
- Tumorigenicity**
- in cancer stem cell clones, 3126
 - of HCCT1166 colon cancer cells, glutathione *S*-transferase π 1 promoting, 9485
 - HMGN1 impacting, 6711
 - inhibition of, reducing overexpressed Sp1 in, 1007
 - of MCF7-MCT-1 cells, increased, 10651
 - of ovarian cancer, suppression of, with truncated EGFR, 3243
 - PP2A A α -induced, 8183
 - reduction of, PRAME in, 7348
 - of T-anaplastic large cell lymphoma, CD26 regulating, 6950
- Tumor immune evasion**
- in colon cancer, Fas ligand in, 9817
- Tumor immunity**
- DC1-induced, 10059
- Tumor-infiltrating dendritic cells (TID)**
- suppressive or protective immune responses induced by, 4955
- Tumor-infiltrating lymphocytes (TILs)**
- NKR expression on, 2921
- Tumor necrosis factor- α (TNF- α)**
- CXCR4 in ovarian cancer up-regulated by, 10355
 - inflammation dependent on, gastric hyperplasia caused by, 9147
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)**
- apoptosis induced by
 - caspase-mediated p65 cleavage promoting, 6111 - colon cancer cells sensitized by, by COX-2 inhibition, 11447
 - galectin-3 inhibiting, 7546
 - luteolin sensitizing, 7815
 - TIMPs preventing, 898
 - tunicamycin enhancing, 6364
 - apoptosis signaled by, in lymphoid tumors, 11265
 - bortezomib plus, apoptosis induced by, 4902
 - colon carcinoma cell lines resistant to, ROS regulating caspase activation in, 7436
 - for glioblastoma multiforme, 11469
 - in lung cancer therapy, 1687
 - mitochondrial membrane lipids altered by, 8286
 - synthetic triterpenoids with, inducing breast cancer cell apoptosis, 4799
 - tumor cell proliferation mediated by, 7888
- Tumor necrosis factor (TNF)**
- glioma growth reduced by, 3928
- Tumor suppressor**
- early growth response 1 as, 5133
 - fps/fes* as, 3518
 - p53 protein, in ribosomal S6 kinase 2 and histone H3 interaction, 3596
 - VDUP1, JAB1 function antagonized by, 4485
- Tumor suppressor gene(s)**
- for breast cancer, homeobox D10 as, 7177
 - epigenetic reactivation of, by small-molecule DNA methyltransferase inhibitor, 6305
 - FEZ1/LZTS1* as, 1207
 - HIN-1* as, 9639
 - p53 promoter, methylation of, maintenance of, interleukin 6 supporting, 4673
 - in prostate cancer, *ALDH1a2* as, 8118
 - RASSF1A* as, 92
 - RASSF1* as, 3497
 - SMARCB1/INI1*, inactivation of, in epithelioid sarcomas, 4012
- Tumor vaccines**
- GM-CSF-secreting, IFN- α augmenting, 2449
 - leveraging activity of, with cytotoxic chemotherapy, 8059
 - surrogate antigen-based, 2938
- Tumstatin**
- as angiogenesis inhibitor, 3967
- Tunicamycin**
- TRAIL-induced apoptosis enhanced by, 6364
- Twist**
- overexpression of, in breast cancer, tumor growth promoted by, 10801
 - in prostate cancer, 5153
- Tyrosine kinase**
- Met, tumorigenesis of, β_4 integrin unleashing, 10674
 - oncogenic, targeting centrosome, 7231
 - receptor, metastasis-associated, in non-small cell lung cancer, identification of, 1778
 - Src, in restoring paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells, 10381
 - Syk, localized to centrosomes, breast cancer cell mitosis and, 10872
- Tyrosine kinase inhibitors (TKI)**
- for lung cancer with epidermal growth factor receptor mutations, 226
 - VEGFR, irradiated tumor vessels and, 5374
- Ubiquitin-conjugating enzymes**
- increased, in breast cancer, 5599
- Ubiquitin ligase activity**
- of BRCA1-BARD1, CDK2 and, 6
- Ubiquitin-proteasome pathway**
- KLF4 destabilization and, 10394
 - in regulation of eukaryotic elongation factor-2 kinase stability, 3806
- Ultrasound imaging**
- in preclinical liver metastases evaluation, 5231
 - targeted, of tumor angiogenesis, 533
- Ultrasound microimaging**
- three-dimensional technology with, for preclinical studies of prostate cancer in mouse model, 6337
- Ultraviolet radiation**
- activation of activator protein 1 and NF- κ B induced by, 6601
 - apoptosis induced by, caspase-3 activation in, BRCA2 phosphorylation regulating, 10657
 - skin tumorigenesis induced by, chemoprevention of, EGFR inhibition in, 3958
- Ultraviolet radiation B (UVB)**
- carcinogenic effects of, DDB2 in protection against, 10298
 - chronic exposure to, skin carcinogenesis from, 6006
 - keratinocyte survival and proliferation after exposure to, epidermal STAT3 in, 5720
 - p53-immunoreactive epidermal cells induced by, tumor p53 mutations in, 3577
 - responses of fibroblasts and keratinocytes induced by, transcription-coupled repair in, 432
- Uniparental disomy**
- in acute myeloid leukemias, 375
 - homozygous gene mutation associated with, 9152
- Urban dust exposure**
- gene expression alterations from, 1251
- Urinary marker**
- for tumor hypoxia, noninvasive approach to, 6151
- Urokinase receptor**
- expression and invasiveness of, thalidomide inhibiting, 10464
- Urothelial carcinoma cell lines**
- alternative splicing of fibroblast growth factor receptor 3 in, 10441

Vaccination

with polyomavirus VP1/VP2Her2 virus-like particles
outgrowth of HER-2/*neu*-expressing tumors
prevented by, 5953
therapeutic, against murine lymphoma, 5958

Vaccine(s)

CEA, oral, induction of immune responses against
CEA by, 6990
dendritic cell, CEA-Hsp70L1 pulsed, antitumor
effect of, 4947
DNA
with GD2 ganglioside mimetic peptides,
protective GD2 cross-reactive antibody
responses induced by, 3410
potency of, enhancing, coadministration with
small interfering RNA in, 309
against survivin, in lung tumor eradication, 553
xenogeneic, autoimmunity induced by, in
mammary cancer inhibition, 1071
expressing of (L3)-galactosyl isotopes for melanoma,
10555
fusion protein, by domains of bacterial exotoxin,
9089
granulocyte-macrophage colony stimulating factor
tumor cell
CD8⁺ T-cell responses to renal cell carcinoma
antigens and, 1079
oral poliovirus, contamination of, with infectious
SV40, 10273
tumor
GM-CSF-secreting, IFN- α augmenting, 2449
leveraging activity of, with cytotoxic
chemotherapy, 8059
surrogate antigen-based, 2938

Vaccinia

oncolytic, replicating, tumor-selectivity of, 9991

Valosin-containing protein (VAP)

phosphorylation of, after DNA damage, 7533

Valproic acid

chromatin structure altered by, 3815
cytokine-induced expansion of human
hematopoietic stem cells enhanced by, 1505
hematopoietic stem cell proliferation stimulated by,
2537

Vascular endothelial growth factor (VEGF)

coexpression of cyclooxygenases with, in esophageal
adenocarcinoma, 5038
COX-2 inhibitors and, 982
CSCL12 and, inducing neoangiogenesis in ovarian
cancer, 465
expression of
FP receptor signaling inducing, 7707
in lung cancer, PDGF-AA regulating, 7241
genetic polymorphisms in, breast cancer survival
and, 5015
proinvasive activity of, STAT3 and, in colon cancer
cells, 195
prostate cancer-mediated osteoblastic activity
promoted by, 10921
in prostate epithelial cells, induction of, by IGF-I,
activated Ras enhancing, 2085
receptors for
blockade of, tumor phenotype reversion by, 1294
inhibition of, hepatocellular carcinoma growth
arrest and, 3691
topotecan blocking, in neuroblastoma cells, 4775

Vascular endothelial growth factor receptor (VEGFR)

inhibition of, for pancreatic cancer, 10371
phosphorylation of, inhibition of, in follicular
thyroid cancer bone metastasis, 4716

Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase

inhibitor of, irradiated tumor vessels and, 5374

Vascular endothelial growth factor receptor-1 (VEGFR-1)

multiple myeloma growth promoted by, 3185

Vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI)

tumor blood volume response to, 9253

Vascular endothelial growth factor receptor-2 (VEGFR-2)

antiangiogenic cancer immunotherapy using, 4939
inhibitor of, AZD2171 as, 4398

Vascular endothelial growth factor receptor 3 (VEGFR-3)

lymphatic endothelium activation mediated by, in
lymphatic metastasis, 4739

Vascular endothelial growth factor-A (VEGF-A)

lymphatic metastasis promoted by, 9261
RNA interference of, hypoxia and, in sarcomas, 5881

Vascular endothelial growth factor-C (VEGF-C)

inhibition of, effects of, on tumor metastasis and
survival, 9004

tumor-secreted, for prostate cancer

lymphangiogenesis, 9789

Vascular endothelial growth factor/Flt1 autocrine loop

hypoxia-inducible factor-1 α interacting with, in
neuroblastoma, 7267

Vascular endothelial growth factor receptor-3, soluble (sVEGFR3)

gene transfer of, AAV-mediated, in lymphogenous
metastasis inhibition, 6901

Vasostatin

as angiogenesis inhibitor, 3967

Vault poly(ADP-ribose) polymerase (VPARP)

mice deficient in, increased tumorigenesis in, 8846

VDUP1 (vitamin D₃ up-regulated protein 1)

JAB1 function antagonized by, 4485

VEGF. See Vascular endothelial growth factor (VEGF)**Velcade. See Bortezomib (Velcade)****Vertebrate cells**

DNA cross-link repair in, 11704

Vhl

haploinsufficiency of, lung cancer susceptibility and,
6576

Vinorelbine (Navelbine)

resistance to, RLIP76 mediating, 991
synergism of, with 2-methoxyestradiol in breast
cancer, 387

Viral gene delivery

in solid tumors, novel method for, 7541

Virotherapy

for ALL, 3347
dose reduction of, cyclophosphamide allowing,
11255
telomerase-dependent, overcoming drug resistance
of hepatocellular carcinomas, 7393

Virus(es)

herpes (See **Herpesvirus**)
herpes simplex (See **Herpes simplex virus**)
measles, targeted to vascular epithelium, 5292
mouse mammary tumor, human cells infected by,
6651
myxoma, antitumor activity of, against gliomas,
9982
oncolytic (See **Oncolytic virus**)
replication of, targeted, immunotherapy plus, for
pancreatic cancer, 9056

Virus-associated I (VAI)-deleted adenovirus

as oncolytic virus, 1523

Vitamin D

CCAAT/enhancer-binding protein δ and, 4762
receptor gene polymorphisms and sun exposure
and, advanced prostate cancer risk and, 5470

Vitamin D receptor

S179D prolactin increasing, in prostate cancer cells,
7509

Vitamin D₃ up-regulated protein 1 (VDUP1)

JAB1 function antagonized by, 4485

Vitamins

B
intake of, breast cancer risk and, 1606

von Hippel-Lindau (VHL) gene

deficient
endolymphatic duct and sac and, 10847
renal cell carcinoma with, HIF2- α transactivation
in, Nox4 for, 9190
mutations of, renal cell carcinoma and, 5221

von Hippel-Lindau (VHL) protein

loss of function of, in hemangioblastoma and clear
cell renal cell carcinoma, 6178

Tid-1 interacting with, angiogenesis regulated by,
2520

VPARP (vault poly(ADP-ribose) polymerase)

mice deficient in, increased tumorigenesis in, 8846

Warburg effect

cellular life span and, 177

Wavelet variance scanning (WAVES)

cancer transcriptome and chromosomal aneuploidy
and, 186

Werner syndrome, 1223**Whole-body fluorescence imaging**

on pancreatic cancer, MRI compared with, 9892

Whole genome tiling-path array comparative

genomic hybridization

microalterations in oral cancer detected by, 7561

Wilms tumor

primary, relapse of, molecular signature for, 2592

Wnt-1

mammary tumorigenesis induced by, PTEN
inhibiting, 6864

Wnt-5a

expression of, in Dukes B colon cancers, prognosis
and, 9142

Wnt/3-catenin signaling

misregulated, in ovarian granulosa cell tumor
development, 9206

Wnts

prostate cancer cells promoting osteoblastic bone
metastases through, 7554

Wnt signaling

in cervical carcinogenesis, 6199
galectin-3 in, 3535
kinase-inactive glycogen synthase kinase 3 β
promoting, 5792
stimulation of, hepatocellular carcinoma growth
and, 6245

WRN gene

DNA helicase activity of, p53 modulating, 1223

Wt1

regulating proapoptotic Bak, 8174

WTH3

regulation of, epigenetic, in drug-resistant breast
cancer cells, 10024
regulation of, in multidrug-resistant and sensitive
MCF7 cells, 7421

WV0X

ErbB-4 interacting with, 6764

X chromosome

inactive, loss of, in breast cancer, 2139

Xenoeugen

action of, in prostate cancer, 54

Xenograft(s)

colon cancer
antiangiogenic effects in, early, detection of, 9253
growth of, enzastaurin suppressing, 7462
glioblastoma, growth of, enzastaurin suppressing,
7462
melanoma, antiangiogenic GM2 monoclonal
antibody for, 6425
pancreatic cancer, gemcitabine with CpG-
oligodeoxynucleotides for, 6388
prostate cancer
effects of CCI-779 on, 2825
growth of, bicalutamide promoting, 9611
small cell lung carcinoma, antiangiogenic GM2
monoclonal antibody for, 6425
tumor, fludolone in therapeutic cure of, 9445
tumor hypoxia in, noninvasive assessment of, 6151

Xenograft model

of breast cancer metastasis, 5578

XIAP protein

anoikis resistance of prostate cancer metastasis
precursor cells and, 2378

X-linked dominant growth suppression, 5690**XRCC1 gene**

polymorphisms in, lung cancer risk and, 722

YAP

ErbB-4 interacting with, 6764

YB-1

as breast cancer oncogene, 4078

YM529

CXCR4-induced prostate cancer invasion inhibited
by, 8818

Yondelis (Trabectedin)

macrophage differentiation inhibited by, 2964

ZD1839

interaction of, with ST1926, 2364

ZD6474

RET isoforms in type 2 MEN and papillary thyroid cancer suppressed by, 3538

Zinc

deficiency of, gene expression in esophageal cancer and, 7790

metabolism of, motaxefin gadolinium disrupting, 3837

oxidative stress responses induced by, in B-cell lines, 11676

Zinc-binding domain

of endostatic, antitumor activity and, 3656

Zoledronate

enhancing therapeutic effects of ST1571 and

paclitaxel against bone metastasis of prostate cancer, 3707

Zonula occludens-1

membrane-type 1 matrix metalloproteinase expression regulated by, in breast cancer cells, 7691

ZR-75-1 breast cancer cells

insensitivity of, to 2-methoxyestradiol, 5802

